0001493152-24-011121.txt : 20240325 0001493152-24-011121.hdr.sgml : 20240325 20240325150121 ACCESSION NUMBER: 0001493152-24-011121 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240325 DATE AS OF CHANGE: 20240325 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Syra Health Corp CENTRAL INDEX KEY: 0001922335 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-EMPLOYMENT AGENCIES [7361] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41822 FILM NUMBER: 24778833 BUSINESS ADDRESS: STREET 1: 1119 KEYSTONE WAY N. STREET 2: #201 CITY: CARMEL STATE: IN ZIP: 46032 BUSINESS PHONE: (317) 922-0922 MAIL ADDRESS: STREET 1: 1119 KEYSTONE WAY N. STREET 2: #201 CITY: CARMEL STATE: IN ZIP: 46032 10-K 1 form10-k.htm
false FY 0001922335 P5Y P3Y P3Y P3Y 0001922335 2023-01-01 2023-12-31 0001922335 2024-03-25 0001922335 2023-12-31 0001922335 2022-12-31 0001922335 us-gaap:NonrelatedPartyMember 2023-12-31 0001922335 us-gaap:NonrelatedPartyMember 2022-12-31 0001922335 us-gaap:RelatedPartyMember 2023-12-31 0001922335 us-gaap:RelatedPartyMember 2022-12-31 0001922335 us-gaap:CommonClassAMember 2023-12-31 0001922335 us-gaap:CommonClassAMember 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-12-31 0001922335 2022-01-01 2022-12-31 0001922335 us-gaap:PreferredStockMember 2021-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2021-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2021-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001922335 us-gaap:RetainedEarningsMember 2021-12-31 0001922335 2021-12-31 0001922335 us-gaap:PreferredStockMember 2022-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2022-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001922335 us-gaap:RetainedEarningsMember 2022-12-31 0001922335 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2022-01-01 2022-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2022-01-01 2022-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001922335 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001922335 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2023-01-01 2023-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001922335 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001922335 us-gaap:PreferredStockMember 2023-12-31 0001922335 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2023-12-31 0001922335 us-gaap:CommonStockMember SYRA:ConvertibleClassBCommonStockMember 2023-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001922335 us-gaap:RetainedEarningsMember 2023-12-31 0001922335 us-gaap:IPOMember 2023-10-03 2023-10-03 0001922335 us-gaap:IPOMember 2023-10-03 0001922335 us-gaap:OverAllotmentOptionMember SYRA:UnderwritingAgreementMember 2023-10-03 2023-10-03 0001922335 us-gaap:OverAllotmentOptionMember SYRA:UnderwritingAgreementMember 2023-10-03 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember SYRA:FamilyAndSocialServicesAdministrationMember 2023-01-01 2023-12-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember SYRA:FamilyAndSocialServicesAdministrationMember 2022-01-01 2022-12-31 0001922335 SYRA:HealthcareWorkforceMember SYRA:FSSANeuroDiagnosticInstituteMember 2023-01-01 2023-12-31 0001922335 SYRA:HealthcareWorkforceMember SYRA:FSSANeuroDiagnosticInstituteMember 2022-01-01 2022-12-31 0001922335 SYRA:PopulationHealthMember SYRA:FSSADivisionOfMentalHealthAndAddictionMember 2023-01-01 2023-12-31 0001922335 SYRA:PopulationHealthMember SYRA:FSSADivisionOfMentalHealthAndAddictionMember 2022-01-01 2022-12-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember SYRA:FamilyAndSocialServicesAdministrationMember 2023-01-01 2023-12-31 0001922335 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember SYRA:FamilyAndSocialServicesAdministrationMember 2022-01-01 2022-12-31 0001922335 SYRA:HealthcareWorkforceMember 2023-01-01 2023-12-31 0001922335 SYRA:HealthcareWorkforceMember 2022-01-01 2022-12-31 0001922335 SYRA:PopulationHealthMember 2023-01-01 2023-12-31 0001922335 SYRA:PopulationHealthMember 2022-01-01 2022-12-31 0001922335 SYRA:DigitalHealthMember 2023-01-01 2023-12-31 0001922335 SYRA:DigitalHealthMember 2022-01-01 2022-12-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2023-01-01 2023-12-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2022-01-01 2022-12-31 0001922335 SYRA:HealtheducationMember 2023-01-01 2023-12-31 0001922335 SYRA:HealtheducationMember 2022-01-01 2022-12-31 0001922335 2023-01-01 2023-04-30 0001922335 2023-10-03 2023-10-03 0001922335 SYRA:SahasraTechnologiesCorpMember 2023-07-11 2023-08-23 0001922335 SYRA:SahasraTechnologiesCorpMember 2023-01-01 2023-12-31 0001922335 SYRA:SahasraTechnologiesCorpMember 2023-12-31 0001922335 SYRA:STLogicsMember 2023-12-31 0001922335 SYRA:STVenturesMember 2021-07-01 0001922335 SYRA:STVenturesMember 2021-07-01 2021-07-01 0001922335 SYRA:STVenturesMember 2022-05-01 2022-05-01 0001922335 SYRA:STVenturesMember 2023-01-01 2023-12-31 0001922335 SYRA:STVenturesMember 2022-01-01 2022-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2023-01-01 2023-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2022-01-01 2022-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2023-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2022-12-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2023-01-01 2023-12-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2022-01-01 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2020-11-21 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-01-01 2022-12-31 0001922335 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001922335 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001922335 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001922335 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001922335 us-gaap:OfficeEquipmentMember 2023-12-31 0001922335 us-gaap:OfficeEquipmentMember 2022-12-31 0001922335 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001922335 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001922335 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001922335 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2022-02-07 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2023-01-01 2023-12-31 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2022-02-07 2022-02-07 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2022-01-01 2022-12-31 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-04-07 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-01-01 2023-04-07 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-10-03 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-10-03 2023-10-03 0001922335 us-gaap:CommonClassAMember 2023-10-03 2023-10-03 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MinimumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MaximumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-01-01 2023-12-31 0001922335 SYRA:STVenturesMember 2022-05-01 0001922335 2022-06-27 2022-06-28 0001922335 us-gaap:CommonStockMember 2022-05-03 0001922335 SYRA:ConvertibleCommonStockBMember 2022-05-03 2022-05-03 0001922335 us-gaap:CommonClassBMember 2022-05-03 2022-05-03 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-03-01 2022-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-06-01 2022-06-30 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-08-01 2022-08-31 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-06-30 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-08-31 0001922335 us-gaap:CommonClassAMember 2023-05-30 0001922335 SYRA:ConvertibleCommonStockBMember 2023-05-30 0001922335 2023-05-30 0001922335 SYRA:ConvertibleCommonStockBMember 2023-01-01 2023-12-31 0001922335 us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001922335 us-gaap:IPOMember SYRA:UnderwritingAgreementMember 2023-10-03 0001922335 SYRA:KingswoodCapitalPartnersLLCMember 2023-10-03 2023-10-03 0001922335 SYRA:KingswoodCapitalPartnersLLCMember 2023-10-03 0001922335 us-gaap:CommonClassAMember 2023-05-10 0001922335 2023-10-03 0001922335 us-gaap:RestrictedStockMember SYRA:ConsultantMember us-gaap:CommonClassAMember 2023-11-01 2023-11-30 0001922335 SYRA:SixConsultantMember 2022-02-01 2022-05-31 0001922335 SYRA:ConvertibleCommonStockBMember 2023-12-31 0001922335 SYRA:ConvertibleCommonStockBMember 2022-12-31 0001922335 SYRA:ConvertibleCommonStockBMember 2021-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 2022-05-03 0001922335 SYRA:ConvertibleCommonStockBIssuancesMember 2020-11-21 2020-11-21 0001922335 SYRA:ConvertibleCommonStockBIssuancesMember 2022-05-03 0001922335 SYRA:ConvertibleCommonStockBIssuancesMember 2022-05-03 2022-05-03 0001922335 SYRA:OmnibusEquityIncentivePlanMember srt:MaximumMember 2022-04-11 2022-04-11 0001922335 SYRA:TenEmployeesMember 2023-11-08 2023-11-08 0001922335 SYRA:TenEmployeesMember 2023-11-08 0001922335 SYRA:ThreeConsultantsMember 2023-11-08 2023-11-08 0001922335 SYRA:ThreeConsultantsMember 2023-11-08 0001922335 SYRA:FiveBoardMembersMember 2023-10-09 2023-10-09 0001922335 SYRA:FiveBoardMembersMember 2023-10-09 0001922335 srt:MinimumMember 2023-12-31 0001922335 srt:MaximumMember 2023-12-31 0001922335 us-gaap:CommonClassAMember 2022-09-01 0001922335 2022-07-01 2022-09-01 0001922335 2022-09-01 0001922335 us-gaap:StockOptionMember 2022-10-01 2022-12-31 0001922335 2020-11-20 2023-12-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-03-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001922335 SYRA:NovemberTwoThousandTwentyThreeMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001922335 2023-10-01 2023-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares utr:sqft xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the year ended December 31, 2023

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from______ to______.

Commission File Number 001-41822

 

 

SYRA HEALTH CORP.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   85-4027995

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification Number)

 

1119 Keystone Way N. #201

Carmel, IN 46032

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (463) 345-8950

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   SYRA   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

 

Large accelerated filer ☐   Accelerated filer ☐   Non-accelerated filer ☒   Smaller reporting company ☒
            Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The Registrant was not a public company as of the last business day of its most recently completed second fiscal quarter and, therefore, cannot calculate the aggregate market value of its voting and non-voting common equity held by non-affiliates as of such date.

 

The number of shares of the registrant’s Class A Common Stock outstanding as of March 25, 2024 was 5,731,587.

 

Documents Incorporated by Reference:

 

Specified portions of the registrant’s proxy statement, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14 A in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “Proxy Statement”), are incorporated by reference into Part III of this Annual Report on Form 10-K. Except with respect to information specifically incorporated by reference in this Annual Report, the Proxy Statement is not deemed to be filed as part hereof.

 

 

 

 
 

 


TABLE OF CONTENTS

 

    Page
Cautionary Note Regarding Forward-Looking Statements 2
Risk Factor Summary 3
   
PART I  
Item 1. Business 4
Item 1A. Risk Factors 12
Item 1B. Unresolved Staff Comments 30
Item 1C. Cybersecurity 30
Item 2. Properties 30
Item 3. Legal Proceedings 30
Item 4. Mine Safety Disclosures 31
     
PART II  
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 31
Item 6. [Reserved] 31
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 39
Item 8. Financial Statements and Supplementary Data F-1
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 40
Item 9A. Controls and Procedures 40
Item 9B. Other Information 41
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 41
     
PART III
Item 10. Directors, Executive Officers and Corporate Governance 41
Item 11. Executive Compensation 41
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 41
Item 13. Certain Relationships and Related Transactions, and Director Independence 41
Item 14. Principal Accountant Fees and Services 41
     
PART IV  
Item 15. Exhibits and Financial Statement Schedules 42
Item 16. Form 10-K Summary 44
     
SIGNATURES 45

 

-1-
 

 

Cautionary Note Regarding Forward-Looking Statements

 

This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. The forward-looking statements in this Annual Report on Form 10-K are only predictions. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, strategy, short- and long-term business operations and objectives, and financial needs. These forward-looking statements include, but are not limited to, statements concerning the following:

 

●our projected financial position and estimated cash burn rate;
   
●our estimates regarding expenses, future revenues and capital requirements;
   
●our ability to continue as a going concern;
   
●our need to raise substantial additional capital to fund our operations;
   
●our ability to compete in the healthcare industry;
   
●the timing, cost and success or failure of new product and service introductions, development and product upgrade releases;
   
●competitive pressures including offerings and pricing;
   
●our ability to establish and maintain strategic relationships;
   
●undetected errors or similar problems in our software products;
   
●compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry;
   
●the possibility of services-related liabilities;
   
●our ability to obtain, maintain and protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;
   
●our reliance on third-party content providers;
   
●the success of competing products or services that are or become available;
   
●our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel; and
   
●the successful development of our sales and marketing capabilities.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors.” Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements.

 

You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

 

-2-
 

 

Risk Factor Summary

 

Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled “Risk Factors”, together with the other information in this Annual Report on Form 10-K. If any of the following risks actually occurs (or if any of those listed elsewhere in this Annual Report on Form 10-K occur), our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business.

 

 

●

Although we have generated approximately $5.5 million and $5.6 million of revenues for the years ended December 31, 2023 and 2022, respectively, our future profitability is uncertain.

     
  ● We will require substantial additional funding and if we are unable to raise capital on favorable terms when needed, we could be forced to curtail, delay or discontinue our business.
     
  ● Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.
     
  ● Our business strategy and future success depend on our ability to cross-sell our solutions.
     
  ● If we are unable to successfully expand our sales force productivity, sales of our solutions and the growth of our business and financial performance could be harmed.
     
  ● Our ability to generate revenue could suffer if we do not continue to update and improve our existing solutions and develop new ones.
     
  ● Achieving market acceptance of new or updated solutions is necessary in order for them to become profitable and will likely require significant efforts and expenditures.
     
  ● Our business would be adversely affected if we cannot obtain, process or distribute data we require to provide our solutions.
     
  ● Disruptions in service or damages to our data or systems failures could have a material adverse impact on our business, results of operations or financial condition. In addition, breaches and failures of information technology (“IT”) systems and the sensitive information we transmit, use and store expose us to potential liability and reputational harm.
     
  ● We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems in providing certain of our solutions to our customers, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with customers, adversely affecting our brand and our business.
     
  ● Failure by our customers to obtain proper permissions or provide us with accurate and appropriate information may result in claims against us or may limit or prevent our use of information, which could harm our business. Additionally, privacy concerns relating to our business could damage our reputation and deter current and potential customers from using our solutions.
     
  ● Our independent content providers may fail to perform adequately or comply with laws, regulations or contractual covenants.
     
  ● Our work with government clients exposes us to additional risks inherent in the government contracting environment.
     
  ● We may be liable for the misdiagnoses, mistreatment, injury or other harm to patients resulting from the use of data that we provide to health care providers, and any resulting claims could negatively impact our operating results and result in a decline in our stock price.
  ● The protection of our intellectual property requires substantial resources and protections of our proprietary rights may not be adequate.
     
  ● We depend on a small number of large customers and the loss of one or more major customers could have a material adverse effect on our business, financial condition and results of operations.
     
  ● We are subject to federal and state healthcare industry regulation including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding government contracting.
     
  ● The dual-class structure of our common stock as contained in our Certificate of Incorporation has the effect of concentrating voting control with those stockholders who held our Class B common stock. This ownership will limit or preclude your ability to influence corporate matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transactions requiring stockholder approval, and that may adversely affect the trading price of our Class A common stock.
     
  ● Our principal stockholders will continue to have significant influence over the election of our board of directors and approval of any significant corporate actions, including any sale of our Company.

 

-3-
 

 

PART I

 

ITEM 1. BUSINESS

 

Overview

 

We are a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. We leverage deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. We provide comprehensive end-to-end solutions in behavioral and mental health, population health, digital health, health education and healthcare workforce.

 

Our Services

 

Behavioral and Mental Health

 

Mental health concerns are rapidly growing on a global scale, yet the shortage of mental health professionals and access to treatment is leaving millions of people without access to mental health resources. According to a Health Affairs report, almost half of all counties in the United States have zero psychiatrists, and according to the U.S. Department of Health and Human Services, 111 million people live in areas where there is a mental health professional shortage. Mental health issues are impacting all segments of the population, especially college students. According to the BestColleges.com survey, nearly half of all students believe that mental health issues have impacted their education and, as a result of the COVID-19 pandemic, 9 in 10 students experienced negative mental health symptoms.

 

We strongly believe in behavioral and mental health equity and our mission is to provide solutions that help improve health care and provide access to all populations, regardless of race, ethnicity, gender, socioeconomic status, sexual orientation, or geographic location. With our specialized services, we believe that we can help solve the behavioral and mental health needs of various organizations, including health organizations, large employers, and schools.

 

Behavioral and Mental Health Prevention & Telehealth App – Syrenity

 

Syrenity is a comprehensive mental health application that is aimed at providing preventative care and interventions for behavioral and mental health With its evidence-based approach, Syrenity is being designed to identify and prevent the progression of negative factors that can influence individuals’ mental health, by offering targeted assignments, education, monitoring symptoms, and providing timely interventions.

 

We believe one of the key selling points of Syrenity is an evidence-based and preventative approach. The app utilizes scientifically proven methods and techniques to assess and address behavioral and mental health concerns. Through a series of assessments, Syrenity will create a personalized profile for each user, which will serve as a starting point for developing targeted activities, education, and interventions. It is anticipated that the app will also generate reports and analytics on the user’s behavioral health.

 

-4-
 

 

Syrenity will enable users to connect with licensed mental health professionals through the telehealth and therapist matching features. Users can schedule virtual consultations with psychologists, psychiatrists, or mental health coaches, eliminating the need for in-person visits and providing convenient access to professional mental health care from the comfort of their own homes.

 

Engagement and interventions are crucial components of Syrenity, as the app is being designed to actively engage users in their mental health journey. Using innovative active and passive interventions such as gamification and personalized goal setting, we believe Syrenity will encourage users to actively participate in their mental health care. The app will also provide evidence-based interventions, such as cognitive behavioral therapy and mindfulness techniques, to help individuals effectively manage their symptoms and improve their mental well-being.

 

Syrenity will utilize an artificial intelligence-driven user diary for engagement, and there will be provision for accessing a virtual coach 24/7. We anticipate that other features will include ADA accessibility, alerts and notifications, and access to community resources.

 

Education is also given a key importance in our telehealth solution, as it empowers users with knowledge about mental health and equips them with skills to manage their condition effectively. The app will provide educational resources, such as articles, videos, and interactive modules, to help users understand their mental health concerns and learn coping strategies. This knowledge will empower users to actively participate in their mental health care and make informed decisions about their well-being.

 

Overall, we believe Syrenity will stand out as a comprehensive and evidence-based digital health app that addresses behavioral and mental health concerns through targeted assignments, education, monitoring symptoms, and evidence-based interventions. We believe its unique features, including profile assessments, engagement and interventions, telehealth services, and education, will make it a powerful tool for individuals looking to improve their mental well-being and prevent the progression of negative factors influencing their mental health.

 

Digital Health

 

We use digital health to bring innovation into the healthcare practice. Our goal is to transform patient care and engagement by connecting physicians, patients, caregivers, payers, and other key stakeholders through healthcare digital platforms with are supported by robust datasets and algorithms powered by artificial intelligence. By providing stakeholders with data, we intend to empower stakeholders to address factors that impact holistic health, including physical, behavioral, and social elements. Currently, we are developing digital and cloud-based platforms to help improve cost savings through the automation of health operations, which also provide clinical insights that personalize care and improve patient satisfaction. Our solutions will include digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps.

 

Within our digital health service line, we intend to offer SyraBot, CarePlus and patient engagement and education services; however, we have not generated any revenue to date.

 

Cloud and Security

 

We intend to offer cloud-based healthcare solutions with secure and scalable infrastructure for healthcare organizations to store and manage patient data. Our cost-effective solution will allow healthcare providers to access patient information from anywhere, with enhanced data security measures.

 

Artificial Intelligence

 

Our AI-powered healthcare solutions will leverage advanced capabilities like natural language processing and predictive analytics to automate tasks, enable data-driven decisions, and enhance patient care. We believe our innovative approach to healthcare uses AI to drive progress and innovation.

 

-5-
 

 

Patient Engagement

 

Our patient engagement solutions are intended to provide patients with easy access to their health information, personalized health plans, and communication channels with healthcare providers. Our tools include reminders for appointments and medication, empowering patients to take an active role in their healthcare journey.

 

Health Apps

 

Our digital health solutions, developed using the latest health information technologies, enable seamless and sustainable transformation for healthcare providers. We help unlock their full care potential in an ever-changing healthcare environment.

 

SyraBot

 

SyraBot is designed to foster connectivity and engagement throughout individuals’ care journeys, offers members round-the-clock access to necessary information via our AI-powered customer support chat system. Some of the Syrabot features include automating manual tasks to streamline healthcare professional (HCP) care, aiding patients in identifying health warning signs, encouraging adherence to therapy and medical regimens, and creating a bias-free space for patients to share personal information. We recognized revenue of $515,250 related to SyraBot during the year ended December 31, 2023.

 

CarePlus

 

We recently launched CarePlus, a user-friendly electronic medical records solution designed for small to mid-sized healthcare organizations. CarePlus offers customizable templates, e-prescribing, laboratory integration, and patient portal access to streamline clinical workflows and efficiently manage patient health information.

 

Patient Engagement and Education

 

We intend to offer an artificial intelligence chatbot trained to have human-like conversations using a process known as natural language processing to facilitate and provide end-to-end query resolution for the patients. Our chatbot will provide instant resolution and reduce the time taken to resolve repetitive queries. Our chatbot will be equipped to handle user queries and drive the conversation toward query resolution. Patients can utilize our chatbot for multiple features such as learning more about their condition, identifying healthcare professionals in their vicinity, scheduling, billing purposes, and learning about their health benefits from a health plan.

 

Population Health

 

We define population health services as the process of assessing and analyzing healthcare and its delivery to create improvement for a population of individuals. We are developing end-to-end solutions and strategies to improve quality of care, access to care, health outcomes, and healthcare policies. We believe that our solutions will assist individuals in reaching their full health potential through preventative care, care coordination and patient engagement. Our team of service providers includes health economists, public health experts, subject matter experts, data scientists, and biostatisticians who apply advanced health analytics to real-world data to provide meaningful insights to improve quality of clinical care and understand patterns and trends around diagnosis, treatment, and continued care. We believe our team helps stratify health risks based on social determinants of health, predict utilization of resources and health care costs, identify patient-level interventions, and recommend population-level strategies.

 

On September 3, 2021, we entered into a professional services contract with the FSSA, Division of Mental Health and Addiction, as amended on April 25, 2023 (as amended, the “Mental Health Agreement”), pursuant to which we are coordinating the work of the State Epidemiological Outcomes Workgroup and supporting data-driven decision-making regarding prevention efforts across state agencies and bodies. The Mental Health Agreement shall remain in effect until June 30, 2025, unless earlier terminated pursuant to the terms thereof. Pursuant to the Mental Health Agreement, we may receive up to approximately $1,246,000. The Mental Health Agreement may be terminated by the state, for, among other reasons, (i) a material breach of the Mental Health Agreement; (ii) failure by us to provide insurance required by the Mental Health Agreement; (iii) upon the occurrence of a default; (iv) if the Director of the State Budget Agency makes a written determination that funds are not appropriated or otherwise available to support continuation of performance of the Mental Health Agreement; or (v) for any reason if the state determines that such termination is in its best interest. We may terminate the Mental Health Agreement if the state, 60 days after receipt of written notice, fails to correct or cure any material breach of the Mental Health Agreement, and we may institute measures to collect monies due up to and including the date of termination. We generated $305,000 and $306,000, or 6% and 5% ,of our net revenues pursuant to the Mental Health Agreement during the years ended December 31, 2023 and 2022, respectively.

 

-6-
 

 

Within our population health service line we offer the following services: analytics as a service, epidemiology, and health equity analytics solutions. During the years ended December 31, 2023 and 2022, we generated $715,499 and $318,036 of revenue, respectively, from such services.

 

Analytics as a Service

 

We perform in-depth research and provide end-to-end high-quality analysis on health and healthcare data and derive insights that can be developed into strategic interventions. We develop predictive analytics on healthcare utilization and cost and test the effectiveness of care management programs. Overall, we conduct data analytics and develop solutions from a health equity lens to help improve health equality and access to care. Some of our analytical capabilities include: data collection, traditional to advanced analytics, predictive analytics, risk stratification, intervention analytics, spatial analytics gap analysis, analytics workforce public policy, and evidence-based research.

 

Epidemiology

 

Epidemiological solutions are a hallmark of our services. We believe that data-driven analysis of emerging trends, patterns, and determinants of health across various populations can provide a deeper understanding of public health issues thereby enabling organizations to influence policy and evidence-based practices. We are currently providing state and local agencies with various epidemiological services to improve public health in the State of Indiana and in the District of Columbia. Some of our epidemiology services include: managing and technical assistance to the state epidemiological outcomes workgroups; monitoring program evaluation substance use, mental health, epidemic and endemic, chronic, and infectious conditions; conducting data-driven discussions; establishing health priorities; and evaluation of regional prevention system.

 

Health Equity Analytics Solutions

 

Achieving health equity requires analysis of healthcare gaps, population risk stratification and strategic interventions involving social determinants of health. Using our health economics specialists and data scientists, we collect data on social determinants of health and provide an in-depth analysis to help develop strategies for interventions at the individual and population level. Our solutions are intended to target health disparities and promote more equitable healthcare for all. Some of our services and solutions include: health risk stratification analytics and programs; health equity gap analysis and solutions; regional health equity dashboard; caregiver vulnerability mapping assessments health equity analysis; strategies to engage with community-based organizations; patient/member engagement; and care coordination improvements.

 

Health Education Services

 

We believe that one of the main drivers of the healthcare education solutions market is the need to address challenges in the healthcare industry through effective and innovative medical and scientific training. With evolving healthcare technology, healthcare professionals must be knowledgeable with respect to various patient-care approaches to make better informed clinical decisions and assure patient satisfaction. We believe that targeted and continuous healthcare education solutions are needed to help healthcare professionals improve their competency, improve health equality and incorporate innovative and new therapeutic options into practice to improve overall patient care quality. Therefore, we aim to provide medical education solutions to pharmaceutical and medical device manufacturers, biotechnology companies, payers, large employers, academic institutions, and government agencies. Specifically, we develop medical education content to drive the organizational and strategic brand goals and vision of our clients. Our education outreach plan utilizes omnichannel delivery approaches from a suite of solutions for in-person, virtual and hybrid arrangements, and our deliverables include traditional print and electronic formats. Some of our targeted education approaches include the utilization of artificial intelligence tools to provide real-time information to customers.

 

Within our health education service line we offer the following services: medical communications, patient education, and healthcare training. We generated $12,306 and $39,300 of our net revenues, during the years ended December 31, 2023 and 2022, respectively.

 

-7-
 

 

Medical Communications

 

We offer expertise in medical communications focused on developing scientific communications based on complex scientific and clinical data, novel therapies and drugs, disease guidelines and real-world perspectives on diseases and their current treatments. We provide pharmaceutical manufactures and medical devices and biotechnology companies with communications and marketing materials to help them better engage with patients and healthcare professionals. Our target learning audience includes various healthcare professions such as specialists, primary care physicians, nurses, pharmacists, and hospital staff. Our teams that deliver communications and marketing materials to our end-users are well-versed with the regulatory and compliance requirements established by the FDA for the development of promotional materials for a branded therapeutic products. We offer content development services in the following areas: disease state and product-specific education; value propositions; sales aides; advisory board meetings; conference coverage; and medical affairs resources.

 

Patient Education

 

We define patient education as the process of influencing patient behavior and attitudes and empowering patients with the knowledge and skills necessary to maintain or improve their health. A key driver of the growth in patient education has been the increasing adoption of digital health technologies, preventative health, and holistic wellness awareness programs in the private and public sector.

 

We offer comprehensive patient education solutions and services to patients, provider groups, payers, health care institutions, and government health agencies to improve intrinsic health education which we believe will lead to increased patient satisfaction, positive experiences, and better health outcomes. We develop evidence-based, compliant content, incorporating the principles of instructional designing models so that the learning experience resonates with people of all demographics, including those of varied backgrounds and age groups. We offer educational content in the following areas: disease education and management; preventative health and wellness; behavioral and mental health; and public health awareness and campaigns. Our educational content is adaptable for integration into any electronic health record, care management platform, and learning management system. We offer our educational materials in various formats including American with Disabilities Act of 1990 (“ADA”) compliant print and electronic resources (i.e. brochures, toolkits, reports), app-based outreach, health blog, microsites, social media content, infographics, email campaigns and video formats.

 

Healthcare Training

 

According to BMC Public Health, health disparities are linked to up to $135 billion in economic losses in the United States per year. We believe health equity will be achieved when all sections of the population have attained their full potential for health and well-being regardless of race, age, sex, health conditions, social position or other socially determined circumstances. To decrease health disparities and improve patient outcomes and satisfaction, we have a team of subject matter experts that create trainings for employees and staff of health organizations, pharmaceutical companies, payers, and large healthcare employers. We offer our trainings in a variety of formats including virtual and classroom training, e-learning trainings, videos, surveys, and online assessments coupled with metrics. Our comprehensive training toolkits include facilitator and discussion guides, work mats and other resources for training. We offer customized training programs in the following areas: health equity, cultural competency, social determinants of health, preventative health, workforce, and sales training; behavioral and mental health; care coordination; and caregiver training.

 

Healthcare Workforce

 

Our healthcare workforce solutions are intended to help evaluate the immediate and longitudinal workforce needs of our client’s organization. Using agile implementation staffing methodologies we make it seamless and cost-efficient to expand our client’s clinical personnel. We recruit experienced nurses and allied health professionals for long-term fixed contract positions at hospitals and healthcare facilities across the country. Currently, we hold contracts with the State of Indiana psychiatric hospital to provide healthcare licensed and ancillary staff. Other staffing positions that we recruit include care coordinators, specialists to fill healthcare management roles, healthcare educators, therapists, healthcare technicians and health plan specialists. Our team of recruiters acts as an extension of our clients’ talent acquisition teams, working with our clients to fill vacant positions. Diversity, equity, and inclusion is at the core of our Company, and we support and help with the recruitment of a diverse workforce for our clients which includes government agencies and private sector organizations in the local community and nationally. We provide dedicated account managers and administrative teams to ensure accountability and transparency.

 

-8-
 

 

On July 27, 2021, we entered into a professional services contract with the FSSA, NeuroDiagnostic Institute, as amended on April 6, 2022, June 29, 2022 and August, 29, 2023 (as amended, the “NeuroDiagnostic Agreement”), pursuant to which we provide medical staffing services to the NeuroDiagnostic Institute. The NeuroDiagnostic Agreement shall remain in effect until January 21, 2025, unless earlier terminated pursuant to the terms thereof. Pursuant to the NeuroDiagnostic Agreement, we shall receive up to approximately $17 million. The NeuroDiagnostic Agreement may be terminated by the state, for, among other reasons, (i) a material breach of the NeuroDiagnostic Agreement; (ii) failure by us to provide insurance required by the NeuroDiagnostic Agreement; (iii) upon the occurrence of a default; (iv) based upon the state’s audit findings; (v) if the Director of the State Budget Agency makes a written determination that funds are not appropriated or otherwise available to support continuation of performance of the NeuroDiagnostic Agreement; or (vi) for any reason if the state determines that such termination is in its best interest. We may terminate the NeuroDiagnostic Agreement if the state, 60 days after receipt of written notice, fails to correct or cure any material breach of the NeuroDiagnostic Agreement, and we may institute measures to collect monies due up to and including the date of termination. We generated $3,734,004 and $5,214,128, or 68% and 93% of our net revenues, pursuant to the NeuroDiagnostic Agreement during the years ended December 31, 2023 and 2022, respectively.

 

Market Opportunity

 

Due to the currently unmet healthcare needs, challenges, and attention to behavioral and mental health, we believe the overall market opportunity for all the services we offer is growing at a rapid pace.

 

Health Education Services: According to Verified Market Research, the global health education market size was valued at approximately $31.6 billion in 2020 and is projected to reach approximately $41.4 billion by 2028, growing at a compound annual growth rate (“CAGR”) of 3.59% from 2021 to 2028. Furthermore, according to Arizton Advisory and Intelligence, the U.S. continuing medical education market size was valued at approximately $2,712.6 million in 2021 and is expected to reach approximately $3,830.5 million by 2027. According to Market Research Future, the medical writing market is expected to cross $5,285.3 billion by 2030 at a CAGR of 10.31% with North America holding the largest share in this market. Furthermore, according to Precedence Research, the medical affairs outsourcing market for the U.S. was estimated at $470.2 million in 2021 and is anticipated to reach $1,288.2 million by 2030.

 

Population Health: According to Grand View Research, the U.S. population health management market size was valued at $20.6 billion in 2021 and is anticipated to grow at a CAGR of 19.5% from 2022 to 2030 which is mainly driven by the growing demand for healthcare IT services and solutions that support value-based healthcare delivery, resulting in a transition from fee-for-service to a value-based payment model. Moreover, according to Verified Market Research, the healthcare quality management market size was valued at $3.2 billion in 2020 and is projected to reach $6.8 billion by 2028, growing at a CAGR of 13.2% from 2021 to 2028. According to Verified Market Research, the rise in the aging population, healthcare expenditure and medical errors, and increase in the volume of unstructured data in healthcare are some of the factors fueling the growth of the healthcare quality management market.

 

Behavioral and Mental Health: According to Precedence Research, the U.S. behavioral health market size is expected to reach approximately $132.4 billion by 2027 with a growing CAGR of 5.3% during the period of 2021 to 2027. Furthermore, according to the National Alliance on Mental Illness, one in five U.S. adults experience mental illness each year and one in six U.S. youth aged 6 to 17 experience a mental health disorder each year. Moreover, according to National Alliance on Mental Illness, suicide is the second leading cause of death among people aged 10 to 34.

 

-9-
 

 

Healthcare Workforce: According to Grand View Research, the U.S. healthcare staffing market size was valued at $24.1 billion in 2021 and is estimated to grow at a CAGR of 5.6% from 2022 to 2030 as a result of increasing demand for temporary staffing for medical professionals due to the rising elderly population and the lack of skilled nursing staff across the country.

 

Digital Health: According to Grand View Research, the U.S. patient engagement solutions market size was valued at approximately $5.2 billion in 2021 and is expected to grow at a CAGR of 15.1% from 2022 to 2030. Furthermore, according to Healthcaredive, the U.S. care coordination software market is expected to reach approximately $3.2 billion by 2022, growing at a CAGR of 15.4%.

 

Growth Strategies

 

We hope to become a leader in clinical healthcare solutions by providing customized and comprehensive end-to-end solutions for our customers in the public and private healthcare sectors and expand our operations to other metropolitan areas. As we continue our expansion, we anticipate that our professional pool and infrastructure will grow to support the breadth and depth of our services. With our rapid growth of sales and business development teams, we intend to replicate our current projects with similar customers across the country. We plan to open offices in multiple geographical locations to support our sales and business development efforts and intend to invest in partnerships with subject matter experts to further enhance our service lines and provide real-world insights. In addition, we are developing in-house proposal teams to ensure appropriate opportunities across government agencies are timely tracked and quality proposals are submitted. In addition to organic efforts, we may expand our footprint by acquiring companies that offer similar service lines. It is anticipated that such companies will strengthen our current service offerings and may also include new services that we may offer to our clients. We recently launched our government solutions service line of business which positions us to work on federal government healthcare and related projects from several agencies such as HHS, CDC, NIH, NASA, DOD. These federal opportunities could be driven as prime contractor, joint ventures, or subcontractors.

 

Government Regulations

 

Our business is heavily regulated. We are subject to oversight by governmental entities in the U.S., and a failure, or alleged failure, by us to comply with statutes, regulations, or other laws could have a material adverse impact to our business operations, reputation, results of operations and financial position.

 

Government Contracts: Our contracts with government entities typically are subject to procurement laws that include socio-economic, employment practices, environmental protection, recordkeeping and accounting, and other requirements. These statutory and regulatory requirements complicate our business and increase our compliance burden. We are subject to audits, investigations, and oversight proceedings about our compliance with contractual and legal requirements. If we fail to comply with these requirements, or we fail an audit, we may be subject to sanctions such as monetary damages, criminal and civil penalties, termination of contracts and suspension or debarment from government contract work. Furthermore, the government may terminate any of our government contracts and subcontracts either at its convenience or for default based on our performance. If a contract is terminated for convenience, we generally are protected by provisions covering reimbursement for costs incurred on the contract and profit on those costs. If a contract is terminated for default, we generally are entitled to payments for our work that has been accepted by the government; however, the government could make claims to reduce the contract value or recover its procurement costs and could assess other special penalties. Additionally, our programs for the government often operate for periods of time under undefinitized contract actions (“UCAs”), which means that we begin performing our obligations before the terms, specifications or price are finally agreed to between the parties. The government’s power to unilaterally definitize a contract can affect our ability to negotiate mutually agreeable contract terms and, if a contract is unilaterally imposed upon us, it may negatively affect our expected profit and cash flows on a program or impose burdensome terms.

 

Governmental entities in the U.S. continue to strengthen their position and scrutiny of practices that may indicate fraud, waste, and abuse affecting government healthcare programs such as Medicare and Medicaid. Our relationships with pharmaceutical and medical product manufacturers, healthcare providers, and other companies and individuals, as well as our provision of products and services to government entities, subject our business to statutes, regulations, and government guidance that are intended to prevent fraud and abuse. Many of these laws are vague or indefinite and have not been interpreted by the courts and, as such, may be interpreted or applied by a prosecutorial, regulatory, or judicial authority in a manner that could require us to make changes in our operations at added expense. Failure to comply with these laws could subject us to federal or state government investigations or qui tam actions, and to liability for damages and civil and criminal penalties, including the loss of pursue government contracts.

 

-10-
 

 

Healthcare Regulation: Our marketing practices are subject to state laws, as well as federal laws, such as the Anti-Kickback Statute and False Claims Act, intended to prevent fraud and abuse in the healthcare industry. The Anti-Kickback Statute generally prohibits corruptly soliciting, offering, receiving, or paying anything of value to generate business. The False Claims Act generally prohibits anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods or services, including to government payers, such as Medicare and Medicaid, that are false or fraudulent and generally treat claims generated through kickbacks as false or fraudulent. The federal government and states also regulate sales and marketing activities and financial interactions between manufacturers and healthcare providers, requiring disclosure to government authorities and the public of such interactions, and the adoption of compliance standards or programs. Furthermore, the U.S. Foreign Corrupt Practices Act (“FCPA”) prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.

 

Data Security and Privacy: We are subject to a variety of privacy and data protection laws that change frequently and have requirements that vary from jurisdiction to jurisdiction. For example, under HIPAA we must maintain administrative, physical, and technological safeguards to protect individually identifiable health information (“protected health information”) and ensure the confidentiality, integrity, and availability of electronic protected health information. We are subject to significant compliance obligations under privacy laws some of which prohibit the transfer of personal information to certain other jurisdictions or otherwise limit our use of data. Many of these laws also require us to provide access or other data rights (modification, deletion, portability, etc.) to consumers’ and patients’ individual personal data records within specified periods of time. Laws such as the federal Cyber Incident Reporting for Critical Infrastructure Act of 2022 may require us to provide notifications of significant data privacy breaches or cybersecurity incidents before our investigations are complete. We are subject to privacy and data protection compliance audits or investigations by various government agencies. Failure to comply with these laws subjects us to potential regulatory enforcement activity, fines, private litigation including class actions, reputational impacts, and other costs. We may also have contractual obligations that might be breached if we fail to comply with privacy and data security laws.

 

Employees

 

As of March 15, 2024, we employed 78 full-time employees and 84 part-time employees. We are not a party to any collective bargaining agreements, and we believe that we maintain good relations with our employees.

 

Our Corporate History

 

We were organized on November 20, 2020 as an Indiana corporation under the name Syra Health Corp. On March 11, 2022, we filed a Certificate of Conversion with the Delaware Secretary of State whereby we converted from an Indiana corporation to a Delaware corporation.

 

Available Information

 

Our annual report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the United States Securities and Exchange Commission, or the SEC, and all amendments to these filings, are available, free of charge, on our website at www.Hepion.com as soon as reasonably practicable following our filing of any of these reports with the SEC. You can also obtain copies free of charge by contacting our Investor Relations department at our office address listed above. The public may read and copy any materials we file with the SEC at the SEC’s Public Reference Room at 100 F Street NE, Room 1580, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy, and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The information posted on or accessible through these websites is not incorporated into this filing.

 

-11-
 

 

ITEM 1A. RISK FACTORS

 

An investment in our securities involves a high degree of risk. You should carefully consider the risks described below as well as the other information included in this Annual Report on Form 10-K, including “Information Regarding Forward-Looking Statements,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K, before making an investment decision. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not currently known to us or that we currently consider immaterial. The trading price of our securities could decline due to any of these risks, and, as a result, you may lose all or part of your investment.

 

Risks Related to Our Financial Position and Need for Additional Capital

 

Although we have generated approximately $5.5 million and $5.6 million of revenues for the years ended December 31, 2023 and 2022, respectively, our future profitability is uncertain.

 

Our likelihood of success must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the development and expansion of a business enterprise. Our net losses were $2,938,343 and $2,118,165 for the years ended December 31, 2023 and 2022, respectively, and our accumulated deficit as of December 31, 2023 and December 31, 2022 was $5,064,955 and $2,126,612, respectively. If we are unable to achieve and maintain profitability, we may be unable to continue our operations.

 

We will require substantial additional funding and if we are unable to raise capital on favorable terms when needed, we could be forced to curtail, delay or discontinue our business.

 

Since our inception, we have not generated sufficient revenues from our operations to continue to fund the development and expansion of our business. To date, we have funded a significant portion of our operations through the sale of our equity securities. As of December 31, 2023 and 2022, we had cash of $3,280,075 and $3,344, respectively. We expect that our existing cash and cash from revenue will be sufficient to fund our current operations through at least 12 months from the date of this annual report. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings or other third-party funding or a combination of these approaches. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or based upon specific strategic considerations.

 

Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our products and services. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities may dilute our stockholders. In addition, the future issuance of shares of Class B common stock may be dilutive to the holders of Class A common stock, particularly with respect to their voting power. The incurrence of indebtedness would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to make certain dividends, incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business.

 

If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue our operations or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations.

 

-12-
 

 

Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing.

 

Our independent registered public accounting firm included in its opinion for the years ended December 31, 2023 and 2022 an explanatory paragraph referring to our recurring losses from operations and expressing substantial doubt in our ability to continue as a going concern without additional capital becoming available. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity or debt financing, reduce expenditures and generate significant revenue. Our financial statements as of December 31, 2023 did not include any adjustments that might result from the outcome of this uncertainty. The reaction of investors to the inclusion of a going concern statement by our auditors, and our potential inability to continue as a going concern, in future years could materially adversely affect our share price and our ability to raise new capital.

 

Risks Related to Our Business and Industry

 

We face significant competition, which may harm our business, results of operations or financial condition.

 

We face substantial competition in the healthcare services markets. Our key competitors include, among others, healthcare consulting service providers, healthcare payment accuracy companies and providers of other data products and data analytics solutions, including healthcare risk adjustment, quality, economic statistics, and other data. We also compete with certain of our customers that internally provide some of the same solutions that we offer. The increasing standardization of certain healthcare services has made it easier for companies to enter these markets with competitive products and services. We cannot fully anticipate whether or when companies in adjacent or other product or service areas may launch competitive products and/or services, and any such entry may lead to obsolescence of our products and/or services or loss of market share or erosion of the prices for our solutions, or both. The extent of this competition may vary by the size of companies, geographical coverage and scope and breadth of products and services offered. Furthermore, some of our competitors are significantly larger and have greater financial or other resources than we do. The vigorous competition we face requires us to provide high quality, innovative products at a competitive price. We cannot guarantee that we will be able to upgrade our existing solutions or introduce new solutions at the same rate as our competitors, or at all, nor can we guarantee that such upgrades or new solutions will achieve market acceptance over or among competitive offerings, or at all. Therefore, these competitive pressures could have a material adverse impact on our business, results of operations or financial condition.

 

If we are unable to retain our existing customers or attract new customers, our business, financial condition, or results of operations could suffer.

 

Our success depends substantially upon the retention of our existing customers and attracting new customers. We may not be able to retain our existing customers or attract new customers if we are unable to provide solutions or services that our existing or prospective customers believe enable them to achieve improved efficiencies and cost-effectiveness. Our success in retaining and attracting customers will also depend, in part, on our ability to be responsive to pricing pressures and changing business models. To remain competitive in the healthcare services markets, we must continuously upgrade our existing solutions, and develop and introduce new solutions on a timely basis. Future advances in the healthcare services market could lead to new products or services that are competitive with our solutions, resulting in pricing pressure or rendering our solutions obsolete or not competitive. We also may not be able to retain or attract customers if our solutions contain errors or otherwise fail to perform properly if our pricing structure is not competitive or if we are unable to renegotiate our customer contracts upon expiration. If we are unable to maintain our customer retention rates, or if we are unable to attract new customers, our business, results of operations or financial condition could be adversely impacted.

 

Our business strategy and future success depend on our ability to cross-sell our solutions.

 

Our ability to generate revenue and growth partly depends on our ability to cross-sell our solutions to our existing customers and new customers. We may not be successful in cross-selling our solutions because our customers may find our additional solutions unnecessary, unattractive, or cost-ineffective. Our failure to sell additional solutions to our existing and new customers could negatively affect our ability to grow our business.

 

-13-
 

 

If we are unable to successfully expand our sales force productivity, sales of our solutions and the growth of our business and financial performance could be harmed.

 

We continue to invest significantly in our sales force to obtain new customers and increase sales to existing customers. There is significant competition for sales personnel with the skills and technical knowledge that we require. Our ability to achieve significant revenue growth and profitably will depend, in large part, on our success in recruiting, training and retaining sufficient numbers of sales personnel to support our sales efforts. A portion of our current sales personnel are new to our Company. New hires require significant training and may require a lengthy onboarding process before they achieve full productivity. Our recent hires and planned hires may not become productive as quickly as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals in the markets where we do business or plan to do business. If we are unable to recruit, train and retain a sufficient number of productive sales personnel, sales of our solutions and the growth of our business could be harmed. Additionally, if our efforts to improve sales force productivity do not result in increased revenue, our operating results could be negatively impacted due to increased operating expenses associated with these efforts.

 

An economic downturn or volatility could have a material adverse impact on our business, results of operations or financial condition.

 

The United States and world economies have experienced significant economic uncertainty and volatility during recent years. A weakening of economic conditions could lead to reductions in demand for our solutions. As a result of volatile or uncertain economic conditions, we may experience the negative effects of increased financial pressures on our customers. For instance, our business could be negatively impacted by increased competitive pricing pressure and a decline in our customers’ creditworthiness, which could result in us incurring increased bad debt expense. Additionally, volatile, or uncertain economic conditions in the United States and other parts of world could lead our state and government customers to terminate, or elect not to renew, existing contracts with us, or not enter into new contracts with us. Furthermore, demand for staffing services is sensitive to changes in economic activity. Many healthcare facilities utilize temporary healthcare professionals to accommodate an increase in hospital admissions. Conversely, when hospital admissions decrease in economic downturns or periods of high inflation, due to reduced consumer spending, the demand for staffing healthcare professionals typically declines. In times of economic downturn and inflation, permanent full-time and part-time healthcare facility staff are generally inclined to work more hours and overtime, resulting in fewer available vacancies and less demand for our services. If we are not able to timely and appropriately adapt to changes resulting from a weak economic environment, it could have a material adverse impact on our business, results of operations or financial condition.

 

Pandemics, such as COVID-19, may adversely impact our business, results of operations, financial condition, liquidity, and cash flows and that of our clients.

 

The COVID-19 pandemic and efforts to control its spread had a significant impact on our operations and the operations of our healthcare clients. Previously, our hospital and other health care provider clients prioritized their resources, capacity and staff as the COVID-19 outbreak strained their organizations which adversely affected our business, including by negatively impacting the demand and timing for implementing our solutions and the timing of payment for our services. For example, while the COVID-19 pandemic had a minimal impact on our revenue for the years ended December 31, 2023 and 2022, it negatively impacted revenue for the year ended December 31, 2021, as we generated less revenue from sales of our professional staffing services than anticipated. In addition, we previously instituted a work-from-home policy for some of our employees and had limited employee travel to essential travel only, which restricted some sales, marketing, and other important business activities.

 

Pandemics, such as COVID-19, may have a material economic effect on our business. While the potential economic impact brought by such pandemics may be difficult to assess or predict, it has caused, and may result in further significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. In addition, a recession, depression, or other sustained adverse market event resulting from a health pandemic could materially and adversely affect our business and the value of our common stock.

 

Our ability to generate revenue could suffer if we do not continue to update and improve our existing solutions and develop new ones.

 

We must continually improve our existing solutions in a timely manner and introduce new and valuable solutions in order to respond to regulatory developments and customer demands and, thereby, retain existing customers and attract new ones. For example, from time to time, government agencies may alter format and data code requirements applicable to electronic transactions. In addition, our customers may request that our solutions be customized to satisfy particular needs. We may not be successful in responding to regulatory developments or changing customer needs. In addition, these regulatory or customer-imposed requirements may impact the profitability of particular solutions and customer engagements. If we do not respond successfully to regulatory changes, as well as evolving industry standards and customer demands, our solutions may become obsolete. If we lower our prices on some of our solutions, we will need to increase our margins on other solutions in order to maintain our overall profitability.

 

-14-
 

 

Achieving market acceptance of new or updated solutions is necessary in order for them to become profitable and will likely require significant efforts and expenditures.

 

Our future financial results will depend in part on whether our new or updated solutions receive sufficient customer acceptance. Achieving market acceptance for new or updated solutions may require substantial marketing efforts and expenditure of significant funds to create awareness and demand by our existing or prospective customers. Failure to achieve broad penetration in target markets with respect to new or updated solutions could have a material adverse impact on our business, results of operations or financial condition.

 

Our business would be adversely affected if we cannot obtain, process or distribute data we require to provide our solutions.

 

Our business relies on our ability to obtain, process, monetize and distribute data in the healthcare industry in a manner that complies with applicable law, regulation and contractual and restrictions. Our failure to obtain and distribute such data in a compliant manner could have a harmful effect on our ability to use and disclose such data which in turn could impair our ability to share such data with our customers or incorporate it into our services and offerings. In addition to complying with requirements in obtaining the data, the use, processing and distribution of such data may require us to obtain consent from third parties or follow additional laws, regulations or contractual restrictions that apply to the healthcare industry. Moreover, we may be subject to claims or liability for use or disclosure of information. Any such claims or liabilities and other failures to comply with applicable requirements could subject us to unexpected costs and adversely affect our operating results.

 

Poor service, system errors or failures of our solutions to conform to specifications could cause unforeseen liabilities or injury, harm our reputation and have a material adverse impact on our business, results of operations or financial condition.

 

Some of our solutions are intended to provide information to healthcare professionals in the course of delivering patient care. Although our contracts may disclaim liability for medical decisions and responsibility for patient care, if use of or inability to use our solutions leads to faulty clinical decisions or injury to patients, such disclaimers may be unenforceable and we could be subject to claims or litigation by healthcare professionals, their patients or our customers. Further, negative publicity regarding our services, whether accurate or inaccurate, could harm our reputation, decrease demand for our services, lead to withdrawals of our services or impair our ability to successfully launch and market our services in the future.

 

We attempt to limit, by contract, our liability for damages arising from our negligence, errors, mistakes or security breaches. However, contractual limitations on liability may not be accepted by our customers, may not be enforceable or may otherwise not provide sufficient protection to us from liability for damages. We maintain liability insurance coverage, including coverage for cyber-liability. It is possible, however, that claims could be denied or exceed the amount of our applicable insurance coverage, if any, or that this coverage may not continue to be available on acceptable terms or in sufficient amounts. Even if these claims do not result in liability to us, investigating and defending against them could be expensive and time consuming and could divert management’s attention away from our operations. In addition, negative publicity caused by these events may negatively impact our customer relationships, market acceptance of our solutions or may harm our reputation and our business.

 

-15-
 

 

Disruptions in service or damages to our data or systems failures, could have a material adverse impact on our business, results of operations or financial condition.

 

Our business operations depend on our ability to maintain and protect our network and computer systems, some of which are outsourced to certain third-party hosting providers. Our operations are vulnerable to interruption and/or damage from a number of sources, many of which are beyond our control, including, without limitation: (1) power loss and telecommunications failures; (2) fire, flood, hurricane and other natural disasters; (3) software and hardware errors, failures or crashes; and (4) cyber and ransomware attacks, computer viruses, hacking, break-ins, sabotage, intentional acts of vandalism and other similar disruptive problems. The occurrence of any of these events could result in interruptions, delays or cessations in service to users of our solutions, which could impair or prohibit our ability to provide our solutions, reduce the attractiveness of our solutions to our customers and could have a material adverse impact on our business, results of operations or financial condition. If customers’ access to our solutions is interrupted, we could be in breach of our agreements with customers and/or exposed to significant claims. Any significant instances of system downtime could negatively affect our reputation and ability to provide our services, which could have a material adverse impact on our business, results of operations or financial condition.

 

Breaches and failures of IT systems and the sensitive information we transmit, use and store, expose us to potential liability and reputational harm.

 

Our business relies on information systems to obtain, process, analyze, and manage data. To the extent IT systems are not successfully implemented or fail, our business and results of operations may be adversely affected. Further, our business relies to a significant degree upon the secure transmission, use and storage of sensitive information, including protected health information and other personally identifiable information, financial information and other confidential information and data within these systems.

 

To protect this information, we seek to implement commercially reasonable security measures and maintain information security policies and procedures informed by requirements under applicable law and recommended practices, in each case, as applicable to the data collected, hosted and processed. Despite our security management efforts our business is vulnerable to unauthorized access to data and/or breaches of confidential information due to criminal conduct, physical break-ins, hackers, employee or insider malfeasance and/or improper employee or contractor access, computer viruses, programming errors, denial-of-service attacks, ransomware events, phishing schemes, fraud, terrorist attacks, human error or other breaches by insiders or third parties or similar disruptive problems. It is not possible to prevent all security threats to our data. Techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and may be difficult to detect for long periods of time. Further, defects in the design or manufacture of applications we develop or procure from third parties could compromise our data. These events, including unauthorized access, misappropriation, disclosure or loss of sensitive information (including financial or personal health information) or a significant disruption of our network, expose us to risks including risks to our ability to provide our solutions, management distraction and the obligation to devote significant financial and other resources to mitigate such problems and increases to our future information security costs. Moreover, unauthorized access, use or disclosure of certain sensitive information in our possession or our failure to satisfy legal requirements, including requirements relating to safeguarding protected health information under the Health Insurance Portability and Accountability Act (“HIPAA”) or state data privacy laws could result in civil and criminal liability and regulatory action, which could result in potential fines and penalties, as well as costs relating to investigation of an incident or breach, corrective actions, required notifications to regulatory agencies and customers, credit monitoring services and other necessary expenses. In addition, actual or perceived breaches of our security management efforts can cause existing customers to terminate their relationship with us and deter existing or prospective customers from using or purchasing our solutions in the future. These events can have a material adverse impact on our business, results of operations, financial condition and reputation.

 

Because our products and services involve the storage, use and transmission of personal information of consumers, we may be the target of attempted cyber and other security threats by outside third parties, including technically sophisticated and well-resourced bad actors attempting to access or steal the data we store. Vendor, insider or employee cyber and security threats also occur and are a significant concern for all companies, including ours. There have, in the past, been a number of high-profile security breaches involving the improper dissemination of personal information of individuals both within and outside of the healthcare industry. These breaches have resulted in lawsuits and governmental enforcement actions that have sought or obtained significant fines and penalties, and have required companies to enter into agreements with government regulators that impose ongoing obligations and requirements, including internal and external (third party) monitorships for five years or more. While we maintain liability insurance coverage including coverage for cyber-liability, claims may not be covered or could exceed the amount of our applicable insurance coverage, if any, or such coverage may not continue to be available on acceptable terms or in sufficient amounts.

 

-16-
 

 

We rely on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems in providing certain of our solutions to our customers, and any failure or interruption in the services provided by these third parties or our own systems could expose us to litigation and negatively impact our relationships with customers, adversely affecting our brand and our business.

 

Our ability to deliver our solutions is dependent on the development and maintenance of the infrastructure of the Internet and other telecommunications services by third parties. This includes maintenance of a reliable network connection with the necessary speed, data capacity and security. As a result, our information systems require an ongoing commitment of significant resources to maintain and enhance existing systems and develop new systems in order to keep pace with continuing changes in information technology, emerging cybersecurity risks and threats, evolving industry and regulatory standards and changing preferences of our customers.

 

We may experience interruptions in these systems, including server failures that temporarily slow down the performance of our solutions. We rely on internal systems as well as vendors, including bandwidth and telecommunications equipment providers, to provide our solutions. We do not maintain redundant systems or facilities for some of these services. Interruptions in these systems, whether due to system failures, computer viruses, physical or electronic break-ins or other catastrophic events, could affect the security or availability of our solutions and prevent or inhibit the ability of our customers to access our solutions.

 

If a catastrophic event were to occur with respect to one or more of these systems or facilities, we may experience an extended period of system unavailability, which could result in substantial costs to remedy those problems or negatively impact our relationship with our customers, results of operations and financial condition.

 

Failure by our customers to obtain proper permissions or provide us with accurate and appropriate information may result in claims against us or may limit or prevent our use of information, which could harm our business. Additionally, privacy concerns relating to our business could damage our reputation and deter current and potential customers from using our solutions.

 

To the extent we are not otherwise permitted to use and/or disclose customer information, we require our customers to provide necessary notices and obtain necessary permissions for the use and disclosure of such information. If they do not provide necessary notices or obtain necessary permissions, then our use and disclosure of information that we receive from them or on their behalf may be limited or prohibited by federal or state privacy or other laws. Such failures by our customers could impair our functions, processes and databases that reflect, contain or are based upon such information. Furthermore, such failures by our customers could interfere with or prevent creation or use of analyses or other data-driven activities that benefit us, or make our solutions less useful. Accordingly, we may be subject to claims or liability for inaccurate data. These claims or liabilities could damage our reputation, subject us to unexpected costs and could have a material adverse impact on our business, results of operations or financial condition.

 

Additionally, in recent years, consumer advocates, media and elected officials increasingly and publicly have criticized companies in data focused industries regarding the collection, storage and use of personal data. Concerns about our practices with regard to the collection, use, disclosure or security of personal information or other privacy related matters, even if unfounded, could damage our reputation and adversely affect our business, results of operations or financial condition.

 

It is difficult to predict the sales cycle and implementation schedule for our products and services.

 

The duration of the sales cycle and implementation schedule for our products and services depends on a number of factors, including the nature and size of the potential client and the extent of the commitment being made by the potential client, all of which may be difficult to predict. Our sales and marketing efforts with respect to hospitals and large health organizations generally involve a lengthy sales cycle due to these organizations’ complex decision-making processes. Additionally, in light of increased government involvement in healthcare and related changes in the operating environment for healthcare organizations, our current and potential clients may react by reducing or deferring investments, including their purchases of our solutions or services. If clients take longer than we expect to decide whether to purchase our solutions, our revenues could decrease, which could materially and adversely impact our business, financial condition and operating results.

 

-17-
 

 

Our independent content providers may fail to perform adequately or comply with laws, regulations or contractual covenants.

 

We depend on some independent content providers for the development of health education and other scientific content resources. Our ability to rely on these services could be impaired as a result of the failure of such providers to comply with applicable laws, regulations and contractual covenants or as a result of events affecting such providers, such as power loss, telecommunication failures, software or hardware errors, computer viruses and similar disruptive problems, fire, flood and natural disasters. Any such failure or event could adversely affect our relationships with our clients and damage our reputation. This could materially and adversely impact our business, financial condition and operating results. We depend on our content providers to deliver high quality content from reliable sources and to continually upgrade their content in response to demand and evolving regulations. If these parties fail to develop and maintain high quality, attractive content, the value of our brand and our business, financial condition and operating results could be materially and adversely impacted.

 

We may be liable for use of content we provide.

 

If any of the content that we provide to our customers, including content we generate as a result of our grant writing services, is incorrect or incomplete, it may give rise to claims against us. While we maintain insurance coverage in an amount that we believe is sufficient for our business, we cannot provide assurance that this coverage will prove to be adequate or will continue to be available on acceptable terms, if at all. A claim that is brought against us that is uninsured or under-insured could materially and adversely impact our business, financial condition and operating results. Even unsuccessful claims could result in substantial costs and diversion of management and other resources.

 

Our financial results may be adversely affected if we underprice our contracts, overrun our cost estimates or fail to receive approval for or experience delays in documenting change orders.

 

Most of our grant writing service contracts are either fee for service contracts or fixed-fee contracts. Our past financial results have been, and our future financial results may be, adversely impacted if we initially underprice our contracts or otherwise overrun our cost estimates and are unable to successfully negotiate a change order. Change orders typically occur when the scope of work we perform needs to be modified from that originally contemplated by our contract with the client. Where we are not successful in converting out-of-scope work into change orders under our current contracts, we will bear the cost of the additional work. Such underpricing, significant cost overruns or delay in documentation of change orders could have a material adverse effect on our business, results of operations, financial condition or cash flows.

 

As we develop new services and clients, enter new lines of business, and focus more of our business on providing a full range of talent solutions, the demands on our business and our operating risks may increase.

 

As part of our strategy, we plan to extend our services. As we focus on developing new services, capabilities and clients, and engage in business in new geographic locations, our operations may be exposed to additional as well as enhanced risks. In particular, our growth efforts may place substantial additional demands on our management and other team members, as well as on our information, financial, administrative, compliance and operational systems. We may not be able to manage these demands successfully. Growth may require increased recruiting efforts, increased regulatory and compliance efforts, increased business development, selling, marketing and other actions that are expensive and entail increased risk. We may need to invest more in our people and systems, controls, compliance efforts, policies and procedures than we anticipate. As our business continues to evolve and we provide a wider range of services, we will become increasingly dependent upon our employees. Failure to identify, hire, train and retain talented employees who share our values could have a negative effect on our reputation and our business. The demands that our current and future growth place on our people and systems, controls, compliance efforts, policies and procedures may exceed the benefits of such growth, and our operating results may suffer, at least in the short-term, and perhaps in the long-term.

 

-18-
 

 

Consolidation in the healthcare industry could adversely impact our business, financial condition and operating results.

 

Many healthcare provider organizations are consolidating to create integrated healthcare delivery systems with greater market power. As provider networks and managed care organizations consolidate, thus decreasing the number of market participants, competition to provide products and services like ours will become more intense, and the importance of establishing and maintaining relationships with key industry participants will increase. These industry participants may try to use their market power to negotiate price reductions for our products and services. Any of these factors could materially and adversely impact our business, financial condition and operating results.

 

If we do not continue to recruit and retain sufficient quality healthcare professionals at reasonable costs, it could increase our operating costs and negatively affect our business and our profitability.

 

We rely significantly on our ability to recruit and retain a sufficient number of healthcare professionals who possess the skills, experience and licenses necessary to meet the requirements of our clients. With clinician burnout rates continuing to rise, an ongoing shortage of certain qualified nurses and physicians in many areas of the United States and low unemployment rates for nurses and physicians, competition for the hiring of these professionals remains intense. Our ability to recruit temporary and permanent healthcare professionals may be exacerbated by continued low levels of unemployment.

 

We compete with healthcare staffing companies, recruitment and placement agencies, including online staffing and recruitment agencies, and with hospitals, healthcare facilities and physician practice groups to attract healthcare professionals based on the quantity, diversity and quality of assignments offered, compensation packages, the benefits that we provide and speed and quality of our service.

 

The costs of recruiting quality healthcare professionals and providing them with competitive compensation packages may be higher than we anticipate, or we may be unable to pass these costs on to our hospital and healthcare facility clients, which may reduce our profitability. Moreover, if we are unable to recruit temporary and permanent healthcare professionals, our service execution may deteriorate and, as a result, we could lose clients or not meet our service level agreements with these clients that have negative financial repercussions.

 

The ability of our clients to increase the efficiency and effectiveness of their staffing management and recruiting efforts may affect the demand for our services that could negatively affect our business.

 

If our clients are able to increase the effectiveness of their staffing and recruitment functions, their need for our services may decline. With the advent of technology and more sophisticated staffing management and recruitment processes, including internal “travel” and other healthcare staffing models, clients may be able to successfully increase the efficiency and effectiveness of their internal staffing management and recruiting efforts, through more effective planning and analytic tools, internet- or social media-based recruiting or otherwise. Such new technologies and processes could reduce the demand for our services, which could negatively affect our business.

 

Our work with government clients exposes us to additional risks inherent in the government contracting environment.

 

Our clients may include national, provincial, state, local and foreign governmental entities and their agencies. Our government work carries various risks inherent in contracting with government entities. These risks include, but are not limited to, the following:

 

  ● Government entities, particularly in the United States, often reserve the right to audit our contracts and conduct reviews, inquiries and investigations of our business practices and performance with respect to government contracts. If a government client discovers improper conduct during its audits or investigations, we may become subject to various civil and criminal penalties, including those under the civil U.S. False Claims Act, and administrative sanctions, which may include termination of contracts, suspension of payments, fines and civil money penalties, and suspensions or debarment from doing business with other government agencies.
     
  ● U.S. government contracting regulations impose strict compliance and disclosure obligations and our failure to comply with these obligations could be a basis for suspension or debarment, or both, from federal government contracting in addition to breach of the specific contract.

 

-19-
 

 

  ● Government contracts are subject to heightened reputational and contractual risks compared to contracts with commercial clients and often involve more extensive scrutiny and publicity. Negative publicity, including allegations of improper or illegal activity, poor contract performance, or information security breaches, regardless of accuracy, may adversely affect our reputation.
     
  ● Terms and conditions of government contracts also tend to be more onerous, are often more difficult to negotiate and involve additional costs.
     
  ● Government entities typically fund projects through appropriated monies. Any change in presidential administrations may affect budget priorities for our ongoing work.
     
  ● Government entities reserve the right to change the scope of or terminate projects at their convenience for lack of approved funding or other reasons, which could limit our recovery of reimbursable expenses or investments. In addition, government contracts may be protested, which could result in administrative procedures and litigation, result in delays in performance and payment, be expensive to defend and be incapable of prompt resolution.

 

The occurrences or conditions described above could affect not only our business with the particular government entities involved, but also our business with other entities of the same or other governmental bodies or with certain commercial clients and could have a material adverse effect on our business, results of operations and financial condition.

 

We may be a party to legal, regulatory and other proceedings that could result in unexpected adverse outcomes.

 

From time to time, we may be a party to legal and regulatory proceedings and investigations, including matters involving governmental agencies and entities with which we do business and other proceedings and investigations arising in the ordinary course of business. In addition, there are an increasing number of, and we may be subject to, investigations and proceedings in the healthcare industry generally that seek recovery under the HIPAA, Anti-Kickback Statute, the False Claims Act, the Civil Money Penalty, the Stark Law, the Sunshine Act, state laws and other statutes and regulations applicable to our business. We also may be subject to legal proceedings under non-healthcare federal, and state laws affecting our business, such as the Telephone Consumer Protection Act, Fair Debt Collection Practices Act, Fair Credit Reporting Act, Controlling the Assault of Non-Solicited Pornography and Marketing Act, Junk Fax Prevention Act, Foreign Corrupt Practices Act, employment, banking and financial services and USPS laws and regulations. Such proceedings are inherently unpredictable, and the outcome can result in verdicts and/or injunctive relief that may affect how we operate our business or we may enter into settlements of claims for monetary payments. In some cases, substantial non-economic remedies or punitive damages may be sought. Governmental investigations, audits and other reviews could also result in criminal penalties or other sanctions, including restrictions, changes in the way we conduct business or exclusion from participation in government programs. We evaluate our exposure to these legal and regulatory proceedings and intend to establish reserves for the estimated liabilities in accordance with accounting principles generally accepted in the United States of America, as necessary. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management’s evaluations or predictions and accompanying changes in established reserves, could have a material adverse impact on our business, results of operations or financial condition.

 

Litigation is costly, time-consuming and disruptive to normal business operations. The defense of these matters could also result in continued diversion of our management’s time and attention away from business operations, which could also harm our business. Even if these matters are resolved in our favor, the uncertainty and expense associated with unresolved legal proceedings could harm our business and reputation.

 

-20-
 

 

We may be liable for the misdiagnoses, mistreatment, injury or other harm to patients resulting from the use of data that we provide to health care providers, and any resulting claims could negatively impact our operating results and result in a decline in our stock price.

 

We provide, and facilitate providing, information for use by health care providers in treating patients. If this data is incorrect or incomplete, the patient could be misdiagnosed or mistreated resulting in adverse consequences, including death, giving rise to claims against us. In addition, certain of our solutions relate to patient health information, and a court or government agency may take the position that our delivery of this information exposes us to personal injury liability or other liability for wrongful delivery or handling of health care services or erroneous health information. While we maintain liability insurance coverage in an amount that we believe is sufficient for the risks associated with our business, we cannot assure you that this coverage will prove to be adequate or will continue to be available on acceptable terms, if at all. A claim brought against us that is uninsured or under-insured could harm our business, financial condition and results of operations. Even unsuccessful claims could result in substantial costs and diversion of management resources and could cause the trading price of our common stock to decline.

 

Our success depends in part on our ability to identify, recruit and retain skilled management and technical personnel. If we fail to recruit and retain suitable candidates or if our relationship with our employees changes or deteriorates, there could be a material adverse impact on our business, results of operations or financial condition.

 

We are highly dependent upon our personnel, including Deepika Vuppalanchi, our Chief Executive Officer and member of our board of directors, and Sandeep Allam, our President and Chairman. The loss of Dr. Vuppalanchi’s or Mr. Allam’s services could impede the achievement of our business objectives. We have not obtained, do not own, nor are we the beneficiary of, key-person life insurance. Furthermore, our future success depends upon our continuing ability to identify, attract, hire and retain highly qualified personnel, including skilled management and scientific personnel, all of whom are in high demand and are often subject to competing offers. Competition for qualified personnel in the healthcare services industry is intense, and we may not be able to hire or retain a sufficient number of qualified personnel to meet our requirements, or be able to do so at salary, benefit and other compensation costs that are acceptable to us. A loss of a substantial number of key or qualified employees, or an inability to attract, retain and motivate additional highly skilled employees required for expansion of our business, could have a material adverse impact on our business, results of operations or financial condition.

 

Our ability to utilize loss carry forwards may be limited.

 

We have incurred net operating losses (“NOLs”) during our history. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all).

 

Federal NOLs incurred in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding such loss, and NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, federal NOLs generated in taxable years ending after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of our taxable income annually for tax years beginning after December 31, 2020. Our NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the “IRS”), and state tax authorities. In addition, in general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (“Code”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs or tax credits to offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation’s stock increases their ownership by more than 50 percentage points over their lowest ownership percentage within a specified testing period. Our existing NOLs or credits may be subject to limitations arising from previous ownership changes and ownership changes, which may further limit our ability to utilize NOLs or credits under Sections 382 and 383 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Sections 382 and 383 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. If we were to determine that an ownership change has occurred and our ability to use our historical NOLs or credits is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. Section 382 and 383 of the Code would apply to all net operating loss and tax credit carryforwards, whether the carryforward period is indefinite or not.

 

-21-
 

 

Unanticipated changes in tax laws may affect future financial results.

 

We are a U.S. corporation and thus subject to U.S. corporate income tax on its worldwide operations. Our principal operations and certain potential customers are located in the United States, and as a result, we are subject to various U.S. federal, state and local taxes. New U.S. laws and policies relating to taxes may have an adverse effect on our business and future profitability. Further, existing U.S. tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us.

 

In recent years, the federal government has made significant changes to U.S. tax laws, including through the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) and the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). On August 16, 2022, the Inflation Reduction Act of 2022 (the “IRA”) was signed into law, with tax provisions primarily focused on implementing a 15% minimum tax on global adjusted financial statement income, effective for tax years beginning after December 31, 2022, and a 1% excise tax on share repurchases occurring after December 31, 2022. We may be subject to the new excise tax with respect to any redemptions of our stock. Further, the current administration had previously set forth several tax proposals that would, if enacted, make further significant changes to U.S. tax laws (including provisions enacted pursuant to the Tax Act). It is unclear whether these or similar changes will be enacted and, if enacted, how soon any such changes could take effect. The passage of any legislation as a result of these proposals and other similar changes in U.S. federal income tax laws could adversely affect our business and future profitability. Investors are urged to consult with their legal and tax advisors with respect to any such legislation and the potential tax consequences of holding our securities.

 

Our use and development of artificial intelligence products may result in reputational harm and liability.

 

We incorporate artificial intelligence in some of the products we offer. For example, some of our targeted education approaches include the utilization of artificial intelligence tools to provide real-time information to customers, and we intend to offer an artificial intelligence chatbot to facilitate and provide end-to-end query resolution for patients. The field of artificial intelligence is rapidly developing, both technologically and from a regulatory and legal standpoint. As we incorporate this technology into our products we may experience unexpected outcomes or impacts related to the technology, creating reputational, legal and regulatory risks.

 

Risks Related to Intellectual Property

 

The protection of our intellectual property requires substantial resources and protections of our proprietary rights may not be adequate.

 

We rely or intend to rely upon a combination of trade secret, copyright and trademark laws, patents, license agreements, confidentiality procedures, nondisclosure agreements and technical measures designed to protect the intellectual property used in our business. The steps we have taken to protect and enforce our proprietary rights and intellectual property may not be adequate. For instance, our agreements with employees, consultants and others who develop intellectual property for or on behalf of us could be breached and could result in our trade secrets and confidential information being publicly disclosed. We may not have adequate remedies for any such breach. Third parties also may infringe upon or misappropriate our intellectual property rights. If we believe a third party has misappropriated our intellectual property, litigation may be necessary to enforce and protect those rights, which would divert management resources, could be expensive and may not effectively protect our intellectual property. Even if we establish infringement, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. As a result, if we fail to maintain adequate intellectual property protection or if a third party infringes or misappropriates our intellectual property, it may have a material adverse impact on our business, results of operations or financial condition.

 

-22-
 

 

Many of our products are based on or incorporate proprietary information. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by generally requiring our employees, consultants, other advisors and other third parties to execute agreements that contain confidentiality provisions. Despite these efforts and precautions, we may be unable to prevent a third party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization and legal remedies may not adequately compensate us for the damages caused by such unauthorized use.

 

In addition, there can be no assurance that our competitors will not independently develop products or services that are equivalent or superior to our solutions.

 

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.

 

We have received confidential and proprietary information from third parties. In addition, we may employ individuals who were previously employed at other healthcare services companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or our employees’ former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our solutions. We may also be subject to claims that former employees, consultants, independent contractors or other third parties have an ownership interest in our intellectual property. Litigation may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. In addition to paying monetary damages, if we fail in defending against any such claims we may lose our rights therein, which could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.

 

We depend on a small number of large customers and the loss of one or more major customers could have a material adverse effect on our business, financial condition and results of operations.

 

For the years ended December 31, 2023 and 2022, FSSA accounted for approximately 68% and 98% of our revenues and 30% and 99% of our accounts receivable, respectively, as due from the combined divisions (NeuroDiagnostic Institute and Division of Mental Health and Addiction) of the FSSA. It is possible that any of our large customers could decide to terminate their relationship with us in the future. The loss of one or both of our top customers, or a substantial decrease in demand by any of those customers for our services and solutions, could have a material adverse effect on our business, results of operations and financial condition.

 

Risks Related to Government Regulations

 

We are subject to federal and state healthcare industry regulation including conduct of operations, costs and payment for services and payment for referrals as well as laws regarding government contracting.

 

The healthcare industry is subject to extensive and complex federal and state laws and regulations related to conduct of operations, costs and payment for services and payment for referrals. We provide talent solutions on a contract basis to our clients, who pay us directly. Accordingly, Medicare, Medicaid and insurance reimbursement policy changes generally do not directly impact us. Nevertheless, reimbursement changes in government programs, particularly Medicare and Medicaid, can and do indirectly affect the demand and the prices paid for our services. For example, our clients could receive reduced or no reimbursements because of a change in the rates or conditions set by federal or state governments that would negatively affect the demand and the prices for our services. Moreover, our hospital, healthcare facility and physician practice group clients could suffer civil and criminal penalties, and be excluded from participating in Medicare, Medicaid and other healthcare programs for failure to comply with applicable laws and regulations that may negatively affect our profitability.

 

A portion of our hospital and healthcare facility clients are state and federal government agencies, where our ability to compete for new contracts and orders, and the profitability of these contracts and orders, may be affected by government legislation, regulation or policy. Additionally, in providing services to state and federal government clients and to clients who participate in state and federal programs, we are also subject to specific laws and regulations, which government agencies have broad latitude to enforce. If we were to be excluded from participation in these programs or should there be regulatory or policy changes or modification of application of existing regulations adverse to us, it would likely materially adversely affect our brand, business, results of operations and cash flows.

 

-23-
 

 

Risks Related to Our Class A Common Stock

 

Nasdaq may delist our Class A common stock from trading on its exchange, which could limit investors’ ability to make transactions in our Class A common stock and subject us to additional trading restrictions.

 

Our Class A common stock is listed on the Nasdaq Capital Market and we expect to meet the minimum initial listing standards set forth in the Nasdaq listing standards, we cannot assure you that our Class A common stock will be, or will continue to be, listed on Nasdaq in the future. In order to continue listing our Class A common stock on Nasdaq, we must maintain certain financial, distribution and stock price levels and must maintain a minimum number of holders of our Class A common stock.

 

If Nasdaq delists our Class A common stock and we are not able to list our Class A common stock on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our stockholders:

 

  ● the liquidity of our Class A common stock;
     
  ● the market price of our Class A common stock;
     
  ● our ability to obtain financing for the continuation of our operations;
     
  ● the number of investors that will consider investing in our Class A common stock;
     
  ● the number of market makers in our Class A common stock;
     
  ● the availability of information concerning the trading prices and volume of our Class A common stock; and
     
  ● the number of broker-dealers willing to execute trades in shares of our Class A common stock.

 

The market price of our Class A common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our Class A common stock.

 

The market price of our Class A common stock is likely to be highly volatile and may be subject to wide fluctuations in response to a variety of factors, including the following:

 

  ● failure to successfully develop and commercialize our digital health platforms;
     
  ● regulatory or legal developments in the United States;
     
  ● changes in physician, hospital or healthcare provider practices that may make our solutions less useful;

 

-24-
 

 

  ● inability to obtain additional funding;
     
  ● failure to meet or exceed financial projections we provide to the public;
     
  ● failure to meet or exceed the estimates and projections of the investment community;
     
  ● changes in the market valuations of companies similar to ours;
     
  ● announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;
     
  ● additions or departures of key scientific or management personnel;
     
  ● sales of our Class A common stock by us or our stockholders in the future;
     
  ● trading volume of our Class A common stock;
     
  ● general economic, industry and market conditions;
     
  ● health epidemics and outbreaks, such as the COVID-19 pandemic, or other natural or manmade disasters which could significantly disrupt our operations; and
     
  ● the other factors described in this “Risk Factors” section.

 

Any of these factors may result in large and sudden changes in the volume and price at which our Class A common stock will trade. In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. If there is extreme market volatility and trading patterns in our Class A common stock, it may create several risks for investors, including the following:

 

  ● the market price of our Class A common stock may experience rapid and substantial increases or decreases unrelated to our actual or expected operating performance, financial condition or prospects, which may make it more difficult for prospective investors to assess the rapidly changing value of our Class A common stock;
     
  ● if our future market capitalization reflects trading dynamics unrelated to our actual or expected operating performance, financial performance or prospects, purchasers of our Class A common stock could incur substantial losses as prices decline once the level of market volatility has abated; and
     
  ● if the future market price of Class A our common stock declines, investors may be unable to resell their shares at or above the price at which they acquired them. We cannot assure you that the market of our Class A common stock will not fluctuate or decline significantly in the future, in which case you could incur substantial losses.

 

Broad market and industry fluctuations, as well as general economic, political, regulatory and market conditions, may negatively affect the market price of our Class A common stock, regardless of our actual operating performance. In addition, shares of our Class A common stock may be more thinly traded than securities of larger, more established healthcare services companies and, as a result of this lack of liquidity, sales of relatively small quantities of shares of our Class A common stock by our stockholders may disproportionately influence the price of our Class A common stock. The market price of our Class A common stock may decline below the initial public offering price, and you may lose some or all of your investment.

 

-25-
 

 

Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.

 

The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflationary pressure and interest rate changes, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. More recently, the closures of Silicon Valley Bank and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation (“FDIC”) created bank-specific and broader financial institution liquidity risk and concerns. Although the Department of the Treasury, the Federal Reserve, and the FDIC jointly confirmed that depositors at SVB and Signature Bank would continue to have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception, future adverse developments with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages, impair the ability of companies to access near-term working capital needs, and create additional market and economic uncertainty. There can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business environment or continued unpredictable and unstable market conditions. If the equity and credit markets deteriorate, or if adverse developments are experienced by financial institutions, it may cause short-term liquidity risk and also make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon our business plans. In addition, there is a risk that one or more of our current clients, financial institutions or other third parties with whom we do business may be adversely affected by the foregoing risks, which may have an adverse effect on our business.

 

The dual-class structure of our common stock as contained in our Certificate of Incorporation has the effect of concentrating voting control with those stockholders who held our Class B common stock. This ownership will limit or preclude your ability to influence corporate matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transactions requiring stockholder approval, and that may adversely affect the trading price of our Class A common stock.

 

Our Class B common stock has 16.5 votes per share, and our Class A common stock has one vote per share. As of December 31, 2023, there were 833,334 shares of our Class B common stock outstanding, representing 79.6% of our total voting securities outstanding. Holders of all of the issued and outstanding shares of our Class B common stock own 833,334 shares of Class B common stock representing approximately 71.5% of the voting power of our outstanding capital stock, assuming the conversion of all outstanding notes into an aggregate of 445,409 shares of our Class A common stock. Such Class B holders shall continue to have voting control until they hold under 50.1% of the voting power of our outstanding capital stock, or approximately 583,000 shares of Class B common stock. In addition, because of the 16.5-to-1 voting ratio between our Class B common stock and Class A common stock, the holders of our Class B common stock could continue to control a majority of the combined voting power of our common stock and therefore control all matters submitted to our stockholders for approval until converted by our Class B common stockholders. This concentrated control may limit or preclude your ability to influence corporate matters for the foreseeable future, including the election of directors, amendments of our organizational documents and any merger, consolidation, sale of all or substantially all of our assets or other major corporate transactions requiring stockholder approval. In addition, this concentrated control may prevent or discourage unsolicited acquisition proposals or offers for our capital stock that you may feel are in your best interest as one of our stockholders. As a result, such concentrated control may adversely affect the market price of our Class A common stock.

 

Future transfers by holders of Class B common stock will generally result in those shares converting to Class A common stock, subject to limited exceptions as specified in our Certificate of Incorporation, such as transfers to family members and certain transfers effected for estate planning purposes.

 

-26-
 

 

We cannot predict the effect our dual-class structure may have on the market price of our Class A common stock.

 

We cannot predict whether our dual-class structure will result in a lower or more volatile market price of our Class A common stock, adverse publicity or other adverse consequences. For example, certain index providers have announced and implemented restrictions on including companies with multiple-class share structures in certain of their indices. In July 2017, FTSE Russell announced that it would require new constituents of its indices to have greater than 5% of the company’s voting rights (aggregated across all of its equity securities, including those that are not listed or trading) in the hands of public stockholders. Pursuant to the FTSE Russell, this 5% minimum voting rights requirement only applies to companies assigned a Developed market nationality within the FTSE Equity Country Classification scheme, and, based upon the FTSE Equity Country Classification Interim Announcement published on March 30, 2023, the United States is assigned a Developed market nationality within the FTSE. In addition, in July 2017, the S&P Dow Jones announced that it would no longer admit companies with multiple-class share structures to certain of its indices; however, in October 2022, the S&P Dow Jones announced that it was conducting a consultation with market participants on the multiple share class eligibility methodology requirement via a survey that closed on December 15, 2022. Subsequently, the S&P Dow Jones Indices announced that, effective as of April 17, 2023, companies with multiple share class structures will be considered eligible for the S&P Composite 1500 and its component indices, including the S&P 500, the S&P MidCap 400 and the S&P SmallCap 600, if they meet all other eligibility criteria. Also in 2017, MSCI, a leading stock index provider, opened public consultations on its treatment of no-vote and multi-class structures and temporarily barred new multi-class listings from certain of its indices; however, in October 2018, MSCI announced its decision to include equity securities “with unequal voting structures” in its indices. Additionally, MSCI announced that the securities of companies exhibiting unequal voting structures will be eligible for addition to the MSCI ACWI IMI and other relevant indexes effective March 1, 2019. Currently, MSCI offers the MSCI World Voting Rights-Adjusted Index. This index specifically includes voting rights in the weighting criteria and construction methodology and aims to better align constituent weights with economic rights and voting power, while continuing to represent the performance of a broad opportunity set. The dual-class structure of our common stock may make us ineligible for inclusion in certain indices and, as a result, mutual funds, exchange-traded funds and other investment vehicles that attempt to passively track those indices would not invest in our Class A common stock. In addition, it is unclear what effect, if any, such policies will have on the valuations of publicly-traded companies excluded from such indices, but it is possible that they may adversely affect valuations, as compared to similar companies that are included. Due to the dual-class structure of our common stock, we may be excluded from certain indices and we cannot assure you that other stock indices (including Nasdaq) will not take similar actions. Given the sustained flow of investment funds into passive strategies that seek to track certain indices, exclusion from certain stock indices may preclude investment by many of these funds and could make our Class A common stock less attractive to other investors. As a result, the market price of our Class A common stock may be adversely affected.

 

Our principal stockholders will continue to have significant influence over the election of our board of directors and approval of any significant corporate actions, including any sale of the Company.

 

Deepika Vuppalanchi, our Chief Executive Officer, Sandeep Allam, our Chairman and President and Priya Prasad, our Chief Financial Officer and Chief Operating Officer, in the aggregate, beneficially own 79.0% of our Class B common stock and 56.5% of our outstanding voting securities. These stockholders currently have, and likely will continue to have, significant influence with respect to the election of our board of directors and approval or disapproval of all significant corporate actions. The concentrated voting power of these stockholders could have the effect of delaying or preventing an acquisition of the Company or another significant corporate transaction.

 

We could be subject to securities class action litigation.

 

In the past, securities class action litigation has been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because healthcare companies have experienced significant share price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

 

-27-
 

 

Anti-takeover provisions contained in our Certificate of Incorporation and our Amended and Restated Bylaws (“Bylaws”), as well as provisions of Delaware law, could impair a takeover attempt.

 

Our Certificate of Incorporation, Bylaws and Delaware law contain provisions which could have the effect of rendering more difficult, delaying or preventing an acquisition deemed undesirable by our board of directors. Our corporate governance documents include or will include provisions:

 

  ● authorizing “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our Class A common stock;
     
  ● limiting the liability of, and providing indemnification to, our directors and officers;
     
  ● limiting the ability of our stockholders to call and bring business before special meetings;
     
  ● requiring advance notice of stockholder proposals for business to be conducted at meetings of our stockholders and for nominations of candidates for election to our board of directors;
     
  ● controlling the procedures for the conduct and scheduling of board of directors and stockholder meetings; and
     
  ● providing our board of directors with the express power to postpone previously scheduled annual meetings and to cancel previously scheduled special meetings.

 

These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management.

 

As a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which prevents some stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of substantially all of our outstanding common stock.

 

Any provision of our Certificate of Incorporation, Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our Class A common stock and could also affect the price that some investors are willing to pay for our Class A common stock.

 

Our Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.

 

Our Certificate of Incorporation requires that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for each of the following:

 

  ● any derivative action or proceeding brought on our behalf;
  ● any action asserting a claim for breach of any fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders;
  ● any action asserting a claim against us or any of our directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law, our Certificate of Incorporation or our Bylaws; or
  ● any action asserting a claim against us, our directors, officers or employees governed by the internal affairs doctrine;

 

except for, as to each of the above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction.

 

The exclusive forum provision is limited to the extent permitted by law, and it will not apply to claims arising under the Exchange Act, the Securities Act of 1933, as amended (the “Securities Act”), or for any other federal securities laws which provide for exclusive or concurrent federal and state jurisdiction.

 

-28-
 

 

Our Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock are deemed to have notice of and consented to this provision.

 

Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our Certificate of Incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States of America. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our Certificate of Incorporation.

 

Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, this provision may limit or discourage a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, and may result in increased costs to our stockholders, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.

 

We note that there is uncertainty as to whether a court would enforce the provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and officers.

 

General Risk Factors

 

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the market price for the shares and trading volume could decline.

 

The trading market for our Class A common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If research analysts do not establish and maintain adequate research coverage or if one or more of the analysts who covers us downgrades our Class A common stock or publishes inaccurate or unfavorable research about our business, the market price for our Class A common stock would likely decline. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our Class A common stock to decline.

 

We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our Class A common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public of, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Class A common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

 

-29-
 

 

In addition, under the JOBS Act, emerging growth companies may delay adopting new or revised accounting standards until such time as those standards apply to private companies. We may, in the future, elect not to avail ourselves of this exemption from new or revised accounting standards and, therefore, may be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

We cannot predict if investors will find our Class A common stock less attractive because we may rely on these exemptions. If some investors find our Class A common less attractive as a result, there may be a less active trading market for our Class A common and our share price may be more volatile.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM IC. CYBERSECURITY

 

We believe cybersecurity is critical to advancing our technological advancements. As a healthcare services company, we face a multitude of cybersecurity threats that range from attacks common to most industries, such as ransomware and denial-of service. Our customers, suppliers, subcontractors, and business partners face similar cybersecurity threats, and a cybersecurity incident impacting us or any of these entities could materially adversely affect our operations, performance, and results of operations. These cybersecurity threats and related risks make it imperative that we expend resources on cybersecurity including protection across our operations and to ensure the appropriate acquisition, access, use, and/or disclosure of protected health information (“PHI”), personal identifiable information (“PII”), and payment card information (“PCI”)

 

The Administrative Simplification Provisions of the Health Insurance Portability and Accountability Act (“HIPAA”) and its implementing regulations include substantial restrictions and requirements with respect to the use and disclosure of a subset of PHI, and require covered entities, including health plans, healthcare clearinghouses, and most healthcare providers, to implement administrative, physical, and technical safeguards to protect the confidentiality, integrity, and availability of electronic PHI maintained or transmitted by them or by others on their behalf.

 

Our Board of Directors oversees management’s processes for identifying and mitigating risks, including cybersecurity risks, to help align our risk exposure with our strategic objectives. The full Board retains oversight of cybersecurity because of its importance. In the event of an incident, we intend to follow our detailed incident response playbook, which outlines the steps to be followed from incident detection to mitigation, recovery, and notification, including notifying functional areas (e.g., legal), as well as senior leadership and the Board, as appropriate. We have implemented a governance structure and processes to assess, identify, manage, and report cybersecurity risks.

 

ITEM 2. PROPERTIES

 

Our corporate headquarters are located at 1119 Keystone Way N. #201 Carmel, IN 46032 pursuant to a three-year lease which commenced on July 1, 2021 and was amended on May 1, 2022 and provides for a monthly rent of $10,711. We believe this to be sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms..

 

ITEM 3. LEGAL PROCEEDINGS

 

From time to time, we may become a party to various legal actions and complaints arising in the ordinary course of business. In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. It is possible that cash flows or results of operations could be materially affected in any particular period by the unfavorable resolution of one or more of these contingencies.

  

In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.

 

-30-
 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

Market Information

 

Our common stock is listed on The Nasdaq Capital Market under the symbol “SYRA.”

 

Holders

 

As of March 25, 2024, there were 14 and 4 stockholders of record of our Class A and Class B common stock, respectively. The actual number of holders of our common stock is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

 

Dividend Policy

 

We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

 

Recent Sales of Unregistered Securities

 

None.

 

Issuer Purchases of Equity Securities

 

None.

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included elsewhere in this annual report. In addition to historical information, this discussion and analysis contains forward-looking statements that are based on our current expectations, estimates and projections about our business and operations and that involve risks, uncertainties and assumptions. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of a number of factors, including those which we discuss under “Risk Factors” and elsewhere in this annual report. See “Information Regarding Forward-Looking Statements.” All amounts in this report are in U.S. dollars, unless otherwise noted.

 

Overview

 

We are a healthcare services company promoting preventative health, holistic wellness, health education, and equitable healthcare for all patient demographics. We leverage deep scientific and healthcare expertise to create strategic frameworks and develop patient-centric solutions for the betterment of patient lives and health outcome linked to developing a healthier population. We are developing comprehensive end-to-end solutions in health education services, population health, behavioral and mental health, healthcare workforce and digital health.

 

-31-
 

 

Recent Developments

 

Line of Credit

 

On February 7, 2022, we entered into a business loan agreement with Citizens State Bank of New Castle pursuant to which we originally received a revolving line of credit of up to $1,500,000, which was subsequently amended on May 22, 2023, and again on August 24, 2023, to $800,000. See “Financing Transactions – Line of Credit.” A total of $301,655, consisting of $300,154 of principal and $1,501 of interest, was paid on October 10, 2023, and the Revolving Line of Credit was closed.

 

Amendment to Certificate of Incorporation

 

On August 28, 2023, we effectuated a 1-for-1.2 reverse stock split of our issued and outstanding common stock. See “Critical Accounting Policies and Estimates – Reverse Stock Split” for additional information.

 

Advances Received from Related Party

 

On various dates from July 11, 2023, through August 23, 2023, Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by the principal owners and management team of Syra, made short term, non-interest bearing advances due upon demand, of which an aggregate $1,295,010 advanced and we repaid an aggregate $1,095,000 of such advances. The Company pays for payroll and related costs for its employees that provide services to STLogics customers. During the year ended December 31, 2023, the Company applied $200,010 of such costs to reduce the balance of the advance to $0, and has a receivable from STLogics of $50,614 for additional costs incurred as of December 31, 2023.

 

Initial Public Offering

 

On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of 1,615,000 units (“Units”) at a public offering price of $4.125 per Unit, with each Unit consisting of (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). The Company received gross proceeds of approximately $6.7 million from the sale of the Units before deducting underwriting discounts, commissions and offering expenses, which totaled $1,928,133. In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to 242,250 Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional 242,500 Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $2,422. In addition, on the Closing Date, the Company issued fully vested warrants to purchase 145,350 shares of the Company’s common stock, having an exercise price of $5.156 per share, exercisable over a 5-year term, to the Representative pursuant to the Company’ IPO.

 

Debt Conversions

 

On October 3, 2023, a total of $1,472,460, consisting of $1,455,000 of principal and $17,460 of interest, was converted into an aggregate 446,206 shares of Class A common stock in accordance with the terms of the convertible promissory notes.

 

-32-
 

 

Results of Operations for the Years Ended December 31, 2023, and 2022

 

The following table summarizes selected items from the statements of operations for the years ended December 31, 2023, and 2022.

 

   For the Year   For the Year     
   Ended   Ended     
   December 31,   December 31,   Increase / 
   2023   2022   (Decrease) 
             
Net revenues               
Healthcare workforce  $4,259,292   $5,260,370   $(1,001,078)
Population health   715,499    318,036    397,463 
Digital health   515,250    -    515,250 
Behavioral and mental health   12,797    -    12,797 
Health education   12,306    39,300    (26,994)
Net revenues   5,515,144    5,617,706    (102,562)
Cost of services   4,103,244    4,555,924    (452,680)
Gross profit   1,411,900    1,061,782    350,118 
                
Operating expenses:               
Salaries and benefits   2,292,295    1,524,971    767,324 
Professional fees   586,463    1,035,902    (449,439)
Research and development expenses   240,048    -    240,048 
Selling, general and administrative expenses   1,131,922    575,755    556,167 
Depreciation   48,771    14,849    33,922 
Total operating expenses:   4,299,499    3,151,477    1,148,022 
                
Operating loss   (2,887,599)   (2,089,695)   (797,904)
                
Total other income (expense)   (50,744)   (28,470)   (22,274)
                
Net loss  $(2,938,343)  $(2,118,165)  $(820,178)

 

Net Revenues

 

Net revenue during the year ended December 31, 2023 was comprised of $4,259,292 of healthcare workforce revenue, $715,499 of population health revenue, $515,250 of digital health revenue, $12,797 of behavioral and mental health revenue, and $12,306 of health education revenue, compared to net revenue during the year ended December 31, 2022 comprised of $5,260,370 of healthcare workforce revenue, $318,036 of population health revenue, and $39,300 of health education revenue. Healthcare workforce revenues decreased in 2023 as the effects of the Covid-19 pandemic subsided, offset by increases in revenues from other healthcare workforce services provided to various state health departments from new contracts. Population health revenues increased in 2023 due to additional services provided to state departments. Digital health services revenues increased in 2023 due to new services that we began to provide to clients. Behavioral and mental health revenues increased in 2023 due to new services that we began to provide psychological evaluation services to state health departments Health education revenues decreased in 2023 as the effects of the Covid-19 pandemic fully subsided and we reshaped our service offerings.

 

Cost of Services

 

Our cost of services included wages and related payroll taxes, employee benefits and certain other employee-related costs of our contract service employees while they work on contract assignments. We incurred $4,103,244 of cost of services for the year ended December 31, 2023, compared to $4,555,924 for the year ended December 31, 2022, a decrease of $452,680, or 10%. Our gross profit was approximately 25% for the year ended December 31, 2023, compared to approximately 19% for the year ended December 31, 2022, an increase of approximately 7%. Our cost of services decreased primarily due to the change in service mix to be more focused on higher margin revenue streams in 2023.

 

-33-
 

 

Operating Expenses

 

Salaries and Benefits

 

Our salaries and benefits include wages and related payroll taxes, employee benefits and certain other employee-related costs of our management and office personnel. We incurred $2,292,295 of salaries and benefits during the year ended December 31, 2023, compared to $1,524,971 for the year ended December 31, 2022, an increase of $767,324, or 50%. Salaries and benefits increased in 2023 as we supported our increased operations and added office personnel to support our IPO process. Salaries and benefits included $535,909 and $579,599 of officer compensation for the years ended December 31, 2023, and 2022, respectively.

 

Professional Fees

 

Professional fees primarily consist of expenses incurred from business development, accounting, legal fees, and consulting activities. We incurred $586,463 of professional fees for the year ended December 31, 2023, compared to $1,035,902 for the year ended December 31, 2022, a decrease of $449,439, or 43%. Professional fees decreased in 2023 mainly due to a decrease in stock-based compensation related to outsourced professionals engaged in the prior year.

 

Research and Development Expenses

 

Research and Development expenses primarily consist of consulting expenses incurred to develop our technology-based solutions. We incurred $240,048 of research and development expenses for the year ended December 31, 2023.

 

Selling, General and Administrative Expenses

 

SG&A primarily consists of marketing, rent, office, insurance, travel and repair and maintenance expenses incurred. We incurred $1,131,922 of SG&A expenses during the year ended December 31, 2023, compared to $575,755 for the year ended December 31, 2022, an increase of $556,167, or 97%. Our SG&A expenses increased primarily due to our increased operations in 2023. SG&A included $128,527 and $107,013 of rent incurred from STVentures, LLC, an entity beneficially owned by our principal owners, our management team and their affiliates, $154,347 and $47,736 of insurance and $3,370 and $30,738 of repairs and maintenance for the years ended December 31, 2023, and 2022, respectively, as we entered into our lease in July of 2021 and commenced operations. Stock based compensation expense declined to $32,832 during the year ended December 31, 2023 compared to $512,910 in the year ended December 31, 2022 primarily due to fewer options issued to consultants for services during the year ended December 31, 2023.

 

Depreciation

 

We incurred $48,771 of depreciation expense for the year ended December 31, 2023, compared to $14,849 of depreciation expense for the year ended December 31, 2022, an increase of $33,922, or 228%. Depreciation increased as we expanded our office space and placed additional office equipment into service during 2022. We expect depreciation to increase in future periods, as we expanded our office space and incurred significant leasehold improvement costs during 2023.

 

Other Income (Expense)

 

Other expense on a net basis consisted of $53,686 of interest incurred on the line of credit that we entered into in 2022, convertible promissory notes payable, and insurance finance charges, as partially offset by $2,942 of interest income. Other expense on a net basis consisted of $28,533 of interest incurred on a line of credit that we entered into in 2022, as partially offset by $63 of interest income.

 

Net Loss

 

Our net loss for the year ended December 31, 2023, was $2,938,343, compared to a net loss of $2,118,165 for the year ended December 31, 2022, an increase of $820,178. Net loss increased primarily due to the increase in salary costs related to expanded operations in 2023.

 

-34-
 

 

Liquidity and Capital Resources

 

We believe that our existing sources of liquidity, along with cash expected to be generated from sales and services, will not be sufficient to fund our operations, anticipated capital expenditures, working capital and other financing requirements for at least the next twelve months from the issuance of the financial statements included elsewhere in this annual report. In the event we are unable to achieve profitable operations in the near term, we may require additional equity and/or debt financing; however, we cannot provide assurance that such financing will be available to us on favorable terms, or at all. We will continue to monitor our expenditures and cash flow position.

 

The following table summarizes total current assets, liabilities, accumulated deficit and working capital (deficit) at December 31, 2023, and December 31, 2022.

 

   December 31,   December 31, 
   2023   2022 
Current Assets  $4,781,110   $1,426,743 
           
Current Liabilities  $910,072   $1,546,345 
           
Accumulated Deficit  $(5,064,955)  $(2,126,612)
           
Working Capital (Deficit)  $3,871,038   $(119,602)

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. To date, we have funded our operations through equity and debt financings. Our primary uses of cash have been for the development of operations, compensation, and professional fees. All funds received have been expended in the furtherance of growing our business and establishing our services and solutions. The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:

 

  ● A substantial increase in working capital requirements to finance our operations;
  ● Addition of administrative and professional personnel as our business continues to grow;
  ● The cost of being a public company; and
  ● Payments for seeking and securing quality staffing personnel.

 

-35-
 

 

Cash Flow Activities for the Years Ended December 31, 2023, and 2022

 

Net Cash Used in Operating Activities

 

Cash used in operating activities for the years ended December 31, 2023, and 2022 was $2,759,068 and $2,244,065, respectively, which was primarily attributable to our net loss for such periods.

 

Net Cash Used in Investing Activities

 

Cash used in investing activities for the years ended December 31, 2023, and 2022 was $15,251 and $121,260, respectively, which related entirely to the purchase of property and equipment in each year.

 

Net Cash Provided by Financing Activities

 

Cash provided by financing activities for the year ended December 31, 2023, was $6,051,050, which consisted of $5,332,283 of proceeds from the sale of our Class A common stock, $1,455,000 of proceeds received from convertible notes payable, $1,295,010 of advances received from related parties, and $300,000 of proceeds received from line of credit, partially offset by $1,050,551 of repayments on the line of credit, $1,095,000 of repayments on advances from related parties, and $185,692 of repayments on notes payable. Cash provided by financing activities for the year ended December 31, 2022, was $2,268,657, which consisted of $2,322,500 of proceeds from the sale of our Class A common stock, $2,819,275 of proceeds received from a line of credit, and $94,000 of advances received from related parties, as partially offset by $596,118 of payments on deferred offering costs, $2,082,800 of repayments on the line of credit, and $288,200 of repayments on advances from related parties.

 

Financing Transactions

 

Advances from Related Party

 

On various dates from July 11, 2023, through August 23, 2023, Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by the principal owners and management team of Syra, made short term, non-interest bearing advances due upon demand, of which an aggregate $1,295,010 was advanced and we repaid an aggregate $1,095,000 of such advances. We pay for payroll and related costs for our employees that provide services to STLogics customers. During the year ended December 31, 2023, we applied $200,010 of such costs to reduce the balance of the advance to $0, and we have a receivable from STLogics of $50,614 for additional costs incurred as of December 31, 2023.

 

Line of Credit

 

On February 7, 2022, we entered into a business loan agreement (as amended, the “loan agreement”) with Citizens State Bank of New Castle pursuant to which we originally received a revolving line of credit of up to $1,500,000 which was subsequently amended to $800,000 (as amended, the “Revolving Line of Credit”). Pursuant to the terms of the Revolving Line of Credit, the outstanding balance would not exceed 75% of our outstanding accounts receivable due from the State of Indiana aged more than 90 days together with all other accounts receivable aged less than 90 days. The Revolving Line of Credit was to terminate on December 31, 2022, unless extended pursuant to the terms thereof. We received extensions on the Revolving Line of Credit such that it terminated on October 24, 2023; however, no further advances were available under the Revolving Line of Credit. In the event of a default, all commitments and obligations pursuant to the Revolving Line of Credit would terminate immediately and, at Citizens State Bank of New Castle’s request, all Indebtedness (as defined in the loan agreement) would become immediately due and payable. Advances on the Revolving Line of Credit are pursuant to a promissory note, dated February 7, 2022, which accrued interest at a variable rate of 1.5% above the national prime interest rate as quoted in the Wall Street Journal, not to be less than 4.75% per annum or more than 21% per annum or the maximum rate allowed by law. Interest was to increase by 2.0% in the event of a default. Pursuant to the promissory note, we were required to pay monthly payments of unpaid interest since March 7, 2022. We could prepay all or a portion of the amount due prior to the date upon which it was due without any penalty. In connection with the Revolving Line of Credit, we entered into a commercial security agreement with Citizens State Bank of New Castle dated February 7, 2022, pursuant to which we granted Citizens State Bank of New Castle a security interest in the Collateral (as defined in the commercial security agreement) to secure the Indebtedness (as defined in the commercial security agreement). During the year ended December 31, 2023, we received proceeds of $300,000 and repaid total advances of $750,397. In addition, we paid an underwriting fee of $14,076 on February 7, 2022, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. A total of $301,655, consisting of $300,154 of principal and $1,501 of interest, was paid on October 10, 2023, and the Revolving Line of Credit was closed.

 

-36-
 

 

Convertible Notes Payable

 

On various dates from January through April 2023, we entered into subscription agreements with accredited investors pursuant to which we issued convertible promissory notes in the aggregate principal amount of $1,455,000. The notes mature on various dates between July 10, 2024, and October 7, 2024, accrue interest at 2% per annum and may be prepaid by us at any time without any penalties. On October 3, 2023, a total of $1,472,460, consisting of $1,455,000 of principal and $17,460 of interest, was converted into an aggregate 446,206 shares of Class A common stock in accordance with the terms of the convertible promissory notes.

 

Common Stock Sales

 

On October 3, 2023 (the “Closing Date”), we completed our initial public offering (the “IPO”) of an aggregate of 1,615,000 units (“Units”) at a public offering price of $4.125 per Unit, with each Unit consisting of (a) one share of our Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between us and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). We received gross proceeds of approximately $6.7 million from the sale of the Units before deducting underwriting discounts, commissions and offering expenses. In addition, pursuant to the Underwriting Agreement, we granted the Representative a 45-day option to purchase up to 242,250 Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, we issued an additional 242,500 Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $2,422.

 

In March 2022, we sold an aggregate of 1,666,662 shares of our Class A common stock at a price of $0.60 per share for gross proceeds of $1 million. In addition, from June to August 2022 we sold an aggregate of 1,102,094 shares of our Class A common stock at a price of $1.20 per share for gross proceeds of $1,322,500.

 

-37-
 

 

Critical Accounting Policies and Estimates

 

The preparation of the financial statements included elsewhere in this annual report requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

 

The critical accounting estimates, assumptions and judgments that we believe have the most significant impact on our financial statements are described below.

 

Accounts Receivable

 

Accounts receivable is carried at their estimated collectible amounts. Accounts receivable is periodically evaluated for collectability based on past credit history with customers and their current financial condition. We had an allowance of $5,520 and $4,533 at December 31, 2023, and December 31, 2022, respectively.

 

Impairment of Long-Lived Assets

 

In accordance with the provisions of Accounting Standards Codification (“ASC”) Topic 360, “Impairment or Disposal of Long-Lived Assets,” all long-lived assets such as property and equipment held and used by us are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

Leases

 

We account for our leases under ASC 842 - Leases. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on our balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As our lease does not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 

Revenue Recognition

 

We recognize revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as we satisfy a performance obligation.

 

We account for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

-38-
 

 

We have the following main forms of revenue:

 

  – Healthcare Workforce Services
  – Behavioral and Mental Health Services
  – Digital Health
  – Population Health
  – Health Education

 

We primarily provide our services to state and local government health agencies, payers, and other private health organizations. Healthcare Workforce, Behavioral and Mental Health and Health Education contracts are accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. We allocate the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

The contracts generally stipulate bi-weekly or monthly billing, and we have elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as we have the right to payment in an amount that corresponds directly with the value of performance completed to date. We may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. We recognize revenue net of penalties.

 

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between our Company and different divisions within the FSSA. Most contracts require monthly payments as the projects progress. We generally do not require collateral or advance payments. For the years ended December 31, 2023, and 2022, FSSA accounted for approximately 67.7% and 98.3% of our revenues and 30.2% and 98.3% of our accounts receivable, respectively, as due from the combined divisions (NeuroDiagnostic Institute and Division of Mental Health and Addiction) of the FSSA. Two other customers accounted for 21.5% and 18.9% of outstanding accounts receivable as of December 31, 2023.

 

Recent Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by us as of the specified effective date.

 

There are no other recently issued accounting pronouncements that we have yet to adopt that are expected to have a material effect on our financial position, results of operations, or cash flows.

 

JOBS Act

 

On April 5, 2012, the JOBS Act was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

 

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (“PCAOB”) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

We are not required to provide the information required by this Item as are a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

-39-
 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

SYRA HEALTH CORP.

 

INDEX TO FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm (PCAOB Firm ID: 2738)   F-2
     
Balance Sheets at December 31, 2023 and 2022   F-3
     
Statements of Operations for the Years Ended December 31, 2023 and 2022   F-4
     
Statements of Stockholders’ Equity (Deficit) for the Years Ended December 31, 2023 and 2022   F-5
     
Statements of Cash Flows for the Years Ended December 31, 2023 and 2022   F-6
     
Notes to the Financial Statements   F-7

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

 

To the Board of Directors and

Stockholders of Syra Health Corp.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Syra Health Corp. (the Company) as of December 31, 2023 and 2022, and the related statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2023 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company had a cash balance of $3,280,075, working capital of $3,871,038 and an accumulated deficit of $5,065,255 since inception, which raises substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters are discussed in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and the significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe our audits provides a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audits of the financial statements that were communicated, or required to be communicated, to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.

 

Due to the net loss for the year, the Company evaluated the need for a going concern.

 

Auditing management’s evaluation of a going concern can be a significant judgement given the fact that the Company uses management estimates on future revenues and expenses which are not able to be substantiated.

 

As discussed in Note 2, the Company has a going concern due to its insufficient cash balance and accumulated net losses.

 

To evaluate the appropriateness of the going concern, we examined and evaluated the financial information along with management’s plans to mitigate the going concern and management’s disclosure on going concern.

 

/s/ M&K CPAS, PLLC

 

We have served as the Company’s auditor since 2022

 

Houston, TX

March 25, 2024

 

F-2
 

 

SYRA HEALTH CORP.

BALANCE SHEETS

 

   December 31,   December 31, 
   2023   2022 
         
ASSETS          
           
Current assets:          
Cash  $3,280,075   $3,344 
Accounts receivable, net   1,060,634    1,201,097 
Accounts receivable related party   

50,614

    

-

 
Other current assets   389,787    222,302 
Total current assets   4,781,110    1,426,743 
           
Deferred offering costs   -    596,118 
Property and equipment, net   78,974    112,493 
Right-of-use asset   63,199    184,288 
           
Total assets  $4,923,283   $2,319,642 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable  $462,991   $432,388 
Accounts payable, related parties   -    3,200 
Accrued expenses   198,978    239,117 
Current portion of operating lease liability, related party   63,199    121,089 
Notes payable   184,904    - 
Revolving line of credit   -    750,551 
Total current liabilities   910,072    1,546,345 
           
Operating lease liability, related party   -    63,199 
           
Total liabilities   910,072    1,609,544 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity (deficit):          
Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares designated, issued and outstanding   -    - 
Class A common stock, $0.001 par value, 100,000,000 shares authorized, 5,588,298 and 3,568,758 shares issued and outstanding at December 31, 2023 and 2022, respectively   5,588    3,569 
Convertible class B common stock, $0.001 par value, 5,000,000 shares authorized, 833,334 shares issued and outstanding   833    833 
Additional paid-in capital   9,071,745    2,832,308 
Accumulated deficit   (5,064,955)   (2,126,612)
Total stockholders’ equity (deficit)   4,013,211    710,098 
           
Total liabilities and stockholders’ equity (deficit)  $4,923,283   $2,319,642 

 

The accompanying notes are an integral part of these financial statements.

 

F-3
 

 

SYRA HEALTH CORP.

STATEMENTS OF OPERATIONS

 

   2023   2022 
   For the Years Ended 
   December 31, 
   2023   2022 
         
Net revenues  $5,515,144   $5,617,706 
Cost of services   4,103,244    4,555,924 
Gross profit   1,411,900    1,061,782 
           
Operating expenses:          
Salaries and benefits   2,292,295    1,524,971 
Professional services   586,463    1,035,902 
Research and development expenses   240,048    - 
Selling, general and administrative expenses   1,131,922    575,755 
Depreciation   48,771    14,849 
Total operating expenses   4,299,499    3,151,477 
           
Operating loss   (2,887,599)   (2,089,695)
           
Other income (expense):          
Interest income   2,942    63 
Interest expense   (53,686)   (28,533)
Total other income (expense)   (50,744)   (28,470)
           
Net loss  $(2,938,343)  $(2,118,165)
           
Weighted average common shares outstanding – basic and diluted   4,877,861    3,041,085 
Net loss per common share – basic and diluted  $(0.60)  $(0.70)

 

The accompanying notes are an integral part of these financial statements.

 

F-4
 

 

SYRA HEALTH CORP.

STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

 

   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
       Class A  

Convertible

Class B

   Additional       Total
Stockholders’		 
   Preferred Stock   Common Stock   Common Stock   Paid-in   Accumulated   Equity 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   (Deficit) 
                                     
Balance, December 31, 2021      -   $     -    -   $-    833,334   $833   $467   $(8,447)  $(7,147)
                                              
Class A common stock sold for cash   -    -    2,768,756    2,769    -    -    2,319,731    -    2,322,500 
                                              
Class A common stock issued for services   -    -    800,002    800    -    -    509,200    -    510,000 
Class A common stock options issued for services   -    -    -    -    -    -    2,910    -    2,910 
                                              
Net loss   -    -    -    -    -    -    -    (2,118,165)   (2,118,165)
                                              
Balance, December 31, 2022   -    -    3,568,758    3,569    833,334    833    2,832,308    (2,126,612)   710,098 
                                              
Cancellation of Class A common stock   -    -    (41,666)   (42)   -    -    42    -    - 
                                              
Class A common stock issued for debt conversion   -    -    446,206    446    -    -    1,472,014    -    1,472,460 
                                              
Stock-based compensation   -    -    -    -    -    -    32,831    -    32,831 
                                              
Class A common stock sold for cash   -    -    1,615,000    1,615    -    -    4,734,550    -    4,736,165 
Net loss   -    -    -    -    -    -    -    (2,938,343)   (2,938,343)
                                              
Balance, December 31, 2023   -   $-    5,588,298   $5,588    833,334   $833   $9,071,745   $(5,064,955)  $4,013,211 

 

The accompanying notes are an integral part of these financial statements.

 

F-5
 

 

SYRA HEALTH CORP.

STATEMENTS OF CASH FLOWS

 

   2023   2022 
   For the Years Ended 
   December 31, 
   2023   2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES          
Net loss  $(2,938,343)  $(2,118,165)
Adjustments to reconcile net loss to net cash used in operating activities:          
Non-cash lease expense   -    95,563 
Depreciation   48,771    14,849 
Amortization of debt discounts   -    14,076 
Common stock issued for services   -    510,000 
Stock-based compensation   32,831    2,910 
Decrease (increase) in assets:          
Accounts receivable   (59,547)   (940,470)
Accounts receivable, related party   

(50,614

)   - 
Other current assets   203,110    (200,798)
Right-of-use asset   121,089    - 
Increase (decrease) in liabilities:          
Accounts payable   30,603    392,276 
Accounts payable, related parties   (3,200)   (82,418)
Accrued expenses   (22,679)   163,675 
Operating lease liability   (121,089)   (95,563)
Net cash used in operating activities   (2,759,068)   (2,244,065)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (15,251)   (121,260)
Net cash used in investing activities   (15,251)   (121,260)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Payments on deferred offering costs   -    (596,118)
Repayment of notes payable   (185,692)   - 
Proceeds received on sale of Class A common stock   5,332,283    2,322,500 
Proceeds received from line of credit   300,000    2,819,275 
Repayments on line of credit   (1,050,551)   (2,082,800)
Advances received from related party   1,295,010    94,000 
Repayments on advances from related party   (1,095,000)   (288,200)
Proceeds received from convertible notes payable   1,455,000    - 
Net cash provided by financing activities   6,051,050    2,268,657 
           
NET CHANGE IN CASH   3,276,731    (96,668)
CASH AT BEGINNING OF PERIOD   3,344    100,012 
CASH AT END OF PERIOD  $3,280,075   $3,344 
           
SUPPLEMENTAL INFORMATION:          
Interest paid  $36,226   $11,651 
Income taxes paid  $-   $- 
           
NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Initial recognition of right-of-use asset and lease liability  $-   $131,187 
Class A common stock issued for debt and interest conversion  $1,472,460   $- 
Cancellation of Class A common stock  $42   $- 
Non-cash application of invoices to STLogics loan  $200,010   $- 
Prepaid asset financed with notes payable  $370,596   $- 

 

The accompanying notes are an integral part of these financial statements.

 

F-6
 

 

SYRA HEALTH CORP.

NOTES TO FINANCIAL STATEMENTS

 

Note 1 – Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Syra Health Corp. (“Syra” or the “Company”) was incorporated in the state of Indiana on November 20, 2020 to provide workforce staffing solutions, health education and healthcare research consulting services to mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, the Company redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana.

 

On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of 1,615,000 units (“Units”) at a public offering price of $4.125 per Unit, with each Unit consisting of (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). The Company received gross proceeds of approximately $6,661,876 from the sale of the Units before deducting underwriting discounts, commissions and offering expenses of $1,928,133 In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to 242,250 Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional 242,500 Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $2,422.

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Concentrations of Credit Risk

 

The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 under current regulations. The Company did not have any cash in excess of FDIC insured limits at December 31, 2023, and 2022, and has not experienced any losses in such accounts.

 

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

F-7
 

 

The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at December 31, 2023, and 2022.

 

Cash and Cash Equivalents

 

Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were no cash equivalents on hand at December 31, 2023, and 2022.

 

Accounts Receivable

 

Accounts receivable are carried at their estimated collectible amounts. Accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $5,520 at December 31, 2023, and $4,533 at December 31, 2022.

 

Deferred Offering Costs

 

Deferred offering costs related to the Company’s initial public offering (“IPO”) consisted principally of professional fees, legal and accounting, and other costs such as printing, and registration costs incurred in connection with the planned IPO of the Company and the sale of its Class A common stock. During the year ended December 31, 2022, the Company incurred $596,118 of costs, directly attributable to its proposed IPO, which were offset against the proceeds from the IPO that closed in 2023. In total, the Company incurred $1,928,133 of offering costs related to the IPO.

 

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a five-year life expectancy.

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 

Impairment of Long-Lived Assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

F-8
 

 

Leases

 

The Company accounts for its leases under ASC 842 – Leases. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

The Company has the following main forms of revenue:

 

  – Healthcare Workforce;
  – Population Health
  – Digital Health
  – Behavioral and Mental Health Services
  – Health Education

 

The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

F-9
 

 

The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognize revenue net of penalties.

 

Disaggregated revenue data

 

The Company’s revenue consists of the following revenue services within its industry: 

 

Net revenues:          
Healthcare workforce  $4,259,292   $5,260,370 
Population health   715,499    318,036 
Digital health   515,250    - 
Behavioral and mental services   12,797    - 
Health education   12,306    39,300 
Net revenues  $5,515,144   $5,617,706 

 

Cost of Services

 

The cost of services includes the wages and the related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while they work on contract assignments.

 

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For each of the years ended December 31, 2023 and 2022, FSSA accounted for approximately 68% and 98% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA – NeuroDiagnostic Institute, representing $3,734,004 and $5,214,128 of the Company’s healthcare workforce revenue, and the FSSA – Division of Mental Health and Addiction, which commenced on September 3, 2021, representing $305,000 and $306,000 of the Company’s Population Health revenues for the years ended December 31, 2023 and 2022, respectively. In addition, the combined divisions of the FSSA represented 30% and 99% of accounts receivable at December 31, 2023, and 2022, respectively.

 

Research and Development Costs

 

Research and development costs are expensed as incurred. The Company’s research and development costs consist of outside consultant fees to develop the Company’s technology-based solutions.

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

 

Basic and Diluted Loss Per Share

 

The Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

F-10
 

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Income Taxes

 

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

 

Uncertain Tax Positions

 

In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 

Recently Adopted Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.

 

F-11
 

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined in Rule 12b-2 of the Exchange Act) to fiscal years beginning after December 15, 2022, including interim periods. Early adoption is permitted. The Company meets the definition of a smaller reporting company and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade receivables, but that there was no material impact to the financial statements from the adoption of ASU 2016-13.

 

There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

 

Note 2 – Going Concern

 

As shown in the accompanying financial statements, as of December 31, 2023, the Company had a cash balance of $3,280,075, working capital of $3,871,038 and an accumulated deficit of $5,064,955 since inception. The Company is too early in its development stage to project revenue with a necessary level of certainty. Therefore, the Company may not have sufficient funds to sustain its operations for the next twelve months from the issuance date of these financial statements and may need to raise additional cash to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has commenced sales and continues to develop its operations. In the event sales do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that the Company will be successful in achieving these objectives.

 

The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means. The Company may not be successful in identifying suitable funding transactions in a sufficient time period or at all, and may not obtain the required capital by other means. If the Company does not succeed in raising additional capital, resources may not be sufficient to fund its business. The Company’s ability to scale production and distribution capabilities and further increase the value of its brands, is largely dependent on its success in raising additional capital. From January through April of 2023, the Company raised a total of $1,455,000 of capital from the sale of convertible notes. On October 3, 2023 the Company completed IPO received net proceeds of approximately $5,332,283. In October 2023, the convertible notes were converted into Class A common stock in accordance with the terms of the convertible promissory notes as a result of the IPO.

 

The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 

Note 3 – Related Party Transactions

 

Advances from Related Party

 

On various dates from July 11, 2023, through August 23, 2023, Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by the principal owners and management team of Syra, made short term, non-interest bearing advances due upon demand, of which an aggregate $1,295,010 advanced and we repaid an aggregate $1,095,000 of such advances. The Company pays for payroll and related costs for its employees that provide services to STLogics customers. During the year ended December 31, 2023, the Company applied $200,010 of such costs to reduce the balance of the advance to $0, and has a receivable from STLogics of $50,614 for additional costs incurred as of December 31, 2023.

 

During the year ended December 31, 2021, the Company’s operations were primarily financed by short term advances from Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by Priya Prasad, the Company’s Chief Financial Officer and Chief Operating Officer, and STLHoldings Corp. which is an entity beneficially owned by the principal owners and management team of Syra. On various dates from December 30, 2020, through April 4, 2022, Sahasra Technologies Corp. made short term, non-interest bearing advances due upon demand to the Company, of which an aggregate $94,000 was loaned during the years ended December 31, 2022. During the year ended December 31, 2022, the Company repaid in full the loans totaling $288,200.

 

F-12
 

 

Office Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, LLC (“STVentures”), an entity beneficially owned by the principal owners and the management team of Syra and their affiliates. The lease commenced on July 1, 2021, and provided for a base monthly rent of $5,332 over the three-year term of the lease, which was subsequently amended to $10,711, on May 1, 2022. A total of $128,527 and $107,013 of rent expense was included in selling, general and administrative expenses for the years ended December 31, 2023, and 2022, respectively.

 

Information Technology (“IT”) Services

 

The Company incurred a total of $3,320 and $23,260 of expenses from RAD CUBE LLC, which is an entity beneficially owned by the principal owners and the management team of the Company and their affiliates, for outsourced IT services which have been presented within selling, general and administrative expenses in the statement of operations during the years ended December 31, 2023, and 2022, respectively. An unpaid balance of $0 and $3,200 was outstanding at December 31, 2023, and 2022, respectively, as presented within accounts payable, related parties. The Company no longer receives services from RAD CUBE LLC.

 

Recruitment and Human Resource Services

 

The Company paid a total of $348,304 and $137,494 of recruitment and human resource services to NLogix, which is an entity beneficially owned by the principal owners and the management team of the Company and their affiliates, which have been presented within cost of sales in the statement of operations during the years ended December 31, 2023 and 2022, respectively.

 

Common Stock Issuances

 

The Company issued 83,334 shares of common stock on November 21, 2020 to its founders for services rendered in connection with the formation of the entity. In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which such shares were subsequently exchanged for 833,334 shares of convertible Class B common stock.

 

Note 4 – Basic and Diluted Earnings per Share

 

During the years ended December 31, 2023, and 2022, the Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

F-13
 

 

Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of December 31, 2023 and 2022 are as follows: 

 

   December 31, 2023   December 31, 2022 
Warrants   1,760,350    - 
Stock options   140,750    39,000 
Total   1,901,100    39,000 

 

Note 5 – Other Current Assets

 

Other current assets at December 31, 2023, and 2022 consisted of the following: 

 

   December 31,   December 31, 
   2023   2022 
EDGE tax credit receivable (1)  $-   $116,361 
Federal and State income tax receivable   73,069    28,734 
Prepaid insurance   316,718    20,040 
Prepaid rent   -    10,711 
Prepaid licensing and office fees   -    16,456 
Retainers paid on professional services   -    30,000 
Total other current assets  $389,787   $222,302 

 

(1)A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.

 

Note 6 – Property and Equipment

 

Property and equipment at December 31, 2023, and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Office equipment – 5 year estimated life  $81,340   $127,549 
Leasehold improvements– 2 year estimated life   60,783    - 
Furniture and fixtures– 7 year estimated life   677    - 
Less: Accumulated depreciation   (63,827)   (15,056)
Total property and equipment, net  $78,974   $112,493 

 

Depreciation of property and equipment was $48,771 and $14,849 for the years ended December 31, 2023, and 2022, respectively.

 

F-14
 

 

Note 7 – Accrued Expenses

 

Accrued expenses at December 31, 2023, and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Accrued payroll and taxes  $148,924   $212,660 
Accrued expenses   50,054    - 
Accrued retirement contributions   -    4,874 
Accrued franchise taxes   -    18,777 
Accrued interest   -    2,806 
Total accrued expenses  $198,978   $239,117 

 

The Company provides postretirement benefits pursuant to Internal Revenue Code of 1986, as amended, Section 401(k) for employees meeting specified criteria. The Company matches 100% of the employees’ contributions that are not in excess of 4% of the employee’s contributions. These matching contributions are fully vested and paid pursuant to the employees’ bi-weekly or semi-monthly pay periods. The Company does not prefund these benefits and has the right to modify or terminate certain of these benefits in the future. For the year ended December 31, 2023, the Company incurred $88,327 of investment retirement account contribution expenses pursuant to the Company’s matching contributions, including $8,778, as accrued at December 31, 2023. For the year ended December 31, 2022, the Company incurred $28,534 of investment retirement account contribution expenses pursuant to the Company’s matching contributions, including $4,874, as accrued at December 31, 2022.

 

Note 8 – Debt

 

Line of Credit

 

On February 7, 2022, the Company entered into a business loan agreement (as amended, the “loan agreement”) with Citizens State Bank of New Castle pursuant to which it originally received a revolving line of credit of up to $1,500,000 which was subsequently amended to $800,000 (as amended, the “Revolving Line of Credit”). Pursuant to the terms of the Revolving Line of Credit, the outstanding balance shall not exceed 75% of the Company’s outstanding accounts receivable due from the State of Indiana aged more than 90 days together with all other accounts receivable aged less than 90 days. The Revolving Line of Credit was to terminate on December 31, 2022, unless extended pursuant to the terms thereof. The Company received extensions on the Revolving Line of Credit such that it will now terminate on October 24, 2023; however, no further advances are available under the Revolving Line of Credit. In the event of a default, all commitments and obligations pursuant to the Revolving Line of Credit will terminate immediately and, at Citizens State Bank of New Castle’s request, all Indebtedness (as defined in the loan agreement) shall become immediately due and payable. Advances on the Revolving Line of Credit are pursuant to a promissory note dated February 7, 2022 which accrues interest at a variable rate of 1.5% above the national prime interest rate as quoted in the Wall Street Journal, not to be less than 4.75% per annum or more than 21% per annum or the maximum rate allowed by law. Interest shall increase by an 2.0% in the event of a default. Pursuant to the promissory note, the Company has been required to pay monthly payments of unpaid interest since March 7, 2022. The Company may prepay all or a portion of the amount due prior to the date upon which it is due without any penalty. In connection with the Revolving Line of Credit, the Company entered into a commercial security agreement with Citizens State Bank of New Castle dated February 7, 2022, pursuant to which it granted Citizens State Bank of New Castle a security interest in the Collateral (as defined in the commercial security agreement) to secure the Indebtedness (as defined in the commercial security agreement).

 

During the year ended December 31, 2023, the Company received proceeds of $300,000 and repaid total advances of $1,050,551. In addition, the Company paid an underwriting fee of $14,076 on February 7, 2022, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. The balance of the line of credit was $0 and $750,551 at December 31, 2023, and December 31, 2022, respectively. The Revolving Line of Credit was closed.

 

During the year ended December 31, 2022, the Company received total advances of $2,819,275, and repaid advances of $2,068,724. In addition, the Company paid an underwriting fee of $14,076, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. The balance of the line of credit was $750,551 at December 31, 2022.

 

F-15
 

 

Convertible Notes payable

 

On various dates from January through April 7, 2023, the Company entered into subscription agreements with accredited investors pursuant to which it issued convertible promissory notes in the aggregate principal amount of $1,455,000. The notes mature on various dates between July 10, 2024 and October 7, 2024, accrue interest at 2% per annum and may be prepaid by the Company at any time without any penalties. The holders may convert the principal amount of the notes together with accrued interest thereon at any time prior to the earlier of the maturity date and the effectiveness of the registration statement relating to the Company’s initial public offering at a conversion price of $6.00 per share. Upon the closing of the Next Equity Financing (as defined herein), the principal amount of the notes together with accrued interest thereon shall automatically convert into such number of shares of the Company’s Class A common stock determined by dividing (x) the outstanding principal balance and unpaid accrued interest of the notes on the date of conversion by (y) the price per share equal to the product of the price per Equity Security (as defined in the notes) sold in the Next Equity Financing multiplied by 80%. “Next Equity Financing” means an initial public offering by the Company of its Equity Securities pursuant to which such Equity Securities are listed on a national securities exchange. In addition, if prior to the maturity date of the notes, the notes remains outstanding, then in the event of a Corporate Transaction (as defined in the notes), the holder of each note may elect to convert the outstanding principal balance and unpaid accrued interest of each note, subject to the terms and conditions contained in the note, into Conversion Shares (as defined in the notes) immediately prior to the closing of such Corporate Transaction based upon a conversion price equal to the lesser of (i) the Corporate Transaction Price (as defined in the notes) or (ii) the quotient resulting from dividing (x) the Valuation Cap (as defined in the notes) by (y) the fully diluted capitalization immediately prior to the closing of the Corporate Transactions.

 

On October 3, 2023, a total of $1,472,460, consisting of $1,455,000 of principal and $17,460 of interest, was converted into an aggregate 446,206 shares of Class A common stock in accordance with the terms of the convertible promissory notes.

 

Notes Payable

 

The Company recognized interest expense for the years ended December 31, 2023, and 2022, as follows:

 

   December 31,   December 31, 
   2023   2022 
         
Interest on line of credit  $27,054   $14,397 
Interest on convertible notes payable   17,460    - 
Interest on notes payable   8,966      
Amortization of underwriting fee on line of credit   -    14,076 
Interest on credit card debt   206    60 
Total interest expense  $53,686   $28,533 

 

Insurance Notes Payable

 

In 2023, the Company entered into three insurance policy financing arrangements to purchase various insurance policies. The total principal of these arrangements is $370,596 with interest rates ranging from 10.38% through 14.05% and monthly payments totaling $32,328 are due through July 2024. During the year ended December 31, 2023, the Company repaid $185,692 on the insurance notes payable, and the remaining balance as of December 31, 2023 was $184,904.

 

Note 9 – Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, a related party. The lease, as amended on May 1, 2022 to expand the office space from 2,976 square feet to 5,978 square feet, commenced on July 1, 2021, and provides for a base monthly rent of $10,711, as increased from $5,332 per month, over the three-year term of the lease. The Company is occupying the space for executive and administrative offices. Rent expense was $128,527 and $107,013 for the years ended December 31, 2023 and 2022 respectively, which is included in other general and administrative expenses within the statements of operations.

 

F-16
 

 

The components of lease expense were as follows:

 

           
   For the Year Ended 
   December 31, 
   2023   2022 
Operating lease cost:          
Amortization of ROU asset  $121,089   $184,288 
Interest on lease liability   7,438    8,733 
Total operating lease cost  $128,527   $175,555 

 

Supplemental balance sheet information related to leases was as follows:

 

   December 31,   December 31, 
   2023   2022 
Operating lease:          
Operating lease assets  $63,199   $184,288 
           
Current portion of operating lease liability, related party  $63,199   $121,089 
Noncurrent operating lease liability, related party   -    63,199 
Total operating lease liability  $63,199   $184,288 
           
Weighted average remaining lease term:          
Operating leases   0.5 years    1.5 years 
           
Weighted average discount rate:          
Operating lease   5.75%   5.75%

 

Supplemental cash flow and other information related to operating leases was as follows:

 

           
   For the Year Ended 
   December 31, 
   2023   2022 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows used for operating leases  $121,089   $107,013 
           
Leased assets obtained in exchange for lease liabilities:          
Total operating lease liabilities  $-   $131,187 

 

Future minimum annual lease payments required under the operating lease and the present value of the net minimum lease payments are as follows at December 31, 2023:

 

For the Year  Minimum Lease 
Ended December 31:  Commitments 
2024  $64,263 
2025   - 
Total   64,263 
Amount representing interest  $(1,064)
Present value of net future minimum lease payments   63,199 
Less current portion   (63,199)
Operating lease liability, related party, long term  $- 

 

F-17
 

 

Note 10 – Commitments and Contingencies

 

Legal Contingencies

 

From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.

 

On June 28, 2022, the Company entered into a settlement agreement with a former employee pursuant to a wrongful termination lawsuit filed in the U.S. District Court, Southern District of Indiana in the amount of $28,000. The Company accrued the full amount of the settlement as of December 31, 2021, and the settlement was paid in July of 2022.

 

In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.

 

Note 11 – Stockholders’ Equity (Deficit)

 

In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which the 83,334 outstanding shares of common stock were exchanged for 833,334 shares of convertible Class B common stock, as retrospectively applied. Each share of Class B common stock is entitled to 16.5 votes and is convertible at any time into ten shares of Class A common stock.

 

During March of 2022, the Company raised $1,000,000 of capital from the sale of 2,000,000 shares of Class A common stock at a share price of $0.50 in a private placement. On various dates between June and August of 2022, the Company also raised $1,322,500 of capital from the sale of 1,102,094 shares of Class A Common Stock at a share price of $1.20 in a private placement.

 

Amendment to Articles of Incorporation

 

On May 2, 2022, the Company filed an Amended and Restated Certificate of Incorporation that was subsequently amended on October 6, 2022 and May 30, 2023 to authorize the following:

 

  ● 100,000,000 shares of Class A common stock with a par value of $0.001 per share;
  ● 5,000,000 shares of convertible Class B common stock with a par value of $0.001 per share; and
  ● 10,000,000 shares of “blank check” preferred stock with a par value of $0.001 per share.

 

Liquidation rights: In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding up of the Company, the holders of Class A common stock and the holders of convertible Class B common stock shall be entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock.

 

Voting: The holders of the Class A common stock and the holders of the convertible Class B common stock shall at all times vote together as one class on all matters, including the election of directors, submitted to a vote or for the consent of the stockholders of the Company. Each holder of shares of convertible Class B common stock shall be entitled to 16.5 votes for each share of convertible Class B common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. Each holder of shares of Class A common stock shall be entitled to one vote for each share of Class A common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company.

 

Each share of convertible Class B common Stock was also convertible into 16.5 fully paid and nonassessable shares of Class A common stock. On October 6, 2022, the Company’s Amended and Restated Certificate of Incorporation was amended to change the conversion ratio from 16.5 shares to 10 shares of Class A common stock. The voting rights remain unchanged.

 

The voting powers, conversion features, if any, designations, preferences, limitations, restrictions and other rights of each series of preferred stock shall be prescribed by resolution of the Board of Directors at the time a specific series of preferred stock is designated. None of the preferred shares have been designated or issued to date.

 

F-18
 

 

Class A Common Stock

 

The Company has 100,000,000 authorized shares of $0.001 par value Class A common stock, and 5,588,298 shares were issued and outstanding as of December 31, 2023. 3,568,758 shares were issued and outstanding as of December 31, 2022.

 

Class A Common Stock Sales

 

On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of 1,615,000 units (“Units”) at a public offering price of $4.125 per Unit, with each Unit consisting of (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). The Company received gross proceeds of approximately $6,661,876 from the sale of the Units before deducting underwriting discounts, commissions and offering expenses of $1,928,133. In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to 242,250 Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional 242,500 Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $2,422.

 

On the Closing Date, the Company granted to the underwriter fully vested warrants to purchase 145,350 shares of the Company’s common stock, having an exercise price of $5.156 per share, exercisable over a 5-year term, to the Representative. The fair value of the warrants was estimated at $352,677 using a Black-Scholes option pricing model and the following assumptions: 1) dividend yield of 0%; 2) risk-free rate of 4.80%; 3) volatility of 122%; 4) a common stock price of $3.03, and 5) an expected term of 5 years. The fair value of the options was recognized as a cost of capital related to the IPO.

 

On May 10, 2023, a stockholder voluntarily surrendered 41,667 shares of Class A common stock, which were subsequently cancelled.

 

In June and August 2022, the Company raised a total of $1,322,500 of capital from the sale of an aggregate of 1,102,094 shares of Class A common stock to a total of 23 accredited investors at a share price of $1.20 in a private placement.

 

During March 2022, the Company raised an aggregate of $1,000,000 of capital from the sale of 2,000,000 shares of Class A common stock to a total of 22 accredited investors at a share price of $0.50 in a private placement.

 

The following is a summary of activity of outstanding stock warrants:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2021   -   $- 
Warrants granted   -    - 
Warrants cancelled   -    - 
Balance, December 31, 2022   -    - 
Warrants granted   2,002,850    6.40 
Warrants exercised   -    - 
Warrants cancelled   (242,500)   (6.50)
Balance, December 31, 2023   1,760,350   $6.39 
Exercisable, December 31, 2023   -   $- 

 

The warrants have a weighted average remaining contractual life of 4.75 years and no intrinsic value as of December 31, 2023.

 

Class A Common Stock Issued for Services

 

In November 2023, the Company award 50,000 shares of restricted stock to a consultant, which vest in four equal quarterly installments. The restricted shares had a fair value of $75,500 based on the stock price at the grant date, and the Company recognized $8,122 of expense during the year ended December 31, 2023. No shares were issued during the year ended December 31, 2023.

 

From February through May 2022, the Company awarded a total of 800,002 shares to six consultants for services provided. The shares were subsequently issued on August 3, 2022. The aggregate fair value of the shares was $510,000, based on recent sales of the Company’s Class A common stock to third parties.

 

Convertible Class B Common Stock

 

The Company has 5,000,000 authorized shares of $0.001 par value convertible Class B common stock, and had 833,334 shares issued and outstanding as of December 31, 2022 and 2021, as retrospectively applied, pursuant to the Company’s subsequent recapitalization in 2022 and effected as of May 3, 2022, whereby the founders exchanged their 83,334 founders shares for 833,334 shares of convertible Class B common stock.

 

F-19
 

 

Convertible Class B Common Stock Issuances

 

On November 21, 2020, the Company issued 83,334 shares of common stock to its founders for services rendered in connection with the formation of the entity. The aggregate fair value of the common stock was $100 based on par value of the Company’s common stock, as there was no immediate intrinsic value in the Company upon inception. In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which the equity was recapitalized with the exchange of the 83,334 shares of common stock for 833,334 shares of convertible Class B common stock, as retrospectively applied. Each share of convertible Class B common stock was convertible into 16.5 shares of Class A common stock, which was subsequently amended to be convertible into ten shares on of Class A common stock on October 4, 2022.

 

Note 12 – Common Stock Options

 

Omnibus Equity Incentive Plan

 

On April 11, 2022, the Company’s board of directors adopted, and the Company’s stockholders approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan (“2022 Plan”). No more than 1,041,667 shares of the Company’s Class A common stock shall be issued pursuant to the exercise of incentive stock options and other securities under the 2022 Plan.

 

Class A Common Stock Option Awards

 

On November 8, 2023, the Company granted options to purchase an aggregate 32,750 shares of the Company’s common stock under the 2022 Plan, having an exercise price of $1.51 per share, exercisable over a 10-year term, to a total of ten employees. The options vest annually over four years from the date of grant.

 

On November 8, 2023, the Company granted options to purchase an aggregate 30,000 shares of the Company’s common stock under the 2022 Plan, having an exercise price of $1.51 per share, exercisable over a 10-year term, to a total of three consultants. The options vest quarterly over one year from the date of grant.

 

On October 9, 2023, the Company granted options to purchase an aggregate 50,000 shares of the Company’s common stock under the 2022 Plan, having an exercise price of $2.68 per share, exercisable over a 10-year term, to a total of five newly appointed board members. The options vest in four (4) equal annual installments with the first installment vesting on the date of grant.

 

The fair value of the options was estimated at $198,383 using a Black-Scholes option pricing model and the following assumptions: 1) dividend yield of 0%; 2) risk-free rate of 4.45% to 4.71%; 3) volatility of 112% to 115% based on; 4) a common stock price ranging from $1.51 to $2.68, and 5) an expected term of 6.25 years. During the year ended December 31, 2023, a total of $21,041 was recognized as expense related to stock options and $196,955 remains to be expensed.

 

On various dates between July 1, 2022 and September 1, 2022, the Company granted options to purchase an aggregate 32,502 shares of the Company’s Class A common stock at an exercise price of $1.20 per share under the 2022 Plan, which represented the recent sales price of securities to third parties. These options will vest 25% on each anniversary until fully vested. The options had no intrinsic value. The aggregate estimated value using the Black-Scholes Pricing Model, based on an expected term of 6.25 years, a weighted average volatility rate of 93%, a weighted average risk-free interest rate of 3.03%, and a weighted average call option value of $0.9328, was $30,317. The options are being expensed over the vesting period, resulting in $2,910 of stock-based compensation expense during the year ended December 31, 2022. During the fourth quarter of 2022, a total of 9,167 options at a strike price of $1.20 per share were cancelled.

 

F-20
 

 

The following is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2021   -   $- 
Options granted   39,000    1.00 
Options cancelled   -      
Balance, December 31, 2022   39,000    1.20 
Options granted   112,750    2.03 
Options forfeited   (11,000)   (1.00)
Balance, December 31, 2023   140,750   $1.82 
Exercisable, December 31, 2023   -   $- 

 

The options had a weighted average remaining life of 9.58 years and no intrinsic value as of December 31, 2023.

 

Note 13 - Income Taxes

 

For the period from November 20, 2020 (inception) through December 31, 2023, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2023, and 2022, the Company had approximately $4,637,000 and $1,731,000 of federal net operating losses. Under the Tax Cuts and Jobs Act of 2017, the net operating loss carry forwards can be carried forward indefinitely, however the deductions are limited to 80% of taxable income.

 

The effective income tax rate for the years ended December 31, 2023 and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Federal statutory income tax rate   21%   21%
State income taxes   3%   3%
Change in valuation allowance   (24)%   (24)%
Net effective income tax rate   -    - 

 

The components of the Company’s deferred tax asset are as follows:

 

                 
    December 31,  
    2023     2022  
Deferred tax assets:                
Net deferred tax assets before valuation allowance   $ 1,029,723     $ 332,400  
Less: Valuation allowance     (1,029,723 )     (332,400 )
Net deferred tax assets   $ -     $ -  

 

Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2023 and 2022, respectively.

 

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

 

Note 14 – Subsequent Events

 

The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.

 

Subsequent to December 31, 2023, two investors exercised 130,789 warrants to purchase Class A Common stock pursuant to which the Company received cash proceeds of $850,139.

 

Subsequent to December 31, 2023, the Company issued 12,500 shares pursuant to the restricted stock award from November 2023.

 

F-21
 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls

 

Our principal executive officer and principal financial officer evaluated the effectiveness of our “disclosure controls and procedures” as of December 31, 2023, the end of the period covered by this Annual Report on Form 10-K. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is accumulated and communicated to a company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Based on the evaluation of our disclosure controls and procedures as of December 31, 2023, our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with U.S. GAAP. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Management identified a material weakness in internal control over financial reporting in connection with the review of our audited consolidated financial statements for the year ended December 31, 2022. A material weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting such that it is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness previously identified was due to (i) the design and implementation of appropriate segregation of duties to separate the roles of authorizing, initiating, and recording transactions or reviewing transactions for the completeness and accuracy of contracts with financial reporting implications and (ii) the Company lacking sufficient appropriate accounting and reporting knowledge to effectively perform review controls surrounding technical accounting matters. During the year ended December 31, 2023, we implemented formal review processes which included review by our Chief Executive Officer and Chief Financial Officer of material contracts and invoices. In addition, we engaged third-party experts to review the accounting treatment for significant transactions. As of December 31, 2023, our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework - 2013. Based on this assessment and implementation of our remediation plans, management concluded that, as of December 31, 2023, our internal controls over financial reporting were effective.

 

-40-
 

 

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to the exemption provided to issuers that are not “large accelerated filers” nor “accelerated filers” under the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as issuers that are “emerging growth companies” under the JOBS Act.

 

Changes in Internal Control Over Financial Reporting

 

Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

ITEM 9B. OTHER INFORMATION

 

During the quarter ended December 31, 2023, none of our directors or executive officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” as such terms are defined under Rule 408 of Regulation S-K.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

Not applicable.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The information required by this item is incorporated by reference from the information contained in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the Annual Meeting of Stockholders to be held in 2024 (the “2024 Proxy Statement”), under the heading “Election of Directors.”

 

ITEM 11. EXECUTIVE COMPENSATION

 

The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement under the heading “Executive Compensation.”

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement under the headings “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.”

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement under the headings “Family Relationships and other Arrangements.”

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required by this item is incorporated by reference from the information contained in the 2024 Proxy Statement under the heading “Proposal 2: Ratification of the Appointment of Our Independent Registered Public Accounting Firm for Fiscal Year Ending December 31, 2024.”

 

-41-
 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

(a) The following documents are filed as part of this report:

 

  (1) Financial Statements:

 

  Page
Index to Consolidated Financial Statements: F-1
   
Consolidated Financial Statements:  
   
Report of the Independent Registered Public Accounting Firm F-2
Consolidated Balance Sheets as of December 31, 2023 and 2022 F-3
Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 F-4
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Years ended December 31, 2023 and 2022 F-5
Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 F-6
Notes to the Consolidated Financial Statements F-7

 

The consolidated financial statements required by this Item are included beginning at page F-1.

 

  (1) Financial Statement Schedules:

 

All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.

 

-42-
 

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation, currently in effect (Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
3.2   Amendment to Amended and Restated Certificate of Incorporation dated October 6, 2022 (Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
3.3   Amendment to Amended and Restated Certificate of Incorporation dated May 30, 2023 (Incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
3.4   Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
3.5   Amendment to Amended and Restated Certificate of Incorporation dated August 28, 2023 (Incorporated by reference to Exhibit 3.6 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
4.1   Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
10.1   Professional Services Contract dated as of May 4, 2021 by and between the Company and Indiana Family and Social Services Administration, NeuroDiagnostic Institute (Incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.2   Amendment No. 1 to Professional Services Contract by and between the Company and Indiana Family and Social Services Administration, NeuroDiagnostic Institute (Incorporated by reference to Exhibit 10.2 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.3   Amendment No. 2 to Professional Services Contract by and between the Company and Indiana Family and Social Services Administration, NeuroDiagnostic Institute (Incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.4+   Syra Health Corp. 2022 Omnibus Equity Incentive Plan (Incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.5+   Employment Agreement by and between the Company and Deepika Vuppalanchi dated April 15, 2021 (Incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.6+   Amendment No. 1 to Employment Agreement by and between the Company and Deepika Vuppalanchi dated September 1, 2021 (Incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.7+   Amendment No. 2 to Employment Agreement by and between the Company and Deepika Vuppalanchi dated March 1, 2022 (Incorporated by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.8+   Amendment No. 3 to Employment Agreement by and between the Company and Deepika Vuppalanchi dated October 18, 2022 (Incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.9   Business Loan Agreement by and between the Company and Citizens State Bank of New Castle dated February 7, 2022 (Incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.10   Commercial Security Agreement by and between the Company and Citizens State Bank of New Castle dated February 7, 2022 (Incorporated by reference to Exhibit 10.11 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.11   Promissory Note by and between the Company and Citizens State Bank of New Castle dated February 7, 2022 (Incorporated by reference to Exhibit 10.12 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.12   Professional Services Contract dated as of September 3, 2021 by and between the Company and Indiana Family and Social Services Administration, Division of Mental Health and Addiction (Incorporated by reference to Exhibit 10.13 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.13   STVentures Lease Agreement dated July 1, 2021 by and between the Company and STVentures LLC (Incorporated by reference to Exhibit 10.14 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)

 

-43-
 

 

10.14   Commercial Lease Addendum dated May 1, 2022 by and between the Company and STVentures LLC (Incorporated by reference to Exhibit 10.15 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.15   Modification of Loan Agreement by and between the Company and Citizens State Bank of New Castle dated December 16, 2022 (Incorporated by reference to Exhibit 10.18 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.16   Modification of Loan Agreement by and between the Company and Citizens State Bank of New Castle dated March 8, 2023 (Incorporated by reference to Exhibit 10.19 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.17+   Employment Agreement by and between the Company and Sandeep Allam dated February 29, 2022 (Incorporated by reference to Exhibit 10.20 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.18+   Amendment No. 1 to Employment Agreement by and between the Company and Sandeep Allam dated October 18, 2022 (Incorporated by reference to Exhibit 10.21 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.19+   Employment Agreement by and between the Company and Priya Prasad dated February 29, 2022 (Incorporated by reference to Exhibit 10.22 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.20+   Amendment No. 1 to Employment Agreement by and between the Company and Priya Prasad dated May 27, 2022 (Incorporated by reference to Exhibit 10.23 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.21+   Amendment No. 2 to Employment Agreement by and between the Company and Priya Prasad dated October 18, 2022 (Incorporated by reference to Exhibit 10.24 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.22   Amendment No. 1 to Professional Services Contract dated as of April 25, 2023 by and between the Company and Indiana Family and Social Services Administration, Division of Mental Health and Addiction (Incorporated by reference to Exhibit 10.25 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.23   Business Loan Agreement by and between the Company and Citizens State Bank of New Castle dated May 22, 2023 (Incorporated by reference to Exhibit 10.26 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.24   Commercial Security Agreement by and between the Company and Citizens State Bank of New Castle dated May 22, 2023 (Incorporated by reference to Exhibit 10.27 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.25   Promissory Note by and between the Company and Citizens State Bank of New Castle dated May 22, 2023 (Incorporated by reference to Exhibit 10.28 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
10.26   Modification of Loan Agreement by and between the Company and Citizens State Bank of New Castle dated August 24, 2023 (Incorporated by reference to Exhibit 10.29 to the Company’s Registration Statement on Form S-1/A filed on September 13, 2023)
23.1*   Consent of M&K CPAS, PLLC, independent registered public accounting firm
24.1*   Power of Attorney (included on the signature page to this registration statement)
31.1*   Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
97.1*   Clawback Policy
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
104*   Cover Page Interactive Data File - the cover page of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 is formatted in Inline XBRL
* Filed herewith.
** Furnished herewith.
+ Indicates a management contract or any compensatory plan, contract or arrangement.
† Certain of the schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(10). The Company hereby undertakes to furnish supplementally a copy of all omitted schedules to the SEC upon its request.

 

ITEM 16. FORM 10-K SUMMARY

 

None.

 

-44-
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on this 25th day of March, 2024.

 

  SYRA HEALTH CORP.
   
  By: /s/ Deepika Vuppalanchi
    Deepika Vuppalanchi
    Chief Executive Officer and Director

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Deepika Vuppalanchi as his or her attorney-in-fact, with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Deepika Vuppalanchi   Chief Executive Officer (Principal Executive Officer)   March 25, 2024 
Deepika Vuppalanchi        
         
/s/ Priya Prasad   Chief Financial Officer and Chief Operating Officer    March 25, 2024
Priya Prasad   (Principal Financial and Accounting Officer)    
         
/s/ Sandeep Allam       March 25, 2024
Sandeep Allam   President and Chairman    
         
/s/ Sherron Rogers   Director   March 25, 2024 
Sherron Rogers        
         
/s/ Andrew M. Dahlem   Director   March 25, 2024 
Andrew M. Dahlem        
         
/s/ Vijayapal R. Reddy   Director   March 25, 2024 
Vijayapal R. Reddy        
         
/s/ Ketan Paranjape   Director   March 25, 2024 
Ketan Paranjape        
         
/s/ Avutu S. Reddy   Director   March 25, 2024
Avutu S. Reddy        

 

-45-

 EX-4.1 2 ex4-1.htm

 

Exhibit 4.1

 

DESCRIPTION OF SECURITIES

 

Class A Common Stock and Class B Common Stock

 

We have authorized Class A common stock and Class B common stock.

 

Dividend Rights

 

Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our Class A common stock and Class B common stock are entitled to share equally, identically, and ratably, on a per share basis, with respect to any dividend or distribution of cash or property paid or distributed by us if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine.

 

Voting Rights

 

Holders of our Class A common stock are entitled to one vote for each share and holders of our Class B common stock are entitled to 16.5 votes per share, on all matters submitted to a vote of stockholders. The holders of our Class A common stock and Class B common stock will generally vote together as a single class on all matters submitted to a vote of our stockholders, unless otherwise required by Delaware law or our Certificate of Incorporation. Delaware law could require either holders of our Class A common stock or Class B common stock to vote separately as a single class if (i) we were to seek to amend our Certificate of Incorporation to increase or decrease the aggregate number of authorized shares of such class or to increase or decrease the par value of a class of our capital stock, then that class would be required to vote separately to approve the proposed amendment; or (ii) we were to seek to amend our Certificate of Incorporation in a manner that alters or changes the powers, preferences or special rights of a class of our capital stock in a manner that affected its holders adversely, then that class would be required to vote separately to approve the proposed amendment.

 

Our Certificate of Incorporation does not provide for cumulative voting for the election of directors.

 

See the section titled “Risk Factors— Risks Related to this Offering and Our Class A Common Stock — The dual-class structure of our common stock as contained in our Certificate of Incorporation has the effect of concentrating voting control with those stockholders who held our Class B common stock prior to this offering. This ownership will limit or preclude your ability to influence corporate matters, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets, or other major corporate transactions requiring stockholder approval, and that may adversely affect the trading price of our Class A common stock.

 

Conversion

 

Each outstanding share of Class B common stock will be convertible at any time at the option of the holder into 10 shares of Class A common stock. In addition, each share of Class B common stock will convert automatically into 10 shares of Class A common stock upon death of the holder thereof or any transfer, whether or not for value, except for certain permitted transfers described in our Certificate of Incorporation, including, but not limited to, trusts for the benefit of the stockholder, and partnerships, corporations and other entities owned by the stockholder.

 

Subdivisions and Combinations

 

If we subdivide or combine in any manner outstanding shares of Class A common stock or Class B common stock, the outstanding shares of the other classes will be subdivided or combined in the same manner.

 

-1-
 

 

No Preemptive or Similar Rights

 

Our Class A common stock and Class B common stock are not entitled to preemptive rights and are not subject to conversion, redemption or sinking fund provisions, except for the conversion provisions with respect to the Class B common stock described above.

 

Right to Receive Liquidation Distributions

 

If we become subject to a liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Class A common stock and Class B common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

Fully Paid and Non-Assessable

 

All of the outstanding shares of our Class A common stock Class B common stock are, and the shares of our Class A common stock to be issued pursuant to this offering will be, fully paid and non-assessable.

 

-2-

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-274905) of our report dated March 25, 2024, of SYRA HEALTH CORP. relating to the audit of the financial statements as of December 31, 2023 and 2022, and for the periods then ended, included in this Annual Report (Form 10-K).

 

/s/ M&K CPA’s, PLLC

 

The Woodlands, Texas

March 25, 2024

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

Certification of Chief Executive Officer of Syra Health Corp.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Deepika Vuppalanchi, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Syra Health Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 25, 2024 /s/ Deepika Vupplanachi
  Deepika Vuppalanchi
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

Certification of Chief Financial Officer of Syra Health Corp.

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Priya Prasad, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Syra Health Corp.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 25, 2024 /s/ Priya Prasad
  Priya Prasad
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

 EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

Statement of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 1350 of Title 18 of the United States Code

 

Pursuant to Section 1350 of Title 18 of the United States Code as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Deepika Vuppalanchi and Priya Prasad, the Chief Executive Officer and Chief Financial Officer, respectively, of Syra Health Corp. (the “Company”), hereby certify that based on the undersigned’s knowledge:

 

1. The Company’s Annual Report on Form 10-K for the period ended December 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 25, 2024 /s/ Deepika Vuppalanchi
  Deepika Vuppalanchi
  Chief Executive Officer
  (Principal Executive Officer)
   
Date: March 25, 2024 /s/ Priya Prasad
  Priya Prasad
  Chief Financial Officer
  (Principal Financial and Accounting Officer)

 

 

 

 EX-97.1 7 ex97-1.htm

 

Exhibit 97.1

 

Syra Health Corp.

 

CLAWBACK POLICY

 

I. Purpose and Scope

 

The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this Clawback Policy (this “Policy”), which provides for the recovery of erroneously awarded Incentive Compensation (as defined below) in the event of a Triggering Event (as defined below). Unless otherwise defined herein, the capitalized terms have the meanings set forth under “XI. Definitions.”

 

II. Administration

 

This Policy is designed to comply with and shall be interpreted to be consistent with Section 10D of the Exchange Act, Rule 10D-1 of the Exchange Act, Nasdaq Listing Rule 5608 and other regulations, rules and guidance of the Securities and Exchange Commission (the “SEC”) thereunder, and related securities regulations and regulations of the stock exchange or association on which Company’s common shares are listed (collectively, the “Listing Standards”). This Policy shall be administered by the Compensation Committee of the Board, or in the absence of such committee, a majority of the independent directors serving on a subcommittee of the Board (any such committee or subcommittee of the Board, the “Committee”).

 

Any determinations made by the Committee shall be final and binding. In addition, the Company shall file all disclosures with respect to this Policy in accordance with the Listing Standards. The Committee hereby has the power and authority to enforce the terms and conditions of this Policy and to use any and all of the Company’s resources it deems appropriate to recoup any excess Incentive Compensation subject to this Policy.

 

III. Covered Executives

 

This Policy applies to the Company’s current and former Covered Executives, as determined by the Committee in accordance with the Listing Standards.

 

IV. Events That Trigger Recoupment Under This Policy

 

The Board or Committee will be required to recoup any excess Incentive Compensation received by any Covered Executive during the three (3) completed fiscal years (together with any intermittent stub fiscal year period(s) of less than nine (9) months resulting from the Company’s transition to different fiscal year measurement dates) immediately preceding the date the Company is deemed (as determined pursuant to the immediately following sentence) to be required to prepare a Covered Accounting Restatement of its financial statements (the “Three-Year Recovery Period”) irrespective of any fault, misconduct or responsibility of such Covered Executive for the Covered Accounting Restatement. For purposes of the immediately preceding sentence, the Company is deemed to be required to prepare a Covered Accounting Restatement on the earlier of: (A) the date upon which the Board or applicable committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Covered Accounting Restatement; or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare a Covered Accounting Restatement (each, a “Triggering Event”).

 

 
 

 

V. Excess Incentive Compensation: Amount Subject to Recovery

 

The amount of Incentive Compensation to be recovered shall be the excess of the Incentive Compensation “received” by the Covered Executive over the amount of Incentive Compensation which would have been received by the Covered Executive had the amount of such Incentive Compensation been calculated based on the restated amounts, as determined by the Committee. For purposes of this Policy, Incentive Compensation shall be deemed “received”, either wholly or in part, in the fiscal year during which any applicable Financial Reporting Measure is attained, even if the payment, vesting or grant of such Incentive Compensation occurs after the end of such fiscal year. Amounts required to be recouped under this Policy shall be calculated on a pre-tax basis. The date of receipt of the Incentive Compensation depends upon the terms of the award of such Incentive Compensation. For example:

 

a.If the grant of an award of Incentive Compensation is based, either wholly or in part, on the satisfaction of a Financial Reporting Measure performance goal, then the award would be deemed received in the fiscal period when that measure was satisfied;

 

b.If the vesting of an equity award of Incentive Compensation occurs only upon the satisfaction of a Financial Reporting Measure performance condition, then the award would be deemed received in the fiscal period when it vests;

 

c.If the earning of a non-equity incentive plan award of Incentive Compensation is based on the satisfaction of the relevant Financial Reporting Measure performance goal, then the non-equity incentive plan award will be deemed received in the fiscal year in which that performance goal is satisfied; and

 

d.If the earning of a cash award of Incentive Compensation is based on the satisfaction of a Financial Reporting Measure performance goal, then the cash award will be deemed received in the fiscal period when that measure is satisfied.

 

It is specifically understood that, to the extent that the impact of the Covered Accounting Restatement on the amount of Incentive Compensation received cannot be calculated directly from the information in the Covered Accounting Restatement (e.g., if such restatement’s impact on the Company’s share price is not clear), then such excess amount of Incentive Compensation shall be determined based on the Committee’s reasonable estimate of the effect of the Covered Accounting Restatement on the share price or total shareholder return upon which the Incentive Compensation was received. The Company shall maintain documentation for the determination of such excess amount and provide such documentation to the Nasdaq Stock Market (“Nasdaq”).

 

2
 

 

VI. Method of Recovery

 

The Committee will determine, in its sole discretion, the methods for recovering excess Incentive Compensation hereunder, which methods may include, without limitation:

 

a.requiring reimbursement of cash Incentive Compensation previously paid;

 

b.seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any equity-based awards;

 

c.offsetting the recouped amount from any compensation otherwise owed by the Company to the Covered Executive;

 

d.cancelling outstanding vested or unvested equity awards; and/or

 

e.taking any other remedial and recovery action permitted by law, as determined by the Committee.

 

Notwithstanding anything in this Section VI, and subject to applicable law, the Committee may cause recoupment under this Policy from any amount of Incentive Compensation approved, awarded, granted, paid or payable to any Covered Executive prior to, on, or following the Effective Date (as defined below).

 

VII. Impracticability

 

The Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Committee in accordance with the Listing Standards. It is specifically understood that recovery will only be deemed impractical if: (A) the direct expense paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered (before concluding that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on the expense of enforcement, the Committee shall make a reasonable attempt to recover such erroneously awarded Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq); (B) recovery would violate home country law where that law was adopted prior to the November 28, 2022 (before concluding that it would be impracticable to recover any amount of erroneously awarded Incentive Compensation based on violation of home country law, the Committee shall obtain an opinion of home country counsel, acceptable to the applicable national securities exchange or association on which Company’s common shares are trading, that recovery would result in such a violation, and must provide such opinion to the exchange or association); or (C) recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a), and the regulations promulgated thereunder.

 

VIII. Other Recoupment Rights; Acknowledgement

 

The Committee may require that any employment agreement, equity award agreement, or similar agreement entered into on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company. The Company shall provide notice and seek written acknowledgement of this Policy from each Covered Executive; provided, that the failure to provide such notice or obtain such acknowledgement shall have no impact on the applicability or enforceability of this Policy to, or against, any Covered Executive.

 

3
 

 

IX. No Indemnification of Covered Executives

 

Notwithstanding any right to indemnification under any plan, policy or agreement of the Company or any of its affiliates, the Company shall not indemnify any Covered Executives against the loss of any excess Incentive Compensation. In addition, the Company will be prohibited from paying or reimbursing a Covered Executive for premiums of any third-party insurance purchased to fund any potential recovery obligations.

 

X. Indemnification

 

To the extent allowable pursuant to applicable law, each member of the Board or the Committee and any officer or other employee to whom authority to administer any component of this Policy is designated shall be indemnified and held harmless by the Company from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by such member in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be a party or in which he or she may be involved by reason of any action or failure to act pursuant to this Policy and against and from any and all amounts paid by him or her in satisfaction of judgment in such action, suit, or proceeding against him or her; provided, however, that he or she gives the Company an opportunity, at its own expense, to handle and defend the same before he or she undertakes to handle and defend it on his or her own behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such individuals may be entitled pursuant to the Company’s Articles of Incorporation or Bylaws, as a matter of law, or otherwise, or any power that the Company may have to indemnify them or hold them harmless.

 

XI. Effective Date

 

This Policy shall be effective as of the date the Policy is adopted by the Board (the “Board Adoption Date”). This Policy shall apply to any Incentive Compensation that is received by Covered Executives on or after October 2, 2023 (the “Effective Date”), even if such Incentive Compensation was approved, awarded, granted, or paid to Covered Executives prior to the Effective Date or the Board Adoption Date.

 

XII. Amendment and Termination; Interpretation

 

The Board may amend this Policy from time to time in its sole discretion and shall amend this Policy as it deems necessary to reflect and comply with further regulations, rules and guidance of the SEC, and Nasdaq Listing Rules. The Board may terminate this Policy at any time. The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. This Policy is designed and intended be interpreted in a manner that is consistent with the requirements of the Listing Standards. To the extent of any inconsistency between this Policy and such regulations, rules and guidance, such regulations, rules and guidance shall control and this Policy shall be deemed amended to incorporate such regulations, rules and guidance until or unless the Board or the Committee expressly determine otherwise. This Policy shall be applicable, binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives, to the fullest extent of the law. For the avoidance of doubt, this Policy shall be in addition to (and not in substitution of) any other clawback policy of the Company in effect from time to time or applicable to any Covered Executive.

 

4
 

 

XIII. Definitions

 

For purposes of this Policy, the following terms shall have the following meanings:

 

1.“Company” means Syra Health Corp.

 

2.A “Covered Accounting Restatement” is any accounting restatement of the Company’s financial statements due to the Company’s material noncompliance with any financial reporting requirement under U.S. securities laws. A Covered Accounting Restatement includes any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (commonly referred to as “Big R” restatements), or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (commonly referred to as “little r” restatements). A Covered Accounting Restatement does not include (A) an out-of-period adjustment when the error is immaterial to the previously issued financial statements, and the correction of the error is also immaterial to the current period; (B) a retrospective application of a change in accounting principle; (C) a retrospective revision to reportable segment information due to a change in the structure of an issuer’s internal organization; (D) a retrospective reclassification due to a discontinued operation; (E) a retrospective application of a change in reporting entity, such as from a reorganization of entities under common control; or (F) a retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.

 

3.“Covered Executive” means any person who:

 

a.Has received applicable Incentive Compensation:

 

i.During the Three-Year Recovery Period; and
ii.After beginning service as an Executive Officer; and

 

5
 

 

b.Has served as an Executive Officer at any time during the performance period for such Incentive Compensation.

 

4.“Exchange Act” means the Securities and Exchange Act of 1934, as amended.

 

5.“Executive Officer(s)” means an “executive officer” as defined in Exchange Act Rule 10D-1(d) and the Listing Standards, and includes any person who is the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the issuer in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company (with any executive officers of the Company’s parent(s) or subsidiaries being deemed Covered Executives of the Company if they perform such policy making functions for the Company), and such other senior executives/employees who may from time to time be deemed subject to the Policy by the Board in its sole discretion. All executive officers of the Company identified by the Board pursuant to 17 CFR 229.401(b) shall be deemed “Executive Officers.”

 

6.“Financial Reporting Measure(s)” means any measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measures, including share price and total shareholder return, including but not limited to, financial reporting measures including “non-GAAP financial measures” for purposes of Exchange Act Regulation G and 17 CFR 229.10, as well other measures, metrics and ratios that are not non-GAAP measures, like same store sales. Financial Reporting Measures may or may not be included in a filing with the SEC, and may be presented outside the Company’s financial statements, such as in Management’s Discussion and Analysis of Financial Conditions and Results of Operations or the performance graph. Financial Reporting Measures include without limitation, any of the following:

 

a.Company share price.
b.Total shareholder return.
c.Revenues.
d.Net income.
e.Earnings before interest, taxes, depreciation, and amortization (EBITDA).
f.Funds from operations.
g.Liquidity measures such as working capital or operating cash flow.
h.Return measures such as return on invested capital or return on assets.
i.Earnings measures such as earnings per share.

 

6
 

 

7.“Incentive Compensation” means any compensation which was approved, awarded or granted to, or earned by a Covered Executive (A) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (B) following on or after the Effective Date (including any award under any long-term or short-term incentive compensation plan of the Company, including any other short-term or long-term cash or equity incentive award or any other payment) that, in each case, is granted, earned, or vested based wholly or in part upon the attainment of any Financial Reporting Measure (i.e., any measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measure that is derived wholly or in part from such measures, including share price and total shareholder return). Incentive Compensation may include (but is not limited to) any of the following:

 

a.Annual bonuses and other short- and long-term cash incentives;
b.Stock options;
c.Stock appreciation rights;
d.Restricted shares;
e.Restricted share units;
f.Performance shares; and
g.Performance units.

 

7
 

 

APPENDIX I

 

Acknowledgment of Clawback Policy

 

I, the undersigned, agree and acknowledge that I am fully bound by, and subject to, all of the terms and conditions of the Syra Health Corp. Clawback Policy (as may be amended, restated, supplemented or otherwise modified from time to time, the “Policy”) of Syra Health Corp. (the “Company”) if I am a “Covered Executive” or become a “Covered Executive.”

 

In the event of any inconsistency between the Policy and the terms of any agreement to which I am a party, or the terms of any compensation plan, program or agreement under which any compensation has been, or will be, granted, awarded, earned or paid, the terms of the Policy shall govern. In the event it is determined by the Compensation Committee of the Board of Directors of the Company (the “Committee”) that any amounts granted, awarded, earned or paid to me must be forfeited or reimbursed by the Company, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. Any capitalized terms used in this Acknowledgement without definition shall have the meaning set forth in the Policy.

 

By:     Date:  
Name:        
Title:        

 

8

 

 GRAPHIC 8 form10-k_001.jpg begin 644 form10-k_001.jpg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end GRAPHIC 9 ex23-1_001.jpg begin 644 ex23-1_001.jpg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end GRAPHIC 10 image_001.jpg begin 644 image_001.jpg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syra-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995512 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Basic and Diluted Earnings per Share link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Lease link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Common Stock Options link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Basic and Diluted Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - Stockholders’ Equity (Deficit) (Tables) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Common Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 995538 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995539 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995540 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995541 - Disclosure - Schedule of Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995542 - Disclosure - Schedule of Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995543 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995544 - Disclosure - Schedule of Property and Equipment (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995546 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995547 - Disclosure - Accrued Expenses (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995548 - Disclosure - Schedule of Recognized Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995549 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995550 - Disclosure - Schedule of Lease Cost expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995551 - Disclosure - Schedule of Supplemental Balance Sheets Information (Details) link:presentationLink link:calculationLink link:definitionLink 995552 - Disclosure - Schedule of Supplemental Cash Flow and Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 995553 - Disclosure - Schedule of Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 995554 - Disclosure - Lease (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995556 - Disclosure - Summary of Activity of Outstanding Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 995557 - Disclosure - Stockholders’ Equity (Deficit) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995558 - Disclosure - Schedule of Share-Based Compensation, Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 995559 - Disclosure - Common Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995560 - Disclosure - Schedule of Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 995561 - Disclosure - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 995562 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995563 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 syra-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 13 syra-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 14 syra-20231231_lab.xml XBRL LABEL FILE Related Party, Type [Axis] Nonrelated Party [Member] Related Party [Member] Class of Stock [Axis] Common Class A [Member] Convertible Class B Common Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Over-Allotment Option [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Underwriting Agreement [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Family and Social Services Administration (FSSA) [Member] Product and Service [Axis] Healthcare Workforce [Member] FSSA – NeuroDiagnostic Institute [Member] Population Health [Member] FSSA – Division of Mental Health and Addiction [Member] Accounts Receivable [Member] Digital Health [Member] Behavioral and Mental Services [Member] Health Education [Member] Sahasra Technologies Corp [Member] ST Logics [Member] STVentures [Member] Information Technology Services [Member] RAD CUBE LLC [Member] Recruitment and Human Resource Services [Member] NLogix [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Long-Lived Tangible Asset [Axis] Office Equipment [Member] Leasehold Improvements [Member] Furniture and Fixtures [Member] Credit Facility [Axis] Revolving Credit Facility [Member] Loan Agreement [Member] Debt Instrument [Axis] Convertible Promissory Notes [Member] Subscription Agreements [Member] Insurance Policy Financing Arrangements [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Convertible Common Stock B [Member] Common Class B [Member] Private Placement [Member] Legal Entity [Axis] Kingswood Capital Partners LLC [Member] Award Type [Axis] Restricted Stock [Member] Title of Individual [Axis] Consultant [Member] Six Consultant [Member] Convertible Common Stock B Issuances [Member] Plan Name [Axis] Omnibus Equity Incentive Plan [Member] Ten Employees [Member] Three Consultants [Member] Five Board Members [Member] Financial Instrument [Axis] Equity Option [Member] Two Investors [Member] Subsequent Event Type [Axis] Subsequent Event [Member] November 2023 [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Accounts receivable Other current assets Total current assets Deferred offering costs Property and equipment, net Right-of-use asset Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities: Accounts payable Accrued expenses Current portion of operating lease liability, related party Notes payable Revolving line of credit Total current liabilities Operating lease liability, related party Total liabilities Commitments and contingencies Stockholders’ equity (deficit): Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares designated, issued and outstanding Common stock value Additional paid-in capital Accumulated deficit Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Net revenues Cost of services Gross profit Operating expenses: Salaries and benefits Professional services Research and development expenses Selling, general and administrative expenses Depreciation Total operating expenses Operating loss Other income (expense): Interest income Interest expense Total other income (expense) Net loss Weighted average common shares outstanding - basic Weighted average common shares outstanding - diluted Net loss per common share - basic Net loss per common share - diluted Balance Balance, shares Class A common stock sold for cash Class A common stock sold for cash, shares Class A common stock issued for services Class A common stock issued for services, shares Class A common stock options issued for services Net loss Cancellation of Class A common stock Cancellation of Class A common stock, shares Class A common stock issued for debt conversion Class A common stock issued for debt conversion ,shares Stock-based compensation Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Non-cash lease expense Amortization of debt discounts Common stock issued for services Stock-based compensation Decrease (increase) in assets: Accounts receivable Accounts receivable, related party Other current assets Right-of-use asset Increase (decrease) in liabilities: Accounts payable Accounts payable, related parties Accrued expenses Operating lease liability Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Payments on deferred offering costs Repayment of notes payable Proceeds received on sale of Class A common stock Proceeds received from line of credit Repayments on line of credit Advances received from related party Repayments on advances from related party Proceeds received from convertible notes payable Net cash provided by financing activities NET CHANGE IN CASH CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD SUPPLEMENTAL INFORMATION: Interest paid Income taxes paid NON-CASH INVESTING AND FINANCING ACTIVITIES: Initial recognition of right-of-use asset and lease liability Class A common stock issued for debt and interest conversion Cancellation of Class A common stock Non-cash application of invoices to STLogics loan Prepaid asset financed with notes payable Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance [Table Text Block] Company Selected Measure Name Named Executive Officers, Footnote [Text Block] Peer Group Issuers, Footnote [Text Block] Changed Peer Group, Footnote [Text Block] PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote [Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Equity Valuation Assumption Difference, Footnote [Text Block] Compensation Actually Paid vs. Total Shareholder Return [Text Block] Compensation Actually Paid vs. Net Income [Text Block] Compensation Actually Paid vs. Company Selected Measure [Text Block] Total Shareholder Return Vs Peer Group [Text Block] Compensation Actually Paid vs. Other Measure [Text Block] Tabular List [Table Text Block] Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Attributable to Parent Company Selected Measure Amount Other Performance Measure Amount Adjustment to Compensation Amount PEO Name Measure Name Non-GAAP Measure Description [Text Block] Additional 402(v) Disclosure [Text Block] Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis [Text Block] Stock Price or TSR Estimation Method [Text Block] Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined [Text Block] Forgone Recovery, Individual Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability [Text Block] Outstanding Recovery, Individual Name Outstanding Recovery Compensation Amount Restatement Does Not Require Recovery [Text Block] Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure [Text Block] Award Timing Method [Text Block] Award Timing Predetermined [Flag] Award Timing MNPI Considered [Flag] Award Timing, How MNPI Considered [Text Block] MNPI Disclosure Timed for Compensation Value [Flag] Awards Close in Time to MNPI Disclosures [Table Text Block] Awards Close in Time to MNPI Disclosures, Individual Name Award Underlying Securities Amount Award Exercise Price Award Grant Date Fair Value Underlying Security Market Price Change, Percent Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Arrangement Duration Aggregate Available Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted [Flag] Insider Trading Policies and Procedures Not Adopted [Text Block] Accounting Policies [Abstract] Nature of Business and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Related Party Transactions [Abstract] Related Party Transactions Earnings Per Share [Abstract] Basic and Diluted Earnings per Share Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Other Current Assets Property, Plant and Equipment [Abstract] Property and Equipment Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Debt Lease Lease Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Stockholders’ Equity (Deficit) Common Stock Options Income Tax Disclosure [Abstract] Income Taxes Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Concentrations of Credit Risk Fair Value of Financial Instruments Cash and Cash Equivalents Accounts Receivable Deferred Offering Costs Property and Equipment Impairment of Long-Lived Assets Leases Segment Reporting Revenue Recognition Cost of Services Significant Concentrations Research and Development Costs Stock-Based Compensation Basic and Diluted Loss Per Share Income Taxes Uncertain Tax Positions Recently Adopted Accounting Standards Schedule of Disaggregation of Revenue Schedule of Diluted Earnings Per Share Schedule of Other Current Assets Schedule of Property and Equipment Schedule of Accrued Expenses Schedule of Recognized Interest Expense Schedule of Lease Cost expenses Schedule of Supplemental Balance Sheets Information Schedule of Supplemental Cash Flow and Other Information Schedule of Minimum Lease Payments Summary of Activity of Outstanding Stock Warrants Schedule of Share-Based Compensation, Stock Options Activity Schedule of Effective Income Tax Rate Schedule of Deferred Tax Assets Schedule of Product Information [Table] Product Information [Line Items] Net revenues Aggregate shares issued Public offering price Warrant exercise price Gross proceeds Offering cost Options to purchase stock Number of warrants issued Gross proceeds from warrant exercise FDIC insured amount Cash equivalents Accounts receivable Property and equipment useful life Revenue percentage Revenues Cash Working capital Accumulated deficit Convertible notes payable Proceeds from commnon stock Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Principal debt Repayments on advances from related party Advanced balance of loan Other liabilities Receivable from related party Lease term Base monthly rent Lease expense Service cost Accounts payable, related parties Conversion of stock, shares converted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total EDGE tax credit receivable Federal and State income tax receivable Prepaid insurance Prepaid rent Prepaid licensing and office fees Retainers paid on professional services Total other current assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, gross Less: Accumulated depreciation Total property and equipment, net Property plant and equipment useful life Accrued payroll and taxes Accrued expenses Accrued retirement contributions Accrued franchise taxes Accrued interest Total accrued expenses Employers contribution percentage match Employees contribution percentage Investment retirement account contribution expenses Accrued retirement contributions Interest on line of credit Interest on convertible notes payable Interest on notes payable Amortization of underwriting fee on line of credit Interest on credit card debt Total interest expense Line of Credit Facility [Table] Line of Credit Facility [Line Items] Revolving line of credit maximum borrowing limit Revolving line of credit Revolving line of facility description Proceeds from payments line of credit Proceeds from repayment of line of credit Underwriting fee Line of credit Principal amount Convertible promissory notes maturity date, description Convertible promissory notes, accrued interest Convertible promissory notes, conversion price Value of conversion of convertible securities issued Periodic interest payment Conversion of Convertible Securities issued, shares Interest rate percentage Repayment of notes payable Schedule Of Lease Cost Expenses Amortization of ROU asset Interest on lease liability Total operating lease cost Schedule Of Supplemental Balance Sheets Information Operating lease assets Noncurrent operating lease liability, related party Total operating lease liability Weighted-average remaining lease term (in years) (Year) Weighted-average discount rate (Rate) Operating cash flows used for operating leases Total operating lease liabilities 2024 2025 Total Amount representing interest Present value of net future minimum lease payments Less current portion Operating lease liability, related party, long term Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Office space Lease rent expense Litigation settlement expense Warrants outstanding beginning balance Weighted average exercises price, outstanding beginning balance Warrants granted Weighted average exercises price, granted Warrants cancelled Weighted average exercises price, cancelled Warrants exercised Weighted average exercises price, exercised Warrants outstanding ending balance Weighted average exercises price, outstanding ending balance Warrants exercisable ending balance Weighted average exercises price, exercisable ending balance Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Shares outstanding Shares of convertible common stock Common stock conversion basis Stock issued during period value new issues Stock issued during period shares new issues Share price Common stock voting rights Common stock shares outstanding Sale of Stock, Number of Shares Issued in Transaction Sale of Stock, Price Per Share Sale of Stock, Description of Transaction Proceeds from Issuance Initial Public Offering Deferred Offering Costs Class of Warrant or Right, Outstanding Proceeds from Issuance of Warrants Granted options Exercise price Granted options term Fair value of the options Dividend yield Risk free rate Volatility rate Exercise price Expected term Common stock, shares surrendered Warrants and rights outstanding term Warrants and rights outstanding intrinsic value Stock issued during period shares issued for services Stock issued during period value issued for services Stock issuance expense Number of options, beginning balance Weighted average exercise prices, ending balance Options granted Weighted average exercise price, granted Options cancelled Options forfeited Weighted average exercise price, forfeited Number of options, ending balance Weighted average exercise prices, ending balance Exercisable ending balance Weighted average exercise price, exercisable Schedule of Stock by Class [Table] Class of Stock [Line Items] Shares issued Vesting period Dividend rate Risk free interest rate Risk free interest rate Expected volatiltity Expected volatiltity rate Share based compensation recognized Share based compensation expense unrecognized Purchase of shares granted options Number of options vested Weighted average volatility rate Weighted average risk free interest rate Weighted average call option value Aggregate intrinsic value Share based compensation expense Number of options cancelled Exercise price of options cancelled Remaining contractual life Federal statutory income tax rate State income taxes Change in valuation allowance Net effective income tax rate Net deferred tax assets before valuation allowance Less: Valuation allowance Net deferred tax assets Tax provisions Income tax benefits Federal net operating losses Subsequent Event [Table] Subsequent Event [Line Items] Warrants to purchase Proceeds from issuance of warrants Restricted stock awarded Accrued retirement contributions. Convertible Promissory Notes [Member] Convertible Class B Common Stock [Member] STVentures [Member] Operating lease interest expense. Initial recognition of right of use asset and lease liability. Underwriting Agreement [Member] Family and Social Services Administration (FSSA) [Member] Sahasra Technologies Corp [Member] Information Technology Services [Member] RAD CUBE LLC [Member] Recruitment and Human Resource Services [Member] NLogix [Member] Employee retention tax credit receivables. Prepaid licensing and office fees. Retainers paid on professional services. Kingswood Capital Partners LLC [Member] Loan Agreement [Member] Preferred stock shares designated. Convertible Common Stock B [Member] Significant Concentrations [Policy Text Block] Working capital. Common stock shares surrendered. Six Consultant [Member] Consultant [Member] Cancellation of common stock. Convertible Common Stock B Issuances [Member] Omnibus Equity Incentive Plan [Member] Ten Employees [Member] Three Consultants [Member] Healthcare Workforce [Member] Population Health Management [Member] Digital Health Services [Member] Behavioral and Mental Services [Member] Health Education [Member] Number of options vested. Weighted average risk free interest rate. Weighted average exercise price. ST Logics [Member] Two Investors [Member] November 2023 [Member] FSSA – NeuroDiagnostic Institute [Member] FSSA – Division of Mental Health and Addiction [Member] Investment retirement account contribution expenses. Subscription Agreements [Member] Insurance Policy Financing Arrangements [Member] Five Board Members [Member] Supplemental balance sheets information table text block. Supplemental cash flow information table text block. Population Health [Member] Digital Health [Member] Number of warrants exercisable. Weighted average exercise price outstanding. Weighted average exercise price exercisable. Weighted average exercise price granted. Weighted average exercise price forfeitures. Weighted average exercise price exercised. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) Shares Issued, Value, Share-Based Payment Arrangement, Forfeited Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Increase (Decrease) in Accounts Receivable Increase (Decrease) in Accounts Receivable, Related Parties Increase (Decrease) in Other Current Assets Increase (Decrease) in Other Operating Assets and Liabilities, Net Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments of Debt Issuance Costs Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Lessee, Operating Leases [Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Revenues Accounts Receivable, after Allowance for Credit Loss Cash and Cash Equivalents, at Carrying Value Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accrued Employee Benefits, Current AccruedRetirementContributions Long-Term Line of Credit Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Effective Income Tax Rate Reconciliation, Percent Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net EX-101.PRE 15 syra-20231231_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - shares
 12 Months Ended
Dec. 31, 2023
Mar. 25, 2024
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Annual Report true  
Document Transition Report false  
Document Period End Date Dec. 31, 2023  
Document Fiscal Period Focus FY  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41822  
Entity Registrant Name SYRA HEALTH CORP.  
Entity Central Index Key 0001922335  
Entity Tax Identification Number 85-4027995  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 1119 Keystone Way N. #201  
Entity Address, City or Town Carmel  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46032  
City Area Code (463)  
Local Phone Number 345-8950  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol SYRA  
Security Exchange Name NASDAQ  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Elected Not To Use the Extended Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   5,731,587
Documents Incorporated by Reference [Text Block] Specified portions of the registrant’s proxy statement, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14 A in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “Proxy Statement”), are incorporated by reference into Part III of this Annual Report on Form 10-K. Except with respect to information specifically incorporated by reference in this Annual Report, the Proxy Statement is not deemed to be filed as part hereof.  
ICFR Auditor Attestation Flag false  
Document Financial Statement Error Correction [Flag] false  
Auditor Firm ID 2738  
Auditor Name M&K CPAS, PLLC  
Auditor Location Houston, TX  
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 3,280,075 $ 3,344
Other current assets 389,787 222,302
Total current assets 4,781,110 1,426,743
Deferred offering costs 596,118
Property and equipment, net 78,974 112,493
Right-of-use asset 63,199 184,288
Total assets 4,923,283 2,319,642
Current liabilities:    
Accrued expenses 198,978 239,117
Current portion of operating lease liability, related party 63,199 121,089
Notes payable 184,904
Revolving line of credit 750,551
Total current liabilities 910,072 1,546,345
Operating lease liability, related party 63,199
Total liabilities 910,072 1,609,544
Commitments and contingencies
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares designated, issued and outstanding
Additional paid-in capital 9,071,745 2,832,308
Accumulated deficit (5,064,955) (2,126,612)
Total stockholders’ equity (deficit) 4,013,211 710,098
Total liabilities and stockholders’ equity (deficit) 4,923,283 2,319,642
Common Class A [Member]    
Stockholders’ equity (deficit):    
Common stock value 5,588 3,569
Convertible Class B Common Stock [Member]    
Stockholders’ equity (deficit):    
Common stock value 833 833
Nonrelated Party [Member]    
Current assets:    
Accounts receivable 1,060,634 1,201,097
Current liabilities:    
Accounts payable 462,991 432,388
Related Party [Member]    
Current assets:    
Accounts receivable 50,614
Current liabilities:    
Accounts payable $ 3,200
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares designated 0 0
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common Class A [Member]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 5,588,298 3,568,758
Common stock, shares outstanding 5,588,298 3,568,758
Convertible Class B Common Stock [Member]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 5,000,000 5,000,000
Common stock, shares issued 833,334 833,334
Common stock, shares outstanding 833,334 833,334
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net revenues $ 5,515,144 $ 5,617,706
Cost of services 4,103,244 4,555,924
Gross profit 1,411,900 1,061,782
Operating expenses:    
Salaries and benefits 2,292,295 1,524,971
Professional services 586,463 1,035,902
Research and development expenses 240,048
Selling, general and administrative expenses 1,131,922 575,755
Depreciation 48,771 14,849
Total operating expenses 4,299,499 3,151,477
Operating loss (2,887,599) (2,089,695)
Other income (expense):    
Interest income 2,942 63
Interest expense (53,686) (28,533)
Total other income (expense) (50,744) (28,470)
Net loss $ (2,938,343) $ (2,118,165)
Weighted average common shares outstanding - basic 4,877,861 3,041,085
Weighted average common shares outstanding - diluted 4,877,861 3,041,085
Net loss per common share - basic $ (0.60) $ (0.70)
Net loss per common share - diluted $ (0.60) $ (0.70)
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Statements of Stockholders' Equity (Deficit) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Convertible Class B Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 833 $ 467 $ (8,447) $ (7,147)
Balance, shares at Dec. 31, 2021 833,334      
Class A common stock sold for cash $ 2,769 2,319,731 2,322,500
Class A common stock sold for cash, shares   2,768,756        
Class A common stock issued for services $ 800 509,200 510,000
Class A common stock issued for services, shares   800,002        
Class A common stock options issued for services 2,910 2,910
Net loss (2,118,165) (2,118,165)
Balance at Dec. 31, 2022 $ 3,569 $ 833 2,832,308 (2,126,612) 710,098
Balance, shares at Dec. 31, 2022 3,568,758 833,334      
Class A common stock sold for cash $ 1,615 4,734,550 $ 4,736,165
Class A common stock sold for cash, shares   1,615,000        
Class A common stock issued for services, shares           0
Net loss (2,938,343) $ (2,938,343)
Cancellation of Class A common stock $ (42) 42
Cancellation of Class A common stock, shares   (41,666)        
Class A common stock issued for debt conversion $ 446 1,472,014 1,472,460
Class A common stock issued for debt conversion ,shares   446,206        
Stock-based compensation 32,831 32,831
Balance at Dec. 31, 2023 $ 5,588 $ 833 $ 9,071,745 $ (5,064,955) $ 4,013,211
Balance, shares at Dec. 31, 2023 5,588,298 833,334      
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (2,938,343) $ (2,118,165)
Adjustments to reconcile net loss to net cash used in operating activities:    
Non-cash lease expense 95,563
Depreciation 48,771 14,849
Amortization of debt discounts 14,076
Common stock issued for services 510,000
Stock-based compensation 32,831 2,910
Decrease (increase) in assets:    
Accounts receivable (59,547) (940,470)
Accounts receivable, related party (50,614)
Other current assets 203,110 (200,798)
Right-of-use asset 121,089
Increase (decrease) in liabilities:    
Accounts payable 30,603 392,276
Accounts payable, related parties (3,200) (82,418)
Accrued expenses (22,679) 163,675
Operating lease liability (121,089) (95,563)
Net cash used in operating activities (2,759,068) (2,244,065)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (15,251) (121,260)
Net cash used in investing activities (15,251) (121,260)
CASH FLOWS FROM FINANCING ACTIVITIES    
Payments on deferred offering costs (596,118)
Repayment of notes payable (185,692)
Proceeds received on sale of Class A common stock 5,332,283 2,322,500
Proceeds received from line of credit 300,000 2,819,275
Repayments on line of credit (1,050,551) (2,082,800)
Advances received from related party 1,295,010 94,000
Repayments on advances from related party (1,095,000) (288,200)
Proceeds received from convertible notes payable 1,455,000
Net cash provided by financing activities 6,051,050 2,268,657
NET CHANGE IN CASH 3,276,731 (96,668)
CASH AT BEGINNING OF PERIOD 3,344 100,012
CASH AT END OF PERIOD 3,280,075 3,344
SUPPLEMENTAL INFORMATION:    
Interest paid 36,226 11,651
Income taxes paid
NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Initial recognition of right-of-use asset and lease liability 131,187
Class A common stock issued for debt and interest conversion 1,472,460
Cancellation of Class A common stock 42
Non-cash application of invoices to STLogics loan 200,010
Prepaid asset financed with notes payable $ 370,596
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure [Table]    
Net Income (Loss) Attributable to Parent $ (2,938,343) $ (2,118,165)
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2023
Insider Trading Arrangements [Line Items]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business and Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Nature of Business and Significant Accounting Policies

Note 1 – Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Syra Health Corp. (“Syra” or the “Company”) was incorporated in the state of Indiana on November 20, 2020 to provide workforce staffing solutions, health education and healthcare research consulting services to mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, the Company redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana.

 

On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of 1,615,000 units (“Units”) at a public offering price of $4.125 per Unit, with each Unit consisting of (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). The Company received gross proceeds of approximately $6,661,876 from the sale of the Units before deducting underwriting discounts, commissions and offering expenses of $1,928,133 In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to 242,250 Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional 242,500 Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $2,422.

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Concentrations of Credit Risk

 

The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 under current regulations. The Company did not have any cash in excess of FDIC insured limits at December 31, 2023, and 2022, and has not experienced any losses in such accounts.

 

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

 

The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at December 31, 2023, and 2022.

 

Cash and Cash Equivalents

 

Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were no cash equivalents on hand at December 31, 2023, and 2022.

 

Accounts Receivable

 

Accounts receivable are carried at their estimated collectible amounts. Accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $5,520 at December 31, 2023, and $4,533 at December 31, 2022.

 

Deferred Offering Costs

 

Deferred offering costs related to the Company’s initial public offering (“IPO”) consisted principally of professional fees, legal and accounting, and other costs such as printing, and registration costs incurred in connection with the planned IPO of the Company and the sale of its Class A common stock. During the year ended December 31, 2022, the Company incurred $596,118 of costs, directly attributable to its proposed IPO, which were offset against the proceeds from the IPO that closed in 2023. In total, the Company incurred $1,928,133 of offering costs related to the IPO.

 

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a five-year life expectancy.

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 

Impairment of Long-Lived Assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

 

Leases

 

The Company accounts for its leases under ASC 842 – Leases. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

The Company has the following main forms of revenue:

 

  – Healthcare Workforce;
  – Population Health
  – Digital Health
  – Behavioral and Mental Health Services
  – Health Education

 

The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

 

The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognize revenue net of penalties.

 

Disaggregated revenue data

 

The Company’s revenue consists of the following revenue services within its industry: 

 

Net revenues:          
Healthcare workforce  $4,259,292   $5,260,370 
Population health   715,499    318,036 
Digital health   515,250    - 
Behavioral and mental services   12,797    - 
Health education   12,306    39,300 
Net revenues  $5,515,144   $5,617,706 

 

Cost of Services

 

The cost of services includes the wages and the related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while they work on contract assignments.

 

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For each of the years ended December 31, 2023 and 2022, FSSA accounted for approximately 68% and 98% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA – NeuroDiagnostic Institute, representing $3,734,004 and $5,214,128 of the Company’s healthcare workforce revenue, and the FSSA – Division of Mental Health and Addiction, which commenced on September 3, 2021, representing $305,000 and $306,000 of the Company’s Population Health revenues for the years ended December 31, 2023 and 2022, respectively. In addition, the combined divisions of the FSSA represented 30% and 99% of accounts receivable at December 31, 2023, and 2022, respectively.

 

Research and Development Costs

 

Research and development costs are expensed as incurred. The Company’s research and development costs consist of outside consultant fees to develop the Company’s technology-based solutions.

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

 

Basic and Diluted Loss Per Share

 

The Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Income Taxes

 

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

 

Uncertain Tax Positions

 

In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 

Recently Adopted Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.

 

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined in Rule 12b-2 of the Exchange Act) to fiscal years beginning after December 15, 2022, including interim periods. Early adoption is permitted. The Company meets the definition of a smaller reporting company and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade receivables, but that there was no material impact to the financial statements from the adoption of ASU 2016-13.

 

There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

 
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Going Concern
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Note 2 – Going Concern

 

As shown in the accompanying financial statements, as of December 31, 2023, the Company had a cash balance of $3,280,075, working capital of $3,871,038 and an accumulated deficit of $5,064,955 since inception. The Company is too early in its development stage to project revenue with a necessary level of certainty. Therefore, the Company may not have sufficient funds to sustain its operations for the next twelve months from the issuance date of these financial statements and may need to raise additional cash to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has commenced sales and continues to develop its operations. In the event sales do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that the Company will be successful in achieving these objectives.

 

The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means. The Company may not be successful in identifying suitable funding transactions in a sufficient time period or at all, and may not obtain the required capital by other means. If the Company does not succeed in raising additional capital, resources may not be sufficient to fund its business. The Company’s ability to scale production and distribution capabilities and further increase the value of its brands, is largely dependent on its success in raising additional capital. From January through April of 2023, the Company raised a total of $1,455,000 of capital from the sale of convertible notes. On October 3, 2023 the Company completed IPO received net proceeds of approximately $5,332,283. In October 2023, the convertible notes were converted into Class A common stock in accordance with the terms of the convertible promissory notes as a result of the IPO.

 

The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

 
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2023
Related Party Transactions [Abstract]  
Related Party Transactions

Note 3 – Related Party Transactions

 

Advances from Related Party

 

On various dates from July 11, 2023, through August 23, 2023, Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by the principal owners and management team of Syra, made short term, non-interest bearing advances due upon demand, of which an aggregate $1,295,010 advanced and we repaid an aggregate $1,095,000 of such advances. The Company pays for payroll and related costs for its employees that provide services to STLogics customers. During the year ended December 31, 2023, the Company applied $200,010 of such costs to reduce the balance of the advance to $0, and has a receivable from STLogics of $50,614 for additional costs incurred as of December 31, 2023.

 

During the year ended December 31, 2021, the Company’s operations were primarily financed by short term advances from Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by Priya Prasad, the Company’s Chief Financial Officer and Chief Operating Officer, and STLHoldings Corp. which is an entity beneficially owned by the principal owners and management team of Syra. On various dates from December 30, 2020, through April 4, 2022, Sahasra Technologies Corp. made short term, non-interest bearing advances due upon demand to the Company, of which an aggregate $94,000 was loaned during the years ended December 31, 2022. During the year ended December 31, 2022, the Company repaid in full the loans totaling $288,200.

 

 

Office Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, LLC (“STVentures”), an entity beneficially owned by the principal owners and the management team of Syra and their affiliates. The lease commenced on July 1, 2021, and provided for a base monthly rent of $5,332 over the three-year term of the lease, which was subsequently amended to $10,711, on May 1, 2022. A total of $128,527 and $107,013 of rent expense was included in selling, general and administrative expenses for the years ended December 31, 2023, and 2022, respectively.

 

Information Technology (“IT”) Services

 

The Company incurred a total of $3,320 and $23,260 of expenses from RAD CUBE LLC, which is an entity beneficially owned by the principal owners and the management team of the Company and their affiliates, for outsourced IT services which have been presented within selling, general and administrative expenses in the statement of operations during the years ended December 31, 2023, and 2022, respectively. An unpaid balance of $0 and $3,200 was outstanding at December 31, 2023, and 2022, respectively, as presented within accounts payable, related parties. The Company no longer receives services from RAD CUBE LLC.

 

Recruitment and Human Resource Services

 

The Company paid a total of $348,304 and $137,494 of recruitment and human resource services to NLogix, which is an entity beneficially owned by the principal owners and the management team of the Company and their affiliates, which have been presented within cost of sales in the statement of operations during the years ended December 31, 2023 and 2022, respectively.

 

Common Stock Issuances

 

The Company issued 83,334 shares of common stock on November 21, 2020 to its founders for services rendered in connection with the formation of the entity. In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which such shares were subsequently exchanged for 833,334 shares of convertible Class B common stock.

 
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Basic and Diluted Earnings per Share
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Basic and Diluted Earnings per Share

Note 4 – Basic and Diluted Earnings per Share

 

During the years ended December 31, 2023, and 2022, the Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

 

Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of December 31, 2023 and 2022 are as follows: 

 

   December 31, 2023   December 31, 2022 
Warrants   1,760,350    - 
Stock options   140,750    39,000 
Total   1,901,100    39,000 

 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Other Current Assets
 12 Months Ended
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Other Current Assets

Note 5 – Other Current Assets

 

Other current assets at December 31, 2023, and 2022 consisted of the following: 

 

   December 31,   December 31, 
   2023   2022 
EDGE tax credit receivable (1)  $-   $116,361 
Federal and State income tax receivable   73,069    28,734 
Prepaid insurance   316,718    20,040 
Prepaid rent   -    10,711 
Prepaid licensing and office fees   -    16,456 
Retainers paid on professional services   -    30,000 
Total other current assets  $389,787   $222,302 

 

(1)A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.

 
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 6 – Property and Equipment

 

Property and equipment at December 31, 2023, and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Office equipment – 5 year estimated life  $81,340   $127,549 
Leasehold improvements– 2 year estimated life   60,783    - 
Furniture and fixtures– 7 year estimated life   677    - 
Less: Accumulated depreciation   (63,827)   (15,056)
Total property and equipment, net  $78,974   $112,493 

 

Depreciation of property and equipment was $48,771 and $14,849 for the years ended December 31, 2023, and 2022, respectively.

 

 
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses

Note 7 – Accrued Expenses

 

Accrued expenses at December 31, 2023, and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Accrued payroll and taxes  $148,924   $212,660 
Accrued expenses   50,054    - 
Accrued retirement contributions   -    4,874 
Accrued franchise taxes   -    18,777 
Accrued interest   -    2,806 
Total accrued expenses  $198,978   $239,117 

 

The Company provides postretirement benefits pursuant to Internal Revenue Code of 1986, as amended, Section 401(k) for employees meeting specified criteria. The Company matches 100% of the employees’ contributions that are not in excess of 4% of the employee’s contributions. These matching contributions are fully vested and paid pursuant to the employees’ bi-weekly or semi-monthly pay periods. The Company does not prefund these benefits and has the right to modify or terminate certain of these benefits in the future. For the year ended December 31, 2023, the Company incurred $88,327 of investment retirement account contribution expenses pursuant to the Company’s matching contributions, including $8,778, as accrued at December 31, 2023. For the year ended December 31, 2022, the Company incurred $28,534 of investment retirement account contribution expenses pursuant to the Company’s matching contributions, including $4,874, as accrued at December 31, 2022.

 
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Debt
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Debt

Note 8 – Debt

 

Line of Credit

 

On February 7, 2022, the Company entered into a business loan agreement (as amended, the “loan agreement”) with Citizens State Bank of New Castle pursuant to which it originally received a revolving line of credit of up to $1,500,000 which was subsequently amended to $800,000 (as amended, the “Revolving Line of Credit”). Pursuant to the terms of the Revolving Line of Credit, the outstanding balance shall not exceed 75% of the Company’s outstanding accounts receivable due from the State of Indiana aged more than 90 days together with all other accounts receivable aged less than 90 days. The Revolving Line of Credit was to terminate on December 31, 2022, unless extended pursuant to the terms thereof. The Company received extensions on the Revolving Line of Credit such that it will now terminate on October 24, 2023; however, no further advances are available under the Revolving Line of Credit. In the event of a default, all commitments and obligations pursuant to the Revolving Line of Credit will terminate immediately and, at Citizens State Bank of New Castle’s request, all Indebtedness (as defined in the loan agreement) shall become immediately due and payable. Advances on the Revolving Line of Credit are pursuant to a promissory note dated February 7, 2022 which accrues interest at a variable rate of 1.5% above the national prime interest rate as quoted in the Wall Street Journal, not to be less than 4.75% per annum or more than 21% per annum or the maximum rate allowed by law. Interest shall increase by an 2.0% in the event of a default. Pursuant to the promissory note, the Company has been required to pay monthly payments of unpaid interest since March 7, 2022. The Company may prepay all or a portion of the amount due prior to the date upon which it is due without any penalty. In connection with the Revolving Line of Credit, the Company entered into a commercial security agreement with Citizens State Bank of New Castle dated February 7, 2022, pursuant to which it granted Citizens State Bank of New Castle a security interest in the Collateral (as defined in the commercial security agreement) to secure the Indebtedness (as defined in the commercial security agreement).

 

During the year ended December 31, 2023, the Company received proceeds of $300,000 and repaid total advances of $1,050,551. In addition, the Company paid an underwriting fee of $14,076 on February 7, 2022, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. The balance of the line of credit was $0 and $750,551 at December 31, 2023, and December 31, 2022, respectively. The Revolving Line of Credit was closed.

 

During the year ended December 31, 2022, the Company received total advances of $2,819,275, and repaid advances of $2,068,724. In addition, the Company paid an underwriting fee of $14,076, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. The balance of the line of credit was $750,551 at December 31, 2022.

 

 

Convertible Notes payable

 

On various dates from January through April 7, 2023, the Company entered into subscription agreements with accredited investors pursuant to which it issued convertible promissory notes in the aggregate principal amount of $1,455,000. The notes mature on various dates between July 10, 2024 and October 7, 2024, accrue interest at 2% per annum and may be prepaid by the Company at any time without any penalties. The holders may convert the principal amount of the notes together with accrued interest thereon at any time prior to the earlier of the maturity date and the effectiveness of the registration statement relating to the Company’s initial public offering at a conversion price of $6.00 per share. Upon the closing of the Next Equity Financing (as defined herein), the principal amount of the notes together with accrued interest thereon shall automatically convert into such number of shares of the Company’s Class A common stock determined by dividing (x) the outstanding principal balance and unpaid accrued interest of the notes on the date of conversion by (y) the price per share equal to the product of the price per Equity Security (as defined in the notes) sold in the Next Equity Financing multiplied by 80%. “Next Equity Financing” means an initial public offering by the Company of its Equity Securities pursuant to which such Equity Securities are listed on a national securities exchange. In addition, if prior to the maturity date of the notes, the notes remains outstanding, then in the event of a Corporate Transaction (as defined in the notes), the holder of each note may elect to convert the outstanding principal balance and unpaid accrued interest of each note, subject to the terms and conditions contained in the note, into Conversion Shares (as defined in the notes) immediately prior to the closing of such Corporate Transaction based upon a conversion price equal to the lesser of (i) the Corporate Transaction Price (as defined in the notes) or (ii) the quotient resulting from dividing (x) the Valuation Cap (as defined in the notes) by (y) the fully diluted capitalization immediately prior to the closing of the Corporate Transactions.

 

On October 3, 2023, a total of $1,472,460, consisting of $1,455,000 of principal and $17,460 of interest, was converted into an aggregate 446,206 shares of Class A common stock in accordance with the terms of the convertible promissory notes.

 

Notes Payable

 

The Company recognized interest expense for the years ended December 31, 2023, and 2022, as follows:

 

   December 31,   December 31, 
   2023   2022 
         
Interest on line of credit  $27,054   $14,397 
Interest on convertible notes payable   17,460    - 
Interest on notes payable   8,966      
Amortization of underwriting fee on line of credit   -    14,076 
Interest on credit card debt   206    60 
Total interest expense  $53,686   $28,533 

 

Insurance Notes Payable

 

In 2023, the Company entered into three insurance policy financing arrangements to purchase various insurance policies. The total principal of these arrangements is $370,596 with interest rates ranging from 10.38% through 14.05% and monthly payments totaling $32,328 are due through July 2024. During the year ended December 31, 2023, the Company repaid $185,692 on the insurance notes payable, and the remaining balance as of December 31, 2023 was $184,904.

 
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Lease
 12 Months Ended
Dec. 31, 2023
Lease  
Lease

Note 9 – Lease

 

The Company leases its current corporate headquarters under a three-year lease from STVentures, a related party. The lease, as amended on May 1, 2022 to expand the office space from 2,976 square feet to 5,978 square feet, commenced on July 1, 2021, and provides for a base monthly rent of $10,711, as increased from $5,332 per month, over the three-year term of the lease. The Company is occupying the space for executive and administrative offices. Rent expense was $128,527 and $107,013 for the years ended December 31, 2023 and 2022 respectively, which is included in other general and administrative expenses within the statements of operations.

 

 

The components of lease expense were as follows:

 

           
   For the Year Ended 
   December 31, 
   2023   2022 
Operating lease cost:          
Amortization of ROU asset  $121,089   $184,288 
Interest on lease liability   7,438    8,733 
Total operating lease cost  $128,527   $175,555 

 

Supplemental balance sheet information related to leases was as follows:

 

   December 31,   December 31, 
   2023   2022 
Operating lease:          
Operating lease assets  $63,199   $184,288 
           
Current portion of operating lease liability, related party  $63,199   $121,089 
Noncurrent operating lease liability, related party   -    63,199 
Total operating lease liability  $63,199   $184,288 
           
Weighted average remaining lease term:          
Operating leases   0.5 years    1.5 years 
           
Weighted average discount rate:          
Operating lease   5.75%   5.75%

 

Supplemental cash flow and other information related to operating leases was as follows:

 

           
   For the Year Ended 
   December 31, 
   2023   2022 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows used for operating leases  $121,089   $107,013 
           
Leased assets obtained in exchange for lease liabilities:          
Total operating lease liabilities  $-   $131,187 

 

Future minimum annual lease payments required under the operating lease and the present value of the net minimum lease payments are as follows at December 31, 2023:

 

For the Year  Minimum Lease 
Ended December 31:  Commitments 
2024  $64,263 
2025   - 
Total   64,263 
Amount representing interest  $(1,064)
Present value of net future minimum lease payments   63,199 
Less current portion   (63,199)
Operating lease liability, related party, long term  $- 

 

 
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10 – Commitments and Contingencies

 

Legal Contingencies

 

From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.

 

On June 28, 2022, the Company entered into a settlement agreement with a former employee pursuant to a wrongful termination lawsuit filed in the U.S. District Court, Southern District of Indiana in the amount of $28,000. The Company accrued the full amount of the settlement as of December 31, 2021, and the settlement was paid in July of 2022.

 

In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.

 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity (Deficit)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Stockholders’ Equity (Deficit)

Note 11 – Stockholders’ Equity (Deficit)

 

In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which the 83,334 outstanding shares of common stock were exchanged for 833,334 shares of convertible Class B common stock, as retrospectively applied. Each share of Class B common stock is entitled to 16.5 votes and is convertible at any time into ten shares of Class A common stock.

 

During March of 2022, the Company raised $1,000,000 of capital from the sale of 2,000,000 shares of Class A common stock at a share price of $0.50 in a private placement. On various dates between June and August of 2022, the Company also raised $1,322,500 of capital from the sale of 1,102,094 shares of Class A Common Stock at a share price of $1.20 in a private placement.

 

Amendment to Articles of Incorporation

 

On May 2, 2022, the Company filed an Amended and Restated Certificate of Incorporation that was subsequently amended on October 6, 2022 and May 30, 2023 to authorize the following:

 

  ● 100,000,000 shares of Class A common stock with a par value of $0.001 per share;
  ● 5,000,000 shares of convertible Class B common stock with a par value of $0.001 per share; and
  ● 10,000,000 shares of “blank check” preferred stock with a par value of $0.001 per share.

 

Liquidation rights: In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding up of the Company, the holders of Class A common stock and the holders of convertible Class B common stock shall be entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock.

 

Voting: The holders of the Class A common stock and the holders of the convertible Class B common stock shall at all times vote together as one class on all matters, including the election of directors, submitted to a vote or for the consent of the stockholders of the Company. Each holder of shares of convertible Class B common stock shall be entitled to 16.5 votes for each share of convertible Class B common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. Each holder of shares of Class A common stock shall be entitled to one vote for each share of Class A common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company.

 

Each share of convertible Class B common Stock was also convertible into 16.5 fully paid and nonassessable shares of Class A common stock. On October 6, 2022, the Company’s Amended and Restated Certificate of Incorporation was amended to change the conversion ratio from 16.5 shares to 10 shares of Class A common stock. The voting rights remain unchanged.

 

The voting powers, conversion features, if any, designations, preferences, limitations, restrictions and other rights of each series of preferred stock shall be prescribed by resolution of the Board of Directors at the time a specific series of preferred stock is designated. None of the preferred shares have been designated or issued to date.

 

 

Class A Common Stock

 

The Company has 100,000,000 authorized shares of $0.001 par value Class A common stock, and 5,588,298 shares were issued and outstanding as of December 31, 2023. 3,568,758 shares were issued and outstanding as of December 31, 2022.

 

Class A Common Stock Sales

 

On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of 1,615,000 units (“Units”) at a public offering price of $4.125 per Unit, with each Unit consisting of (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). The Company received gross proceeds of approximately $6,661,876 from the sale of the Units before deducting underwriting discounts, commissions and offering expenses of $1,928,133. In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to 242,250 Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional 242,500 Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $2,422.

 

On the Closing Date, the Company granted to the underwriter fully vested warrants to purchase 145,350 shares of the Company’s common stock, having an exercise price of $5.156 per share, exercisable over a 5-year term, to the Representative. The fair value of the warrants was estimated at $352,677 using a Black-Scholes option pricing model and the following assumptions: 1) dividend yield of 0%; 2) risk-free rate of 4.80%; 3) volatility of 122%; 4) a common stock price of $3.03, and 5) an expected term of 5 years. The fair value of the options was recognized as a cost of capital related to the IPO.

 

On May 10, 2023, a stockholder voluntarily surrendered 41,667 shares of Class A common stock, which were subsequently cancelled.

 

In June and August 2022, the Company raised a total of $1,322,500 of capital from the sale of an aggregate of 1,102,094 shares of Class A common stock to a total of 23 accredited investors at a share price of $1.20 in a private placement.

 

During March 2022, the Company raised an aggregate of $1,000,000 of capital from the sale of 2,000,000 shares of Class A common stock to a total of 22 accredited investors at a share price of $0.50 in a private placement.

 

The following is a summary of activity of outstanding stock warrants:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2021   -   $- 
Warrants granted   -    - 
Warrants cancelled   -    - 
Balance, December 31, 2022   -    - 
Warrants granted   2,002,850    6.40 
Warrants exercised   -    - 
Warrants cancelled   (242,500)   (6.50)
Balance, December 31, 2023   1,760,350   $6.39 
Exercisable, December 31, 2023   -   $- 

 

The warrants have a weighted average remaining contractual life of 4.75 years and no intrinsic value as of December 31, 2023.

 

Class A Common Stock Issued for Services

 

In November 2023, the Company award 50,000 shares of restricted stock to a consultant, which vest in four equal quarterly installments. The restricted shares had a fair value of $75,500 based on the stock price at the grant date, and the Company recognized $8,122 of expense during the year ended December 31, 2023. No shares were issued during the year ended December 31, 2023.

 

From February through May 2022, the Company awarded a total of 800,002 shares to six consultants for services provided. The shares were subsequently issued on August 3, 2022. The aggregate fair value of the shares was $510,000, based on recent sales of the Company’s Class A common stock to third parties.

 

Convertible Class B Common Stock

 

The Company has 5,000,000 authorized shares of $0.001 par value convertible Class B common stock, and had 833,334 shares issued and outstanding as of December 31, 2022 and 2021, as retrospectively applied, pursuant to the Company’s subsequent recapitalization in 2022 and effected as of May 3, 2022, whereby the founders exchanged their 83,334 founders shares for 833,334 shares of convertible Class B common stock.

 

 

Convertible Class B Common Stock Issuances

 

On November 21, 2020, the Company issued 83,334 shares of common stock to its founders for services rendered in connection with the formation of the entity. The aggregate fair value of the common stock was $100 based on par value of the Company’s common stock, as there was no immediate intrinsic value in the Company upon inception. In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which the equity was recapitalized with the exchange of the 83,334 shares of common stock for 833,334 shares of convertible Class B common stock, as retrospectively applied. Each share of convertible Class B common stock was convertible into 16.5 shares of Class A common stock, which was subsequently amended to be convertible into ten shares on of Class A common stock on October 4, 2022.

 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Common Stock Options
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Common Stock Options

Note 12 – Common Stock Options

 

Omnibus Equity Incentive Plan

 

On April 11, 2022, the Company’s board of directors adopted, and the Company’s stockholders approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan (“2022 Plan”). No more than 1,041,667 shares of the Company’s Class A common stock shall be issued pursuant to the exercise of incentive stock options and other securities under the 2022 Plan.

 

Class A Common Stock Option Awards

 

On November 8, 2023, the Company granted options to purchase an aggregate 32,750 shares of the Company’s common stock under the 2022 Plan, having an exercise price of $1.51 per share, exercisable over a 10-year term, to a total of ten employees. The options vest annually over four years from the date of grant.

 

On November 8, 2023, the Company granted options to purchase an aggregate 30,000 shares of the Company’s common stock under the 2022 Plan, having an exercise price of $1.51 per share, exercisable over a 10-year term, to a total of three consultants. The options vest quarterly over one year from the date of grant.

 

On October 9, 2023, the Company granted options to purchase an aggregate 50,000 shares of the Company’s common stock under the 2022 Plan, having an exercise price of $2.68 per share, exercisable over a 10-year term, to a total of five newly appointed board members. The options vest in four (4) equal annual installments with the first installment vesting on the date of grant.

 

The fair value of the options was estimated at $198,383 using a Black-Scholes option pricing model and the following assumptions: 1) dividend yield of 0%; 2) risk-free rate of 4.45% to 4.71%; 3) volatility of 112% to 115% based on; 4) a common stock price ranging from $1.51 to $2.68, and 5) an expected term of 6.25 years. During the year ended December 31, 2023, a total of $21,041 was recognized as expense related to stock options and $196,955 remains to be expensed.

 

On various dates between July 1, 2022 and September 1, 2022, the Company granted options to purchase an aggregate 32,502 shares of the Company’s Class A common stock at an exercise price of $1.20 per share under the 2022 Plan, which represented the recent sales price of securities to third parties. These options will vest 25% on each anniversary until fully vested. The options had no intrinsic value. The aggregate estimated value using the Black-Scholes Pricing Model, based on an expected term of 6.25 years, a weighted average volatility rate of 93%, a weighted average risk-free interest rate of 3.03%, and a weighted average call option value of $0.9328, was $30,317. The options are being expensed over the vesting period, resulting in $2,910 of stock-based compensation expense during the year ended December 31, 2022. During the fourth quarter of 2022, a total of 9,167 options at a strike price of $1.20 per share were cancelled.

 

 

The following is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2021   -   $- 
Options granted   39,000    1.00 
Options cancelled   -      
Balance, December 31, 2022   39,000    1.20 
Options granted   112,750    2.03 
Options forfeited   (11,000)   (1.00)
Balance, December 31, 2023   140,750   $1.82 
Exercisable, December 31, 2023   -   $- 

 

The options had a weighted average remaining life of 9.58 years and no intrinsic value as of December 31, 2023.

 
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 13 - Income Taxes

 

For the period from November 20, 2020 (inception) through December 31, 2023, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2023, and 2022, the Company had approximately $4,637,000 and $1,731,000 of federal net operating losses. Under the Tax Cuts and Jobs Act of 2017, the net operating loss carry forwards can be carried forward indefinitely, however the deductions are limited to 80% of taxable income.

 

The effective income tax rate for the years ended December 31, 2023 and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Federal statutory income tax rate   21%   21%
State income taxes   3%   3%
Change in valuation allowance   (24)%   (24)%
Net effective income tax rate   -    - 

 

The components of the Company’s deferred tax asset are as follows:

 

                 
    December 31,  
    2023     2022  
Deferred tax assets:                
Net deferred tax assets before valuation allowance   $ 1,029,723     $ 332,400  
Less: Valuation allowance     (1,029,723 )     (332,400 )
Net deferred tax assets   $ -     $ -  

 

Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2023 and 2022, respectively.

 

In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

 
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent Events
 12 Months Ended
Dec. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events

Note 14 – Subsequent Events

 

The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.

 

Subsequent to December 31, 2023, two investors exercised 130,789 warrants to purchase Class A Common stock pursuant to which the Company received cash proceeds of $850,139.

 

Subsequent to December 31, 2023, the Company issued 12,500 shares pursuant to the restricted stock award from November 2023.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business and Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 
Concentrations of Credit Risk

Concentrations of Credit Risk

 

The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 under current regulations. The Company did not have any cash in excess of FDIC insured limits at December 31, 2023, and 2022, and has not experienced any losses in such accounts.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

  - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

 

The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at December 31, 2023, and 2022.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were no cash equivalents on hand at December 31, 2023, and 2022.

 
Accounts Receivable

Accounts Receivable

 

Accounts receivable are carried at their estimated collectible amounts. Accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $5,520 at December 31, 2023, and $4,533 at December 31, 2022.

 
Deferred Offering Costs

Deferred Offering Costs

 

Deferred offering costs related to the Company’s initial public offering (“IPO”) consisted principally of professional fees, legal and accounting, and other costs such as printing, and registration costs incurred in connection with the planned IPO of the Company and the sale of its Class A common stock. During the year ended December 31, 2022, the Company incurred $596,118 of costs, directly attributable to its proposed IPO, which were offset against the proceeds from the IPO that closed in 2023. In total, the Company incurred $1,928,133 of offering costs related to the IPO.

 
Property and Equipment

Property and Equipment

 

Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a five-year life expectancy.

 

Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.

 
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

In accordance with the provisions of ASC Topic 360, “Impairment or Disposal of Long-Lived Assets”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.

 

 
Leases

Leases

 

The Company accounts for its leases under ASC 842 – Leases. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.

 

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

 
Segment Reporting

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.

 
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.

 

The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.

 

The Company has the following main forms of revenue:

 

  – Healthcare Workforce;
  – Population Health
  – Digital Health
  – Behavioral and Mental Health Services
  – Health Education

 

The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.

 

 

The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognize revenue net of penalties.

 

Disaggregated revenue data

 

The Company’s revenue consists of the following revenue services within its industry: 

 

Net revenues:          
Healthcare workforce  $4,259,292   $5,260,370 
Population health   715,499    318,036 
Digital health   515,250    - 
Behavioral and mental services   12,797    - 
Health education   12,306    39,300 
Net revenues  $5,515,144   $5,617,706 

 
Cost of Services

Cost of Services

 

The cost of services includes the wages and the related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while they work on contract assignments.

 
Significant Concentrations

Significant Concentrations

 

The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For each of the years ended December 31, 2023 and 2022, FSSA accounted for approximately 68% and 98% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA – NeuroDiagnostic Institute, representing $3,734,004 and $5,214,128 of the Company’s healthcare workforce revenue, and the FSSA – Division of Mental Health and Addiction, which commenced on September 3, 2021, representing $305,000 and $306,000 of the Company’s Population Health revenues for the years ended December 31, 2023 and 2022, respectively. In addition, the combined divisions of the FSSA represented 30% and 99% of accounts receivable at December 31, 2023, and 2022, respectively.

 
Research and Development Costs

Research and Development Costs

 

Research and development costs are expensed as incurred. The Company’s research and development costs consist of outside consultant fees to develop the Company’s technology-based solutions.

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

 
Basic and Diluted Loss Per Share

Basic and Diluted Loss Per Share

 

The Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.

 

 

Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.

 

The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.

 
Uncertain Tax Positions

Uncertain Tax Positions

 

In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.

 

The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 
Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.

 

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined in Rule 12b-2 of the Exchange Act) to fiscal years beginning after December 15, 2022, including interim periods. Early adoption is permitted. The Company meets the definition of a smaller reporting company and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade receivables, but that there was no material impact to the financial statements from the adoption of ASU 2016-13.

 

There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business and Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Schedule of Disaggregation of Revenue

The Company’s revenue consists of the following revenue services within its industry: 

 

Net revenues:          
Healthcare workforce  $4,259,292   $5,260,370 
Population health   715,499    318,036 
Digital health   515,250    - 
Behavioral and mental services   12,797    - 
Health education   12,306    39,300 
Net revenues  $5,515,144   $5,617,706 
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Basic and Diluted Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Earnings Per Share [Abstract]  
Schedule of Diluted Earnings Per Share

Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of December 31, 2023 and 2022 are as follows: 

 

   December 31, 2023   December 31, 2022 
Warrants   1,760,350    - 
Stock options   140,750    39,000 
Total   1,901,100    39,000 
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Other Current Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of Other Current Assets

Other current assets at December 31, 2023, and 2022 consisted of the following: 

 

   December 31,   December 31, 
   2023   2022 
EDGE tax credit receivable (1)  $-   $116,361 
Federal and State income tax receivable   73,069    28,734 
Prepaid insurance   316,718    20,040 
Prepaid rent   -    10,711 
Prepaid licensing and office fees   -    16,456 
Retainers paid on professional services   -    30,000 
Total other current assets  $389,787   $222,302 

 

(1)A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment at December 31, 2023, and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Office equipment – 5 year estimated life  $81,340   $127,549 
Leasehold improvements– 2 year estimated life   60,783    - 
Furniture and fixtures– 7 year estimated life   677    - 
Less: Accumulated depreciation   (63,827)   (15,056)
Total property and equipment, net  $78,974   $112,493 
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses at December 31, 2023, and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Accrued payroll and taxes  $148,924   $212,660 
Accrued expenses   50,054    - 
Accrued retirement contributions   -    4,874 
Accrued franchise taxes   -    18,777 
Accrued interest   -    2,806 
Total accrued expenses  $198,978   $239,117 
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Debt (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Recognized Interest Expense

The Company recognized interest expense for the years ended December 31, 2023, and 2022, as follows:

 

   December 31,   December 31, 
   2023   2022 
         
Interest on line of credit  $27,054   $14,397 
Interest on convertible notes payable   17,460    - 
Interest on notes payable   8,966      
Amortization of underwriting fee on line of credit   -    14,076 
Interest on credit card debt   206    60 
Total interest expense  $53,686   $28,533 
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Lease (Tables)
 12 Months Ended
Dec. 31, 2023
Lease  
Schedule of Lease Cost expenses

The components of lease expense were as follows:

 

           
   For the Year Ended 
   December 31, 
   2023   2022 
Operating lease cost:          
Amortization of ROU asset  $121,089   $184,288 
Interest on lease liability   7,438    8,733 
Total operating lease cost  $128,527   $175,555 
Schedule of Supplemental Balance Sheets Information

Supplemental balance sheet information related to leases was as follows:

 

   December 31,   December 31, 
   2023   2022 
Operating lease:          
Operating lease assets  $63,199   $184,288 
           
Current portion of operating lease liability, related party  $63,199   $121,089 
Noncurrent operating lease liability, related party   -    63,199 
Total operating lease liability  $63,199   $184,288 
           
Weighted average remaining lease term:          
Operating leases   0.5 years    1.5 years 
           
Weighted average discount rate:          
Operating lease   5.75%   5.75%
Schedule of Supplemental Cash Flow and Other Information

Supplemental cash flow and other information related to operating leases was as follows:

 

           
   For the Year Ended 
   December 31, 
   2023   2022 
Cash paid for amounts included in the measurement of lease liabilities:          
Operating cash flows used for operating leases  $121,089   $107,013 
           
Leased assets obtained in exchange for lease liabilities:          
Total operating lease liabilities  $-   $131,187 
Schedule of Minimum Lease Payments

Future minimum annual lease payments required under the operating lease and the present value of the net minimum lease payments are as follows at December 31, 2023:

 

For the Year  Minimum Lease 
Ended December 31:  Commitments 
2024  $64,263 
2025   - 
Total   64,263 
Amount representing interest  $(1,064)
Present value of net future minimum lease payments   63,199 
Less current portion   (63,199)
Operating lease liability, related party, long term  $- 
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity (Deficit) (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Summary of Activity of Outstanding Stock Warrants

The following is a summary of activity of outstanding stock warrants:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2021   -   $- 
Warrants granted   -    - 
Warrants cancelled   -    - 
Balance, December 31, 2022   -    - 
Warrants granted   2,002,850    6.40 
Warrants exercised   -    - 
Warrants cancelled   (242,500)   (6.50)
Balance, December 31, 2023   1,760,350   $6.39 
Exercisable, December 31, 2023   -   $- 
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Common Stock Options (Tables)
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Schedule of Share-Based Compensation, Stock Options Activity

The following is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2021   -   $- 
Options granted   39,000    1.00 
Options cancelled   -      
Balance, December 31, 2022   39,000    1.20 
Options granted   112,750    2.03 
Options forfeited   (11,000)   (1.00)
Balance, December 31, 2023   140,750   $1.82 
Exercisable, December 31, 2023   -   $- 
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate

The effective income tax rate for the years ended December 31, 2023 and 2022 consisted of the following:

 

   December 31,   December 31, 
   2023   2022 
Federal statutory income tax rate   21%   21%
State income taxes   3%   3%
Change in valuation allowance   (24)%   (24)%
Net effective income tax rate   -    - 
Schedule of Deferred Tax Assets

The components of the Company’s deferred tax asset are as follows:

 

                 
    December 31,  
    2023     2022  
Deferred tax assets:                
Net deferred tax assets before valuation allowance   $ 1,029,723     $ 332,400  
Less: Valuation allowance     (1,029,723 )     (332,400 )
Net deferred tax assets   $ -     $ -  
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Disaggregation of Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Net revenues $ 5,515,144 $ 5,617,706
Healthcare Workforce [Member]    
Product Information [Line Items]    
Net revenues 4,259,292 5,260,370
Population Health [Member]    
Product Information [Line Items]    
Net revenues 715,499 318,036
Digital Health [Member]    
Product Information [Line Items]    
Net revenues 515,250
Behavioral and Mental Services [Member]    
Product Information [Line Items]    
Net revenues 12,797
Health Education [Member]    
Product Information [Line Items]    
Net revenues $ 12,306 $ 39,300
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Oct. 03, 2023
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]      
Gross proceeds $ 5,332,283 $ 5,332,283 $ 2,322,500
Offering cost   $ 1,928,133 $ 596,118
Options to purchase stock   112,750 39,000
FDIC insured amount   $ 250,000  
Cash equivalents   0 $ 0
Accounts receivable   $ 5,520 4,533
Property and equipment useful life   5 years  
Revenues   $ 5,515,144 5,617,706
FSSA – NeuroDiagnostic Institute [Member] | Healthcare Workforce [Member]      
Product Information [Line Items]      
Revenues   3,734,004 5,214,128
FSSA – Division of Mental Health and Addiction [Member] | Population Health [Member]      
Product Information [Line Items]      
Revenues   $ 305,000 $ 306,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Family and Social Services Administration (FSSA) [Member]      
Product Information [Line Items]      
Revenue percentage   68.00% 98.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Family and Social Services Administration (FSSA) [Member]      
Product Information [Line Items]      
Revenue percentage   30.00% 99.00%
IPO [Member]      
Product Information [Line Items]      
Aggregate shares issued 1,615,000    
Public offering price $ 4.125    
Warrant exercise price $ 6.50    
Gross proceeds $ 6,661,876    
Offering cost $ 1,928,133    
Over-Allotment Option [Member] | Underwriting Agreement [Member]      
Product Information [Line Items]      
Aggregate shares issued 242,250    
Options to purchase stock 242,250    
Number of warrants issued 242,500    
Gross proceeds from warrant exercise $ 2,422    
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Going Concern (Details Narrative) - USD ($)
 4 Months Ended 12 Months Ended
Oct. 03, 2023
Apr. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash     $ 3,280,075  
Working capital     3,871,038  
Accumulated deficit     5,064,955 $ 2,126,612
Convertible notes payable   $ 1,455,000 1,455,000
Proceeds from commnon stock $ 5,332,283   $ 5,332,283 $ 2,322,500
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Related Party Transactions (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
May 03, 2022
May 01, 2022
Jul. 01, 2021
Aug. 23, 2023
Dec. 31, 2023
Dec. 31, 2022
Nov. 21, 2020
Related Party Transaction [Line Items]              
Repayments on advances from related party         $ 1,095,000 $ 288,200  
Advanced balance of loan         200,010  
Advances received from related party         1,295,010 94,000  
Lease expense         128,527 175,555  
Service cost         $ 4,103,244 $ 4,555,924  
Convertible Class B Common Stock [Member]              
Related Party Transaction [Line Items]              
Common stock, shares issued 83,334       833,334 833,334 83,334
Conversion of stock, shares converted 833,334         833,334  
Sahasra Technologies Corp [Member]              
Related Party Transaction [Line Items]              
Principal debt       $ 1,295,010      
Repayments on advances from related party       $ 1,095,000      
Advanced balance of loan         $ 200,010    
Other liabilities         0    
ST Logics [Member]              
Related Party Transaction [Line Items]              
Receivable from related party         50,614    
STVentures [Member]              
Related Party Transaction [Line Items]              
Lease term   3 years 3 years        
Base monthly rent   $ 10,711 $ 5,332        
Lease expense         128,527 $ 107,013  
RAD CUBE LLC [Member] | Information Technology Services [Member]              
Related Party Transaction [Line Items]              
Service cost         3,320 23,260  
Accounts payable, related parties         0 3,200  
NLogix [Member] | Recruitment and Human Resource Services [Member]              
Related Party Transaction [Line Items]              
Service cost         $ 348,304 $ 137,494  
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Diluted Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 1,901,100 39,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 1,760,350
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Total 140,750 39,000
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Other Current Assets (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
EDGE tax credit receivable [1] $ 116,361
Federal and State income tax receivable 73,069 28,734
Prepaid insurance 316,718 20,040
Prepaid rent 10,711
Prepaid licensing and office fees 16,456
Retainers paid on professional services 30,000
Total other current assets $ 389,787 $ 222,302
[1] A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Property and Equipment (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Less: Accumulated depreciation $ (63,827) $ (15,056)
Total property and equipment, net 78,974 112,493
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 81,340 127,549
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 60,783
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 677
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Property and Equipment (Details) (Parenthetical)
Dec. 31, 2023
Property, Plant and Equipment [Line Items]  
Property plant and equipment useful life 5 years
Office Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property plant and equipment useful life 5 years
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property plant and equipment useful life 2 years
Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Property plant and equipment useful life 7 years
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Property and Equipment (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation $ 48,771 $ 14,849
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Accrued Expenses (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued payroll and taxes $ 148,924 $ 212,660
Accrued expenses 50,054
Accrued retirement contributions 4,874
Accrued franchise taxes 18,777
Accrued interest 2,806
Total accrued expenses $ 198,978 $ 239,117
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Employers contribution percentage match 100.00%  
Employees contribution percentage 4.00%  
Investment retirement account contribution expenses $ 88,327 $ 28,534
Accrued retirement contributions $ 8,778 $ 4,874
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Recognized Interest Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Interest on line of credit $ 27,054 $ 14,397
Interest on convertible notes payable 17,460
Interest on notes payable 8,966  
Amortization of underwriting fee on line of credit 14,076
Interest on credit card debt 206 60
Total interest expense $ 53,686 $ 28,533
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Debt (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Oct. 03, 2023
Feb. 07, 2022
Apr. 07, 2023
Dec. 31, 2023
Dec. 31, 2022
Line of Credit Facility [Line Items]          
Proceeds from repayment of line of credit       $ 1,050,551 $ 2,082,800
Underwriting fee       14,076
Line of credit       750,551
Value of conversion of convertible securities issued $ 1,472,460     1,472,460  
Periodic interest payment       17,460
Repayment of notes payable       185,692
Notes payable       184,904
Common Class A [Member]          
Line of Credit Facility [Line Items]          
Conversion of Convertible Securities issued, shares 446,206        
Subscription Agreements [Member] | Convertible Promissory Notes [Member]          
Line of Credit Facility [Line Items]          
Principal amount $ 1,455,000   $ 1,455,000    
Convertible promissory notes maturity date, description     July 10, 2024 and October 7, 2024    
Convertible promissory notes, accrued interest     2.00%    
Convertible promissory notes, conversion price     $ 6.00    
Periodic interest payment $ 17,460        
Insurance Policy Financing Arrangements [Member]          
Line of Credit Facility [Line Items]          
Principal amount       370,596  
Periodic interest payment       $ 32,328  
Insurance Policy Financing Arrangements [Member] | Minimum [Member]          
Line of Credit Facility [Line Items]          
Interest rate percentage       10.38%  
Insurance Policy Financing Arrangements [Member] | Maximum [Member]          
Line of Credit Facility [Line Items]          
Interest rate percentage       14.05%  
Revolving Credit Facility [Member] | Loan Agreement [Member]          
Line of Credit Facility [Line Items]          
Revolving line of credit maximum borrowing limit   $ 1,500,000      
Revolving line of credit   800,000      
Revolving line of facility description       Pursuant to the terms of the Revolving Line of Credit, the outstanding balance shall not exceed 75% of the Company’s outstanding accounts receivable due from the State of Indiana aged more than 90 days together with all other accounts receivable aged less than 90 days. The Revolving Line of Credit was to terminate on December 31, 2022, unless extended pursuant to the terms thereof. The Company received extensions on the Revolving Line of Credit such that it will now terminate on October 24, 2023; however, no further advances are available under the Revolving Line of Credit. In the event of a default, all commitments and obligations pursuant to the Revolving Line of Credit will terminate immediately and, at Citizens State Bank of New Castle’s request, all Indebtedness (as defined in the loan agreement) shall become immediately due and payable. Advances on the Revolving Line of Credit are pursuant to a promissory note dated February 7, 2022 which accrues interest at a variable rate of 1.5% above the national prime interest rate as quoted in the Wall Street Journal, not to be less than 4.75% per annum or more than 21% per annum or the maximum rate allowed by law. Interest shall increase by an 2.0% in the event of a default. Pursuant to the promissory note, the Company has been required to pay monthly payments of unpaid interest since March 7, 2022. The Company may prepay all or a portion of the amount due prior to the date upon which it is due without any penalty. In connection with the Revolving Line of Credit, the Company entered into a commercial security agreement with Citizens State Bank of New Castle dated February 7, 2022, pursuant to which it granted Citizens State Bank of New Castle a security interest in the Collateral (as defined in the commercial security agreement) to secure the Indebtedness (as defined in the commercial security agreement).  
Proceeds from payments line of credit       $ 300,000 2,819,275
Proceeds from repayment of line of credit       $ 1,050,551 2,068,724
Underwriting fee   $ 14,076     $ 14,076
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Lease Cost expenses (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease    
Amortization of ROU asset $ 121,089 $ 184,288
Interest on lease liability 7,438 8,733
Total operating lease cost $ 128,527 $ 175,555
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Supplemental Balance Sheets Information (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Lease    
Operating lease assets $ 63,199 $ 184,288
Current portion of operating lease liability, related party 63,199 121,089
Noncurrent operating lease liability, related party 63,199
Total operating lease liability $ 63,199 $ 184,288
Weighted-average remaining lease term (in years) (Year) 6 months 1 year 6 months
Weighted-average discount rate (Rate) 5.75% 5.75%
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Supplemental Cash Flow and Other Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Lease    
Operating cash flows used for operating leases $ 121,089 $ 107,013
Total operating lease liabilities $ 131,187
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Minimum Lease Payments (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Lease    
2024 $ 64,263  
2025  
Total 64,263  
Amount representing interest (1,064)  
Present value of net future minimum lease payments 63,199 $ 184,288
Less current portion (63,199) (121,089)
Operating lease liability, related party, long term $ 63,199
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Lease (Details Narrative)
 12 Months Ended
May 01, 2022
USD ($)
ft²
Jul. 01, 2021
USD ($)
ft²
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Defined Benefit Plan Disclosure [Line Items]        
Lease rent expense     $ 128,527 $ 175,555
STVentures [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Lease term 3 years 3 years    
Office space | ft² 2,976 5,978    
Base monthly rent $ 10,711 $ 5,332    
Lease rent expense     $ 128,527 $ 107,013
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Commitments and Contingencies (Details Narrative)
Jun. 28, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Litigation settlement expense $ 28,000
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Activity of Outstanding Stock Warrants (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Warrants outstanding beginning balance
Weighted average exercises price, outstanding beginning balance
Warrants granted 2,002,850
Weighted average exercises price, granted $ 6.40
Warrants cancelled (242,500)
Weighted average exercises price, cancelled $ (6.50)
Warrants exercised  
Weighted average exercises price, exercised  
Warrants outstanding ending balance 1,760,350
Weighted average exercises price, outstanding ending balance $ 6.39
Warrants exercisable ending balance  
Weighted average exercises price, exercisable ending balance  
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)
 1 Months Ended 2 Months Ended 4 Months Ended 12 Months Ended
Oct. 03, 2023
May 03, 2022
Nov. 21, 2020
Nov. 30, 2023
Aug. 31, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 01, 2022
May 31, 2022
Dec. 31, 2023
Dec. 31, 2022
May 30, 2023
May 10, 2023
Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Stock issued during period value new issues                   $ 4,736,165 $ 2,322,500      
Preferred stock, shares authorized                   1,000,000 1,000,000 10,000,000    
Preferred stock, par value                   $ 0.001 $ 0.001 $ 0.001    
Deferred Offering Costs                   $ 1,928,133 $ 596,118      
Fair value of the options                   $ 198,383        
Dividend yield                   0.00%        
Expected term               6 years 3 months   6 years 3 months        
Warrants and rights outstanding term 4 years 9 months                          
Warrants and rights outstanding intrinsic value $ 0                          
Stock issued during period shares issued for services                   0        
Stock issued during period value issued for services                     $ 510,000      
Six Consultant [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Stock issued during period shares issued for services                 800,002          
Stock issued during period value issued for services                 $ 510,000          
Kingswood Capital Partners LLC [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Granted options 145,350                          
Exercise price $ 5.156                          
Granted options term 5 years                          
Fair value of the options $ 352,677                          
Dividend yield 0.00%                          
Risk free rate 4.80%                          
Volatility rate 122.00%                          
Exercise price $ 3.03                          
Expected term 5 years                          
IPO [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Sale of Stock, Number of Shares Issued in Transaction 1,615,000                          
Sale of Stock, Price Per Share $ 4.125                          
Sale of Stock, Description of Transaction (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”).                          
Proceeds from Issuance Initial Public Offering $ 6,661,876                          
Deferred Offering Costs $ 1,928,133                          
Exercise price $ 6.50                          
IPO [Member] | Underwriting Agreement [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Class of Warrant or Right, Outstanding 242,500                          
Over-Allotment Option [Member] | Underwriting Agreement [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Sale of Stock, Number of Shares Issued in Transaction 242,250                          
Proceeds from Issuance of Warrants $ 2,422                          
Convertible Common Stock B [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares of convertible common stock   833,334                        
Common stock conversion basis                   Each share of convertible Class B common Stock was also convertible into 16.5 fully paid and nonassessable shares of Class A common stock. On October 6, 2022, the Company’s Amended and Restated Certificate of Incorporation was amended to change the conversion ratio from 16.5 shares to 10 shares of Class A common stock. The voting rights remain unchanged.        
Common stock, shares authorized                   5,000,000   5,000,000    
Common stock, par value                   $ 0.001   $ 0.001    
Common stock voting rights                   Each holder of shares of convertible Class B common stock shall be entitled to 16.5 votes for each share of convertible Class B common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company.        
Common stock, shares issued                     833,334     833,334
Common stock shares outstanding                     833,334     833,334
Common Class B [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Common stock conversion basis   Each share of Class B common stock is entitled to 16.5 votes and is convertible at any time into ten shares of Class A common stock                        
Common Class A [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares of convertible common stock 446,206                          
Common stock, shares authorized                   100,000,000 100,000,000 100,000,000    
Common stock, par value                   $ 0.001 $ 0.001 $ 0.001    
Common stock voting rights                   Each holder of shares of Class A common stock shall be entitled to one vote for each share of Class A common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company.        
Common stock, shares issued                   5,588,298 3,568,758      
Common stock shares outstanding                   5,588,298 3,568,758      
Exercise price               $ 1.20            
Common stock, shares surrendered                         41,667  
Stock issuance expense                   $ 8,122        
Common Class A [Member] | Restricted Stock [Member] | Consultant [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Stock issued during period shares issued for services       50,000                    
Stock issued during period value issued for services       $ 75,500                    
Common Class A [Member] | Private Placement [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Stock issued during period value new issues         $ 1,322,500 $ 1,322,500 $ 1,000,000              
Stock issued during period shares new issues         1,102,094 1,102,094 2,000,000              
Share price         $ 1.20 $ 1.20 $ 0.50              
Convertible Class B Common Stock [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Common stock, shares authorized                   5,000,000 5,000,000      
Common stock, par value                   $ 0.001 $ 0.001      
Common stock, shares issued   83,334 83,334             833,334 833,334      
Common stock shares outstanding                   833,334 833,334      
Conversion of stock, shares converted   833,334                 833,334      
Convertible Common Stock B Issuances [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares of convertible common stock   833,334                        
Common stock conversion basis   Each share of convertible Class B common stock was convertible into 16.5 shares of Class A common stock, which was subsequently amended to be convertible into ten shares on of Class A common stock                        
Common stock shares outstanding   83,334                        
Stock issued during period shares issued for services     83,334                      
Stock issued during period value issued for services     $ 100                      
Common Stock [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares outstanding   83,334                        
Common Stock [Member] | Common Class A [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares outstanding                   5,588,298 3,568,758    
Stock issued during period value new issues                   $ 1,615 $ 2,769      
Stock issued during period shares new issues                   1,615,000 2,768,756      
Stock issued during period shares issued for services                     800,002      
Stock issued during period value issued for services                     $ 800      
Common Stock [Member] | Convertible Class B Common Stock [Member]                            
Accumulated Other Comprehensive Income (Loss) [Line Items]                            
Shares outstanding                   833,334 833,334     833,334
Stock issued during period value new issues                        
Stock issued during period value issued for services                          
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Share-Based Compensation, Stock Options Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Number of options, beginning balance 39,000
Weighted average exercise prices, ending balance $ 1.20
Options granted 112,750 39,000
Weighted average exercise price, granted $ 2.03 $ 1.00
Options cancelled  
Options forfeited (11,000)  
Weighted average exercise price, forfeited $ (1.00)  
Number of options, ending balance 140,750 39,000
Weighted average exercise prices, ending balance $ 1.82 $ 1.20
Exercisable ending balance  
Weighted average exercise price, exercisable  
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Common Stock Options (Details Narrative) - USD ($)
 2 Months Ended 3 Months Ended 12 Months Ended
Nov. 08, 2023
Oct. 09, 2023
Apr. 11, 2022
Sep. 01, 2022
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]              
Shares issued           $ 4,736,165 $ 2,322,500
Fair value of the options           $ 198,383  
Dividend rate           0.00%  
Risk free interest rate           4.45%  
Risk free interest rate           4.71%  
Expected volatiltity           112.00%  
Expected volatiltity rate           115.00%  
Expected term       6 years 3 months   6 years 3 months  
Share based compensation recognized           $ 21,041  
Share based compensation expense unrecognized           196,955  
Number of options vested       25.00%      
Weighted average volatility rate       93.00%      
Weighted average risk free interest rate       3.03%      
Weighted average call option value       $ 0.9328      
Aggregate intrinsic value       $ 30,317      
Share based compensation expense           $ 32,831 $ 2,910
Remaining contractual life           9 years 6 months 29 days  
Equity Option [Member]              
Class of Stock [Line Items]              
Number of options cancelled         9,167    
Exercise price of options cancelled         $ 1.20    
Common Class A [Member]              
Class of Stock [Line Items]              
Exercise price       $ 1.20      
Purchase of shares granted options       32,502      
Ten Employees [Member]              
Class of Stock [Line Items]              
Granted options 32,750            
Exercise price $ 1.51            
Granted options term 10 years            
Vesting period 4 years            
Three Consultants [Member]              
Class of Stock [Line Items]              
Granted options 30,000            
Exercise price $ 1.51            
Granted options term 10 years            
Vesting period 1 year            
Five Board Members [Member]              
Class of Stock [Line Items]              
Granted options   50,000          
Exercise price   $ 2.68          
Granted options term   10 years          
Maximum [Member]              
Class of Stock [Line Items]              
Exercise price           $ 2.68  
Minimum [Member]              
Class of Stock [Line Items]              
Exercise price           $ 1.51  
Omnibus Equity Incentive Plan [Member] | Maximum [Member]              
Class of Stock [Line Items]              
Shares issued     $ 1,041,667        
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Effective Income Tax Rate (Details)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Federal statutory income tax rate 21.00% 21.00%
State income taxes 3.00% 3.00%
Change in valuation allowance (24.00%) (24.00%)
Net effective income tax rate
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Net deferred tax assets before valuation allowance $ 1,029,723 $ 332,400
Less: Valuation allowance (1,029,723) (332,400)
Net deferred tax assets
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details Narrative) - USD ($)
 37 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Tax provisions $ 0  
Income tax benefits 0  
Federal net operating losses $ 4,637,000 $ 1,731,000
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Subsequent Events (Details Narrative) - Subsequent Event [Member]
 3 Months Ended
Mar. 31, 2024
USD ($)
shares
November 2023 [Member]  
Subsequent Event [Line Items]  
Restricted stock awarded 12,500
Two Investors [Member] | Common Class A [Member]  
Subsequent Event [Line Items]  
Warrants to purchase 130,789
Proceeds from issuance of warrants | $ $ 850,139
EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

5CW\;T<#P4 (@G / M " 1Y4 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " E>'E8F!M:GOL! M #+(P &@ @ %:60$ >&PO7W)E;',O=V]R:V)O;VLN>&UL M+G)E;'-02P$"% ,4 " E>'E8=-+&8MX! !:(P $P M@ &-6P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 !$ ),2 "<70$ " ! end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 152 315 1 true 57 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://syrahealth.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://syrahealth.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://syrahealth.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://syrahealth.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Stockholders' Equity (Deficit) Sheet http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit Statements of Stockholders' Equity (Deficit) Statements 5 false false R6.htm 00000006 - Statement - Statements of Cash Flows Sheet http://syrahealth.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995512 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies Nature of Business and Significant Accounting Policies Notes 9 false false R10.htm 995513 - Disclosure - Going Concern Sheet http://syrahealth.com/role/GoingConcern Going Concern Notes 10 false false R11.htm 995514 - Disclosure - Related Party Transactions Sheet http://syrahealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 995515 - Disclosure - Basic and Diluted Earnings per Share Sheet http://syrahealth.com/role/BasicAndDilutedEarningsPerShare Basic and Diluted Earnings per Share Notes 12 false false R13.htm 995516 - Disclosure - Other Current Assets Sheet http://syrahealth.com/role/OtherCurrentAssets Other Current Assets Notes 13 false false R14.htm 995517 - Disclosure - Property and Equipment Sheet http://syrahealth.com/role/PropertyAndEquipment Property and Equipment Notes 14 false false R15.htm 995518 - Disclosure - Accrued Expenses Sheet http://syrahealth.com/role/AccruedExpenses Accrued Expenses Notes 15 false false R16.htm 995519 - Disclosure - Debt Sheet http://syrahealth.com/role/Debt Debt Notes 16 false false R17.htm 995520 - Disclosure - Lease Sheet http://syrahealth.com/role/Lease Lease Notes 17 false false R18.htm 995521 - Disclosure - Commitments and Contingencies Sheet http://syrahealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 995522 - Disclosure - Stockholders??? Equity (Deficit) Sheet http://syrahealth.com/role/StockholdersEquityDeficit Stockholders??? Equity (Deficit) Notes 19 false false R20.htm 995523 - Disclosure - Common Stock Options Sheet http://syrahealth.com/role/CommonStockOptions Common Stock Options Notes 20 false false R21.htm 995524 - Disclosure - Income Taxes Sheet http://syrahealth.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 995525 - Disclosure - Subsequent Events Sheet http://syrahealth.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 995526 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) Policies http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies 23 false false R24.htm 995527 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables Nature of Business and Significant Accounting Policies (Tables) Tables http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies 24 false false R25.htm 995528 - Disclosure - Basic and Diluted Earnings per Share (Tables) Sheet http://syrahealth.com/role/BasicAndDilutedEarningsPerShareTables Basic and Diluted Earnings per Share (Tables) Tables http://syrahealth.com/role/BasicAndDilutedEarningsPerShare 25 false false R26.htm 995529 - Disclosure - Other Current Assets (Tables) Sheet http://syrahealth.com/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://syrahealth.com/role/OtherCurrentAssets 26 false false R27.htm 995530 - Disclosure - Property and Equipment (Tables) Sheet http://syrahealth.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://syrahealth.com/role/PropertyAndEquipment 27 false false R28.htm 995531 - Disclosure - Accrued Expenses (Tables) Sheet http://syrahealth.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://syrahealth.com/role/AccruedExpenses 28 false false R29.htm 995532 - Disclosure - Debt (Tables) Sheet http://syrahealth.com/role/DebtTables Debt (Tables) Tables http://syrahealth.com/role/Debt 29 false false R30.htm 995533 - Disclosure - Lease (Tables) Sheet http://syrahealth.com/role/LeaseTables Lease (Tables) Tables http://syrahealth.com/role/Lease 30 false false R31.htm 995534 - Disclosure - Stockholders??? Equity (Deficit) (Tables) Sheet http://syrahealth.com/role/StockholdersEquityDeficitTables Stockholders??? Equity (Deficit) (Tables) Tables http://syrahealth.com/role/StockholdersEquityDeficit 31 false false R32.htm 995535 - Disclosure - Common Stock Options (Tables) Sheet http://syrahealth.com/role/CommonStockOptionsTables Common Stock Options (Tables) Tables http://syrahealth.com/role/CommonStockOptions 32 false false R33.htm 995536 - Disclosure - Income Taxes (Tables) Sheet http://syrahealth.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://syrahealth.com/role/IncomeTaxes 33 false false R34.htm 995537 - Disclosure - Schedule of Disaggregation of Revenue (Details) Sheet http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails Schedule of Disaggregation of Revenue (Details) Details 34 false false R35.htm 995538 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative) Sheet http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative Nature of Business and Significant Accounting Policies (Details Narrative) Details http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables 35 false false R36.htm 995539 - Disclosure - Going Concern (Details Narrative) Sheet http://syrahealth.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://syrahealth.com/role/GoingConcern 36 false false R37.htm 995540 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://syrahealth.com/role/RelatedPartyTransactions 37 false false R38.htm 995541 - Disclosure - Schedule of Diluted Earnings Per Share (Details) Sheet http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails Schedule of Diluted Earnings Per Share (Details) Details 38 false false R39.htm 995542 - Disclosure - Schedule of Other Current Assets (Details) Sheet http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails Schedule of Other Current Assets (Details) Details 39 false false R40.htm 995543 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 40 false false R41.htm 995544 - Disclosure - Schedule of Property and Equipment (Details) (Parenthetical) Sheet http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical Schedule of Property and Equipment (Details) (Parenthetical) Details 41 false false R42.htm 995545 - Disclosure - Property and Equipment (Details Narrative) Sheet http://syrahealth.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://syrahealth.com/role/PropertyAndEquipmentTables 42 false false R43.htm 995546 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 43 false false R44.htm 995547 - Disclosure - Accrued Expenses (Details Narrative) Sheet http://syrahealth.com/role/AccruedExpensesDetailsNarrative Accrued Expenses (Details Narrative) Details http://syrahealth.com/role/AccruedExpensesTables 44 false false R45.htm 995548 - Disclosure - Schedule of Recognized Interest Expense (Details) Sheet http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails Schedule of Recognized Interest Expense (Details) Details 45 false false R46.htm 995549 - Disclosure - Debt (Details Narrative) Sheet http://syrahealth.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://syrahealth.com/role/DebtTables 46 false false R47.htm 995550 - Disclosure - Schedule of Lease Cost expenses (Details) Sheet http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails Schedule of Lease Cost expenses (Details) Details 47 false false R48.htm 995551 - Disclosure - Schedule of Supplemental Balance Sheets Information (Details) Sheet http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails Schedule of Supplemental Balance Sheets Information (Details) Details 48 false false R49.htm 995552 - Disclosure - Schedule of Supplemental Cash Flow and Other Information (Details) Sheet http://syrahealth.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationDetails Schedule of Supplemental Cash Flow and Other Information (Details) Details 49 false false R50.htm 995553 - Disclosure - Schedule of Minimum Lease Payments (Details) Sheet http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails Schedule of Minimum Lease Payments (Details) Details 50 false false R51.htm 995554 - Disclosure - Lease (Details Narrative) Sheet http://syrahealth.com/role/LeaseDetailsNarrative Lease (Details Narrative) Details http://syrahealth.com/role/LeaseTables 51 false false R52.htm 995555 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://syrahealth.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://syrahealth.com/role/CommitmentsAndContingencies 52 false false R53.htm 995556 - Disclosure - Summary of Activity of Outstanding Stock Warrants (Details) Sheet http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails Summary of Activity of Outstanding Stock Warrants (Details) Details 53 false false R54.htm 995557 - Disclosure - Stockholders??? Equity (Deficit) (Details Narrative) Sheet http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative Stockholders??? Equity (Deficit) (Details Narrative) Details http://syrahealth.com/role/StockholdersEquityDeficitTables 54 false false R55.htm 995558 - Disclosure - Schedule of Share-Based Compensation, Stock Options Activity (Details) Sheet http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails Schedule of Share-Based Compensation, Stock Options Activity (Details) Details 55 false false R56.htm 995559 - Disclosure - Common Stock Options (Details Narrative) Sheet http://syrahealth.com/role/CommonStockOptionsDetailsNarrative Common Stock Options (Details Narrative) Details http://syrahealth.com/role/CommonStockOptionsTables 56 false false R57.htm 995560 - Disclosure - Schedule of Effective Income Tax Rate (Details) Sheet http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails Schedule of Effective Income Tax Rate (Details) Details 57 false false R58.htm 995561 - Disclosure - Schedule of Deferred Tax Assets (Details) Sheet http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails Schedule of Deferred Tax Assets (Details) Details 58 false false R59.htm 995562 - Disclosure - Income Taxes (Details Narrative) Sheet http://syrahealth.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://syrahealth.com/role/IncomeTaxesTables 59 false false R60.htm 995563 - Disclosure - Subsequent Events (Details Narrative) Sheet http://syrahealth.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://syrahealth.com/role/SubsequentEvents 60 false false All Reports Book All Reports [dq-60521-EntityPublicFloat-Missing] Submission type 10-K should have a non-empty value for EntityPublicFloat in the Required Context. form10-k.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:LesseeOperatingLeaseTermOfContract, us-gaap:PropertyPlantAndEquipmentUsefulLife - form10-k.htm 97, 100, 116, 117 form10-k.htm syra-20231231.xsd syra-20231231_cal.xml syra-20231231_def.xml syra-20231231_lab.xml syra-20231231_pre.xml form10-k_001.jpg image_001.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "SYRA", "nsuri": "http://syrahealth.com/20231231", "dts": { "inline": { "local": [ "form10-k.htm" ] }, "schema": { "local": [ "syra-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "syra-20231231_cal.xml" ] }, "definitionLink": { "local": [ "syra-20231231_def.xml" ] }, "labelLink": { "local": [ "syra-20231231_lab.xml" ] }, "presentationLink": { "local": [ "syra-20231231_pre.xml" ] } }, "keyStandard": 292, "keyCustom": 23, "axisStandard": 20, "axisCustom": 0, "memberStandard": 25, "memberCustom": 32, "hidden": { "total": 120, "http://fasb.org/us-gaap/2023": 105, "http://xbrl.sec.gov/dei/2023": 3, "http://syrahealth.com/20231231": 12 }, "contextCount": 152, "entityCount": 1, "segmentCount": 57, "elementCount": 568, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 662, "http://xbrl.sec.gov/dei/2023": 38, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://syrahealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://syrahealth.com/role/BalanceSheets", "longName": "00000002 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R3": { "role": "http://syrahealth.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "shortName": "Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "SYRA:PreferredStockSharesDesignated", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R4": { "role": "http://syrahealth.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Statements of Operations", "shortName": "Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GrossProfit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "longName": "00000005 - Statement - Statements of Stockholders' Equity (Deficit)", "shortName": "Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_custom_ConvertibleClassBCommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember_custom_ConvertibleClassBCommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://syrahealth.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Statements of Cash Flows", "shortName": "Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31", "name": "us-gaap:OtherNoncashExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-12-31", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies", "longName": "995512 - Disclosure - Nature of Business and Significant Accounting Policies", "shortName": "Nature of Business and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://syrahealth.com/role/GoingConcern", "longName": "995513 - Disclosure - Going Concern", "shortName": "Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://syrahealth.com/role/RelatedPartyTransactions", "longName": "995514 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://syrahealth.com/role/BasicAndDilutedEarningsPerShare", "longName": "995515 - Disclosure - Basic and Diluted Earnings per Share", "shortName": "Basic and Diluted Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://syrahealth.com/role/OtherCurrentAssets", "longName": "995516 - Disclosure - Other Current Assets", "shortName": "Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://syrahealth.com/role/PropertyAndEquipment", "longName": "995517 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://syrahealth.com/role/AccruedExpenses", "longName": "995518 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://syrahealth.com/role/Debt", "longName": "995519 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://syrahealth.com/role/Lease", "longName": "995520 - Disclosure - Lease", "shortName": "Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://syrahealth.com/role/CommitmentsAndContingencies", "longName": "995521 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://syrahealth.com/role/StockholdersEquityDeficit", "longName": "995522 - Disclosure - Stockholders\u2019 Equity (Deficit)", "shortName": "Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://syrahealth.com/role/CommonStockOptions", "longName": "995523 - Disclosure - Common Stock Options", "shortName": "Common Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://syrahealth.com/role/IncomeTaxes", "longName": "995524 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://syrahealth.com/role/SubsequentEvents", "longName": "995525 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies", "longName": "995526 - Disclosure - Nature of Business and Significant Accounting Policies (Policies)", "shortName": "Nature of Business and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables", "longName": "995527 - Disclosure - Nature of Business and Significant Accounting Policies (Tables)", "shortName": "Nature of Business and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://syrahealth.com/role/BasicAndDilutedEarningsPerShareTables", "longName": "995528 - Disclosure - Basic and Diluted Earnings per Share (Tables)", "shortName": "Basic and Diluted Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://syrahealth.com/role/OtherCurrentAssetsTables", "longName": "995529 - Disclosure - Other Current Assets (Tables)", "shortName": "Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://syrahealth.com/role/PropertyAndEquipmentTables", "longName": "995530 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://syrahealth.com/role/AccruedExpensesTables", "longName": "995531 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://syrahealth.com/role/DebtTables", "longName": "995532 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://syrahealth.com/role/LeaseTables", "longName": "995533 - Disclosure - Lease (Tables)", "shortName": "Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://syrahealth.com/role/StockholdersEquityDeficitTables", "longName": "995534 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)", "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://syrahealth.com/role/CommonStockOptionsTables", "longName": "995535 - Disclosure - Common Stock Options (Tables)", "shortName": "Common Stock Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://syrahealth.com/role/IncomeTaxesTables", "longName": "995536 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "995537 - Disclosure - Schedule of Disaggregation of Revenue (Details)", "shortName": "Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R35": { "role": "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "longName": "995538 - Disclosure - Nature of Business and Significant Accounting Policies (Details Narrative)", "shortName": "Nature of Business and Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-10-032023-10-03", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashFDICInsuredAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R36": { "role": "http://syrahealth.com/role/GoingConcernDetailsNarrative", "longName": "995539 - Disclosure - Going Concern (Details Narrative)", "shortName": "Going Concern (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995540 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-112023-08-23_custom_SahasraTechnologiesCorpMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R38": { "role": "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails", "longName": "995541 - Disclosure - Schedule of Diluted Earnings Per Share (Details)", "shortName": "Schedule of Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R39": { "role": "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails", "longName": "995542 - Disclosure - Schedule of Other Current Assets (Details)", "shortName": "Schedule of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "SYRA:EmployeeRetentionTaxCreditReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "SYRA:EmployeeRetentionTaxCreditReceivables", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "995543 - Disclosure - Schedule of Property and Equipment (Details)", "shortName": "Schedule of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical", "longName": "995544 - Disclosure - Schedule of Property and Equipment (Details) (Parenthetical)", "shortName": "Schedule of Property and Equipment (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_OfficeEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_OfficeEquipmentMember", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R42": { "role": "http://syrahealth.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "995545 - Disclosure - Property and Equipment (Details Narrative)", "shortName": "Property and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails", "longName": "995546 - Disclosure - Schedule of Accrued Expenses (Details)", "shortName": "Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedPayrollTaxesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://syrahealth.com/role/AccruedExpensesDetailsNarrative", "longName": "995547 - Disclosure - Accrued Expenses (Details Narrative)", "shortName": "Accrued Expenses (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails", "longName": "995548 - Disclosure - Schedule of Recognized Interest Expense (Details)", "shortName": "Schedule of Recognized Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LineOfCreditFacilityPeriodicPaymentInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LineOfCreditFacilityPeriodicPaymentInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R46": { "role": "http://syrahealth.com/role/DebtDetailsNarrative", "longName": "995549 - Disclosure - Debt (Details Narrative)", "shortName": "Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RepaymentsOfLinesOfCredit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-10-032023-10-03", "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R47": { "role": "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails", "longName": "995550 - Disclosure - Schedule of Lease Cost expenses (Details)", "shortName": "Schedule of Lease Cost expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R48": { "role": "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails", "longName": "995551 - Disclosure - Schedule of Supplemental Balance Sheets Information (Details)", "shortName": "Schedule of Supplemental Balance Sheets Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "SYRA:SupplementalBalanceSheetsInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R49": { "role": "http://syrahealth.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationDetails", "longName": "995552 - Disclosure - Schedule of Supplemental Cash Flow and Other Information (Details)", "shortName": "Schedule of Supplemental Cash Flow and Other Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "SYRA:SupplementalCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeasePayments", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "SYRA:SupplementalCashFlowInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R50": { "role": "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails", "longName": "995553 - Disclosure - Schedule of Minimum Lease Payments (Details)", "shortName": "Schedule of Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R51": { "role": "http://syrahealth.com/role/LeaseDetailsNarrative", "longName": "995554 - Disclosure - Lease (Details Narrative)", "shortName": "Lease (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-05-01_custom_STVenturesMember", "name": "us-gaap:AreaOfLand", "unitRef": "Sqft", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R52": { "role": "http://syrahealth.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995555 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2022-06-272022-06-28", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-06-272022-06-28", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R53": { "role": "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails", "longName": "995556 - Disclosure - Summary of Activity of Outstanding Stock Warrants (Details)", "shortName": "Summary of Activity of Outstanding Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "longName": "995557 - Disclosure - Stockholders\u2019 Equity (Deficit) (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Deficit) (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-05-30", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R55": { "role": "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails", "longName": "995558 - Disclosure - Schedule of Share-Based Compensation, Stock Options Activity (Details)", "shortName": "Schedule of Share-Based Compensation, Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R56": { "role": "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "longName": "995559 - Disclosure - Common Stock Options (Details Narrative)", "shortName": "Common Stock Options (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R57": { "role": "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails", "longName": "995560 - Disclosure - Schedule of Effective Income Tax Rate (Details)", "shortName": "Schedule of Effective Income Tax Rate (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R58": { "role": "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails", "longName": "995561 - Disclosure - Schedule of Deferred Tax Assets (Details)", "shortName": "Schedule of Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R59": { "role": "http://syrahealth.com/role/IncomeTaxesDetailsNarrative", "longName": "995562 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "From2020-11-202023-12-31", "name": "us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2020-11-202023-12-31", "name": "us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R60": { "role": "http://syrahealth.com/role/SubsequentEventsDetailsNarrative", "longName": "995563 - Disclosure - Subsequent Events (Details Narrative)", "shortName": "Subsequent Events (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "From2024-01-012024-03-31_custom_NovemberTwoThousandTwentyThreeMember_us-gaap_SubsequentEventMember", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31_custom_NovemberTwoThousandTwentyThreeMember_us-gaap_SubsequentEventMember", "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price of options cancelled", "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time." } } }, "auth_ref": [ "r119" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "verboseLabel": "Accounts payable, related parties", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21", "r674" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r644" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r587", "r643", "r680", "r872" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts receivable", "verboseLabel": "Receivable from related party", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r239", "r240" ] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Accrued Employee Benefits, Current", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_AccruedPayrollTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedPayrollTaxesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued payroll and taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "SYRA_AccruedRetirementContributions": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "AccruedRetirementContributions", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued retirement contributions", "documentation": "Accrued retirement contributions.", "label": "AccruedRetirementContributions" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r53", "r158", "r525" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r169", "r170", "r438", "r439", "r440", "r441", "r442", "r443" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r169", "r170", "r438", "r439", "r440", "r441", "r442", "r443" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r736" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r90", "r674", "r877" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r390", "r391", "r392", "r555", "r803", "r804", "r805", "r852", "r881" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r742" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r742" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class A common stock options issued for services", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r70", "r71", "r359" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r706", "r718", "r728", "r754" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r709", "r721", "r731", "r757" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r742" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r749" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r713", "r722", "r732", "r749", "r758", "r762", "r770" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based compensation recognized", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r389", "r397" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of debt discounts", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r5", "r76", "r101", "r322" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r714" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r209" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r44" ] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfLand", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Office space", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r421" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r129", "r160", "r182", "r216", "r230", "r234", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r422", "r424", "r437", "r517", "r592", "r674", "r687", "r819", "r820", "r861" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r154", "r165", "r182", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r422", "r424", "r437", "r674", "r819", "r820", "r861" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r714" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r699", "r701", "r714" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r699", "r701", "r714" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r699", "r701", "r714" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price" } } }, "auth_ref": [ "r765" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r766" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r761" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r761" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r385", "r386", "r387", "r388" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r764" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r763" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r762" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r762" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "SYRA_BehavioralAndMentalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "BehavioralAndMentalServicesMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Behavioral and Mental Services [Member]", "documentation": "Behavioral and Mental Services [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Nature of Business and Significant Accounting Policies", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r106", "r107" ] }, "SYRA_CancellationOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "CancellationOfCommonStock", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cancellation of Class A common stock", "documentation": "Cancellation of common stock." } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r140", "r519", "r566", "r586", "r674", "r687", "r792" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r156", "r650" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r39" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "CASH AT BEGINNING OF PERIOD", "periodEndLabel": "CASH AT END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r103", "r179" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "NET CHANGE IN CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r103" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r792", "r871" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FDIC insured amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r151", "r161", "r162", "r163", "r182", "r203", "r204", "r206", "r208", "r214", "r215", "r274", "r291", "r293", "r294", "r295", "r298", "r299", "r328", "r329", "r332", "r335", "r342", "r437", "r546", "r547", "r548", "r549", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r567", "r578", "r601", "r624", "r637", "r638", "r639", "r640", "r641", "r779", "r798", "r806" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r161", "r162", "r163", "r214", "r328", "r329", "r330", "r332", "r335", "r340", "r342", "r546", "r547", "r548", "r549", "r668", "r779", "r798" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price", "verboseLabel": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r343" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants issued", "verboseLabel": "Purchase of shares granted options", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r343" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r741" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r741" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r31", "r82", "r518", "r577" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r112", "r285", "r286", "r645", "r816" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r881" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r881" ] }, "us-gaap_CommonStockConversionBasis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConversionBasis", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock conversion basis", "documentation": "Description of basis for conversion of convertible common stock." } } }, "auth_ref": [ "r163" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r677", "r678", "r679", "r681", "r682", "r683", "r684", "r803", "r804", "r852", "r875", "r881" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r89" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r89", "r578" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r89" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "verboseLabel": "Common stock shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r89", "r578", "r598", "r881", "r882" ] }, "SYRA_CommonStockSharesSurrendered": { "xbrltype": "sharesItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "CommonStockSharesSurrendered", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares surrendered", "documentation": "Common stock shares surrendered." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock value", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r89", "r521", "r674" ] }, "us-gaap_CommonStockVotingRights": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockVotingRights", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock voting rights", "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights." } } }, "auth_ref": [ "r57" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r746" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r745" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r747" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r744" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r46", "r48", "r74", "r75", "r238", "r644" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r46", "r48", "r74", "r75", "r238", "r543", "r644" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r46", "r48", "r74", "r75", "r238", "r644", "r781" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r83", "r143" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r46", "r48", "r74", "r75", "r238" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r46", "r48", "r74", "r75", "r238", "r644" ] }, "SYRA_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ConsultantMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Consultant [Member]" } } }, "auth_ref": [] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of stock, shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "SYRA_ConvertibleClassBCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ConvertibleClassBCommonStockMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Class B Common Stock [Member]", "documentation": "Convertible Class B Common Stock [Member]" } } }, "auth_ref": [] }, "SYRA_ConvertibleCommonStockBIssuancesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ConvertibleCommonStockBIssuancesMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Common Stock B Issuances [Member]", "documentation": "Convertible Common Stock B Issuances [Member]" } } }, "auth_ref": [] }, "SYRA_ConvertibleCommonStockBMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ConvertibleCommonStockBMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Common Stock B [Member]", "documentation": "Convertible Common Stock B [Member]" } } }, "auth_ref": [] }, "SYRA_ConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ConvertiblePromissoryNotesMember", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes [Member]", "documentation": "Convertible Promissory Notes [Member]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of services", "verboseLabel": "Service cost", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r97", "r500" ] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cost of Services", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r784" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r47", "r238" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r113", "r180", "r300", "r306", "r307", "r308", "r309", "r310", "r311", "r316", "r323", "r324", "r326" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r86", "r87", "r130", "r131", "r186", "r301", "r302", "r303", "r304", "r305", "r307", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r446", "r663", "r664", "r665", "r666", "r667", "r799" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible promissory notes, conversion price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r114", "r303" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible promissory notes, accrued interest", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r28", "r77", "r319" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r28", "r302" ] }, "us-gaap_DebtInstrumentMaturityDateDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDateDescription", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible promissory notes maturity date, description", "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities." } } }, "auth_ref": [ "r29" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r186", "r301", "r302", "r303", "r304", "r305", "r307", "r312", "r313", "r314", "r315", "r317", "r318", "r319", "r320", "r321", "r322", "r446", "r663", "r664", "r665", "r666", "r667", "r799" ] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest on convertible notes payable", "verboseLabel": "Periodic interest payment", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r30" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred Offering Costs", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r159" ] }, "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based compensation expense unrecognized", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [] }, "us-gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCosts", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred offering costs", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent." } } }, "auth_ref": [ "r128", "r793" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Offering cost", "verboseLabel": "Deferred Offering Costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r814" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Net deferred tax assets before valuation allowance", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r408" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net deferred tax assets", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r850" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r409" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employees contribution percentage", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employers contribution percentage match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/PropertyAndEquipmentDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r52" ] }, "SYRA_DigitalHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "DigitalHealthMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Digital Health [Member]", "documentation": "Digital Health [Member]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r822" ] }, "SYRA_DisclosureLeaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "DisclosureLeaseAbstract", "lang": { "en-us": { "role": { "label": "Lease", "verboseLabel": "Schedule Of Lease Cost Expenses", "terseLabel": "Schedule Of Supplemental Balance Sheets Information" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r701" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r699", "r701", "r714" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r699", "r701", "r714", "r750" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r700" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r688" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r701" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r701" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r735" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r691" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r174", "r192", "r193", "r194", "r195", "r196", "r201", "r203", "r206", "r207", "r208", "r212", "r435", "r436", "r513", "r529", "r654" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net loss per common share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r174", "r192", "r193", "r194", "r195", "r196", "r203", "r206", "r207", "r208", "r212", "r435", "r436", "r513", "r529", "r654" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r44", "r45" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://syrahealth.com/role/BasicAndDilutedEarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Earnings per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r200", "r209", "r210", "r211" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r404" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Federal statutory income tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r183", "r404", "r417" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r849", "r851" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfEffectiveIncomeTaxRateDetails" ], "lang": { "en-us": { "role": { "label": "State income taxes", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r849", "r851" ] }, "SYRA_EmployeeRetentionTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "EmployeeRetentionTaxCreditReceivables", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "EDGE tax credit receivable", "documentation": "Employee retention tax credit receivables." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r694" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r690" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r690" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r778" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r690" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r775" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r714" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r690" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r690" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r690" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r690" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r776" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r152", "r169", "r170", "r171", "r187", "r188", "r189", "r191", "r197", "r199", "r213", "r275", "r276", "r344", "r390", "r391", "r392", "r413", "r414", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r438", "r439", "r440", "r441", "r442", "r443", "r457", "r538", "r539", "r540", "r555", "r624" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r706", "r718", "r728", "r754" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r749" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "SYRA_FSSADivisionOfMentalHealthAndAddictionMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "FSSADivisionOfMentalHealthAndAddictionMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FSSA \u0096 Division of Mental Health and Addiction [Member]", "documentation": "FSSA \u2013 Division of Mental Health and Addiction [Member]" } } }, "auth_ref": [] }, "SYRA_FSSANeuroDiagnosticInstituteMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "FSSANeuroDiagnosticInstituteMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "FSSA \u0096 NeuroDiagnostic Institute [Member]", "documentation": "FSSA \u2013 NeuroDiagnostic Institute [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7", "r19" ] }, "SYRA_FamilyAndSocialServicesAdministrationMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "FamilyAndSocialServicesAdministrationMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Family and Social Services Administration (FSSA) [Member]", "documentation": "Family and Social Services Administration (FSSA) [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r325", "r340", "r432", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r528", "r659", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r808", "r809", "r810", "r811" ] }, "SYRA_FiveBoardMembersMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "FiveBoardMembersMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Five Board Members [Member]", "documentation": "Five Board Members [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r710", "r722", "r732", "r758" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r710", "r722", "r732", "r758" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r710", "r722", "r732", "r758" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r710", "r722", "r732", "r758" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r710", "r722", "r732", "r758" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r96", "r182", "r216", "r229", "r233", "r235", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r437", "r656", "r819" ] }, "SYRA_HealthcareWorkforceMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "HealthcareWorkforceMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Healthcare Workforce [Member]", "documentation": "Healthcare Workforce [Member]" } } }, "auth_ref": [] }, "SYRA_HealtheducationMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "HealtheducationMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Health Education [Member]", "documentation": "Health Education [Member]" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IPOMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r699", "r701", "r714" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r111" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r183", "r400", "r405", "r406", "r411", "r415", "r418", "r419", "r420", "r551" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax benefits", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r139", "r149", "r198", "r199", "r221", "r403", "r416", "r530" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r168", "r401", "r402", "r406", "r407", "r410", "r412", "r545" ] }, "us-gaap_IncomeTaxUncertaintiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxUncertaintiesPolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Uncertain Tax Positions", "documentation": "Disclosure of accounting policy for tax positions taken in the tax return filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other types of contingencies related to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r40" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableRelatedParties", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable, related parties", "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, related party", "label": "Increase (Decrease) in Accounts Receivable, Related Parties", "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in assets:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r782", "r796" ] }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r796" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use asset", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r4" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r713", "r722", "r732", "r749", "r758", "r762", "r770" ] }, "SYRA_InformationTechnologyServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "InformationTechnologyServicesMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Information Technology Services [Member]", "documentation": "Information Technology Services [Member]" } } }, "auth_ref": [] }, "SYRA_InitialRecognitionOfRightofuseAssetAndLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "InitialRecognitionOfRightofuseAssetAndLeaseLiability", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Initial recognition of right-of-use asset and lease liability", "documentation": "Initial recognition of right of use asset and lease liability." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r768" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r702", "r774" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r702", "r774" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r702", "r774" ] }, "SYRA_InsurancePolicyFinancingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "InsurancePolicyFinancingArrangementsMember", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Insurance Policy Financing Arrangements [Member]", "documentation": "Insurance Policy Financing Arrangements [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 }, "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "totalLabel": "Total interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r78", "r135", "r172", "r220", "r445", "r609", "r685", "r878" ] }, "us-gaap_InterestExpenseMediumTermNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMediumTermNotes", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest on notes payable", "documentation": "Interest expense on medium-Term notes." } } }, "auth_ref": [ "r134" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest on credit card debt", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://syrahealth.com/role/DebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Interest Expense", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r175", "r177", "r178" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r99", "r219" ] }, "SYRA_InvestmentRetirementAccountContributionExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "InvestmentRetirementAccountContributionExpenses", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/AccruedExpensesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Investment retirement account contribution expenses", "documentation": "Investment retirement account contribution expenses." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Common stock issued for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "SYRA_KingswoodCapitalPartnersLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "KingswoodCapitalPartnersLLCMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Kingswood Capital Partners LLC [Member]", "documentation": "Kingswood Capital Partners LLC [Member]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://syrahealth.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lease Cost expenses", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r857" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r110" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r451" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://syrahealth.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r858" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r456" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r456" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r456" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Amount representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r456" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r856" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://syrahealth.com/role/Lease" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r447" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r182", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r423", "r424", "r425", "r437", "r576", "r655", "r687", "r819", "r861", "r862" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r94", "r132", "r523", "r674", "r800", "r812", "r854" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r155", "r182", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r423", "r424", "r425", "r437", "r674", "r819", "r861", "r862" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Revolving line of credit", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r20", "r131", "r870" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of underwriting fee on line of credit", "verboseLabel": "Underwriting fee", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": [ "r23" ] }, "us-gaap_LineOfCreditFacilityDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityDescription", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revolving line of facility description", "documentation": "Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity." } } }, "auth_ref": [ "r23" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r799" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revolving line of credit maximum borrowing limit", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r23" ] }, "us-gaap_LineOfCreditFacilityPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityPeriodicPaymentInterest", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfRecognizedInterestExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest on line of credit", "documentation": "Amount of the required periodic payment applied to interest." } } }, "auth_ref": [ "r23" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r23", "r799" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revolving line of credit", "verboseLabel": "Line of credit", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r86", "r130" ] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Litigation settlement expense", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [] }, "SYRA_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "LoanAgreementMember", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loan Agreement [Member]", "documentation": "Loan Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_LoansAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansAssumed1", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash application of invoices to STLogics loan", "verboseLabel": "Advanced balance of loan", "documentation": "The fair value of loans assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r238", "r670", "r822", "r873", "r874" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r287", "r288", "r289", "r290", "r357", "r499", "r537", "r568", "r569", "r632", "r633", "r634", "r635", "r636", "r646", "r647", "r658", "r668", "r671", "r676", "r821", "r863", "r864", "r865", "r866", "r867", "r868" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r741" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name" } } }, "auth_ref": [ "r741" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r287", "r288", "r289", "r290", "r357", "r499", "r537", "r568", "r569", "r632", "r633", "r634", "r635", "r636", "r646", "r647", "r658", "r668", "r671", "r676", "r821", "r863", "r864", "r865", "r866", "r867", "r868" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r761" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r769" ] }, "SYRA_NLogixMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "NLogixMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "NLogix [Member]", "documentation": "NLogix [Member]" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r238", "r670", "r822", "r873", "r874" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r176" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r176" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r103", "r104", "r105" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows", "http://syrahealth.com/role/StatementsOfOperations", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r95", "r105", "r133", "r153", "r166", "r167", "r171", "r182", "r190", "r192", "r193", "r194", "r195", "r198", "r199", "r205", "r216", "r229", "r233", "r235", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r436", "r437", "r527", "r600", "r622", "r623", "r656", "r685", "r819" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Adopted Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r739" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r769" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r769" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r100" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r801", "r802" ] }, "us-gaap_NotesIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesIssued1", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Prepaid asset financed with notes payable", "documentation": "The fair value of notes issued in noncash investing and financing activities." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r131", "r870" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r24" ] }, "SYRA_NovemberTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "NovemberTwoThousandTwentyThreeMember", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "November 2023 [Member]", "documentation": "November 2023 [Member]" } } }, "auth_ref": [] }, "SYRA_NumberOfOptionsVested": { "xbrltype": "percentItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "NumberOfOptionsVested", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options vested", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "SYRA_OmnibusEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "OmnibusEquityIncentivePlanMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Omnibus Equity Incentive Plan [Member]", "documentation": "Omnibus Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r216", "r229", "r233", "r235", "r656" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Lease expense", "verboseLabel": "Total operating lease cost", "terseLabel": "Lease rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r855" ] }, "SYRA_OperatingLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "OperatingLeaseInterestExpense", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest on lease liability", "documentation": "Operating lease interest expense." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails", "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Total operating lease liability", "verboseLabel": "Present value of net future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r449" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails", "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liability, related party", "negatedLabel": "Less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r449" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfMinimumLeasePaymentsDetails", "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, related party", "verboseLabel": "Noncurrent operating lease liability, related party", "terseLabel": "Operating lease liability, related party, long term", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r449" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating cash flows used for operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r450", "r452" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use asset", "verboseLabel": "Operating lease assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r448" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ScheduleOfLeaseCostExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of ROU asset", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r797" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate (Rate)", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r455", "r673" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalBalanceSheetsInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (in years) (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r454", "r673" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Federal net operating losses", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r72" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other current assets", "totalLabel": "Total other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r164", "r674" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Other Current Assets", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r81", "r516", "r572", "r573", "r687", "r876" ] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash lease expense", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r105" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure Amount" } } }, "auth_ref": [ "r741" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r701" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r708", "r720", "r730", "r756" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r711", "r723", "r733", "r759" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r711", "r723", "r733", "r759" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OverAllotmentOptionMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r737" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Base monthly rent", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments on deferred offering costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issuance expense", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r35" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r102" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r740" ] }, "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued retirement contributions", "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as current." } } }, "auth_ref": [ "r61", "r62", "r87", "r120" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r739" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r742" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r738" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ] }, "SYRA_PopulationHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "PopulationHealthMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Population Health [Member]", "documentation": "Population Health [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r695" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r696" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r677", "r678", "r681", "r682", "r683", "r684", "r875", "r881" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r88", "r328" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r88", "r578" ] }, "SYRA_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "PreferredStockSharesDesignated", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares designated", "documentation": "Preferred stock shares designated." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r88", "r328" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://syrahealth.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r88", "r578", "r598", "r881", "r882" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value, 1,000,000 shares authorized, no shares designated, issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r88", "r520", "r674" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r651", "r660", "r813" ] }, "SYRA_PrepaidLicensingAndOfficeFees": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "PrepaidLicensingAndOfficeFees", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid licensing and office fees", "documentation": "Prepaid licensing and office fees." } } }, "auth_ref": [] }, "us-gaap_PrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidRent", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid rent", "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r652", "r661", "r813" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Federal and State income tax receivable", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r653", "r662", "r813" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds received from convertible notes payable", "verboseLabel": "Convertible notes payable", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative", "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds received on sale of Class A common stock", "verboseLabel": "Gross proceeds", "terseLabel": "Proceeds from commnon stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "verboseLabel": "Proceeds from issuance of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from payments line of credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r34", "r799" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds received from line of credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Advances received from related party", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds from warrant exercise", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r795" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r236", "r500", "r531", "r532", "r533", "r534", "r535", "r536", "r649", "r669", "r675", "r783", "r817", "r818", "r822", "r873" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "auth_ref": [ "r236", "r500", "r531", "r532", "r533", "r534", "r535", "r536", "r649", "r669", "r675", "r783", "r817", "r818", "r822", "r873" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalFees", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Professional services", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r685", "r879", "r880" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r109", "r144", "r147", "r148" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r110", "r157", "r526" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "verboseLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r515", "r526", "r674" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r144", "r147", "r524" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://syrahealth.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r110" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Property and equipment useful life", "verboseLabel": "Property plant and equipment useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r737" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r737" ] }, "SYRA_RadCubeLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "RadCubeLLCMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "RAD CUBE LLC [Member]", "documentation": "RAD CUBE LLC [Member]" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r287", "r288", "r289", "r290", "r355", "r357", "r385", "r386", "r387", "r475", "r499", "r537", "r568", "r569", "r632", "r633", "r634", "r635", "r636", "r646", "r647", "r658", "r668", "r671", "r676", "r679", "r815", "r821", "r864", "r865", "r866", "r867", "r868" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative" ], "auth_ref": [ "r287", "r288", "r289", "r290", "r355", "r357", "r385", "r386", "r387", "r475", "r499", "r537", "r568", "r569", "r632", "r633", "r634", "r635", "r636", "r646", "r647", "r658", "r668", "r671", "r676", "r679", "r815", "r821", "r864", "r865", "r866", "r867", "r868" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r703", "r715", "r725", "r751" ] }, "SYRA_RecruitmentAndHumanResourceServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "RecruitmentAndHumanResourceServicesMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Recruitment and Human Resource Services [Member]", "documentation": "Recruitment and Human Resource Services [Member]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r356", "r461", "r462", "r571", "r572", "r573", "r574", "r575", "r597", "r599", "r631" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r184", "r185", "r461", "r462", "r463", "r464", "r571", "r572", "r573", "r574", "r575", "r597", "r599", "r631" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal debt", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r80", "r461" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r604", "r605", "r608" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r356", "r461", "r462", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r571", "r572", "r573", "r574", "r575", "r597", "r599", "r631", "r860" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r458", "r459", "r460", "r462", "r465", "r552", "r553", "r554", "r606", "r607", "r608", "r628", "r630" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments on line of credit", "label": "Proceeds from repayment of line of credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r36", "r799" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of notes payable", "label": "Repayment of notes payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r36" ] }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfRelatedPartyDebt", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments on advances from related party", "label": "Repayments on advances from related party", "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r84", "r399", "r869" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r398" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r704", "r716", "r726", "r752" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r705", "r717", "r727", "r753" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r712", "r724", "r734", "r760" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r44" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r91", "r118", "r522", "r541", "r542", "r550", "r579", "r674" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r152", "r187", "r188", "r189", "r191", "r197", "r199", "r275", "r276", "r390", "r391", "r392", "r413", "r414", "r426", "r428", "r429", "r431", "r434", "r538", "r540", "r555", "r881" ] }, "SYRA_RetainersPaidOnProfessionalServices": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "RetainersPaidOnProfessionalServices", "crdr": "debit", "calculation": { "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails": { "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Retainers paid on professional services", "documentation": "Retainers paid on professional services." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net revenues", "verboseLabel": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r217", "r218", "r228", "r231", "r232", "r236", "r237", "r238", "r353", "r354", "r500" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r150", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r648" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r173", "r182", "r217", "r218", "r228", "r231", "r232", "r236", "r237", "r238", "r274", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r437", "r514", "r819" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/ScheduleOfSupplementalCashFlowAndOtherInformationDetails" ], "lang": { "en-us": { "role": { "label": "Total operating lease liabilities", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r453", "r673" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r769" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r769" ] }, "SYRA_STLogicsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "STLogicsMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "ST Logics [Member]", "documentation": "ST Logics [Member]" } } }, "auth_ref": [] }, "SYRA_STVenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "STVenturesMember", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "STVentures [Member]", "documentation": "STVentures [Member]" } } }, "auth_ref": [] }, "SYRA_SahasraTechnologiesCorpMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "SahasraTechnologiesCorpMember", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sahasra Technologies Corp [Member]", "documentation": "Sahasra Technologies Corp [Member]" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Salaries and benefits", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r794" ] }, "us-gaap_SaleOfStockDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Description of Transaction", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination." } } }, "auth_ref": [ "r9", "r73", "r127" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate shares issued", "verboseLabel": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Public offering price", "verboseLabel": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r238", "r780" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://syrahealth.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://syrahealth.com/role/BasicAndDilutedEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Diluted Earnings Per Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://syrahealth.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r124" ] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://syrahealth.com/role/LeaseDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r8", "r63", "r64", "r65", "r66" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://syrahealth.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r123" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://syrahealth.com/role/OtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://syrahealth.com/role/ScheduleOfPropertyAndEquipmentDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r79", "r80", "r604", "r605", "r608" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation, Stock Options Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r69" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r54", "r55", "r56", "r57", "r58", "r59", "r60", "r116", "r117", "r118", "r161", "r162", "r163", "r214", "r328", "r329", "r330", "r332", "r335", "r340", "r342", "r546", "r547", "r548", "r549", "r668", "r779", "r798" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitTables" ], "lang": { "en-us": { "role": { "label": "Summary of Activity of Outstanding Stock Warrants", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r67" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r689" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r693" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r692" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r697" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r222", "r223", "r224", "r225", "r226", "r227", "r237", "r657" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://syrahealth.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r672" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "verboseLabel": "Dividend rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r386" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Volatility rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected volatiltity rate", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected volatiltity", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk free rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r387" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average call option value", "documentation": "Weighted average exercise price." } } }, "auth_ref": [] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average risk free interest rate", "documentation": "Weighted average risk free interest rate." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average volatility rate", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r385" ] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Warrants exercisable ending balance", "documentation": "Number of warrants exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Warrants cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Warrants outstanding beginning balance", "periodEndLabel": "Warrants outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r11", "r12" ] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average exercises price, exercisable ending balance", "documentation": "Weighted average exercise price exercisable.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercises price, exercised", "documentation": "Weighted average exercise price exercised." } } }, "auth_ref": [] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercises price, cancelled", "documentation": "Weighted average exercise price forfeitures." } } }, "auth_ref": [] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercises price, granted", "documentation": "Weighted average exercise price granted." } } }, "auth_ref": [] }, "SYRA_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/SummaryOfActivityOfOutstandingStockWarrantsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercises price, outstanding beginning balance", "periodEndLabel": "Weighted average exercises price, outstanding ending balance", "documentation": "Weighted average exercise price outstanding.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options cancelled", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r370" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted options", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r830" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Options to purchase stock", "verboseLabel": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r368" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of the options", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of options, beginning balance", "periodEndLabel": "Number of options, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r364", "r365" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise prices, ending balance", "periodEndLabel": "Weighted average exercise prices, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r364", "r365" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r384", "r385", "r386", "r387", "r388" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Weighted average exercise price, forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r370" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://syrahealth.com/role/ScheduleOfShare-basedCompensationStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r368" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r358", "r363", "r382", "r383", "r384", "r385", "r388", "r393", "r394", "r395", "r396" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expected term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r384" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted options term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r122" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remaining contractual life", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r122" ] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://syrahealth.com/role/CommonStockOptions" ], "lang": { "en-us": { "role": { "label": "Common Stock Options", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r115", "r121" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "SYRA_SignificantConcentrationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "SignificantConcentrationsPolicyTextBlock", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Concentrations", "documentation": "Significant Concentrations [Policy Text Block]" } } }, "auth_ref": [] }, "SYRA_SixConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "SixConsultantMember", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Six Consultant [Member]", "documentation": "Six Consultant [Member]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r698" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/RelatedPartyTransactionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative", "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r151", "r161", "r162", "r163", "r182", "r203", "r204", "r206", "r208", "r214", "r215", "r274", "r291", "r293", "r294", "r295", "r298", "r299", "r328", "r329", "r332", "r335", "r342", "r437", "r546", "r547", "r548", "r549", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r567", "r578", "r601", "r624", "r637", "r638", "r639", "r640", "r641", "r779", "r798", "r806" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r33", "r152", "r169", "r170", "r171", "r187", "r188", "r189", "r191", "r197", "r199", "r213", "r275", "r276", "r344", "r390", "r391", "r392", "r413", "r414", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r438", "r439", "r440", "r441", "r442", "r443", "r457", "r538", "r539", "r540", "r555", "r624" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r187", "r188", "r189", "r213", "r500", "r544", "r567", "r570", "r571", "r572", "r573", "r574", "r575", "r578", "r581", "r582", "r583", "r584", "r585", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r599", "r602", "r603", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r680" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/BalanceSheetsParenthetical", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r187", "r188", "r189", "r213", "r500", "r544", "r567", "r570", "r571", "r572", "r573", "r574", "r575", "r578", "r581", "r582", "r583", "r584", "r585", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r599", "r602", "r603", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r680" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r707", "r719", "r729", "r755" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Class A common stock issued for debt and interest conversion", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r41", "r42", "r43" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class A common stock issued for debt conversion ,shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r10", "r32", "r57", "r118", "r317" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of Convertible Securities issued, shares", "verboseLabel": "Shares of convertible common stock", "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)." } } }, "auth_ref": [ "r10", "r57", "r88", "r89", "r118" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class A common stock issued for services, shares", "verboseLabel": "Stock issued during period shares issued for services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class A common stock sold for cash, shares", "verboseLabel": "Stock issued during period shares new issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r10", "r88", "r89", "r118", "r546", "r624", "r638" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock awarded", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r10", "r118" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancellation of Class A common stock, shares", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Class A common stock issued for debt conversion", "verboseLabel": "Value of conversion of convertible securities issued", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r10", "r33", "r118" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class A common stock issued for services", "verboseLabel": "Stock issued during period value issued for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class A common stock sold for cash", "verboseLabel": "Stock issued during period value new issues", "terseLabel": "Shares issued", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r88", "r89", "r118", "r555", "r624", "r638", "r686" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancellation of Class A common stock", "label": "Shares Issued, Value, Share-Based Payment Arrangement, Forfeited", "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r18" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r679" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of options cancelled", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://syrahealth.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://syrahealth.com/role/BalanceSheets", "http://syrahealth.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r89", "r92", "r93", "r108", "r580", "r598", "r625", "r626", "r674", "r687", "r800", "r812", "r854", "r881" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://syrahealth.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r115", "r181", "r327", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r341", "r344", "r433", "r627", "r629", "r642" ] }, "SYRA_SubscriptionAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "SubscriptionAgreementsMember", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subscription Agreements [Member]", "documentation": "Subscription Agreements [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r444", "r467" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r444", "r467" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r444", "r467" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r444", "r467" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r444", "r467" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://syrahealth.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r466", "r468" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://syrahealth.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "Going Concern", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r85" ] }, "SYRA_SupplementalBalanceSheetsInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "SupplementalBalanceSheetsInformationTableTextBlock", "presentation": [ "http://syrahealth.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Balance Sheets Information", "documentation": "Supplemental balance sheets information table text block." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://syrahealth.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL INFORMATION:" } } }, "auth_ref": [] }, "SYRA_SupplementalCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "SupplementalCashFlowInformationTableTextBlock", "presentation": [ "http://syrahealth.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Supplemental Cash Flow and Other Information", "documentation": "Supplemental cash flow information table text block." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r748" ] }, "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions", "crdr": "debit", "presentation": [ "http://syrahealth.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax provisions", "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement." } } }, "auth_ref": [ "r125", "r126" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://syrahealth.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued franchise taxes", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "SYRA_TenEmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "TenEmployeesMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ten Employees [Member]", "documentation": "Ten Employees [Member]" } } }, "auth_ref": [] }, "SYRA_ThreeConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "ThreeConsultantsMember", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Consultants [Member]", "documentation": "Three Consultants [Member]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r807", "r859" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r747" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r136", "r137", "r138", "r241", "r242", "r243" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://syrahealth.com/role/CommonStockOptionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r325", "r340", "r432", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r528", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r808", "r809", "r810", "r811" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r771" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r772" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r770" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r770" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Aggregate Available" } } }, "auth_ref": [ "r773" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r771" ] }, "SYRA_TwoInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "TwoInvestorsMember", "presentation": [ "http://syrahealth.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Two Investors [Member]", "documentation": "Two Investors [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://syrahealth.com/role/DebtDetailsNarrative", "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r421" ] }, "SYRA_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "UnderwritingAgreementMember", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesDetailsNarrative", "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriting Agreement [Member]", "documentation": "Underwriting Agreement [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r767" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://syrahealth.com/role/NatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r49", "r50", "r51", "r141", "r142", "r145", "r146" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://syrahealth.com/role/ScheduleOfDilutedEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r677", "r678", "r681", "r682", "r683", "r684" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding intrinsic value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://syrahealth.com/role/StockholdersEquityDeficitDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r853" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r202", "r208" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://syrahealth.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r201", "r208" ] }, "SYRA_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://syrahealth.com/20231231", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://syrahealth.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://syrahealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r777" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "c(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-3" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-10" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482620/740-10-25-8" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r779": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org//705/tableOfContent" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 85 0001493152-24-011121-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-011121-xbrl.zip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�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

LE,=A^#:3H@R>Z M80DTV.^GEUV8]1=SP16+Y!\U9-W.OW'PGO/O-?FT&%+I6,$RL^7"2X7KCJE3 MS6JL+*R9X455V!LQEU1%5B6YDE^95$+$J;J45' <6+5N)J$'%3LM9['3S<9. M2UGL-(N='HF6:/]7 ZN*;*E0I>4P8%O$A+ MIL"/B1N"XD#IQ9B8[MS;D")5QV"Z$P,;AMW0D

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�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

    /?M\C^_/4^82K*^BHHK2A9__X878^V_ M__#N?='ZOQT4RK8;IIIIR#7KF\G;SE\^\R*.T_V*D"PU]4!:>)">S#U*XFQ% MLM#W(JMN26OVU4<^=,B:M9_.%K,-'^Y,GXRPZ6L-T;?[+/%_7251P.:;R]_R M,-M>D$7HAYE-5XV-#-'SMO+DI#GY%S$48Y^]ZE1V,&1CHG]'[%YA?SA 2J MWE=O9VRZH^G-!'HVHU,OT]=T;4NREM!\^*-37E]E>>!UF8MYF-+/I MA4]W; <.F#P!5?M;D3JOGR.MF1R,)!:?FVU Z1E]]NF8'J35Y\)[-7$J* M]L9=_IB2WW*F)I=/7%>,E"G*8^TAAMI+#+6GL.W'@_<8]2_=8:LC[0-@HE@U M,MR> -994[TA]P>P'IIK#K17@'5/6ZG/?0.L.^V2O>XA8)V0%!U\I8;U#%A] MN%4;UDU3O0%6<%C'E!5ZX]=?D2"/V$IP$:;>]TUM=!_G^_S#6N+CW O.K@SY+?C="WV@]9B=&AT6,FJRS VHXEUL2_A MX.WV+]^G, [7^5JHS-S;"ANPM3" 1GH]&]L.8&VE$>SOMOWMT%1_-M[UVJ-; MO@"RYMFIG>T!\TPX[; ^B'/RS_S;%FK2N<7!+1FVO%@W-,!\Q$\.;[B+3,"= MG]CT+N:)N@&CPME^3NK<]G!6G"Y#!]9"_]Q<+A:$XT-VMIL[=H*UI@'4S "G M7;(@[)P7L.]U/"R:6AC EF:K'H"J0]V664\VP/I=^BL\[U+B?[M,GMX2/RA/ M?4^;BS#UHR3-FYX8E6-DJR+O,O]!]+TX]\E:Z:^3EY3RR:F'CBI;ZJ^STZ\> M#1["-5OH>NBPMK7^.GT=IR%;X1ZHQQ?H*5^:EX4_6.>>FYL .K5F8\>*EE_&[R1ONDIQS M8-F/1OW/'B+Q' M$HGV?V%E&D7>CM"K"HD'UJ*\4XZ-OPJC'<\+FJQ5Z)1()(J.UH%BGQ@'S2G[?L#[B.[))J 'XPY) O+_'Q%LF&Q+,_R?W:$9HM(4@W2H, M!/L'3+ 5$B+A+>ZF0XX/!/!V:2#B/Z)N/!0R(D%^OR)1Q,]N7@S2]X?00ZW8I*,8HATZ54"C85I:&..,Y,'3X-DM",48Y:^J$0\'YG,E#O>@Z M#LCS?Y&M#NA642C2*&=,K7@H4,]IR#U6[D/?/&FTRT+!1CE9Z@5$0?O!>[X. MF%0BL(*#9 9=606*/1)HIW1#12@=*.=- M"]%12)D& >5A1\5_;L*8O--1(2T.OB/"(T CIB.PO[>#_3T<=I1SJ%%,1V#_ M8 ?[!SCL*&=1HYB8L)]SMUSZD'Q5W$ K"T,A1SF+&D3$!%RL-#,ZI\E36"33 M,Z'>J@&%'O&(JA<65>&+11ZB[55)*-Z(QU6Y<)@XSY,T\Z+_%VY,.TEY>2CF MB =7G:!C&Q@+WKG10N5*U"@"Q1?EK"H59VQ(.<.4>&KU/2P!!13E "H39F0\ M;Q)^][%*8JT]MET*BBO*25(EU-@3+W$Y)9QIPK;=PH^+QQK0V6*AFGEUY:&(HYSUS(+B(G^=ICFAMOA+:D%9 M0#GV084>>YXA?LZFO>V[]X\//&)&,\.%>+A^%X63LV[M:=XYTV'N*H&%'C$2T2]L$C^:1GA M?0Z?R(67>64/=?BK:D#Q1[Q0U N+YC]/S]G"LTST=^:-@E"T$5UAI:*A@'R_ M]J*H2C:N [E1$ HRHL^K5#04D"_7A"[9I/:1)E^S51G;J0-;40$*.J)GJU94 M'/"?]W'D1?R;%GE):7!V D38E4)BI=W8O51P+Y[>I0K4=>6AN*,&5JH%'1EY MD<2WOG\2G;EFYS:=TX.Y%I0%E.,J5&B4[@.]2'"VO>.IBKF; MP@-YSL[8AW[5;XH U:'\H&84 L,P,DW7_H(*@W="IUE&T@(VM3.!KCR4")0# ML5E0M#0@;."NLTM*$WJ>L$G4US, J0=E C7?D%EPC-NNA%Z%='VM.*LUBH!3 MR*'=8S7%P8%4[>-Q4 *)\Z];%L4'#!O$E_C:= J! 45[ZZU+9($V/]\V^K] M#?M%]5?I'P]:LT[X??#TT:YG!XF_WT_>3'87P^SGLLJDK'.T3BR\]%&@GJ=O MEIZW*5.D1UE:_6:O(>4O?MGU9[;875[/D\(NILD57E:'U3Y>VX^23+S+"I"A M+&<: 2V=ZW<86"%[.$(4 M4SV"%3P889X;8FV<5)L_>ULHY1QYY:3I;"'NC?HG15'%CYK+; K2EJ#WV@4-*O4NF!416 MUC$:5*K58$0F"?9Z41CA1<^FIBE*5A8X1?5OQM9@*@=?*>BQ4Y3D,;Y_WDT9 MLO$3H5G(1JCXZEGMOD.)-*\)J8B6FAT,.U021Y:)X@E*LZFA60Y(Q% \J(^T M#?67R^<([.4U+!3]5G%HYLBA6%" *V- (2HZ$?Q5<[)9G:#:,25UL+^XAF0P9$?G22A$O:@51J:F1EP0&1 M#A"BEA6=!B #W< ?[*1L-1H,N+.^%R]CWQ12*WLHNI)DEB,50]YGR>I M-+BR+-"FY"Y>K;+;XG!(AH69)T5<#\M._EY(-/R#1T0DJ M1#$M+?AG;(M3Q0M816Y"[S&,PBPD*1O9PD2P2B*&<,I'>;8U'P[A+8#/B^C' M=EM4T =7KEA_-P.?29GDH58/9!P!8 MR\^E&9HNHO#24D<%, M"=:,Z*1V@!+X',!/1E R,\T2DG""QK^536PE\#>LHOP!$ MT$==%_M3#Q:G =[XZX>S$[ \S:N)0?3UBQ?EFF@;:6$H28,9,*QITN]!=DP=^$4=,$J0ME;#!;A35C M<$30R6O+9K,U@),SF-FBATW "]B?FS9&W>\;X10/9@HYYNRE1:-7PI&CY.<" MR17)0K^V-AR$S'_0ALQ/_G30Q'^\AM /)-EK"/UK"/T?/(3^-9Q1&&)Q#FY8CK'_?-X5WX.L]5YGF:LF_3RV8]R MKCX\^I3]7_#@/>L\%3HTAFQ8,!#8\EKH#)<#4V.:S18?DR00-[Z$/H4^2>^3 M2+M@J>M@FQCLF#-+CT[01YJDZ9PF"YTWT$$A;%.#'042^4[8G6076'#YO"$Q M&^[FN5]3!=LN8<>D47;TL73O11XM?%M^]I8Z#_QV26SK@QG=Q""!(R3PL&7>45T)+1+8ML3;$E0R8I.PAW#C7U^Q;3C@NU>HD3DT2FETNWEM-6P[0BV M](!00.?JGD01?YJ9Q$RZB/5U&JS#..22\7??C:1!ZV.;&ZQG."M=$*K+]#/E3,4/&9,EO?=V< M(SO,C0XDDNI*K1&&4UX&20;9QS2*H2>>LES>9$*>,&D_$Y[.E@33)Z:52W*; M54]/HBC'+V6PN' >N&T'-E]4*O M"2AT@JMH\LJ3RS!&%<71N74V_LW[U-DOYM4K0Y^5/9*G[P=+?43Z#JK^'31X5/=TA8\1H_ M/2@G)QP_72C0>;+>)#&?GH QU/)JITB+7!+T6.I&MTSAU(KBCA&B4[;F_D N M4.WFW(6P'E-LM;PTMF]@%SYT&/F.QF^&0#)O1/+.?-2 E9\9.C#)"63:;1!*FG'F 'S,8%3"XRJI M]3P;Q["J; <[EJN?0>HNK]/@7WGA4)P^) J36>6X00)NUB%Q*M 7 L\V(K_% M'6$;P#3,2"E?(?L=\9-E'.HCC4;K '9<&5B31J8$704'=43%3WQCM;=X"MH@?6];-/^ .KCQ@^ MA9V/)RJ8+6HVOWOBLY+ZQT>/;!8];*^7Z0>,GZOK3S$,^E<#<+OHD8']3"2G MHPC@W>YCS'Q M7\;(FX@C;FAL2'3 7"CK_D G@E2=%;>S0C9T< M5A$;DEIHYAC>ESE-GD)&Y=GV,YOQK^-=+I"IGX5/Q=N,YGP9'=IRY3$7#9%M M"T]'Q-"7PV&#P <+Y^\.^"G8Y@XV8WPG%?MA1 [Z^I#T-D:'^1JV$T1O*C(D M&>B:-LM6A-XRD5C_C0D^I(6Q?2 &I2-L3LDZS->:.=M<%=L?8D1VP4"B4\[-=?S)[LK=E2=% MIM1C&-5\ V;T//)"74RN93/8/A0CJD(G@-'50G[M8S!I2,ICNSB,2+0>LLZ6 MD2="'Y.4H-JV&%B4,,DN2/'?.CQI2C+ GMZB"6P_BC$G!UM@T2>&=H^GOEC8 M4H84"9_TJ31@M;']+NQ9,;&JQNBD+\XA@MZ1B/=S[E']-6F7MM!]+,;0%#F M+TQOQ$GV/*<<\P(YJZ5$4AO=?:)_W5"#]!*U88=6>=G+%F!KG9"V@>Y0,9!F M: ![:?I127H3>H]A!#0KV[:#[BOAQD94@['#N]&YM^6+YP/U@D[[T'HAA M!5(O;"K8H\7_7,"F'S9]MYY,79- ZX M [)XUU)-LTT;8/^BD1V,(%PEG:5^ ?8%.&Y]S =P11G;6=%>4>R1>WG+QU48 M>['?S_*A;0NJ-L/'@1V]? PYLR!<( M#38GO2+%>FNN+=1,J)TTY@\ M#3)Z5>@X-7#A%.IK02DSI,/P 9]^,*% M[1$17JP,GM!G$Q#_PS0.#G]1*UDD M:6E?:OE1SE-,7#[[*R]>DCLVF5TN%D1G7!N['U!U=0_ 17VR2$/T8?A<4B-IU,M)0)5O-I% SHLJY*[C14+7!7GF MU#_0!J Z,GRJ*KB.6**#ON>^CC/"8,UXOCM#Y$.C()2=X1+46T+==#V3"NX M(=SG_L%[YO<>1D[:9:&T#)?M_4A:5.*C,U,F0-E['<3![H E\M@![N/A34!Y M'#[-N\4UO"U" ST?=\WS;WI1+17G;'$7+E=9LLA3(F*?6->,7KF\K6Y-0G;+CF:^U8:!2#LC)< KLC!X-4;'0RA">+<5XZ M+ 6E8CA/KB.ID DM86+8[+M"_I3XWRZ3I[?$#XK#]/QIPW-E14F:T[UK49%W M]Z>??F"3SN3-9%^"_6/N;2=/Z61.J-C,LM%?^_OQN7?K/2STR0_V:L3^P5T% MOZ2US^^_?M-,I5S3+%835/'X80&0X&GSH'!PX]W<_17YK6HH9(/A,_S\(GY%:QYME\)'6*'>SL[4,P2-I M];X')FV6E,3'5JX1A^HKZ?BX:CL-_O60\)1]:JUM%,$'5J.TC;[6LAV/I+.[ M#A@TME4.'U:I*ARJ:ZO7XRKK)^+QO8Y:50\*X".J4=2#GM8R.X^YWWU@!Y2S M2&XDJ?6^5@P>Y=G[V>_HW6]+VEX/WV;4SY-[$A%^!UMR?^NM%4<.15$P^OV; MIK0X)J:.H^#-/[W?2>S92#BI[3MF9$%; L1[89Q:E(7!P/?O-F(!O$'6L;<]2R*[881.Y"[#MC5]LII@T@8YG_=!FAH/ M=*I:.U1KRG0M@*D;Y%#?!W5F?$:F4#(!<(MV:8\PL >N#"9N$/N /7&6J* / M._'>1-<1IZ@,YFP0&T,?@TV+RMCCS'O,(X_>A&D&N>G2% ?S,H@)HL-8,DF. M/^,I#\.JLF .!C%%]#*?81I JWG4@@EC)3 E@Y@E["D!HH#OCUU_WD;"S3ZS M1KT8/#DJBI%(WND6XKB/*W2XP%<.'WE),$M#9G:1,*"YOL>;ML1N@OMZF+"6 M%@1#/5RXB %JC7P8EE+M)<%A"3"V0V;RU6(KDVC\:T>U>\_NCV HATR/JX6R M(]/UW[Y_V:F2\O3)6 ],QR%FVVP !H^%( -\EI7SET0;Q M?=\*XN-![6Q#NYTDBPEK(8E)DJ?1=C+]ZC%.@@EODL2IZ.48,7U5?V:+ECPM ML@[5$%9SE+O&XOM5AS01?O*2^.[C-BS4+Q"EXHP=^L=33I6I.B[8?]4^^]*" M^.#KU*<&MK3W(P< GF;H&1#@US"T/T(86GT8D8S0=1@+B/B8,D\;[1JX@2H= M)VX("&-O1I?+K)1!;1YHE,$-4P&!F"@[CX)RU0&VR]VF86IR@%*6Q@U,44#9 MVI@HQ1P9]?OLUSGU9_0AI9=I%A:)X#Z1;)4$!@9@-7%#4XQLV(@_MO$WS]@@ MCGDZ9<@$I"F.&YABY, H*-YT?YMD_R2[*928A@2L)F[DBI$.&_%'9N:*B9O$ MI-I9L V;VBJJ*HL;QV)$7R\B+MX7.7E(+I^Y$8:P71U/'.J+/89R4K)J #?0 MQ989"!@.T/4E3*H\>/](UN0\R>.,;F^\KU:.(6"A+W>\(1]K,-% MXE;#;J-C4[@A/$=1I63<#D:\C3QHYZ(KCQO'TQ-Y9D#P&8*>M5KE<0-TAF,( M]TQ67Q 2DK*#R1WY+0_I3E+#7&E3'S=:IR<&[0%SY.Y8W/8^A&S%7^KOCS\T M[X]%S4E1=>3TKT6GUZ+'-_J[847140P;_-/I.8.%Z=2G>!/R/FBNA'7E\:]T MM)C7[1D:*<:^#S[-2TJSWIBO*D?, _MZ58GAM%\,1_8!A6:7Y1K%\.&&*[=< M@EZOXCN]JL'C.,Z\E 1U!ZDII3S/DWA3^&R[+S,OWAD60NPEB8,Y.S_Q'?A% MLO;"6,W?,%]#5@,YLU+VAY%_Y'2WY!M;8.W&G6O5F3DF0T74<7$7>4H][HRBR=X$EZE(YL;2=C;[S. TH M /1F660O@@[S3%M2)-C_D7S=]PIAX*V K(+ 9 (@,P8@T*ZV8>,#%-%9->"H^TAV&-$VC/M58F^!K)#P3%\ MX-Z'B"Y]C@,:;9?WQ,]IF(5$?<.L*8[K&F!%@4Y>#/POGZD_IZ&O4_U:&=P+ M>RND6Y)AP/N1G=A%M,J5%U*>:%"'LZPP[CVZ%>!J64=&_G",;3_]F@D].%_% MR[GT<696R50']TH(:=ZXJ,N/,>Z,@V2348TAC9E82#F@]C9K# WB#M^ A$K_'7E@10,8F.SHL L-,HD M(_JA#9N5E0.B/HA!K<-D(Q,2<<)YH.LX \XW];) U ;MK"XLXV)O U MQ8'X#V(@.V:N0:>@VK0"@O0518'0#V(8ZS#A*$1%@?TBIT46( W>^S) H >Q MBW4 NBD<"L(U*^AR.7WRPDB=L%A7 7Q&<@1\K=Q.6F?F213ZK+]SFNS\HNK6 MF3^;K#-5 Q,O#B:\%1*P@@B&FKHD5A8;1<5Q''K+C@3U3ABW_X!JSAARM+0< M./X"H1AY0I/WZS;)RJX9C&T6U=TQ"!W'F0:;T:? =$N]%?&B;/6MGZR+"?#6 MR]@,-5NGQ:)1GGNP:E9, MB+6&)_N6=Y/F\;-D)U_KEHC3QS3C08\2':Z<6S5UOB>1+[A,:RX=@*YA(5)E4-%/VK;VJ0C.BP!I*)T;T'8F8@,'R4=CRTQ!MB%UNV1AUQ/!C=$)@,F)\3FG"5N%LBT3D[\&ON%[:=D(;1FX MJXIB9=M71=')JB\\X#>K2V(>A8"J..-,V3&KO:5=*\@C$4QC8ZQU@8H,P%C354+*IU%8]M*R M:U7/2' 3%GGM0F)WF.O<(/;8,Q/:S-!Q''1.#, +\BA=[7YJCCI1$&G_^9C9 M;2OEY7'&UV%O .-'60%]EZBCH3$T#%([H?HWQ$ME!HSWK1?#BI)=U(=_5^C$ M._9_0B_N_WDW_:7V1 EO6J/3O+BR-(Y&WQ"VFR*&P.\&W1.K&KW&>O1*HD8QBD_!F;; M"[((_5"VRWO?\DZIU_[W?_O+^W=__MND:&7RI[*=_T RU8M> STC7)(]]8M M%FZ3C%@-.XLFL,WV4FJ:U\^VB#@QFOA$D,2B[[.-ZM[Y?Y:Z8YA&PV[5LZB4'4$1\GQM)US'XD#]ZS?/O8ZI"XV? MQ4N%Q3.W1!995Q9LED.+:^K*BUQ0=/R%/W><%>&]=V'ZZSDE09CQGW16/DTE MM PY79D!0(!.TRY)7LV;_SIF8N7B$%>,;C5AP.IHB7:Z4F<%"SJ)YUZZXB9B M]A]^('_RHGTG(;9U6'6T5#V=QY\-+.@D\FA6LG-S++TZ[HA/6,A$\D*)S'P5K1K36T+$E=->08 MT-#'?N% 4_C-@(G55D)+OM25/P $Z#3=DR57L#NR26@'&" MSN(=>2)Q3JZ8V-R3A&KJ0(ESR=QC0N!8DA2.O+5[@0.3$X (7A]>'6ZTN&"S0)2(W7898F0R ( J0QETQXAC@0DZ?_+W4F=5_J)KH8-L8\P/5$;3 M:J?&H/RZ8]\Y C-TOINQ_^"%SU@1RJ,[!A\@%NB<[3QPX&=Y90TH2^Z8=$S2 MG[8)IQ+N,T\EE7EAG%6>%YIY5E\+2K%#-AD "NBC\)9\K0E&DYC]Z)/:W1IX M=-JW!*74'3--5[1.TE-*O,XI]9-J);_HZB=5?.+52^J8BZXP]99+2I9E*L#2 M:F%\7K:Z'H)5/S4?*2M4G!B=AM1JZL'8RH@!2;"&//1./]/:O;\B01ZQZ73* M]#+@0+.ST3Z1_^6S'^6,_\)ZN-[D5:K.#BG:AO@6=GR+76ZWX=!V8NQ+DF,I MAWLK%8:+!1,6TT"YC;0N3,F>\\EY^9H:V204P^T5GJ29AXY["'V0A+*U79NK6QH M]DN?N0WL86:=-LX>("<&&D_II1Y=K4PBO#CZIO24$\==QQEA!&:%45GK6A@S<%1U;Q%]>VF1>NY8W)P8;,(O4#W:6@E'1/GCAMO+3%7'.L$/)= A MHJQP2LGIM#(/Y0B5;S:1N!?QHC./;1U][LLR4U?9R^XG?V;'_PB?# M#HVAQ9OVD\83")83FP1EJC_UQJ&59 F2\ _[ZNBT4ICM3G?RC'<_>Y1Z<9;. MZ%VX7,'RRW1O$OO2!Y34[%C$G!B,[4R!ZE'8RMXDRQ?X.NJZC3JI4VN=EZF? MA4\6RV ?;9_8.#P20R<&9"W=H'HDMO(_U9,.(H_ EY)]<*]7EXL%X8I#=KV\ M\S)R1_PD]MFF"W;F:&EKEU9/+GMA'R"BGT[V0E07QJSWQ7WN-#[NGL"R0>Q4 M4\IQVLNX MG=,DR/VL:0B!C%!E5=-8;"GP("/2/GK*+%D]D=G001(5%T)KU(UEX8:YF0%4>F0PFK"GV9#/O=;Y^7#?\0NP&?=?_G MA/[*M,,GG\CZD5 )QKR"ICS:]DV/6_L6P2CS0!<[\V231P*.H@=:H%6%T4SY MMBCKI1T(XHMPR=U< ?A*2Z)E [0%5R/G0,B>D97W%";4BU@'/XD;N*J;6IP! M]= 2P=FB#L9@( X*NMF2[@ML !-UJRQ:2JYND[1"5G2C27F2U>S7]R6P?2'- MIPUYQB59[NS3?#/1-N2V-$_<\CLN;M23F3Y:\7Y=@V_+CTUV7WNUBKQ:15ZM M(J]6$02KB,U RQ_3, @]NN49WDHW 869I$)"7>6TJ=((-HSAQ(:G?8]NO37[ M\8%Z<A5 UCVT<;FH]XN>MVR3V]K^IJ:#:>E3M=FT;\7*ZI$1\7FMDTM; GO@Z:F#=" 5 !'T2;+VJ=;;E MNJ>?"K65W!A 72=$K6@UG7.$+=XWTSY<6\D-M@!::.*I+A3VWKO*+M_JI&FU M,E;$?O4&H(!-HF!8N#@1GI'87ZT]:C!,F&NZ,JG.%O*J#UI-C MJZ8;Y$'5T\A=4SSLN5*\\%#>&=T2]8:Q=AZ5%'=N7E0HH,20I!0>?4ILOP]H M/&TI:Z _=M&1(1,&PY!D<&W[Y/TKH=7"FJJ]"V7EW)C.NO@6RJ2IN=2,!W]A M"#OHCLZS4%,\33UX6!*%O'BE63>"] ->%&UMH4%;SUV@! M:;3 CZ_1 J_1 D=&"[CBB/JRHP6&F>P="A?HU8TFYSTK$S*DUVF:D^ ZKETH MP1QJS*V::S%W9I#2Y#7F=BC<$-GGFK1X,R+=5',<=8U+D7120XVS87*7$@ M.8,](]QAJ.GD=H(5GE#RB9WGN+]K=L[T9\OV$E^\*-><94WUT,QT1_%D1@*= ML+9;PBTQ1]HVBX,-#N[PHQ7\I(\ORD>Z/J=DD4?PVQ5W2H73]'R ML(TTY2\*\,2<:@H[-8;N$-X0G"VNPMB+A=<1^TT9%V5,\=%3\WB[ M8M;/8S;'@.K(]W2]*H!D,PT&$'/SIKA$YU?V?-@7KQ\K+L^;A;!O\08A5":H M,TLYFTEC$E2OQ+,30K[FS@ D*%^[T:WH';?S;X<'N#\?2C&'ND3-" M'=CLWQ$Q!R#^*DZB M9,F=/A*ZT08-&.I@FT'4.G3P)#1$\(%"-.X?;M@'?7T"_&8A[.,%$%:I:(/A M^(7UFVVV34@VBV$[;$&QE(LW$)IW7G">/Y*;FW,MFNUBZ+?+,#A5\@T$YRT? M",]:* ^+0&$AA M'5#-TXG_M !BJ'63^#0/1;9CUN-_Y&LOOB-IDE.?@ BQJ(^W1-C28@T*^FWB MSA9>^L9#'B905WE!BXM96/SLJ+4N&?/^22#+/:U"X#Q4?/ M:C<_VKD-4A$ZJ0V7PD^I/?49#8X!^E2F&.Q%Z$%ZD,G?VFHJ;P39E0EJ]X>9 M1G4X.<#MI@C;2P\G=;U+@[Z62Q8[*_K,4*#S=9,P>:9IFJ])H'$&;Q3#=CWJ MR(A4V)-V&9EE*T)O0N\QC$1$I)K!=DEL5Z&.)*I$1A]*T@B@\YQR*-2\Z&NY M9%6WX @"Q4F/N[K#$7R9T]?"#N?OR#4$"O2Q>QV.!)!*GKTHV-S8((A@6=P3(;1'J5T#OMA-HJB!TPWW51H/C8.:HCAVH'S7S8=.>'1J>(*=V>)CD@1U*^A]LL=!%N:IKH,=)=^1)#,, M)[WWJ#97;(+@.ROP#K-9'CW(_LC-I5S^DZ:V9K.K9YC4C5Y%!:><'JS&KA8! M!Z98;F8M4G?7>EE:7[4V%$!5]*CZSJP!49'P-WX4Q?[:Z2*,\FP?959E"2VC M'W:=KD51O&M&452-39+%I&QN4K4W80U.1(N[B JD.(JFA.;X"74-[+B):9R% M 4KM"VZHS# #KKF7ZPTT_%B0(V4YV\H;T/MX#/K15T7L!T?TN!5YY_BK M-29W%'---Y1DA,$'TI@Z,M@O6):Y-DUO(S:*8=^V0W6U08=46/3CXN5Z$R5; M0L2AJ$AB;*)#4P7[QK8C-480T&DZZTP,HJ5)V=2D: O;N%#E^1?Y_M2\)UD9AO$T0WWZ61:S6)WA*F!\.?WGL]9Y\)L[^4@VZCSRL"ZR .\)Q[K M7JE6H*$O Z6@K(_Z].SU4MC;I9Y)D\KH%CTB4SG/\&.DJ%82VV-Q4)I:B+A" ME<%3HUX(>V\[*$%].G"HWE4LOG03^B1.>:[;F+^[P_YU193+DJ$.MO/A .L1 M"*7! O%$3D.:SED/9O&<)@N2\CNS_7O9"IY -;'=!P=@RP(Q]!FO)IS1(T-6 M%MN#<)CY3XU*]TQ\">L9>B:^@U>EQ4L ]4< -*>[#[K37=76Q(N#R:XU[/.= M\JT#\PD.4!7[.EG91?!%L:D%-RSD8!:5=\$F.?%O>94];!F?+%3UQMV;69CN M0I\NN7'I-E79R[/M _NL_E845/EEDUF7%/W^42T:^ZCI"A)4V0TR+906RF-= M2.P+Q>*HM.N:Z29+41S;8F:AC,W=K$Y^]!.("$E8)5%PO=[0Y*E(G&WB2%L) MVR;3G2D %NA\7>4T#GG^/";95?BL3Q185M+5P38 =&?+C 0Z64KA# \_F^HA M7_G -\S0]LIWP703+K1NJX#*+\YBV$;FY$T"&D. ]HW.'YI& ,/!'_U]SI=X MY*_;,-7=/RSEZJ TG-EEHCH6.C7U?9J3H$RUIHN;^E%G02N;F53MH/O4%((RT34O KQIJZV$=L'"<64]8[Q%(EX$DI!,60=[()EI:5]^& ! WY-40ZB, MQ3HC,5F$ #=E4SWT UI7L@Q(G'0*N3D/;!!W;L+W>IXP0$@64E*^=<-_083\ MPMY0(,#7C;264]NH&OU^!?W\:*U(0Z",/D^(R0N:55):&/UH:4VD1F9T/J[C MC# ,R@EJO+8<5SVK.@E1R>F7$9L)DQ-%72_K:[+*&@J.\7@'OF90WMR_W/S M\*$\<."?V5_(T>."K:DQ#UB+,QH^YL*UB*VPY>:.?O(RIO?Q\N#OA/I,368+ M\4?=X?[HID_N(-,;G.C343O(-REFY$NZ[4N^#BB)3I1,Z:4#$>2'W'O4'7?UD M&?, \FHO7VJ;QH#[%YT!=]_@I&JQVEMAVW+Y2T=V::WDY9'< =A,/UL429FN M/)]OZ+=L,@^3(/3+-V@JP#7N 3:-H*>YTM'5=!"P1\>!_<\CZQ03*^?=L^82 M6!U[5V-%HQ4DZ 0VILQ/3/GR-7^7ZS;)=)G)3/6PMS%6E,% 0.=*-D'P1TR* MQ^6OB#$Y*+@!["W/T?.F!A9T&AO:)JSZX(%6EL:VLQXSO X$=HT-,!'XQM1C M.'@AUE,! D.@DJ:*&U[S1R] SL0?R3IW8PX],E1S M@R6CY@&(NG$IPNBP:_J (EG9TZ1%)@EZ?-!AITP!0?+2;M"A5BHM#ZY$^-R1 MIR1ZXE< !]TSA248JF&;%'3JU: %! #Z/II'5,P64_XRRK*X!=#.7HKB;HP8 MVPE,(4S-QH'D/++O$;\]N$UB;_^;VIN;QA@?ZX;4$&TT(R\J+8D]K774N/K]E0:!@6X-[_/'U*>A>"UH]V7UF.!U]%6 M+/S9818@F QV\5X^,3!/HM#?7H4Q^P=/H%Z32DN.30/0 3/<0U?'Q?>_#9/WZYX_L[Q93$_E[[LQO*#IY^#CM? MNTD=&5NE-E<==,3@<8B7',N>#!>=P/P4QN$Z7^O@;!2!S@G]NS@T\6JA*14& M9?Q_\IZ-L!X6@<+:O]>"&5:9,.B[0-F45?;T+*$T^BPY1WO^N)!Y0 ;"!=D9+.W&X4%%;+_5OL:> M! WTX<:.^SXA0U"U-&!- YNB.;PE.==0W(D:8*MIMJ M%XZ,"*!S)),*U0]\,!?7OF9#F#OX::Z#._TT)H:0EP9R/-AKL%TY5LE]TH0* M.W@9\*DF\K 4MO&_"X$R.='GU<-;C$]>EE.^D_(R MI; JL#Z?J+2W19(>,8 MCU7DPQWO+>MWO"QB\J!$JNL#F?S)729-V#A&9>WJL/@Q%6\\A3YY!V53VP3X M;.\NHP"(T$D5URS7:9J3H*YT7[PHKW6:X;"7Y9[X?,H)=2&I1S8+)=\IRTXO M4)[TCLFM"'2G[$)=(]%/3PD4P^!^Q:!-Z^/@YPP#6.BK MAGKG(EPH@C(KE+?4')QLVL"[@!QD>Z<""9W7NKT-=OQ5U\"[W>S)X.CDN;C> M*:.125H8RHM31B:-V(X]7"">%CI/=M']FJ<+?OA.E_E*-#3A+4U(/Z\7*#QA M]ST0G]2$O//BRM)(;XYM"$\7$"]%;^["Y2ICBR7K5YJ2K/[\L#&GA'U+6*X! M6AJDPZ)'0=?F NW+!>J=;L.IM3\K&)T7K MDUKSKXN8W2+6<<5Z,[)*H >(E#DQKDA%]X'JCUM$Q^#/A"P()IDQ?O"6Y(SPFJ/HCSPRJN7"T M;PG-3>Y8&N$PNN97 Y-C%K'ZN>#<2U=74?*U M>D$-=NQX#SYV\/8G_ /BY5SQB=>SA\58+"\D-==RJO*G>MIH2HP^.3:./[-' MIK Q?T_A\ME?\:"MJX1:[UJ.:O2$#AD]@.?8[%D&.![HJF:J_*";*LNVRJN% MJK772;'MRTV8]A"%HNQ8R,DM(_;A*XF>R*??B:',_VKJ$3FF([@G0RY![/ZDF9>6QA.6EKCU;8SW%0GJGX&Z ^*VJ, MW>K6W E9BHX"S%Y5?BI4)29+[B#UQS(,NF=1TFV-3V_L(U_!N&=0 ES!O)AA M.^[U3?^NWV2$.N#;(,0#O#OSP_?-DW%Q"N[KX9F7> S>6R'*EX'/2,Q^ MR/BCP.F^KZGAA1G+9I#3=]D/-4OY\-^A:7>S)K#Y/1I@=3?2W'728?F[V":! M\=^LN2.1B"SP:+:MYZL^V];_HL^;:M/&RZ'81FKT]W#J73)E6Y65=8,V>V75 M<#9LLNC[AR],'JY#^I<(6L6P,Y2I->7@@0&%>$[:[+@K@PBB-3S,!ZF+G-S/ M:AT&6&;DT*"S.*7$FRUNO%B3YZ%>!GO0'$-+6U9T^"LC[E5"[[0'X%9![ 1\ MQQ"AD!J=C5%#*P9\%+H[,\/$6KAAC=@G-^,/R/"9F,E)8C_%2J,L]R;+"\\PXC+65D'YC M4S7,?ZXU/1%M3ZK&C_2Y.5J)+W_+^?NCQA'9+(=DA^3I,,[88L&T<\V5JAP: MNR>USK;[(N7"/_WJ4?Z"UTSD0RODV&=C2&O4W.;Z5S+&^3KR)"!7B*:A M.F\$-D4&E8P=>8^YB5)9 HZ&(-5AT'#ROGPFU ]3(I*&J8P.F#W"/JKIU18= M'C=4V<7Y]R-?!HG&(##D-['/M5B3;0/T@;([##'BRIX[,CV">H-]1,>9&BV( M0C?%###"KA*Z(*$PI8\ZM1U\%SO3/];T)@$?TY=IQ.FQ)KDC4R2X1]C/&N!, MDY:$O<2ILA)TW#U@[:O8CRU@39,MX$]H'[CKNR/3'+ _V,]"X$QR5F2]Q"G. M,2/C+^_Q7[QPQL[(P>C%/',9G\HN\63MC!:*.]@#'TY;&E^\,JO6%N[1J9Q: M^R$%\FGTQTK&T$XX!R]4"94['(Z (S,JN$?H3ZR@[DFAC/6NR0@N#]SQ8)5$ MC,X2#NZ\Y8<9Q"'ISRU/AUIK__YO?WG_[L]_FQ2MY_N..7=%IN#E/? MS]>Y<-@6F:NXUE.R8HK/$+R.&:/D)DE-T59VK;@1"@ Z%=@)AA]E!>SOC3G@ MRKXE-VCMHM#=2+]Q*0I+/.\B/."$6O,N)S%??/2!5X9J+X92@YSHT56-;ID" MK!3%W: +I(H-?A0"'1E9U8N/<1*+_8&2)\S6EO&FBL1TK"I=/O.[&[9DV3M10!]L]3:TR]=,Y2'#T&:OHFI!(S63_^.6!NP'/ M%M=Q$#Z%0>Y%BNF9E544=604'C%%JV6K16PB4O)SF*U$BF=^D%B%FX?$L$V4 M"61J!)E&-0=FKDRB#>82DN91YAG.K^UB>!->%_"DMW]2P8<*, ^?@5!+2T+1 M[M^"W0_:&O'1]_1B5:Q'+QIV@(=%D7,A=G7)YD2'BRO\E$$]6WR.0]U;X+;M8#OA]D5L)_@ZAY*Y\'A>S9EC+R#;]>H. M[+HZV"Z./6F"&197Q_H7+^(/,7\5?[$?XLWJV&Z2PXYL.5@G/:"U=;_LJL"QB7RYAZ=41'!4JPD;.X0W0:1J*Z,G52L?S)-0*&3.J]F<\M!::J' MG96K)RIA\#C&HOWHA-;'3EDU"*O.C]':?/(EX:XS=SS-"^R<>E@!/:M3_S.L M#!&7&"OFC&*C;;''J2J@)S4::H-SB(A[C($LO?I:4.Y.R"8$L0"?X &QYMXM MTKZQ?]24]#JN>3=JCI!6K4"5PWD#4P?L7HJRB,.U>7>EK@%5 N>-209,7@KA M%R3U:2C". YB0$#>+I+JCDZ(X>FQ@3_QIT3CI6;J, MYB^?(YU1<2*$;>*--:'LNV[-@F*$/FAET\RNWYK1:ZJ''T,UW#3=QL[I MCLMZJ$AXI=\-@!$@=W#/\!] _^::@>.F^9'8NEEZ6/=V'ZZQ4E M#.B,,.:S$?51_FGTR%$7]5''TLO2QVKD?4EX/%449EN$&;+Y<:A.NF[4'I&I MEZ:5^B?!AL&WRZ-? X0\.JV#SCY'V^60IAMF_"RFL>T,^4VHZKE^*S \+X.E MJ6[X)=WGE/*GY*C4U:Z(Y]95@3+J[/6 641'YH+*H#AEAPAA4:R==[GJJ$>T MN28X7=?-,Z! H1 MRANIJ9^%3^*M;?$2]DZ0VMO:?VF]K5U^8)(L)L4GA/UB4O_&_RQ>X)Z4GYE4 MW]F]N?WZTO:XM\!%&,ZQX,X<[K^J;8968>S?#]:/I!IN%] M,;2!V;8#V.F^QE94"!U_>/4]])+\2-DV82Q7U?)CV+G'1E%+#OF\"6F1[W5XIWWIQ["3LXTR$VI@/GD5 MNDKH@H19S@VG@ZN0]&/8V=]&42$-S/:+Z4_%8AJ3)3>?G/9B*@$&:46U[@EV M*KQQEM6.!+ULK7;8N/,+/,QD,!\M'/O.+[(8D2Y'Y,OXQ:B?T_8="U4=S*?+ M)0O/JP+O-MP"%?Z>SM#SI^13V$D71SK3*"!^5;T*%YRY$]P!]-R28^MI1Y/. M^->\-8_04HKR9O66.Z=EX=.^N[7+W)^:E[E%,XW;VNJ2=K)KZ_6Z%C(M[&_> M.9QG6Q&%?_!BFV0HZRJY\30=; SJY*A/$ZCI)43?;IK^'LKT$9.6CD_HW=0]+G2H)AU+4;I5QH3<]?>OFH[4RQ5'@/>PKBK-U M'#[F:3%'7L<^ZSI;+_FWM4_]F:MANR7HWX.%R3#D_87A$=([OO=3OP5;^[,; M"FTQGQQVO^8',#*Z2@6O.@A5Y8$1/L1+CF75U4&>I#: ^!3&!M1/2R"=]@UPRH3YO6][='F6_WSVA]>G]<>80X_L>>U M'TA\N=Y$R9:05+L5E!5$<_[KY\UGM>P#18T_L+^2_3/3!L 5A='\C'H"78O! M0,!?L1W_6>+1H/B:'GA5830GAWZ UV. [[W%7\'B)N^Z%4AO<-%4.;G5VRQ2 M;5SC&R=-YAA964F9QBC9TU+*PXUX]67!%KEI'!2Q M[&&\G"TD'4X?6#=2^9],DUR_7W%#"PQ:W=" ?A' GE9KU]2F6552%/V=G2&4 M7I8\0H80^FRL2VO1>E+>+AE(K3IRL+#V>M@BST<+D,Z>3AE3-\=CV$[[H8_! M+LZL=.GU,0_\QSQ<4(37!SM>'^S "IVUGK!>'^6PFZS%_WPA:;;;+)BRV_;V M%>S8V5$60PV^IZLTI_R2RV!QM&/NK5Y?:SF)UUH&._6/HFM'O,ARHEN](=\) M*=UD1E);;0^PPV/1M!? R\N:.*4"%VYPF(I8]0 [^-4M13SDY74VU;]P,^Y\ M:N@#=L@L^GY R\W+FE,5(H\ZJQKZ@!X:ZYH^*J?6%Z&/I_(HUKO3OM=X??G* M\9>OQG%=&LP,/=KS5D?KUS02[9) /I9XI^-4,Q=!ZT-Y=^+ZP0X4= XORC-% MO8\WH?S0%)19)XS_G:%")UEZ=5ODNV&R$];= M, M)>NY%$0G.MLU;7,MK;YN&H0K@A+F^)Q@QC_2*&(E*B/)>@5]4*=\R5)1% M=X$#,:D1P)&QVNN^M'&!C?*,LZ$/4+UY>69H$#D#!44-*0CP$7O>C_&[ 54W M7&,S#C8GJW$FV\?0<':T@^#:@4<&Y=27UX/= MOF[X[D"?]5S1-CNEQ2D;QY M+&>8([H$]C\]Z<6W+^H<55Y;S8+3[K"AUAU.N QW)"!,!8,9+0Y_[>=X-21! M&X"RYH;YTPX6=!JGOD\BMFY5AKL[LLFIOV)JE_)(J4BL8G,O#%CO10&-6=.^ M*2BU;E@XNT*%3K+<)E]HXC3/5@D-?R?!YYB!78MVX^GB#F]X1":DVKHQDV^R M^W+N1^@@5"&=,,PZ@YI2S3'?V+U<+ A_V[9\3OC!>^:G/?5SNC]^IWM.=]?: MI&ANPMJ;\ :QW\W=2;?ONCDKL[82SAPEI^N.^$GLAU%8C,#LBJVLU(MX0HN< M]6%[4%@M;R^-(P?" HANS \]0HJ^A$%D$6E.V#GGAO4@VI73[4&/:Q4[G'48 MC3"A>!*J<+[B:]IU7-U=LD+3-"59R@^V!4%1E'SU8IW/4.\?P@Y['49A.F#M MJ [QG4T8YV(+1,HG'VW50]X&=B!I7\SK$.J>4"')O*AQNXNYN]F MMN2LO,1"DMX2@ >=LN+I;9R 6)SXFED['@#>N/KQ?7.QW-M2B$-O6[V4-9+K M7O"O/,U$DK-[DC$FQ(_L=//O$1#UG$/K1.?+M&)D4K[JQD3?G,RYBZ!M+5Y6%_3$\V2DN[ MD676Q$7S/C*NK,53X=JSZ.P MJM@.:$.J_D&2"PL@T:=AR\0JEYZ_.BQK/(D=TS3R1:[)T'Q) M3TB07C%$^)-5W#]H_\2,FG)3/<>V4"9"83"<=IY@^7ME1037'4DS&O)X[<)6 MP:=!@Y-CU_:P[Y,XV*PNGLN_\/_A@7;L-_\?4$L! A0#% @ *'AY M6/\''%XO P YPX H ( ! &5X,C,M,2YH=&U02P$" M% ,4 " H>'E8V*$5*B\( "W2 "@ @ %7 P 97@S M,2TQ+FAT;5!+ 0(4 Q0 ( "AX>5AS":%H%P@ !-( * M " :X+ !E>#,Q+3(N:'1M4$L! A0#% @ *'AY6.0D5DU\! YB0 M H ( ![1, &5X,S(M,2YH=&U02P$"% ,4 " H>'E8 MFDC4NC0) "D.@ "0 @ &1& 97@T+3$N:'1M4$L! A0# M% @ *'AY6-7NJ+F*(@ -34! H ( !["$ &5X.3'E8C:O@*S4M @!R@1, # M@ &>1 9F]R;3$P+6LN:'1M4$L! A0#% @ *'AY6.-0V#(/9 +F8 M ! ( !_7$" &9O'E8-.T2ZMX; B'0 #0 @ $ZU@( :6UA9V5?,# Q M+FIP9U!+ 0(4 Q0 ( "AX>5A:@9%$OPX %*D 1 " M 4/R @!S>7)A+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0 ( "AX>5A5VK(#NA( M '[N 5 " 3$! P!S>7)A+3(P,C,Q,C,Q7V-A;"YX;6Q0 M2P$"% ,4 " H>'E84E[IO14O X$@, %0 @ $>% , M&UL4$L! A0#% @ *'AY6+\T-@=0;@ MO'<& !4 ( !9D,# '-Y5C@*V)-FQ P!S J>7)A+3(P,C,Q,C,Q7W!R92YX;6Q02P4& X #@!- P CP,$ end XML 87 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001922335 2023-01-01 2023-12-31 0001922335 2024-03-25 0001922335 2023-12-31 0001922335 2022-12-31 0001922335 us-gaap:NonrelatedPartyMember 2023-12-31 0001922335 us-gaap:NonrelatedPartyMember 2022-12-31 0001922335 us-gaap:RelatedPartyMember 2023-12-31 0001922335 us-gaap:RelatedPartyMember 2022-12-31 0001922335 us-gaap:CommonClassAMember 2023-12-31 0001922335 us-gaap:CommonClassAMember 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-12-31 0001922335 2022-01-01 2022-12-31 0001922335 us-gaap:PreferredStockMember 2021-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2021-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001922335 us-gaap:RetainedEarningsMember 2021-12-31 0001922335 2021-12-31 0001922335 us-gaap:PreferredStockMember 2022-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2022-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001922335 us-gaap:RetainedEarningsMember 2022-12-31 0001922335 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001922335 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001922335 us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001922335 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001922335 us-gaap:PreferredStockMember 2023-12-31 0001922335 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember us-gaap:CommonStockMember 2023-12-31 0001922335 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001922335 us-gaap:RetainedEarningsMember 2023-12-31 0001922335 us-gaap:IPOMember 2023-10-03 2023-10-03 0001922335 us-gaap:IPOMember 2023-10-03 0001922335 us-gaap:OverAllotmentOptionMember SYRA:UnderwritingAgreementMember 2023-10-03 2023-10-03 0001922335 us-gaap:OverAllotmentOptionMember SYRA:UnderwritingAgreementMember 2023-10-03 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001922335 SYRA:FSSANeuroDiagnosticInstituteMember SYRA:HealthcareWorkforceMember 2023-01-01 2023-12-31 0001922335 SYRA:FSSANeuroDiagnosticInstituteMember SYRA:HealthcareWorkforceMember 2022-01-01 2022-12-31 0001922335 SYRA:FSSADivisionOfMentalHealthAndAddictionMember SYRA:PopulationHealthMember 2023-01-01 2023-12-31 0001922335 SYRA:FSSADivisionOfMentalHealthAndAddictionMember SYRA:PopulationHealthMember 2022-01-01 2022-12-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001922335 SYRA:FamilyAndSocialServicesAdministrationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001922335 SYRA:HealthcareWorkforceMember 2023-01-01 2023-12-31 0001922335 SYRA:HealthcareWorkforceMember 2022-01-01 2022-12-31 0001922335 SYRA:PopulationHealthMember 2023-01-01 2023-12-31 0001922335 SYRA:PopulationHealthMember 2022-01-01 2022-12-31 0001922335 SYRA:DigitalHealthMember 2023-01-01 2023-12-31 0001922335 SYRA:DigitalHealthMember 2022-01-01 2022-12-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2023-01-01 2023-12-31 0001922335 SYRA:BehavioralAndMentalServicesMember 2022-01-01 2022-12-31 0001922335 SYRA:HealtheducationMember 2023-01-01 2023-12-31 0001922335 SYRA:HealtheducationMember 2022-01-01 2022-12-31 0001922335 2023-01-01 2023-04-30 0001922335 2023-10-03 2023-10-03 0001922335 SYRA:SahasraTechnologiesCorpMember 2023-07-11 2023-08-23 0001922335 SYRA:SahasraTechnologiesCorpMember 2023-01-01 2023-12-31 0001922335 SYRA:SahasraTechnologiesCorpMember 2023-12-31 0001922335 SYRA:STLogicsMember 2023-12-31 0001922335 SYRA:STVenturesMember 2021-07-01 0001922335 SYRA:STVenturesMember 2021-07-01 2021-07-01 0001922335 SYRA:STVenturesMember 2022-05-01 2022-05-01 0001922335 SYRA:STVenturesMember 2023-01-01 2023-12-31 0001922335 SYRA:STVenturesMember 2022-01-01 2022-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2023-01-01 2023-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2022-01-01 2022-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2023-12-31 0001922335 SYRA:InformationTechnologyServicesMember SYRA:RadCubeLLCMember 2022-12-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2023-01-01 2023-12-31 0001922335 SYRA:RecruitmentAndHumanResourceServicesMember SYRA:NLogixMember 2022-01-01 2022-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2020-11-21 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-01-01 2022-12-31 0001922335 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001922335 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001922335 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001922335 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001922335 us-gaap:OfficeEquipmentMember 2023-12-31 0001922335 us-gaap:OfficeEquipmentMember 2022-12-31 0001922335 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001922335 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001922335 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001922335 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2022-02-07 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2023-01-01 2023-12-31 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2022-02-07 2022-02-07 0001922335 us-gaap:RevolvingCreditFacilityMember SYRA:LoanAgreementMember 2022-01-01 2022-12-31 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-04-07 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-01-01 2023-04-07 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-10-03 0001922335 SYRA:ConvertiblePromissoryNotesMember SYRA:SubscriptionAgreementsMember 2023-10-03 2023-10-03 0001922335 us-gaap:CommonClassAMember 2023-10-03 2023-10-03 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MinimumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 srt:MaximumMember SYRA:InsurancePolicyFinancingArrangementsMember 2023-12-31 0001922335 SYRA:InsurancePolicyFinancingArrangementsMember 2023-01-01 2023-12-31 0001922335 SYRA:STVenturesMember 2022-05-01 0001922335 2022-06-27 2022-06-28 0001922335 us-gaap:CommonStockMember 2022-05-03 0001922335 SYRA:ConvertibleCommonStockBMember 2022-05-03 2022-05-03 0001922335 us-gaap:CommonClassBMember 2022-05-03 2022-05-03 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-03-01 2022-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-03-31 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-06-01 2022-06-30 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-08-01 2022-08-31 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-06-30 0001922335 us-gaap:CommonClassAMember us-gaap:PrivatePlacementMember 2022-08-31 0001922335 us-gaap:CommonClassAMember 2023-05-30 0001922335 SYRA:ConvertibleCommonStockBMember 2023-05-30 0001922335 2023-05-30 0001922335 SYRA:ConvertibleCommonStockBMember 2023-01-01 2023-12-31 0001922335 us-gaap:CommonClassAMember 2023-01-01 2023-12-31 0001922335 us-gaap:IPOMember SYRA:UnderwritingAgreementMember 2023-10-03 0001922335 SYRA:KingswoodCapitalPartnersLLCMember 2023-10-03 2023-10-03 0001922335 SYRA:KingswoodCapitalPartnersLLCMember 2023-10-03 0001922335 us-gaap:CommonClassAMember 2023-05-10 0001922335 2023-10-03 0001922335 SYRA:ConsultantMember us-gaap:RestrictedStockMember us-gaap:CommonClassAMember 2023-11-01 2023-11-30 0001922335 SYRA:SixConsultantMember 2022-02-01 2022-05-31 0001922335 SYRA:ConvertibleCommonStockBMember 2023-12-31 0001922335 SYRA:ConvertibleCommonStockBMember 2022-12-31 0001922335 SYRA:ConvertibleCommonStockBMember 2021-12-31 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 0001922335 SYRA:ConvertibleClassBCommonStockMember 2022-05-03 2022-05-03 0001922335 SYRA:ConvertibleCommonStockBIssuancesMember 2020-11-21 2020-11-21 0001922335 SYRA:ConvertibleCommonStockBIssuancesMember 2022-05-03 0001922335 SYRA:ConvertibleCommonStockBIssuancesMember 2022-05-03 2022-05-03 0001922335 srt:MaximumMember SYRA:OmnibusEquityIncentivePlanMember 2022-04-11 2022-04-11 0001922335 SYRA:TenEmployeesMember 2023-11-08 2023-11-08 0001922335 SYRA:TenEmployeesMember 2023-11-08 0001922335 SYRA:ThreeConsultantsMember 2023-11-08 2023-11-08 0001922335 SYRA:ThreeConsultantsMember 2023-11-08 0001922335 SYRA:FiveBoardMembersMember 2023-10-09 2023-10-09 0001922335 SYRA:FiveBoardMembersMember 2023-10-09 0001922335 srt:MinimumMember 2023-12-31 0001922335 srt:MaximumMember 2023-12-31 0001922335 us-gaap:CommonClassAMember 2022-09-01 0001922335 2022-07-01 2022-09-01 0001922335 2022-09-01 0001922335 us-gaap:StockOptionMember 2022-10-01 2022-12-31 0001922335 2020-11-20 2023-12-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-03-31 0001922335 SYRA:TwoInvestorsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001922335 SYRA:NovemberTwoThousandTwentyThreeMember us-gaap:SubsequentEventMember 2024-01-01 2024-03-31 0001922335 2023-10-01 2023-12-31 iso4217:USD shares iso4217:USD shares utr:sqft pure false FY 0001922335 P5Y P3Y P3Y P3Y 10-K true 2023-12-31 --12-31 2023 false 001-41822 SYRA HEALTH CORP. DE 85-4027995 1119 Keystone Way N. #201 Carmel IN 46032 (463) 345-8950 Common Stock, par value $0.001 per share SYRA NASDAQ No No Yes Yes Non-accelerated Filer true true false false false false 5731587 Specified portions of the registrant’s proxy statement, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14 A in connection with the registrant’s 2023 Annual Meeting of Stockholders (the “Proxy Statement”), are incorporated by reference into Part III of this Annual Report on Form 10-K. Except with respect to information specifically incorporated by reference in this Annual Report, the Proxy Statement is not deemed to be filed as part hereof. 2738 M&K CPAS, PLLC Houston, TX 3280075 3344 1060634 1201097 50614 50614 389787 222302 4781110 1426743 596118 78974 112493 63199 184288 4923283 2319642 462991 432388 3200 3200 198978 239117 63199 121089 184904 750551 910072 1546345 63199 910072 1609544 0.001 0.001 1000000 1000000 0 0 0 0 0 0 0.001 0.001 100000000 100000000 5588298 5588298 3568758 3568758 5588 3569 0.001 0.001 5000000 5000000 833334 833334 833334 833334 833 833 833 833 9071745 2832308 -5064955 -2126612 4013211 710098 4923283 2319642 5515144 5617706 4103244 4555924 1411900 1061782 2292295 1524971 586463 1035902 240048 1131922 575755 48771 14849 4299499 3151477 -2887599 -2089695 2942 63 53686 28533 -50744 -28470 -2938343 -2118165 4877861 4877861 3041085 3041085 -0.60 -0.60 -0.70 -0.70 833334 833 467 -8447 -7147 2768756 2769 2319731 2322500 800002 800 509200 510000 2910 2910 -2118165 -2118165 3568758 3569 833334 833 2832308 -2126612 710098 3568758 3569 833334 833 2832308 -2126612 710098 41666 42 -42 446206 446 1472014 1472460 32831 32831 1615000 1615 4734550 4736165 -2938343 -2938343 5588298 5588 833334 833 9071745 -5064955 4013211 5588298 5588 833334 833 9071745 -5064955 4013211 -2938343 -2118165 95563 48771 14849 14076 510000 32831 2910 59547 940470 50614 -203110 200798 -121089 30603 392276 -3200 -82418 -22679 163675 -121089 -95563 -2759068 -2244065 15251 121260 -15251 -121260 596118 185692 5332283 2322500 300000 2819275 1050551 2082800 1295010 94000 1095000 288200 1455000 6051050 2268657 3276731 -96668 3344 100012 3280075 3344 36226 11651 131187 1472460 42 200010 370596 <p id="xdx_801_eus-gaap--BusinessDescriptionAndAccountingPoliciesTextBlock_zeSZtyVlTnf5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_825_zQ4jNJsk0Bx9">Nature of Business and Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nature of Business</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syra Health Corp. (“Syra” or the “Company”) was incorporated in the state of Indiana on November 20, 2020 to provide workforce staffing solutions, health education and healthcare research consulting services to mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities and pharmaceutical manufacturers. On March 11, 2022, the Company redomiciled to Delaware. The Company’s corporate office is located in Carmel, Indiana.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNq7GsJzbn6h" title="Aggregate shares issued">1,615,000</span> units (“Units”) at a public offering price of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgKgHBW0qGvk" title="Public offering price">4.125</span> per Unit, with each Unit consisting of (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z9sA6kB2UkPa" title="Warrant exercise price">6.50</span> per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). The Company received gross proceeds of approximately $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zVjkLbhq73dk" title="Gross proceeds">6,661,876</span> from the sale of the Units before deducting underwriting discounts, commissions and offering expenses of $<span id="xdx_90A_eus-gaap--DeferredOfferingCosts_iI_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmn8d9F24EN8" title="Offering cost">1,928,133</span> In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_z5xQpFyE8eJc" title="Options to purchase stock">242,250</span> Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zbSppyPFhmP4" title="Number of warrants issued">242,500</span> Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $<span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pid_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zlQ82ZQgchZc" title="Gross proceeds from warrant exercise">2,422</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ze4mK8vhWr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zUlN5uKY2Tol">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zpUjEc683eah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zqTFOA8CF9g9">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zNlus4SSpQgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z0RBozeos0vh">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zEXxrBt7ALL7" title="FDIC insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at December 31, 2023, and 2022, and has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvKQZ80j6zK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_z1Bh1ZXdl8I6">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at December 31, 2023, and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLf3kyowrBb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zQtQ9JC3b7Z8">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were <span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zzfc3fruYdq8" title="Cash equivalents"><span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zcW78HbZ9PN7" title="Cash equivalents">no</span></span> cash equivalents on hand at December 31, 2023, and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zklflwOodsec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zPvbkjx0wmH8">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are carried at their estimated collectible amounts. Accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $<span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20231231_zkh78VwcbdX1" title="Accounts receivable">5,520</span> at December 31, 2023, and $<span id="xdx_904_eus-gaap--AccountsReceivableNet_iI_c20221231_zG63ueTN6Yc1" title="Accounts receivable">4,533</span> at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--DeferredChargesPolicyTextBlock_z4Z9sNBBdMqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zn9qOI2BPr36">Deferred Offering Costs</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred offering costs related to the Company’s initial public offering (“IPO”) consisted principally of professional fees, legal and accounting, and other costs such as printing, and registration costs incurred in connection with the planned IPO of the Company and the sale of its Class A common stock. During the year ended December 31, 2022, the Company incurred $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zcmkwGoTh2ke" title="Offering cost">596,118</span> of costs, directly attributable to its proposed IPO, which were offset against the proceeds from the IPO that closed in 2023. In total, the Company incurred $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_c20231231_ztayfeddiSEh" title="Offering cost">1,928,133</span> of offering costs related to the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9vqOJZOdhRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zH4pL9jWmCb9">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231_zbt1TraFZpW7" title="Property and equipment useful life::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0584">five</span></span>-year life expectancy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zS2TjdTZaa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zCDJ7ALVFMza">Impairment of Long-Lived Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the provisions of ASC Topic 360, “<i>Impairment or Disposal of Long-Lived Assets</i>”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zmnrwFhJFdRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zxCOCnweIhJ">Leases</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842 – <i>Leases</i>. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTmupzEsW3Uh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zqBUQTR5AHna">Segment Reporting</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 280, “<i>Segment Reporting</i>,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z6HsFyz4zU8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zAqudUjdbZRg">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following main forms of revenue:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare Workforce;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Population Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Behavioral and Mental Health Services</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Education</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.25pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognize revenue net of penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregated revenue data</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zCjjIQ0j2Pti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue consists of the following revenue services within its industry: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zT9z6tmlwZM8" style="display: none">Schedule of Disaggregation of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Healthcare workforce</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zO9SUugS9SYi" style="width: 14%; text-align: right" title="Revenues">4,259,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zQFVzybljvGj" style="width: 14%; text-align: right" title="Revenues">5,260,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Population health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--PopulationHealthMember_z80WVwhFag5a" style="text-align: right" title="Revenues">715,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--PopulationHealthMember_zmQ3cEhRmFm2" style="text-align: right" title="Revenues">318,036</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Digital health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zWOZXyBd3RMc" style="text-align: right" title="Revenues">515,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zquSaLEsCh5f" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0606">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Behavioral and mental services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zUMYedvrw9Ob" style="text-align: right" title="Revenues">12,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zTD5PKJs9vri" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Health education</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealtheducationMember_z3GRdXmP75Wg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">12,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealtheducationMember_zmZ1ombK8gA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">39,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zq8N3zFZfku6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">5,515,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231_zrIPvmu3SYd8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">5,617,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zmyQAgddTMOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CostOfSalesPolicyTextBlock_zvpBxY6GPtDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zB192NPuSR02">Cost of Services</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of services includes the wages and the related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while they work on contract assignments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--SignificantConcentrationsPolicyTextBlock_zI3D7MlKSvdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zqS0QTag6ejj">Significant Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For each of the years ended December 31, 2023 and 2022, FSSA accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zu1FOo9UKC2j" title="Revenue percentage">68</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zIaQRydqaVxd" title="Revenue percentage">98</span>% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA – NeuroDiagnostic Institute, representing $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_ztUr23wr74K" title="Revenues">3,734,004</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_zwNG7jagIlri" title="Revenues">5,214,128</span> of the Company’s healthcare workforce revenue, and the FSSA – Division of Mental Health and Addiction, which commenced on September 3, 2021, representing $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_zo3oyxxMVYnl" title="Revenues">305,000</span> and $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_zkSpGOdp19tf" title="Revenues">306,000</span> of the Company’s Population Health revenues for the years ended December 31, 2023 and 2022, respectively. In addition, the combined divisions of the FSSA represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zylwBZ0nQimk" title="Revenue percentage">30</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zuizbhBou8qh" title="Revenue percentage">99</span>% of accounts receivable at December 31, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOraEmz4xLFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zy1P5qgPYM0b">Research and Development Costs</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. The Company’s research and development costs consist of outside consultant fees to develop the Company’s technology-based solutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z9zotG4UVGB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zEcBHVK9bGel">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zL0Jqr3iEeEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zbHnYygvFbJ7">Basic and Diluted Loss Per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_za3IkOLg5vCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zUnFI5Ex7QTg">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxUncertaintiesPolicy_zCK2NZclVwCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zSyShNjpIvr2">Uncertain Tax Positions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zphnwYeBteo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_z2mKeF6wQFMb">Recently Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments – Credit Losses</i> (Topic 326): <i>Measurement of Credit Losses on Financial Instruments</i> (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined in Rule 12b-2 of the Exchange Act) to fiscal years beginning after December 15, 2022, including interim periods. Early adoption is permitted. The Company meets the definition of a smaller reporting company and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade receivables, but that there was no material impact to the financial statements from the adoption of ASU 2016-13.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.</span></p> <p id="xdx_85B_za8v0fP3XGwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1615000 4.125 6.50 6661876 1928133 242250 242500 2422 <p id="xdx_845_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_ze4mK8vhWr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zUlN5uKY2Tol">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zpUjEc683eah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zqTFOA8CF9g9">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zNlus4SSpQgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z0RBozeos0vh">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zEXxrBt7ALL7" title="FDIC insured amount">250,000</span> under current regulations. The Company did not have any cash in excess of FDIC insured limits at December 31, 2023, and 2022, and has not experienced any losses in such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 <p id="xdx_848_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvKQZ80j6zK8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_z1Bh1ZXdl8I6">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting Standards Codification (“ASC”) 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company’s financial assets and liabilities, such as cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. The Company’s advances from related party approximates the fair value of such instruments based upon management’s best estimate of interest rates that would be available to the Company for similar financial arrangements at December 31, 2023, and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zLf3kyowrBb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zQtQ9JC3b7Z8">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value. There were <span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20231231_zzfc3fruYdq8" title="Cash equivalents"><span id="xdx_902_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_zcW78HbZ9PN7" title="Cash equivalents">no</span></span> cash equivalents on hand at December 31, 2023, and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84B_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zklflwOodsec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zPvbkjx0wmH8">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable are carried at their estimated collectible amounts. Accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $<span id="xdx_906_eus-gaap--AccountsReceivableNet_iI_c20231231_zkh78VwcbdX1" title="Accounts receivable">5,520</span> at December 31, 2023, and $<span id="xdx_904_eus-gaap--AccountsReceivableNet_iI_c20221231_zG63ueTN6Yc1" title="Accounts receivable">4,533</span> at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5520 4533 <p id="xdx_84A_eus-gaap--DeferredChargesPolicyTextBlock_z4Z9sNBBdMqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zn9qOI2BPr36">Deferred Offering Costs</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred offering costs related to the Company’s initial public offering (“IPO”) consisted principally of professional fees, legal and accounting, and other costs such as printing, and registration costs incurred in connection with the planned IPO of the Company and the sale of its Class A common stock. During the year ended December 31, 2022, the Company incurred $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zcmkwGoTh2ke" title="Offering cost">596,118</span> of costs, directly attributable to its proposed IPO, which were offset against the proceeds from the IPO that closed in 2023. In total, the Company incurred $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_c20231231_ztayfeddiSEh" title="Offering cost">1,928,133</span> of offering costs related to the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 596118 1928133 <p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z9vqOJZOdhRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zH4pL9jWmCb9">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is stated at cost, less accumulated depreciation. The cost of office equipment is depreciated using the straight-line method based on a <span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dxL_c20231231_zbt1TraFZpW7" title="Property and equipment useful life::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0584">five</span></span>-year life expectancy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation are eliminated and any resulting gain or loss is reflected in operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zS2TjdTZaa1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zCDJ7ALVFMza">Impairment of Long-Lived Assets</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the provisions of ASC Topic 360, “<i>Impairment or Disposal of Long-Lived Assets</i>”, all long-lived assets such as property and equipment held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is evaluated by a comparison of the carrying amount of an asset to its estimated future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--LesseeLeasesPolicyTextBlock_zmnrwFhJFdRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zxCOCnweIhJ">Leases</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its leases under ASC 842 – <i>Leases</i>. The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of obligations under operating leases, and obligations under operating leases, non-current on the Company’s balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date, adjusted by the deferred rent liabilities at the adoption date. As the Company’s lease does not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company’s terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zTmupzEsW3Uh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zqBUQTR5AHna">Segment Reporting</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC Topic 280, “<i>Segment Reporting</i>,” requires annual and interim reporting for an enterprise’s operating segments and related disclosures about its products, services, geographic areas and major customers. An operating segment is defined as a component of an enterprise that engages in business activities from which it may earn revenues and expenses, and about which separate financial information is regularly evaluated by the chief operating decision maker in deciding how to allocate resources. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z6HsFyz4zU8a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zAqudUjdbZRg">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenues when both parties to the contract have approved the contract, the rights and obligations of the parties are identified, payment terms are identified, and collectability of consideration is probable. Payment terms vary by client and the services offered.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the following main forms of revenue:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare Workforce;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Population Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Digital Health</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Behavioral and Mental Health Services</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">–</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Education</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.25pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company primarily provides its services to state health and social service agencies and universities. Healthcare Workforce, Health Education and Behavioral Mental Health Service contracts are primarily accounted for as a single performance obligation satisfied over time because the customer simultaneously receives and consumes the benefits of our medical staffing on an hourly or daily basis. Population Health and Digital Health contracts generally consist of multiple performance obligations that are distinct, such as to provide data analytics and reporting, training, or develop technology for implementation and maintenance with the customer. The Company allocates the transaction price across the performance obligations based on the estimated fair value of the distinct performance obligations. Depending on the performance obligation, revenue is recognized at a point in time when the customer obtains the benefit of the services are provide, or over time in the case of digital health revenue where the customer simultaneously receives and consumes benefits of the contract, such as ongoing performance of our technology product.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The contracts generally stipulate bi-weekly or monthly billing, and the Company has elected the “as invoiced” practical expedient to recognize revenue based on the hours incurred at the contractual rate as the Company has the right to payment in an amount that corresponds directly with the value of performance completed to date. The Company may also be subject to penalties for violations of certain ethical standards and non-performance measures within these state contracts. The Company recognize revenue net of penalties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Disaggregated revenue data</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zCjjIQ0j2Pti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue consists of the following revenue services within its industry: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zT9z6tmlwZM8" style="display: none">Schedule of Disaggregation of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Healthcare workforce</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zO9SUugS9SYi" style="width: 14%; text-align: right" title="Revenues">4,259,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zQFVzybljvGj" style="width: 14%; text-align: right" title="Revenues">5,260,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Population health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--PopulationHealthMember_z80WVwhFag5a" style="text-align: right" title="Revenues">715,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--PopulationHealthMember_zmQ3cEhRmFm2" style="text-align: right" title="Revenues">318,036</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Digital health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zWOZXyBd3RMc" style="text-align: right" title="Revenues">515,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zquSaLEsCh5f" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0606">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Behavioral and mental services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zUMYedvrw9Ob" style="text-align: right" title="Revenues">12,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zTD5PKJs9vri" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Health education</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealtheducationMember_z3GRdXmP75Wg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">12,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealtheducationMember_zmZ1ombK8gA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">39,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zq8N3zFZfku6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">5,515,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231_zrIPvmu3SYd8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">5,617,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zmyQAgddTMOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--DisaggregationOfRevenueTableTextBlock_zCjjIQ0j2Pti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenue consists of the following revenue services within its industry: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zT9z6tmlwZM8" style="display: none">Schedule of Disaggregation of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Net revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Healthcare workforce</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zO9SUugS9SYi" style="width: 14%; text-align: right" title="Revenues">4,259,292</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember_zQFVzybljvGj" style="width: 14%; text-align: right" title="Revenues">5,260,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Population health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--PopulationHealthMember_z80WVwhFag5a" style="text-align: right" title="Revenues">715,499</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--PopulationHealthMember_zmQ3cEhRmFm2" style="text-align: right" title="Revenues">318,036</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Digital health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zWOZXyBd3RMc" style="text-align: right" title="Revenues">515,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--DigitalHealthMember_zquSaLEsCh5f" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0606">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Behavioral and mental services</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zUMYedvrw9Ob" style="text-align: right" title="Revenues">12,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--BehavioralAndMentalServicesMember_zTD5PKJs9vri" style="text-align: right" title="Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Health education</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealtheducationMember_z3GRdXmP75Wg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">12,306</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealtheducationMember_zmZ1ombK8gA" style="border-bottom: Black 1.5pt solid; text-align: right" title="Net revenues">39,300</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Net revenues</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zq8N3zFZfku6" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">5,515,144</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Revenues_c20220101__20221231_zrIPvmu3SYd8" style="border-bottom: Black 2.5pt double; text-align: right" title="Net revenues">5,617,706</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4259292 5260370 715499 318036 515250 12797 12306 39300 5515144 5617706 <p id="xdx_849_eus-gaap--CostOfSalesPolicyTextBlock_zvpBxY6GPtDe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zB192NPuSR02">Cost of Services</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cost of services includes the wages and the related payroll taxes, employee benefits and certain other employee-related costs of the Company’s contract service employees, while they work on contract assignments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_ecustom--SignificantConcentrationsPolicyTextBlock_zI3D7MlKSvdi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_zqS0QTag6ejj">Significant Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The majority of accounts receivable and revenue contracts are between the Company and different divisions within the Indiana Family and Social Services Administration (“FSSA”). Most contracts require monthly payments as the projects progress. The Company generally does not require collateral or advance payments. For each of the years ended December 31, 2023 and 2022, FSSA accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zu1FOo9UKC2j" title="Revenue percentage">68</span>% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zIaQRydqaVxd" title="Revenue percentage">98</span>% of revenues, respectively, which was derived through a combination of divisions within the State of Indiana, including the FSSA – NeuroDiagnostic Institute, representing $<span id="xdx_90C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_ztUr23wr74K" title="Revenues">3,734,004</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--HealthcareWorkforceMember__srt--MajorCustomersAxis__custom--FSSANeuroDiagnosticInstituteMember_zwNG7jagIlri" title="Revenues">5,214,128</span> of the Company’s healthcare workforce revenue, and the FSSA – Division of Mental Health and Addiction, which commenced on September 3, 2021, representing $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_zo3oyxxMVYnl" title="Revenues">305,000</span> and $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__custom--PopulationHealthMember__srt--MajorCustomersAxis__custom--FSSADivisionOfMentalHealthAndAddictionMember_zkSpGOdp19tf" title="Revenues">306,000</span> of the Company’s Population Health revenues for the years ended December 31, 2023 and 2022, respectively. In addition, the combined divisions of the FSSA represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_dp_c20230101__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zylwBZ0nQimk" title="Revenue percentage">30</span>% and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FamilyAndSocialServicesAdministrationMember_zuizbhBou8qh" title="Revenue percentage">99</span>% of accounts receivable at December 31, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.68 0.98 3734004 5214128 305000 306000 0.30 0.99 <p id="xdx_84C_eus-gaap--ResearchAndDevelopmentExpensePolicy_zOraEmz4xLFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zy1P5qgPYM0b">Research and Development Costs</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. The Company’s research and development costs consist of outside consultant fees to develop the Company’s technology-based solutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z9zotG4UVGB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_zEcBHVK9bGel">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 Stock Compensation (“ASC 718”). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zL0Jqr3iEeEa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zbHnYygvFbJ7">Basic and Diluted Loss Per Share</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_za3IkOLg5vCa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zUnFI5Ex7QTg">Income Taxes</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under the Financial Accounting Standards Board (“FASB”) ASC 740 Income Taxes (“ASC 740”), which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided for significant deferred tax assets when it is more likely than not, that such asset will not be recovered through future operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxUncertaintiesPolicy_zCK2NZclVwCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zSyShNjpIvr2">Uncertain Tax Positions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 740, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various taxing authorities may periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The Company recognizes interest and penalties related to uncertain tax positions, if any, as an income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zphnwYeBteo4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_z2mKeF6wQFMb">Recently Adopted Accounting Standards</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the FASB that are adopted by the Company as of the specified effective date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13, <i>Financial Instruments – Credit Losses</i> (Topic 326): <i>Measurement of Credit Losses on Financial Instruments</i> (“ASU 2016-13”). ASU 2016-13 changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans, and other instruments, entities will be required to use a new forward-looking “expected loss” model that generally will result in the earlier recognition of allowances for losses. The guidance also requires increased disclosures. The amendments contained in ASU 2016-13 were originally effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years for the Company. In November 2019, the FASB issued ASU No. 2019-10, which delayed the effective date of ASU 2016-13 for smaller reporting companies (as defined in Rule 12b-2 of the Exchange Act) to fiscal years beginning after December 15, 2022, including interim periods. Early adoption is permitted. The Company meets the definition of a smaller reporting company and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company adopted ASU 2016-13 effective January 1, 2023. The Company determined that the update applied to trade receivables, but that there was no material impact to the financial statements from the adoption of ASU 2016-13.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.</span></p> <p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9DKBNe23gQ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_820_ztfBqT5G1Gl3">Going Concern</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As shown in the accompanying financial statements, as of December 31, 2023, the Company had a cash balance of $<span id="xdx_90B_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20231231_zF5gFJPN5Gxh" title="Cash">3,280,075</span>, working capital of $<span id="xdx_906_ecustom--WorkingCapital_iI_c20231231_zNAARzlOqfi8" title="Working capital">3,871,038</span> and an accumulated deficit of $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20231231_zaVqDOC5xDVb" title="Accumulated deficit">5,064,955</span> since inception. The Company is too early in its development stage to project revenue with a necessary level of certainty. Therefore, the Company may not have sufficient funds to sustain its operations for the next twelve months from the issuance date of these financial statements and may need to raise additional cash to fund its operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company has commenced sales and continues to develop its operations. In the event sales do not materialize at the expected rates, management would seek additional financing or would attempt to conserve cash by further reducing expenses. There can be no assurance that the Company will be successful in achieving these objectives.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company continues to pursue sources of additional capital through debt and financing transactions or arrangements, including equity financing or other means. The Company may not be successful in identifying suitable funding transactions in a sufficient time period or at all, and may not obtain the required capital by other means. If the Company does not succeed in raising additional capital, resources may not be sufficient to fund its business. The Company’s ability to scale production and distribution capabilities and further increase the value of its brands, is largely dependent on its success in raising additional capital. From January through April of 2023, the Company raised a total of $<span id="xdx_905_eus-gaap--ProceedsFromConvertibleDebt_c20230101__20230430_zzizmbgR3Bw8" title="Convertible notes payable">1,455,000</span> of capital from the sale of convertible notes. On October 3, 2023 the Company completed IPO received net proceeds of approximately $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20231003__20231003_zwbOLWXyGUG8" title="Proceeds from commnon stock">5,332,283</span>. In October 2023, the convertible notes were converted into Class A common stock in accordance with the terms of the convertible promissory notes as a result of the IPO.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3280075 3871038 -5064955 1455000 5332283 <p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcJhNE5FGmPg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_822_z2f2bMYWo80e">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Advances from Related Party</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On various dates from July 11, 2023, through August 23, 2023, Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by the principal owners and management team of Syra, made short term, non-interest bearing advances due upon demand, of which an aggregate $<span id="xdx_901_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230711__20230823__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SahasraTechnologiesCorpMember_zOxns3ExpK92" title="Principal debt">1,295,010</span> advanced and we repaid an aggregate $<span id="xdx_908_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230711__20230823__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SahasraTechnologiesCorpMember_zDMedUhszx0b" title="Repayment of debt from related party">1,095,000</span> of such advances. The Company pays for payroll and related costs for its employees that provide services to STLogics customers. During the year ended December 31, 2023, the Company applied $<span id="xdx_90B_eus-gaap--LoansAssumed1_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SahasraTechnologiesCorpMember_zWILZGFCDVOg" title="Advanced balance of loan">200,010</span> of such costs to reduce the balance of the advance to $<span id="xdx_90C_eus-gaap--OtherLiabilities_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SahasraTechnologiesCorpMember_zr5c3dCp3LV4" title="Other liabilities">0</span>, and has a receivable from STLogics of $<span id="xdx_901_eus-gaap--AccountsReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STLogicsMember_zYvN86z9qHBh" title="Receivable from related party">50,614</span> for additional costs incurred as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company’s operations were primarily financed by short term advances from Sahasra Technologies Corp., doing business as STLogics, which is an entity beneficially owned by Priya Prasad, the Company’s Chief Financial Officer and Chief Operating Officer, and STLHoldings Corp. which is an entity beneficially owned by the principal owners and management team of Syra. On various dates from December 30, 2020, through April 4, 2022, Sahasra Technologies Corp. made short term, non-interest bearing advances due upon demand to the Company, of which an aggregate $<span id="xdx_901_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20221231_zZkvX6nkG9of" title="Advances received from related party">94,000</span> was loaned during the years ended December 31, 2022. During the year ended December 31, 2022, the Company repaid in full the loans totaling $<span id="xdx_909_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231_zHFsGpurzpVg" title="Repayments on advances from related party">288,200</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Office Lease</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases its current corporate headquarters under a <span id="xdx_904_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zATcnBVuDb7f" title="Lease term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0680">three-year</span></span> lease from STVentures, LLC (“STVentures”), an entity beneficially owned by the principal owners and the management team of Syra and their affiliates. The lease commenced on July 1, 2021, and provided for a base monthly rent of $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20210701__20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_z9OYftSuXj46" title="Base monthly rent">5,332</span> over the three-year term of the lease, which was subsequently amended to $<span id="xdx_90D_eus-gaap--PaymentsForRent_c20220501__20220501__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zeOARf0zIgj6" title="Base monthly rent">10,711</span>, on May 1, 2022. A total of $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zYxHSqGWflh" title="Lease expense">128,527</span> and $<span id="xdx_90D_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zGzA312QCgT" title="Lease expense">107,013</span> of rent expense was included in selling, general and administrative expenses for the years ended December 31, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Information Technology (“IT”) Services</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred a total of $<span id="xdx_902_eus-gaap--CostOfGoodsAndServicesSold_c20230101__20231231__srt--ProductOrServiceAxis__custom--InformationTechnologyServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RadCubeLLCMember_zCHSczTYTNTg" title="Service cost">3,320</span> and $<span id="xdx_902_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__custom--InformationTechnologyServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RadCubeLLCMember_zqZiDFp5BSE7" title="Service cost">23,260</span> of expenses from RAD CUBE LLC, which is an entity beneficially owned by the principal owners and the management team of the Company and their affiliates, for outsourced IT services which have been presented within selling, general and administrative expenses in the statement of operations during the years ended December 31, 2023, and 2022, respectively. An unpaid balance of $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_c20231231__srt--ProductOrServiceAxis__custom--InformationTechnologyServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RadCubeLLCMember_zsT77ZSEEnfa" title="Accounts payable, related parties">0</span> and $<span id="xdx_90A_eus-gaap--AccountsPayableCurrent_iI_c20221231__srt--ProductOrServiceAxis__custom--InformationTechnologyServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RadCubeLLCMember_zhxk9ibZqy12" title="Accounts payable, related parties">3,200</span> was outstanding at December 31, 2023, and 2022, respectively, as presented within accounts payable, related parties. The Company no longer receives services from RAD CUBE LLC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recruitment and Human Resource Services</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid a total of $<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20230101__20231231__srt--ProductOrServiceAxis__custom--RecruitmentAndHumanResourceServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NLogixMember_zrXPhDumXfYd" title="Service cost">348,304</span> and $<span id="xdx_905_eus-gaap--CostOfGoodsAndServicesSold_c20220101__20221231__srt--ProductOrServiceAxis__custom--RecruitmentAndHumanResourceServicesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NLogixMember_zEJiQIP1AIH2" title="Service cost">137,494</span> of recruitment and human resource services to NLogix, which is an entity beneficially owned by the principal owners and the management team of the Company and their affiliates, which have been presented within cost of sales in the statement of operations during the years ended December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Common Stock Issuances</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20201121__us-gaap--StatementClassOfStockAxis__custom--ConvertibleClassBCommonStockMember_zIgHOORZ2WK5" title="Common stock, shares issued">83,334</span> shares of common stock on November 21, 2020 to its founders for services rendered in connection with the formation of the entity. In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which such shares were subsequently exchanged for <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleClassBCommonStockMember_zYGKRDuw52Oj" title="Conversion of stock, shares converted">833,334</span> shares of convertible Class B common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1295010 1095000 200010 0 50614 94000 288200 5332 10711 128527 107013 3320 23260 0 3200 348304 137494 83334 833334 <p id="xdx_803_eus-gaap--EarningsPerShareTextBlock_z0EOanPHQfl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_82E_z0kZYt77s6Yc">Basic and Diluted Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the years ended December 31, 2023, and 2022, the Company used the two-class method to compute net loss per common share because it had issued securities, other than a single class of common stock, that contractually entitled the holders to participate in dividends and earnings. These participating securities included the Company’s Class A common stock, which was authorized pursuant to the Company’s amendment to its Certificate of Incorporation on May 2, 2022, and convertible Class B common stock which are entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current period earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports the more dilutive of the approaches (two-class or “if-converted”) as its diluted net income per share during the period. For the periods presented, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKk6VTg28iId" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of December 31, 2023 and 2022 are as follows: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zzrcYRGadbNk" style="display: none">Schedule of Diluted Earnings Per Share</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231_zEQmIFKgpcb9" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zpvugWlRBtqc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLzWtrfnptb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,760,350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhM2JIOyac1b" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">140,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zGyCMEeXhVr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,901,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">39,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zdKyvcEfNtm" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p id="xdx_890_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zKk6VTg28iId" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common shares consisting of shares potentially dilutive that are excluded from the calculated of diluted earnings per share because they are anti-dilutive as of December 31, 2023 and 2022 are as follows: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zzrcYRGadbNk" style="display: none">Schedule of Diluted Earnings Per Share</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20230101__20231231_zEQmIFKgpcb9" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220101__20221231_zpvugWlRBtqc" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLzWtrfnptb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">1,760,350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zhM2JIOyac1b" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Stock options</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">140,750</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zGyCMEeXhVr6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,901,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">39,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1760350 140750 39000 1901100 39000 <p id="xdx_80B_eus-gaap--OtherCurrentAssetsTextBlock_zot2ugwXTsv" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_824_zHwq4H8Rwbi">Other Current Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_ziGju22fxx44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets at December 31, 2023, and 2022 consisted of the following: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zPaFXue9H3t7" style="display: none">Schedule of Other Current Assets</span></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zsnFkz6iNqZb" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20221231_z8eYTnoB1Xv3" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_ecustom--EmployeeRetentionTaxCreditReceivables_iI_maOACzG3O_zm02MyXzb3C4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EDGE tax credit receivable <sup id="xdx_F46_zZixY1JbQoy9">(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">116,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidTaxes_iI_maOACzG3O_z24wpO5HFlg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal and State income tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,734</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACzG3O_zVqiMczgQ2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">316,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,040</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidRent_iI_maOACzG3O_zTMuhCCk7Waa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Prepaid rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrepaidLicensingAndOfficeFees_iI_maOACzG3O_zgoTG8SJfXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid licensing and office fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,456</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--RetainersPaidOnProfessionalServices_iI_maOACzG3O_zwHrEAobj4Te" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Retainers paid on professional services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAssetsCurrent_iTI_mtOACzG3O_zH9kMv86Nbmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">389,787</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">222,302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F0F_zA8GVzORoJLc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_z4MLAGIfsfj2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.</span></td> </tr></table> <p id="xdx_8AD_zRm6lQXaVGul" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_ziGju22fxx44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current assets at December 31, 2023, and 2022 consisted of the following: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zPaFXue9H3t7" style="display: none">Schedule of Other Current Assets</span></span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zsnFkz6iNqZb" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_499_20221231_z8eYTnoB1Xv3" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_402_ecustom--EmployeeRetentionTaxCreditReceivables_iI_maOACzG3O_zm02MyXzb3C4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EDGE tax credit receivable <sup id="xdx_F46_zZixY1JbQoy9">(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0723">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">116,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidTaxes_iI_maOACzG3O_z24wpO5HFlg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal and State income tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,734</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_maOACzG3O_zVqiMczgQ2c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">316,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,040</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PrepaidRent_iI_maOACzG3O_zTMuhCCk7Waa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Prepaid rent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0732">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PrepaidLicensingAndOfficeFees_iI_maOACzG3O_zgoTG8SJfXb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid licensing and office fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,456</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--RetainersPaidOnProfessionalServices_iI_maOACzG3O_zwHrEAobj4Te" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Retainers paid on professional services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0738">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAssetsCurrent_iTI_mtOACzG3O_zH9kMv86Nbmh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">389,787</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">222,302</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F0F_zA8GVzORoJLc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_z4MLAGIfsfj2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.</span></td> </tr></table> 116361 73069 28734 316718 20040 10711 16456 30000 389787 222302 <p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmHniqzZm26b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_824_zENZvM5y5ly5">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2p4TkwRrd2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment at December 31, 2023, and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zYw45Y1tOcb9" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zv3GcRRZgOOf" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_490_20221231_zz5bWraSzsj9" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgegyd1WR6m3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Office equipment – <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z5SepmwNeqai" title="Property plant and equipment useful life">5</span> year estimated life</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">81,340</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">127,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLV6YJLiAma9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Leasehold improvements– <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvyRDJISsGja" title="Property plant and equipment useful life">2</span> year estimated life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziMCyOIWsOCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Furniture and fixtures– <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zqaUCxWnFgm2" title="Property plant and equipment useful life">7</span> year estimated life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjhJii1Uy8p3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zEUffnbwf1Fj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,056</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_z6pvK36LhwLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,493</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zZiQ8vljbSB" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation of property and equipment was $<span id="xdx_905_eus-gaap--Depreciation_c20230101__20231231_zmMJDeTrKaCh" title="Depreciation">48,771</span> and $<span id="xdx_90D_eus-gaap--Depreciation_c20220101__20221231_zJg5uBFfcI3h" title="Depreciation">14,849</span> for the years ended December 31, 2023, and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89B_eus-gaap--PropertyPlantAndEquipmentTextBlock_z2p4TkwRrd2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment at December 31, 2023, and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zYw45Y1tOcb9" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_49B_20231231_zv3GcRRZgOOf" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_490_20221231_zz5bWraSzsj9" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zgegyd1WR6m3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Office equipment – <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z5SepmwNeqai" title="Property plant and equipment useful life">5</span> year estimated life</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">81,340</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">127,549</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zLV6YJLiAma9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Leasehold improvements– <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zvyRDJISsGja" title="Property plant and equipment useful life">2</span> year estimated life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0755">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_ziMCyOIWsOCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Furniture and fixtures– <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFByb3BlcnR5IGFuZCBFcXVpcG1lbnQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zqaUCxWnFgm2" title="Property plant and equipment useful life">7</span> year estimated life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0760">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zjhJii1Uy8p3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Property and equipment, gross</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">677</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0765">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zEUffnbwf1Fj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less: Accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,827</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(15,056</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentNet_iI_z6pvK36LhwLi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,974</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">112,493</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> P5Y 81340 127549 P2Y 60783 P7Y 677 677 63827 15056 78974 112493 48771 14849 <p id="xdx_803_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zHDsWQKkdWza" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_825_zALygCJBmhDh">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zop3S9TCSuo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses at December 31, 2023, and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zeAFcvv6llR4" style="display: none">Schedule of Accrued Expenses</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_498_20231231_zbjlgeEHoEg5" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_492_20221231_z6KQO6FMWkS1" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCz1hd_z4EcBHQLUsYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Accrued payroll and taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">148,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">212,660</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCz1hd_ze2aLfz6gJUg" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,054</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent_iI_maALCz1hd_zNWBEiRHk7Ze" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued retirement contributions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,874</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--TaxesPayableCurrent_iI_maALCz1hd_zTsDc0LjlU49" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued franchise taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,777</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_maALCz1hd_zjx3biKLv5eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz1hd_zRIqdaxcCB5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">198,978</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">239,117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zJInxhdTBkN4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides postretirement benefits pursuant to Internal Revenue Code of 1986, as amended, Section 401(k) for employees meeting specified criteria. The Company matches <span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_pid_dp_uPure_c20230101__20231231_zwhfyuFHQq62" title="Employers contribution percentage match">100</span>% of the employees’ contributions that are not in excess of <span id="xdx_90C_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_pid_dp_uPure_c20230101__20231231_zohiuHWJoBV8" title="Employees contribution percentage">4</span>% of the employee’s contributions. These matching contributions are fully vested and paid pursuant to the employees’ bi-weekly or semi-monthly pay periods. The Company does not prefund these benefits and has the right to modify or terminate certain of these benefits in the future. For the year ended December 31, 2023, the Company incurred $<span id="xdx_90E_ecustom--InvestmentRetirementAccountContributionExpenses_c20230101__20231231_zN1ffJ0B44V3" title="Investment retirement account contribution expenses">88,327</span> of investment retirement account contribution expenses pursuant to the Company’s matching contributions, including $<span id="xdx_90C_ecustom--AccruedRetirementContributions_iI_c20231231_zicuDaAcCaN" title="Accrued retirement contributions">8,778</span>, as accrued at December 31, 2023. For the year ended December 31, 2022, the Company incurred $<span id="xdx_903_ecustom--InvestmentRetirementAccountContributionExpenses_c20220101__20221231_zjgKTYbNQ9Jl" title="Investment retirement account contribution expenses">28,534</span> of investment retirement account contribution expenses pursuant to the Company’s matching contributions, including $<span id="xdx_90D_ecustom--AccruedRetirementContributions_iI_c20221231_zNcU3IMafQf1" title="Accrued retirement contributions">4,874</span>, as accrued at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zop3S9TCSuo1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses at December 31, 2023, and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zeAFcvv6llR4" style="display: none">Schedule of Accrued Expenses</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_498_20231231_zbjlgeEHoEg5" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_492_20221231_z6KQO6FMWkS1" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCz1hd_z4EcBHQLUsYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Accrued payroll and taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">148,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">212,660</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_maALCz1hd_ze2aLfz6gJUg" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,054</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrent_iI_maALCz1hd_zNWBEiRHk7Ze" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accrued retirement contributions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,874</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--TaxesPayableCurrent_iI_maALCz1hd_zTsDc0LjlU49" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued franchise taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,777</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestPayableCurrent_iI_maALCz1hd_zjx3biKLv5eh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Accrued interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz1hd_zRIqdaxcCB5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">198,978</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">239,117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 148924 212660 50054 4874 18777 2806 198978 239117 1 0.04 88327 8778 28534 4874 <p id="xdx_807_eus-gaap--DebtDisclosureTextBlock_zg1JcigEdaAg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_829_zaYePdreAnE8">Debt</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Line of Credit</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2022, the Company entered into a business loan agreement (as amended, the “loan agreement”) with Citizens State Bank of New Castle pursuant to which it originally received a revolving line of credit of up to $<span id="xdx_90E_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20220207__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zFGCwbCLSVIg" title="Revolving line of credit maximum borrowing limit">1,500,000</span> which was subsequently amended to $<span id="xdx_90E_eus-gaap--LineOfCredit_iI_c20220207__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zh4eYcQFt2Z3" title="Revolving line of credit">800,000</span> (as amended, the “Revolving Line of Credit”). <span id="xdx_901_eus-gaap--LineOfCreditFacilityDescription_c20230101__20231231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zBb6nGc2UPMg" title="Revolving line of facility description">Pursuant to the terms of the Revolving Line of Credit, the outstanding balance shall not exceed 75% of the Company’s outstanding accounts receivable due from the State of Indiana aged more than 90 days together with all other accounts receivable aged less than 90 days. The Revolving Line of Credit was to terminate on December 31, 2022, unless extended pursuant to the terms thereof. The Company received extensions on the Revolving Line of Credit such that it will now terminate on October 24, 2023; however, no further advances are available under the Revolving Line of Credit. In the event of a default, all commitments and obligations pursuant to the Revolving Line of Credit will terminate immediately and, at Citizens State Bank of New Castle’s request, all Indebtedness (as defined in the loan agreement) shall become immediately due and payable. Advances on the Revolving Line of Credit are pursuant to a promissory note dated February 7, 2022 which accrues interest at a variable rate of 1.5% above the national prime interest rate as quoted in the Wall Street Journal, not to be less than 4.75% per annum or more than 21% per annum or the maximum rate allowed by law. Interest shall increase by an 2.0% in the event of a default. Pursuant to the promissory note, the Company has been required to pay monthly payments of unpaid interest since March 7, 2022. The Company may prepay all or a portion of the amount due prior to the date upon which it is due without any penalty. In connection with the Revolving Line of Credit, the Company entered into a commercial security agreement with Citizens State Bank of New Castle dated February 7, 2022, pursuant to which it granted Citizens State Bank of New Castle a security interest in the Collateral (as defined in the commercial security agreement) to secure the Indebtedness (as defined in the commercial security agreement).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2023, the Company received proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromLinesOfCredit_c20230101__20231231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zMmrNCqml1De" title="Proceeds from payments line of credit">300,000</span> and repaid total advances of $<span id="xdx_90F_eus-gaap--RepaymentsOfLinesOfCredit_c20230101__20231231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zdhtnWADXbg3" title="Proceeds from repayment of line of credit">1,050,551</span>. In addition, the Company paid an underwriting fee of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20220207__20220207__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z3ihKTpfTHAl" title="Underwriting fee">14,076</span> on February 7, 2022, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. The balance of the line of credit was $<span id="xdx_902_eus-gaap--LinesOfCreditCurrent_iI_dxL_c20231231_zjQSYFj7wE4l" title="Line of credit::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0825">0</span></span> and $<span id="xdx_902_eus-gaap--LinesOfCreditCurrent_iI_c20221231_zXm0PMkLl98a" title="Line of credit">750,551</span> at December 31, 2023, and December 31, 2022, respectively. The Revolving Line of Credit was closed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2022, the Company received total advances of $<span id="xdx_90B_eus-gaap--ProceedsFromLinesOfCredit_c20220101__20221231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zPsAMKOwg2Kd" title="Proceeds from payments line of credit">2,819,275</span>, and repaid advances of $<span id="xdx_90A_eus-gaap--RepaymentsOfLinesOfCredit_c20220101__20221231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_zItEMiMG06Gk" title="Proceeds from repayment of line of credit">2,068,724</span>. In addition, the Company paid an underwriting fee of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20220101__20221231__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember_z3rZTotqg5z9" title="Underwriting fee">14,076</span>, which was amortized over the original life of the line of credit using the straight-line method, which approximated the effective interest method. The balance of the line of credit was $<span id="xdx_900_eus-gaap--LinesOfCreditCurrent_iI_c20221231_zkYCLuli0ULf" title="Line of credit">750,551</span> at December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible Notes payable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On various dates from January through April 7, 2023, the Company entered into subscription agreements with accredited investors pursuant to which it issued convertible promissory notes in the aggregate principal amount of $<span id="xdx_90C_eus-gaap--NotesPayable_iI_c20230407__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zjlvyQbk9V84" title="Convertible promissory notes, aggregate principal amont">1,455,000</span>. The notes mature on various dates between <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20230407__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z2F3XDh3jhck" title="Convertible promissory notes maturity date, description">July 10, 2024 and October 7, 2024</span>, accrue interest at <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20230101__20230407__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z7FNUHEUvWkh" title="Convertible promissory notes, accrued interest">2</span>% per annum and may be prepaid by the Company at any time without any penalties. The holders may convert the principal amount of the notes together with accrued interest thereon at any time prior to the earlier of the maturity date and the effectiveness of the registration statement relating to the Company’s initial public offering at a conversion price of $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230407__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z13znAxHfA27" title="Convertible promissory notes, conversion price">6.00</span> per share. Upon the closing of the Next Equity Financing (as defined herein), the principal amount of the notes together with accrued interest thereon shall automatically convert into such number of shares of the Company’s Class A common stock determined by dividing (x) the outstanding principal balance and unpaid accrued interest of the notes on the date of conversion by (y) the price per share equal to the product of the price per Equity Security (as defined in the notes) sold in the Next Equity Financing multiplied by 80%. “Next Equity Financing” means an initial public offering by the Company of its Equity Securities pursuant to which such Equity Securities are listed on a national securities exchange. In addition, if prior to the maturity date of the notes, the notes remains outstanding, then in the event of a Corporate Transaction (as defined in the notes), the holder of each note may elect to convert the outstanding principal balance and unpaid accrued interest of each note, subject to the terms and conditions contained in the note, into Conversion Shares (as defined in the notes) immediately prior to the closing of such Corporate Transaction based upon a conversion price equal to the lesser of (i) the Corporate Transaction Price (as defined in the notes) or (ii) the quotient resulting from dividing (x) the Valuation Cap (as defined in the notes) by (y) the fully diluted capitalization immediately prior to the closing of the Corporate Transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On October 3, 2023, a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20231003__20231003_zO8SBcRIxRHi" title="Value of conversion of convertible securities issued">1,472,460</span>, consisting of $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20231003__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zrlcTBO1YKY5" title="Convertible promissory notes, aggregate principal amont">1,455,000</span> of principal and $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPaymentInterest_c20231003__20231003__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_z7CN75V5BNAg" title="Convertible promissory notes, interest amount">17,460</span> of interest, was converted into an aggregate <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20231003__20231003__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zDdnRgGMQ8Oh" title="Conversion of Convertible Securities issued, shares">446,206</span> shares of Class A common stock in accordance with the terms of the convertible promissory notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes Payable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_zJii7iAfqiyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized interest expense for the years ended December 31, 2023, and 2022, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zkntshZkVCN4" style="display: none">Schedule of Recognized Interest Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_497_20230101__20231231_zIsxXJ7DBg52" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zPwbtE7iRNhf" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--LineOfCreditFacilityPeriodicPaymentInterest_maIEOzqtb_zmuqYzHkpCRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Interest on line of credit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">27,054</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,397</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentPeriodicPaymentInterest_maIEOzqtb_zozQstaWSP1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Interest on convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,460</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestExpenseMediumTermNotes_maIEOzqtb_znuDHYAmYVE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Interest on notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,966</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_maIEOzqtb_zvU9MZBOIHu7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Amortization of underwriting fee on line of credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestExpenseOther_maIEOzqtb_znCTdh8CpWd8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Interest on credit card debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_iT_mtIEOzqtb_zfcbJF3eVRJk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total interest expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zcY7IcQ8AQP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Insurance Notes Payable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2023, the Company entered into three insurance policy financing arrangements to purchase various insurance policies. The total principal of these arrangements is $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zN5CpvP5OR28" title="Principal amount">370,596</span> with interest rates ranging from <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zGqbtl1dVuA7" title="Interest rate percentage">10.38</span>% through <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zsrXDj7Tts53" title="Interest rate percentage">14.05</span>% and monthly payments totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentInterest_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--InsurancePolicyFinancingArrangementsMember_zkfwaz6Zoidh" title="Periodic interest payment">32,328</span> are due through July 2024. During the year ended December 31, 2023, the Company repaid $<span id="xdx_90A_eus-gaap--RepaymentsOfNotesPayable_c20230101__20231231_zrTPyONHdzC7" title="Repayment of notes payable">185,692</span> on the insurance notes payable, and the remaining balance as of December 31, 2023 was $<span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_c20231231_z57uKfkZibwa" title="Notes payable">184,904</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1500000 800000 Pursuant to the terms of the Revolving Line of Credit, the outstanding balance shall not exceed 75% of the Company’s outstanding accounts receivable due from the State of Indiana aged more than 90 days together with all other accounts receivable aged less than 90 days. The Revolving Line of Credit was to terminate on December 31, 2022, unless extended pursuant to the terms thereof. The Company received extensions on the Revolving Line of Credit such that it will now terminate on October 24, 2023; however, no further advances are available under the Revolving Line of Credit. In the event of a default, all commitments and obligations pursuant to the Revolving Line of Credit will terminate immediately and, at Citizens State Bank of New Castle’s request, all Indebtedness (as defined in the loan agreement) shall become immediately due and payable. Advances on the Revolving Line of Credit are pursuant to a promissory note dated February 7, 2022 which accrues interest at a variable rate of 1.5% above the national prime interest rate as quoted in the Wall Street Journal, not to be less than 4.75% per annum or more than 21% per annum or the maximum rate allowed by law. Interest shall increase by an 2.0% in the event of a default. Pursuant to the promissory note, the Company has been required to pay monthly payments of unpaid interest since March 7, 2022. The Company may prepay all or a portion of the amount due prior to the date upon which it is due without any penalty. In connection with the Revolving Line of Credit, the Company entered into a commercial security agreement with Citizens State Bank of New Castle dated February 7, 2022, pursuant to which it granted Citizens State Bank of New Castle a security interest in the Collateral (as defined in the commercial security agreement) to secure the Indebtedness (as defined in the commercial security agreement). 300000 1050551 14076 750551 2819275 2068724 14076 750551 1455000 July 10, 2024 and October 7, 2024 0.02 6.00 1472460 1455000 17460 446206 <p id="xdx_898_eus-gaap--InterestIncomeAndInterestExpenseDisclosureTableTextBlock_zJii7iAfqiyb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized interest expense for the years ended December 31, 2023, and 2022, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B3_zkntshZkVCN4" style="display: none">Schedule of Recognized Interest Expense</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_497_20230101__20231231_zIsxXJ7DBg52" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zPwbtE7iRNhf" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_407_eus-gaap--LineOfCreditFacilityPeriodicPaymentInterest_maIEOzqtb_zmuqYzHkpCRg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Interest on line of credit</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">27,054</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">14,397</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DebtInstrumentPeriodicPaymentInterest_maIEOzqtb_zozQstaWSP1g" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Interest on convertible notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,460</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0859">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InterestExpenseMediumTermNotes_maIEOzqtb_znuDHYAmYVE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Interest on notes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,966</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_maIEOzqtb_zvU9MZBOIHu7" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Amortization of underwriting fee on line of credit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestExpenseOther_maIEOzqtb_znCTdh8CpWd8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Interest on credit card debt</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">206</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_iT_mtIEOzqtb_zfcbJF3eVRJk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total interest expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">53,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,533</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 27054 14397 17460 8966 14076 206 60 53686 28533 370596 0.1038 0.1405 32328 185692 184904 <p id="xdx_80A_eus-gaap--LesseeOperatingLeasesTextBlock_z4ndMpnPWbmc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_826_zfnVwchX37da">Lease</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases its current corporate headquarters under a <span id="xdx_906_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zjuIbOwWAAi5" title="Lease term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0887">three</span></span>-year lease from STVentures, a related party. The lease, as amended on May 1, 2022 to expand the office space from <span id="xdx_90A_eus-gaap--AreaOfLand_iI_uSqft_c20220501__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zkPbD0BW4Cf" title="Office space">2,976</span> square feet to <span id="xdx_903_eus-gaap--AreaOfLand_iI_uSqft_c20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_z1D5tMW0Ogaf" title="Office space">5,978</span> square feet, commenced on July 1, 2021, and provides for a base monthly rent of $<span id="xdx_908_eus-gaap--PaymentsForRent_c20220501__20220501__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_ztSQftS080q8" title="Base monthly rent">10,711</span>, as increased from $<span id="xdx_90F_eus-gaap--PaymentsForRent_c20210701__20210701__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zJaXZyOrm73i" title="Base monthly rent">5,332</span> per month, over the <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dxL_c20220501__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zPZYvS9Zbzmk" title="Lease term::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0897">three</span></span>-year term of the lease. The Company is occupying the space for executive and administrative offices. Rent expense was $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zeL4YPVTzyM1" title="Lease rent expense">128,527</span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseExpense_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--STVenturesMember_zH6dcfjV7LRc" title="Lease rent expense">107,013</span> for the years ended December 31, 2023 and 2022 respectively, which is included in other general and administrative expenses within the statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zZBuY3coZgnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BD_zu0E5CnCStw5" style="display: none">Schedule of Lease Cost expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20230101__20231231_z5Q2vGGa97tc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220101__20221231_zxMSkQqhFtc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="6" style="text-align: center">For the Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_zG9ZXmF4KXYd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Amortization of ROU asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">121,089</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">184,288</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseInterestExpense_zffhjfNaMwAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Interest on lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,438</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,733</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_zRbIhVloRbVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zIgm3jAxG2l5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--SupplementalBalanceSheetsInformationTableTextBlock_zUmlz2DFSLY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zsKsdOfQ7ky7" style="display: none">Schedule of Supplemental Balance Sheets Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_49A_20231231_zLdN4dWGr5i7" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_491_20221231_zwoCZYstAX47" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_znvKMUrdciy8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 2.5pt">Operating lease assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">63,199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">184,288</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzW6A_zxOddujikmvi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liability, related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">63,199</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">121,089</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzW6A_zRNixq9ybYs" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Noncurrent operating lease liability, related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,199</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_mtOLLzW6A_zckWeiYHruWh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average remaining lease term:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zw6zaJM4OoD1" title="Weighted-average remaining lease term (in years) (Year)">0.5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z8u96YqaHyik" title="Weighted-average remaining lease term (in years) (Year)">1.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average discount rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zFf63fMHRG8l" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zBNN2mz9ayN3" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A4_zOIXcIGrV2y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--SupplementalCashFlowInformationTableTextBlock_zn7Lelx2LLp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow and other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zfcS1vimthj1" style="display: none">Schedule of Supplemental Cash Flow and Other Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_497_20230101__20231231_zCWEzfifysIc" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_495_20220101__20221231_zMGYUJFGOj2a" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="6" style="text-align: center">For the Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zXGzRJdB7Tsd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 2.5pt">Operating cash flows used for operating leases</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">121,089</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">107,013</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Leased assets obtained in exchange for lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z6pIGYz16bxf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">131,187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zDaSza5cRs8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ze0B3wFQh8jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum annual lease payments required under the operating lease and the present value of the net minimum lease payments are as follows at December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BA_zHnXVq3ARzfl" style="display: none">Schedule of Minimum Lease Payments</span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">For the Year</td><td> </td> <td colspan="2" id="xdx_49C_20231231_zehymtSPCS7" style="text-align: center">Minimum Lease</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Ended December 31:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Commitments</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zSX7ooNVWu4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">64,263</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zIxjTEdW5jw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_z3z6GzPqETwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,263</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQqVfwPIMKVa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,064</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_z7D1uHiNPVM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Present value of net future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_z3SBdrxhAFr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,199</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF1XwwnFUana" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Operating lease liability, related party, long term</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zRePWLipT8f6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 2976 5978 10711 5332 128527 107013 <p id="xdx_899_eus-gaap--LeaseCostTableTextBlock_zZBuY3coZgnh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of lease expense were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span id="xdx_8BD_zu0E5CnCStw5" style="display: none">Schedule of Lease Cost expenses</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20230101__20231231_z5Q2vGGa97tc" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20220101__20221231_zxMSkQqhFtc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="6" style="text-align: center">For the Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease cost:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_zG9ZXmF4KXYd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Amortization of ROU asset</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">121,089</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">184,288</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseInterestExpense_zffhjfNaMwAf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Interest on lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,438</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,733</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseExpense_zRbIhVloRbVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">128,527</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">175,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 121089 184288 7438 8733 128527 175555 <p id="xdx_89C_ecustom--SupplementalBalanceSheetsInformationTableTextBlock_zUmlz2DFSLY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental balance sheet information related to leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zsKsdOfQ7ky7" style="display: none">Schedule of Supplemental Balance Sheets Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_49A_20231231_zLdN4dWGr5i7" style="text-align: center">December 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_491_20221231_zwoCZYstAX47" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Operating lease:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseRightOfUseAsset_iI_znvKMUrdciy8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 2.5pt">Operating lease assets</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">63,199</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">184,288</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLLzW6A_zxOddujikmvi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Current portion of operating lease liability, related party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">63,199</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">121,089</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_maOLLzW6A_zRNixq9ybYs" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Noncurrent operating lease liability, related party</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,199</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_mtOLLzW6A_zckWeiYHruWh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: justify; padding-bottom: 2.5pt">Total operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">184,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Weighted average remaining lease term:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zw6zaJM4OoD1" title="Weighted-average remaining lease term (in years) (Year)">0.5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_z8u96YqaHyik" title="Weighted-average remaining lease term (in years) (Year)">1.5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted average discount rate:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20231231_zFf63fMHRG8l" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20221231_zBNN2mz9ayN3" title="Weighted-average discount rate (Rate)">5.75</span></td><td style="text-align: left">%</td></tr> </table> 63199 184288 63199 121089 63199 63199 184288 P0Y6M P1Y6M 0.0575 0.0575 <p id="xdx_892_ecustom--SupplementalCashFlowInformationTableTextBlock_zn7Lelx2LLp9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow and other information related to operating leases was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zfcS1vimthj1" style="display: none">Schedule of Supplemental Cash Flow and Other Information</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_497_20230101__20231231_zCWEzfifysIc" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_495_20220101__20221231_zMGYUJFGOj2a" style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="6" style="text-align: center">For the Year Ended</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash paid for amounts included in the measurement of lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OperatingLeasePayments_zXGzRJdB7Tsd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify; padding-bottom: 2.5pt">Operating cash flows used for operating leases</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">121,089</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">107,013</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Leased assets obtained in exchange for lease liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_z6pIGYz16bxf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">131,187</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 121089 107013 131187 <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ze0B3wFQh8jd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future minimum annual lease payments required under the operating lease and the present value of the net minimum lease payments are as follows at December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BA_zHnXVq3ARzfl" style="display: none">Schedule of Minimum Lease Payments</span> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center">For the Year</td><td> </td> <td colspan="2" id="xdx_49C_20231231_zehymtSPCS7" style="text-align: center">Minimum Lease</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: center">Ended December 31:</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Commitments</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zSX7ooNVWu4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">64,263</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_zIxjTEdW5jw9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_z3z6GzPqETwl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,263</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zQqVfwPIMKVa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,064</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_z7D1uHiNPVM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Present value of net future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_z3SBdrxhAFr9" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,199</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zF1XwwnFUana" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Operating lease liability, related party, long term</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 64263 64263 1064 63199 63199 <p id="xdx_806_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zXGH5j59QmFj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_82F_z9a9dkjyZsS">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Legal Contingencies</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may be involved in various disputes and litigation matters that arise in the ordinary course of business. The Company is currently not a party to any material legal proceedings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2022, the Company entered into a settlement agreement with a former employee pursuant to a wrongful termination lawsuit filed in the U.S. District Court, Southern District of Indiana in the amount of $<span id="xdx_90F_eus-gaap--LitigationSettlementExpense_c20220627__20220628_zPRktWEns7rc" title="Litigation settlement expense">28,000</span>. The Company accrued the full amount of the settlement as of December 31, 2021, and the settlement was paid in July of 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In January 2024, a former employee filed a wrongful termination lawsuit against the Company in the U.S. District Court, Southern District of Indiana. The Company plans to vigorously defend itself against the claims, which it believes are without merit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 28000 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zHoXQf2cBpLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_825_zoR28FU5yqO6">Stockholders’ Equity (Deficit)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which the <span id="xdx_90E_eus-gaap--SharesOutstanding_iI_pid_c20220503__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1xW8NcLG0Zi" title="Shares outstanding">83,334</span> outstanding shares of common stock were exchanged for <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220503__20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zUOQafCSVW2a" title="Shares of convertible common stock issued">833,334</span> shares of convertible Class B common stock, as retrospectively applied. <span id="xdx_90E_eus-gaap--CommonStockConversionBasis_c20220503__20220503__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassBMember_zKfgWwSFYJp" title="Common stock conversion basis">Each share of Class B common stock is entitled to 16.5 votes and is convertible at any time into ten shares of Class A common stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During March of 2022, the Company raised $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220301__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zs5FHj6ti095" title="Stock issued during period value new issues">1,000,000</span> of capital from the sale of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zc5HVW36Me8j" title="Stock issued during period shares new issues">2,000,000</span> shares of Class A common stock at a share price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_znDQBdjhUWY8" title="Share price">0.50</span> in a private placement. On various dates between June and August of 2022, the Company also raised $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220601__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zuGEHPyezUG" title="Stock issued during period value new issues"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXQnHTo73BS2" title="Stock issued during period value new issues">1,322,500</span></span> of capital from the sale of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220601__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zBpMD96Ud1ah" title="Stock issued during period shares new issues"><span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zyVHxe1WUNsc" title="Stock issued during period shares new issues">1,102,094</span></span> shares of Class A Common Stock at a share price of $<span id="xdx_902_eus-gaap--SharePrice_iI_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zT0n8Qc3Yiib" title="Share price"><span id="xdx_90F_eus-gaap--SharePrice_iI_c20220831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjktbReeCv55" title="Share price">1.20</span></span> in a private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Amendment to Articles of Incorporation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 2, 2022, the Company filed an Amended and Restated Certificate of Incorporation that was subsequently amended on October 6, 2022 and May 30, 2023 to authorize the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20230530__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z4RyKcjfbHk3" title="Common stock, shares authorized">100,000,000</span> shares of Class A common stock with a par value of $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20230530__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zrRDeRjI78t1" title="Common stock, par value">0.001</span> per share;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20230530__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zbXFkBmwdehd" title="Common stock, shares authorized">5,000,000</span> shares of convertible Class B common stock with a par value of $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20230530__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zThDPFqI7Dgg" title="Common stock, par value">0.001</span> per share; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20230530_zak7XLokXeci" title="Preferred stock, shares authorized">10,000,000</span> shares of “blank check” preferred stock with a par value of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20230530_zg0cQKd6RGfe" title="Preferred stock, par value">0.001</span> per share.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidation rights: In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding up of the Company, the holders of Class A common stock and the holders of convertible Class B common stock shall be entitled to share equally, on a per share basis, in all assets of the Company of whatever kind available for distribution to the holders of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting: The holders of the Class A common stock and the holders of the convertible Class B common stock shall at all times vote together as one class on all matters, including the election of directors, submitted to a vote or for the consent of the stockholders of the Company. <span id="xdx_90A_eus-gaap--CommonStockVotingRights_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zvxhqX65u2Ql" title="Common stock voting rights">Each holder of shares of convertible Class B common stock shall be entitled to 16.5 votes for each share of convertible Class B common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company.</span> <span id="xdx_908_eus-gaap--CommonStockVotingRights_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zXXQDwHIhooe" title="Common stock voting rights">Each holder of shares of Class A common stock shall be entitled to one vote for each share of Class A common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--CommonStockConversionBasis_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zcQ70lsxxyn2" title="Common stock conversion basis">Each share of convertible Class B common Stock was also convertible into 16.5 fully paid and nonassessable shares of Class A common stock. On October 6, 2022, the Company’s Amended and Restated Certificate of Incorporation was amended to change the conversion ratio from 16.5 shares to 10 shares of Class A common stock. The voting rights remain unchanged.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The voting powers, conversion features, if any, designations, preferences, limitations, restrictions and other rights of each series of preferred stock shall be prescribed by resolution of the Board of Directors at the time a specific series of preferred stock is designated. None of the preferred shares have been designated or issued to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Class A Common Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zIXu2Ku9hXC7" title="Common stock, shares authorized">100,000,000</span> authorized shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zVuq3CS9O0ba" title="Common stock, par value">0.001</span> par value Class A common stock, and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfRt7klFjGrj" title="Common stock, shares issued"><span id="xdx_90E_eus-gaap--CommonStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zUYqyRCb1Ar" title="Common stock, shares outstanding">5,588,298</span></span> shares were issued and outstanding as of December 31, 2023. <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zeREkzOO1O81" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zpvHAfa5qgYb" title="Common stock, shares outstanding">3,568,758</span></span> shares were issued and outstanding as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Class A Common Stock Sales</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 3, 2023 (the “Closing Date”), the Company completed its initial public offering (the “IPO”) of an aggregate of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zP6aflMo3RCi">1,615,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">units (“Units”) at a public offering price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zXDypo44YRDa">4.125 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per Unit, with each Unit consisting of <span id="xdx_90F_eus-gaap--SaleOfStockDescriptionOfTransaction_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zrkNB0C88qQl">(a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”).</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zkNQK8d8ynl6">6,661,876 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the sale of the Units before deducting underwriting discounts, commissions and offering expenses of $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zBaW42cfWr5l">1,928,133</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In addition, pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day option to purchase up to <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20231003__20231003__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBaQ0JmiuSGc">242,250 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units at the initial public offering price, less the underwriting discount, to cover over-allotments, if any (the “Over-Allotment Option”). On the Closing Date, the Company issued an additional <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zakdS8ImBqgb">242,500 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants to the underwriters pursuant to the partial exercise by the underwriters of the Over-Allotment Option, generating gross proceeds of $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOfWarrants_c20231003__20231003__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementMember_zRSR74c4PI12">2,422</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the Closing Date, the Company granted to the underwriter fully vested warrants to purchase <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231003__20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zxohX3EqgBy9" title="Granted options">145,350</span> shares of the Company’s common stock, having an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zpOOvZcr01Hc" title="Exercise price">5.156</span> per share, exercisable over a <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231003__20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zwfu1FpG28G1" title="Granted options term">5</span>-year term, to the Representative. The fair value of the warrants was estimated at $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zvBY4AeFCyVc" title="Fair value of the options">352,677</span> using a Black-Scholes option pricing model and the following assumptions: 1) dividend yield of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20231003__20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zi5O1o3VnaM6" title="Dividend yield">0</span>%; 2) risk-free rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20231003__20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zNhGlChMWl5" title="Risk free rate">4.80</span>%; 3) volatility of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20231003__20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zAUCtL4Y3oQl" title="Volatility rate">122</span>%; <span style="background-color: white">4) a common stock price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zvbYJxzJrr5a" title="Exercise price">3.03</span>, and 5) an expected term of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231003__20231003__dei--LegalEntityAxis__custom--KingswoodCapitalPartnersLLCMember_zta3pwWZSu9j" title="Expected term">5</span> years. The fair value of the options was recognized as a cost of capital related to the IPO.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2023, a stockholder voluntarily surrendered <span id="xdx_906_ecustom--CommonStockSharesSurrendered_iI_c20230510__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zprG3ZhdopLd" title="Common stock, shares surrendered">41,667</span> shares of Class A common stock, which were subsequently cancelled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June and August 2022, the Company raised a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220601__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zH0CtF4d0ak7" title="Stock issued during period value new issues"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zx7lraUwdcd4" title="Stock issued during period value new issues">1,322,500</span></span> of capital from the sale of an aggregate of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220601__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zo7WRhqufGY9" title="Stock issued during period shares new issues"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220801__20220831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zIoF348P7xd4" title="Stock issued during period shares new issues">1,102,094</span></span> shares of Class A common stock to a total of 23 accredited investors at a share price of $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zhpQxbmRt9x5" title="Share price"><span id="xdx_902_eus-gaap--SharePrice_iI_c20220831__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjG40ImNx0Yc" title="Share price">1.20</span></span> in a private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During March 2022, the Company raised an aggregate of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220301__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zHpPAbJ1qZd2" title="Stock issued during period value new issues">1,000,000</span> of capital from the sale of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220301__20220331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zxuim31Speh3" title="Stock issued during period shares new issues">2,000,000</span> shares of Class A common stock to a total of 22 accredited investors at a share price of $<span id="xdx_900_eus-gaap--SharePrice_iI_c20220331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zn1JFvHUqAg6" title="Share price">0.50</span> in a private placement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zX5By5gGVAv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of activity of outstanding stock warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zgoD7ewhppRg" style="display: none; font-family: Times New Roman, Times, Serif">Summary of Activity of Outstanding Stock Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prices</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zQVu4GBNf7Wg" style="text-align: right" title="Warrants outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z5AIWM7CBIah" style="text-align: right" title="Weighted average exercises price, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_zHCRp8REZud9" style="text-align: right" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20220101__20221231_zjGkbooswKU7" style="text-align: right" title="Weighted average exercises price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrants cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20220101__20221231_zPMTXea0FJd5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice_pid_c20220101__20221231_zfi5yN0CRkg5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercises price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zf9vW7P6AiFd" style="text-align: right" title="Warrants outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zGHNGUxGP51f" style="text-align: right" title="Weighted average exercises price, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: left">Warrants granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zSE5ROxGaelh" style="width: 14%; text-align: right" title="Warrants granted">2,002,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20230101__20231231_z6G3AVJseWg1" style="width: 14%; text-align: right" title="Weighted average exercises price, granted">6.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231_z8HID50oHRl" style="text-align: right" title="Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20230101__20231231_zI9uoDcUaB7c" style="text-align: right" title="Weighted average exercises price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrants cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20230101__20231231_zPYRkId9l9dj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants cancelled">(242,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice_pid_c20230101__20231231_zfc5isrMUrG2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercises price, cancelled">(6.50</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_zZo1anofnIHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding ending balance">1,760,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_z7MPV0QHZHSh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercises price, outstanding ending balance">6.39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231_zECWK2G4eLz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_z12cHnB2ciXd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercises price, exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p id="xdx_8A9_zApx8r5pnyaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">The warrants have a weighted average remaining contractual life of</span> <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231003_ziCpIDs4rb7i" title="Warrants and rights outstanding term">4.75</span> <span style="background-color: white">years and <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_do_c20231003_zlyidUfIYtFa" title="Warrants and rights outstanding intrinsic value">no</span> intrinsic value as of December 31, 2023.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class A Common Stock Issued for Services</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the Company award <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20231101__20231130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zUSjcry7RA4g" title="Shares issued for services">50,000</span> shares of restricted stock to a consultant, which vest in four equal quarterly installments. The restricted shares had a fair value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20231101__20231130__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--ConsultantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z4L5QUpAxyl" title="Value of shares issued for services">75,500</span> based on the stock price at the grant date, and the Company recognized $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zWFIVAh0QAPf" title="Stock issuance expense">8,122</span> of expense during the year ended December 31, 2023. <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_do_c20230101__20231231_zsUzsguGdvea" title="Value of shares issued for services">No</span> shares were issued during the year ended December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From February through May 2022, the Company awarded a total of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220201__20220531__srt--TitleOfIndividualAxis__custom--SixConsultantMember_zCgGfPZSS6xj" title="Shares issued for services">800,002</span> shares to six consultants for services provided. The shares were subsequently issued on August 3, 2022. The aggregate fair value of the shares was $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220201__20220531__srt--TitleOfIndividualAxis__custom--SixConsultantMember_zfYIxhCPFUKe" title="Stock issued during period value issued for services">510,000</span>, based on recent sales of the Company’s Class A common stock to third parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible Class B Common Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zpp6WtZ2N7m" title="Common stock, shares authorized">5,000,000</span> authorized shares of $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zZQHcNOl0Ad7" title="Common stock, par value">0.001</span> par value convertible Class B common stock, and had <span id="xdx_90A_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zDMwv3rRxFKk" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zJFd8i6BRHjl" title="Common stock, shares outstanding"><span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_z0jPk77be5zl" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBMember_zaF5ecwf4RJk" title="Common stock, shares outstanding">833,334</span></span></span></span> shares issued and outstanding as of December 31, 2022 and 2021, as retrospectively applied, pursuant to the Company’s subsequent recapitalization in 2022 and effected as of May 3, 2022, whereby the founders exchanged their <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleClassBCommonStockMember_zJ4HcNEmdHQh" title="Common stock, shares issued">83,334</span> founders shares for <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_pid_c20220503__20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleClassBCommonStockMember_zoeHmm4kF4Ec" title="Conversion of stock, shares converted">833,334</span> shares of convertible Class B common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible Class B Common Stock Issuances</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 21, 2020, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20201121__20201121__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBIssuancesMember_zEYDT0Ot5xN4" title="Stock issued during period shares issued for services">83,334</span> shares of common stock to its founders for services rendered in connection with the formation of the entity. The aggregate fair value of the common stock was $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20201121__20201121__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBIssuancesMember_zeiWSRMOldL1" title="Stock issued during period value issued for services">100</span> based on par value of the Company’s common stock, as there was no immediate intrinsic value in the Company upon inception. In 2022, the Company’s board of directors approved a recapitalization of the Company’s equity, effected as of May 3, 2022, pursuant to which the equity was recapitalized with the exchange of the <span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBIssuancesMember_zC0WpZ92b4X" title="Common stock shares outstanding">83,334</span> shares of common stock for <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20220503__20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBIssuancesMember_zySl4EVperp2" title="Shares of convertible common stock">833,334</span> shares of convertible Class B common stock, as retrospectively applied. <span id="xdx_900_eus-gaap--CommonStockConversionBasis_c20220503__20220503__us-gaap--StatementClassOfStockAxis__custom--ConvertibleCommonStockBIssuancesMember_zNwMqsgLakji" title="Common stock conversion basis">Each share of convertible Class B common stock was convertible into 16.5 shares of Class A common stock, which was subsequently amended to be convertible into ten shares on of Class A common stock</span> on October 4, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 83334 833334 Each share of Class B common stock is entitled to 16.5 votes and is convertible at any time into ten shares of Class A common stock 1000000 2000000 0.50 1322500 1322500 1102094 1102094 1.20 1.20 100000000 0.001 5000000 0.001 10000000 0.001 Each holder of shares of convertible Class B common stock shall be entitled to 16.5 votes for each share of convertible Class B common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. Each holder of shares of Class A common stock shall be entitled to one vote for each share of Class A common stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. Each share of convertible Class B common Stock was also convertible into 16.5 fully paid and nonassessable shares of Class A common stock. On October 6, 2022, the Company’s Amended and Restated Certificate of Incorporation was amended to change the conversion ratio from 16.5 shares to 10 shares of Class A common stock. The voting rights remain unchanged. 100000000 0.001 5588298 5588298 3568758 3568758 1615000 4.125 (a) one share of the Company’s Class A common stock and (b) one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Class A common stock at an exercise price equal to $6.50 per share, exercisable until the fifth anniversary of the issuance date, pursuant to that certain underwriting agreement dated as of September 28, 2023 (the “Underwriting Agreement”) by and between the Company and Kingswood, a division of Kingswood Capital Partners, LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Representative”). 6661876 1928133 242250 242500 2422 145350 5.156 P5Y 352677 0 0.0480 1.22 3.03 P5Y 41667 1322500 1322500 1102094 1102094 1.20 1.20 1000000 2000000 0.50 <p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zX5By5gGVAv5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of activity of outstanding stock warrants:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8BE_zgoD7ewhppRg" style="display: none; font-family: Times New Roman, Times, Serif">Summary of Activity of Outstanding Stock Warrants</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prices</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231_zQVu4GBNf7Wg" style="text-align: right" title="Warrants outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1068">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_z5AIWM7CBIah" style="text-align: right" title="Weighted average exercises price, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrants granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231_zHCRp8REZud9" style="text-align: right" title="Warrants granted"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20220101__20221231_zjGkbooswKU7" style="text-align: right" title="Weighted average exercises price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1074">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrants cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20220101__20221231_zPMTXea0FJd5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice_pid_c20220101__20221231_zfi5yN0CRkg5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercises price, cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231_zf9vW7P6AiFd" style="text-align: right" title="Warrants outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_zGHNGUxGP51f" style="text-align: right" title="Weighted average exercises price, outstanding beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 64%; text-align: left">Warrants granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231_zSE5ROxGaelh" style="width: 14%; text-align: right" title="Warrants granted">2,002,850</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsGrantedWeightedAverageExercisePrice_pid_c20230101__20231231_z6G3AVJseWg1" style="width: 14%; text-align: right" title="Weighted average exercises price, granted">6.40</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrants exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231_z8HID50oHRl" style="text-align: right" title="Warrants exercised"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisedWeightedAverageExercisePrice_pid_c20230101__20231231_zI9uoDcUaB7c" style="text-align: right" title="Weighted average exercises price, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrants cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_pid_di_c20230101__20231231_zPYRkId9l9dj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants cancelled">(242,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsForfeituresWeightedAverageExercisePrice_pid_c20230101__20231231_zfc5isrMUrG2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercises price, cancelled">(6.50</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231_zZo1anofnIHk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding ending balance">1,760,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_z7MPV0QHZHSh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercises price, outstanding ending balance">6.39</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_pid_c20230101__20231231_zECWK2G4eLz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1100">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20230101__20231231_z12cHnB2ciXd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercises price, exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1102">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> 2002850 6.40 242500 -6.50 1760350 6.39 P4Y9M 0 50000 75500 8122 0 800002 510000 5000000 0.001 833334 833334 833334 833334 83334 833334 83334 100 83334 833334 Each share of convertible Class B common stock was convertible into 16.5 shares of Class A common stock, which was subsequently amended to be convertible into ten shares on of Class A common stock <p id="xdx_80E_eus-gaap--ShareholdersEquityAndShareBasedPaymentsTextBlock_zi0m9cbElOJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_823_z6HszjtLyN07">Common Stock Options</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Omnibus Equity Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 11, 2022, the Company’s board of directors adopted, and the Company’s stockholders approved, the Syra Health Corp. 2022 Omnibus Equity Incentive Plan (“2022 Plan”). No more than <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220411__20220411__us-gaap--PlanNameAxis__custom--OmnibusEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zrjMT84bm7U2" title="Shares issued">1,041,667</span> shares of the Company’s Class A common stock shall be issued pursuant to the exercise of incentive stock options and other securities under the 2022 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Class A Common Stock Option Awards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 8, 2023, the Company granted options to purchase an aggregate <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231108__20231108__srt--TitleOfIndividualAxis__custom--TenEmployeesMember_zazQg2xIvPF6" title="Granted options">32,750</span> shares of the Company’s common stock under the 2022 Plan, having an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231108__srt--TitleOfIndividualAxis__custom--TenEmployeesMember_zkrFYNbbH0Dc" title="Granted options exercise price">1.51</span> per share, exercisable over a <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231108__20231108__srt--TitleOfIndividualAxis__custom--TenEmployeesMember_z6CZ4tzZIvI7" title="Granted options term">10</span>-year term, to a total of ten employees. The options vest annually over <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20231108__20231108__srt--TitleOfIndividualAxis__custom--TenEmployeesMember_zvRW3igzsUo" title="Vesting period">four years </span>from the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 8, 2023, the Company granted options to purchase an aggregate <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231108__20231108__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_z8ZMPNyHoWge" title="Granted options">30,000</span> shares of the Company’s common stock under the 2022 Plan, having an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231108__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_z1QYuzM0wBN9" title="Granted options exercise price">1.51</span> per share, exercisable over a <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231108__20231108__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_zIel4G9qMVn4" title="Granted options term">10</span>-year term, to a total of three consultants. The options vest quarterly over <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20231108__20231108__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember_zjQkd1ThTrO2" title="Vesting period">one year</span> from the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 9, 2023, the Company granted options to purchase an aggregate <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20231009__20231009__srt--TitleOfIndividualAxis__custom--FiveBoardMembersMember_z8bFOiMJ7uKi" title="Granted options">50,000</span> shares of the Company’s common stock under the 2022 Plan, having an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20231009__srt--TitleOfIndividualAxis__custom--FiveBoardMembersMember_z4zIzbV1aVql" title="Granted options exercise price">2.68</span> per share, exercisable over a <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20231009__20231009__srt--TitleOfIndividualAxis__custom--FiveBoardMembersMember_zV3jpU5Yr1zc" title="Granted options term">10</span>-year term, to a total of five newly appointed board members. The options vest in four (4) equal annual installments with the first installment vesting on the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the options was estimated at $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231_zj0p4L8DSHy4" title="Fair value of the options">198,383</span> using a Black-Scholes option pricing model and the following assumptions: 1) dividend yield of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zqnnuqdUdrT6" title="Dividend rate">0</span>%; 2) risk-free rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_zuJW5H2Gk6e1" title="Risk free interest rate">4.45</span>% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zW9VRo56jeY2" title="Risk free interest rate">4.71</span>%; 3) volatility of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_z9K8P83JSWhd" title="Expected volatiltity">112</span>% to <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_zRWhs7DShOuf" title="Expected volatiltity rate">115</span>% based on; 4) a common stock price ranging from $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MinimumMember_zcX6cQItZAF7" title="Exercise price">1.51</span> to $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__srt--RangeAxis__srt--MaximumMember_zJTKevhdFH03" title="Exercise price">2.68</span>, and 5) an expected term of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z8JJ9z16YgW8" title="Expected term">6.25</span> years. During the year ended December 31, 2023, a total of $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231_zViiJL6Dxkqc" title="Share based compensation recognized">21,041</span> was recognized as expense related to stock options and $<span id="xdx_90C_eus-gaap--DeferredCompensationLiabilityCurrentAndNoncurrent_iI_c20231231_zBblKUS3aRxf" title="Share based compensation expense unrecognized">196,955</span> remains to be expensed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On various dates between July 1, 2022 and September 1, 2022, the Company granted options to purchase an aggregate <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220901__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z3EIUK1kaIYa" title="Purchase of shares granted options">32,502</span> shares of the Company’s Class A common stock at an exercise price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220901__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zC4MUegn2Bn9" title="Exercise price">1.20</span> per share under the 2022 Plan, which represented the recent sales price of securities to third parties. These options will vest <span id="xdx_907_ecustom--NumberOfOptionsVested_pid_dp_uPure_c20220701__20220901_zAaJQekLbUJ3" title="Number of options vested">25</span>% on each anniversary until fully vested. The options had no intrinsic value. The aggregate estimated value using the Black-Scholes Pricing Model, based on an expected term of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20220901_zJ4GdPRTV2F1" title="Expected term">6.25</span> years, a weighted average volatility rate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_pid_dp_uPure_c20220701__20220901_zIacNHfA7019" title="Weighted average volatility rate">93</span>%, a weighted average risk-free interest rate of <span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate_pid_dp_uPure_c20220701__20220901_zkLE1Ax8K04g" title="Weighted average risk free interest rate">3.03</span>%, and a weighted average call option value of $<span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice_c20220701__20220901_z8Dg12sWtCw7" title="Weighted average call option value">0.9328</span>, was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20220901_zHnkSlOyBPN7" title="Aggregate intrinsic value">30,317</span>. The options are being expensed over the vesting period, resulting in $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220101__20221231_zmvbGWGA4v4" title="Share based compensation expense">2,910</span> of stock-based compensation expense during the year ended December 31, 2022. During the fourth quarter of 2022, a total of <span id="xdx_908_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_c20221001__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zM58UORYVMO3" title="Number of options cancelled">9,167</span> options at a strike price of $<span id="xdx_902_eus-gaap--AcceleratedShareRepurchasesFinalPricePaidPerShare_c20221001__20221231__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zE8zggl44TWg" title="Exercise price of options cancelled">1.20</span> per share were cancelled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYmNCeTv69G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of activity of outstanding stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zXlqqOwjfy1g" style="display: none">Schedule of Share-Based Compensation, Stock Options Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prices</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zMV0dJNNKzwc" style="text-align: right" title="Number of options, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zKcpaWMxz3Ze" style="text-align: right" title="Weighted average exercise prices"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zjpghYnC1hug" style="width: 14%; text-align: right" title="Options granted">39,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zeJSnS4PG9I3" style="width: 14%; text-align: right" title="Weighted average exercise price, granted">1.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zFHYiSsMxe5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Balance, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zE4qlNZXkyE" style="text-align: right" title="Number of options, beginning balance">39,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_z5FwIrKaZL04" style="text-align: right" title="Weighted average exercise prices, ending balance">1.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_ziojzBgHhDTh" style="text-align: right" title="Options granted">112,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zpSqd8nSrlSc" style="text-align: right" title="Weighted average exercise price, granted">2.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231_zoCgpjHuccn9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options forfeited">(11,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20230101__20231231_z6r17Xi85CX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited">(1.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zHm19TjLvPtk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending balance">140,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zOvYxoQ5KIq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise prices, ending balance">1.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zsVBBedoq73e" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z0UnSRqeK1Rl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zlFDoLYah6Ih" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The options had a weighted average remaining life of <span id="xdx_905_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zu2zCFdIFAfe" title="Remaining contractual life">9.58</span> years and no intrinsic value as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 1041667 32750 1.51 P10Y P4Y 30000 1.51 P10Y P1Y 50000 2.68 P10Y 198383 0 0.0445 0.0471 1.12 1.15 1.51 2.68 P6Y3M 21041 196955 32502 1.20 0.25 P6Y3M 0.93 0.0303 0.9328 30317 2910 9167 1.20 <p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zYmNCeTv69G9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of activity of outstanding stock options:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 9pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zXlqqOwjfy1g" style="display: none">Schedule of Share-Based Compensation, Stock Options Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: center">Number</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">of Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Prices</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Balance, December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zMV0dJNNKzwc" style="text-align: right" title="Number of options, beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zKcpaWMxz3Ze" style="text-align: right" title="Weighted average exercise prices"><span style="-sec-ix-hidden: xdx2ixbrl1220">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: justify">Options granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zjpghYnC1hug" style="width: 14%; text-align: right" title="Options granted">39,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zeJSnS4PG9I3" style="width: 14%; text-align: right" title="Weighted average exercise price, granted">1.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Options cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zFHYiSsMxe5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1226">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Balance, December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zE4qlNZXkyE" style="text-align: right" title="Number of options, beginning balance">39,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_z5FwIrKaZL04" style="text-align: right" title="Weighted average exercise prices, ending balance">1.20</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Options granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_ziojzBgHhDTh" style="text-align: right" title="Options granted">112,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zpSqd8nSrlSc" style="text-align: right" title="Weighted average exercise price, granted">2.03</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Options forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231_zoCgpjHuccn9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options forfeited">(11,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_iN_di_c20230101__20231231_z6r17Xi85CX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, forfeited">(1.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2.5pt">Balance, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zHm19TjLvPtk" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, ending balance">140,750</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zOvYxoQ5KIq5" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise prices, ending balance">1.82</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Exercisable, December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20231231_zsVBBedoq73e" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20231231_z0UnSRqeK1Rl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"><span style="-sec-ix-hidden: xdx2ixbrl1246">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 39000 1.00 39000 1.20 112750 2.03 11000 1.00 140750 1.82 P9Y6M29D <p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zJ9HoO6becmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 - <span id="xdx_829_zESgHokc5Gy2">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the period from November 20, 2020 (inception) through December 31, 2023, the Company incurred a net operating loss and, accordingly, <span id="xdx_909_eus-gaap--TaxAdjustmentsSettlementsAndUnusualProvisions_do_c20201120__20231231_zHSbHxCPZOGa" title="Tax provisions">no</span> provision for income taxes has been recorded. In addition, <span id="xdx_909_eus-gaap--IncomeTaxExpenseBenefit_do_c20201120__20231231_zQSBqrQHjvUe" title="Income tax benefits">no</span> benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At December 31, 2023, and 2022, the Company had approximately $<span id="xdx_90F_eus-gaap--OperatingLossCarryforwards_iI_c20231231_zwWXwtFV9cT5" title="Federal net operating losses">4,637,000</span> and $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zTOyzRVZwUx7" title="Federal net operating losses">1,731,000</span> of federal net operating losses. Under the Tax Cuts and Jobs Act of 2017, the net operating loss carry forwards can be carried forward indefinitely, however the deductions are limited to 80% of taxable income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zC8llHTEcDU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective income tax rate for the years ended December 31, 2023 and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zba6rmNiQzs3" style="display: none">Schedule of Effective Income Tax Rate</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_493_20230101__20231231_zh3KUJLDgqAb" style="text-align: center">December 31,</td><td style="white-space: nowrap"> </td><td> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zROV5t1TvDi1" style="text-align: center">December 31,</td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zqW7ceSAA6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zGde13nB30dk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zQOLDdNKOCi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_z0aqgAI7jUye" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Net effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AB_zQkCmoPt5Pz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhco4WRplrXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s deferred tax asset are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_ztYNRpgwOov6" style="display: none">Schedule of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td id="xdx_491_20231231_zaEADamY0aHg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td id="xdx_49D_20221231_zwu98LcL57Gj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iI_maDTALNzq7j_z3vkq1oLSdUj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets before valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,029,723</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">332,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzq7j_zlG44baq1tA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,029,723</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(332,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzq7j_zjvm0vAeEkr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A5_zRk7g8OJ3qrl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 4637000 1731000 <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zC8llHTEcDU4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective income tax rate for the years ended December 31, 2023 and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zba6rmNiQzs3" style="display: none">Schedule of Effective Income Tax Rate</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" id="xdx_493_20230101__20231231_zh3KUJLDgqAb" style="text-align: center">December 31,</td><td style="white-space: nowrap"> </td><td> </td> <td colspan="2" id="xdx_49B_20220101__20221231_zROV5t1TvDi1" style="text-align: center">December 31,</td><td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maDEF_zqW7ceSAA6s6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maDEF_zGde13nB30dk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">%</td></tr> <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maDEF_zQOLDdNKOCi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td></tr> <tr id="xdx_401_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtDEF_z0aqgAI7jUye" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Net effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1272">-</span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.21 0.21 0.03 0.03 -0.24 -0.24 <p id="xdx_893_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zhco4WRplrXc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the Company’s deferred tax asset are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_ztYNRpgwOov6" style="display: none">Schedule of Deferred Tax Assets</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td id="xdx_491_20231231_zaEADamY0aHg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td id="xdx_49D_20221231_zwu98LcL57Gj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31,</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred tax assets:</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iI_maDTALNzq7j_z3vkq1oLSdUj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets before valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,029,723</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">332,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTALNzq7j_zlG44baq1tA2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Valuation allowance</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,029,723</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(332,400</span></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzq7j_zjvm0vAeEkr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1282">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1283">-</span></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 1029723 332400 1029723 332400 <p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zSFJKMzrrcKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_825_zzy6rKonEh0a">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates events that have occurred after the balance sheet date through the date these financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2023, two investors exercised <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlEBBlzyBPAb" title="Warrants to purchase">130,789</span> warrants to purchase Class A Common stock pursuant to which the Company received cash proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfWarrants_c20240101__20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoInvestorsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIsdM12beCyk" title="Proceeds from issuance of warrants">850,139</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2023, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20240101__20240331__us-gaap--AwardTypeAxis__custom--NovemberTwoThousandTwentyThreeMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z07LcKNz13j9" title="Restricted stock awarded">12,500</span> shares pursuant to the restricted stock award from November 2023.</span></p> 130789 850139 12500 false false false false A refundable corporate income tax credit from the State of Indiana, called the Economic Development for a Growing Economy (“EDGE”) Tax Credit, which provides an incentive to businesses to support jobs creation, capital investment and to improve the standard of living for Indiana residents.